Dr. Reddy's Laboratories Limited (RDY) 20-F30 Jun 212021 FY Annual report (foreign)Financial data

Company Profile

Cover Page

Cover Page	12 Months Ended
Cover Page	Mar. 31, 2021shares
Document Information [Line Items]
Document Type	20-F
Amendment Flag	false
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Entity Registrant Name	DR REDDYS LABORATORIES LTD
Entity Central Index Key	0001135951
Current Fiscal Year End Date	--03-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	166,301,231
Entity Shell Company	false
Entity Emerging Growth Company	false
Document Annual Report	true
Document Transition Report	false
Document Shell Company Report	false
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	true
American depositary shares [Member]
Document Information [Line Items]
Trading Symbol	RDY
Title of 12(b) Security	American depositary shares, each
Security Exchange Name	NYSE

CONSOLIDATED STATEMENTS OF FINA

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION ₨ in Millions, $ in Millions	Mar. 31, 2021INR (₨)		Mar. 31, 2021USD ($)		Mar. 31, 2020INR (₨)
Current assets
Cash and cash equivalents	₨ 14,829		$ 203		₨ 2,053
Other investments	19,744		270		23,687
Trade and other receivables	49,641		679		50,278
Inventories	45,412		621		35,066
Derivative financial instruments	1,218		17		1,105
Tax assets	2,745		38		4,379
Other current assets	14,509		198		13,802
Total current assets before assets held for sale	148,098		2,025		130,370
Assets held for sale	151		2		0
Total current assets	148,249		2,027		130,370
Non-current assets
Property, plant and equipment	57,111		781		52,332
Goodwill	4,568		62		3,994
Other intangible assets	35,648		487		27,659
Trade and other receivables	118		2		1,737
Investment in equity accounted investees	3,375		46		2,763
Other investments	4,958		68		328
Deferred tax assets	10,630		145		12,214
Other non-current assets	834		11		844
Total non-current assets	117,242		1,603		101,871
Total assets	265,491		3,630		232,241
Current liabilities
Trade and other payables	23,744		325		16,659
Short-term borrowings	23,136		316		16,441
Long-term borrowings, current portion	864		12		4,266
Provisions	3,435		47		3,800
Tax liabilities	1,389		19		573
Derivative financial instruments	326		4		1,602
Bank overdraft	9		0	[1]	91
Other current liabilities	30,488		417		29,382
Total current liabilities	83,391		1,140		72,814
Non-current liabilities
Long-term borrowings	6,299		86		1,304
Deferred tax liabilities	338		5		275
Provisions	58		1		54
Other non-current liabilities	2,343		32		2,806
Total non-current liabilities	9,038		124		4,439
Total liabilities	92,429		1,264		77,253
Equity
Share capital	832		11		831
Treasury shares	(1,967)	[2]	(27)		(1,006)	[2]
Share premium	8,887		122		8,495
Share-based payment reserve	1,461		20		1,233
Capital redemption reserve	173		2		173
Special economic zone re-investment reserve	1,326		18		0
Retained earnings	156,023		2,133		144,247
Other components of equity	6,327		87		1,015
Total equity	173,062		2,366		154,988
Total liabilities and equity	₨ 265,491		$ 3,630		₨ 232,241

[1]	Rounded to the nearest million.
[2]	Pursuant to the special resolution approved by the shareholders in the Annual General Meeting held on July 27, 2018, the Dr. Reddy’s Employees ESOS Trust (the “ESOS Trust”) was formed to support the Dr. Reddy’s Employees Stock Option Scheme, 2018 by acquiring, from the Company or through secondary market acquisitions, equity shares which are used for issuance to eligible employees (as defined therein) upon exercise of stock options thereunder. During the years ended March 31, 2021 and 2020, an aggregate of 85,250 and 1,150 equity shares, respectively were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy’s Employees Stock Option Scheme, 2018. The options exercised had an exercise price of Rs.2,607 or Rs.2,814 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the “share based payment reserve” was transferred to “share premium” in the consolidated statements of changes in equity.In addition, any difference between the carrying amount of treasury shares and the consideration received was recognized in the “share premium”. As of March 31, 2021 and 2020, the ESOS Trust had outstanding 575,201 and 395,950 shares, respectively, which it purchased from the secondary market for an aggregate consideration of Rs.1,967 and Rs.1,006, respectively. Refer to Note 29 of these consolidated financial statements for further details on the Dr. Reddy’s Employees Stock Option Scheme, 2018.

CONSOLIDATED INCOME STATEMENTS

CONSOLIDATED INCOME STATEMENTS ₨ in Millions, $ in Millions		12 Months Ended
CONSOLIDATED INCOME STATEMENTS ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)₨ / shares	Mar. 31, 2021USD ($)$ / shares	Mar. 31, 2020INR (₨)₨ / shares	Mar. 31, 2019INR (₨)₨ / shares
Analysis of income and expense [abstract]
Revenues	[1]	₨ 189,722	$ 2,594	₨ 174,600	₨ 153,851
Cost of revenues		86,645	1,185	80,591	70,421
Gross profit		103,077	1,409	94,009	83,430
Selling, general and administrative expenses		54,650	747	50,129	48,680
Research and development expenses		16,541	226	15,410	15,607
Impairment of non-current assets		8,588	117	16,767	210
Other income, net		(982)	(13)	(4,290)	(1,955)
Total operating expenses		78,797	1,077	78,016	62,542
Results from operating activities (A)		24,280	332	15,993	20,888
Finance income		2,623	36	2,461	2,280
Finance expense		(970)	(13)	(983)	(1,163)
Finance income, net (B)		1,653	23	1,478	1,117
Share of profit of equity accounted investees, net of tax (C)		480	7	561	438
Profit before tax [(A)+(B)+(C)]		26,413	361	18,032	22,443
Tax (expense)/benefit, net		9,175	125	(1,466)	3,648
Profit for the year		₨ 17,238	$ 236	₨ 19,498	₨ 18,795
Earnings per share:
Basic earnings per share of Rs.5/- each \| (per share)		₨ 103.94	$ 1.42	₨ 117.63	₨ 113.28
Diluted earnings per share of Rs.5/- each \| (per share)		₨ 103.65	$ 1.52	₨ 117.40	₨ 113.09

[1]	Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME ₨ in Millions, $ in Millions	12 Months Ended
	Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)		Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Statement of comprehensive income [abstract]
Profit for the year	₨ 17,238	$ 236		₨ 19,498	₨ 18,795
Items that will not be reclassified to the consolidated income statement:
Changes in the fair value of financial instruments	4,242	58		(469)	(403)
Actuarial gains/(losses) on post-employment benefit obligations	(216)	(3)		57	10
Tax impact on above items	(220)	(3)		(22)	(414)
Total of items that will not be reclassified to the consolidated income statement	3,806	52		(434)	(807)
Items that will be reclassified subsequently to the consolidated income statement:
Changes in fair value of financial instruments	7	0	[1]	(7)
Foreign currency translation adjustments	706	10		311	(53)
Foreign currency translation reserve re-classified to the income statement on disposal of foreign operation					(113)
Effective portion of changes in fair value of cash flow hedges, net	1,123	15		(951)	180
Tax impact on above items	(319)	(4)		232	(55)
Total of items that will be reclassified subsequently to the consolidated income statement	1,517	21		(415)	(41)
Other comprehensive income for the year, net of tax	5,323	73		(849)	(848)
Total comprehensive income for the year	₨ 22,561	$ 308		₨ 18,649	₨ 17,947

[1]	Rounded to the nearest million.

CONSOLIDATED STATEMENTS OF CHAN

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY ₨ in Millions, $ in Millions		INR (₨)	USD ($)	Share capital[member]INR (₨)		Share capital[member]USD ($)	Share premium [member]INR (₨)	Share premium [member]USD ($)	Treasury shares [member]INR (₨)	Treasury shares [member]USD ($)	Share based payments reserve [member]INR (₨)	Share based payments reserve [member]USD ($)	Fair value reserve [Member]INR (₨)	[1]	Fair value reserve [Member]USD ($)	[1]	Foreign currency translation reserve [member]INR (₨)	Foreign currency translation reserve [member]USD ($)	Hedging reserve [member]INR (₨)	Hedging reserve [member]USD ($)	Capital redemption reserve [member]INR (₨)	Capital redemption reserve [member]USD ($)	Special Economic Zone Reinvestment Reserve [Member]INR (₨)	[2]	Special Economic Zone Reinvestment Reserve [Member]USD ($)	[2]	Actuarial gains/ (losses) [member]INR (₨)	Actuarial gains/ (losses) [member]USD ($)	Retained earnings [member]INR (₨)		Retained earnings [member]USD ($)
Beginning Balance at Mar. 31, 2018		₨ 126,460		₨ 830			₨ 7,790		₨ 0		₨ 1,021		₨ (1,046)				₨ 4,184		₨ 45		₨ 173		₨ 0				₨ (402)		₨ 113,865
Adjustment on account of transition to IFRS 9 at Mar. 31, 2018	[3]	(62)		0			0		0		0		(50)				0		0		0		0				0		(12)
Adjusted balance as of April 1, 2018 at Mar. 31, 2018		126,398		830			7,790		0		1,021		(1,096)	[4]			4,184		45		173		0				(402)		113,853
Total comprehensive income
Profit for the year		18,795		0			0		0		0		0				0		0		0		0				0		18,795
Net change in fair value of equity and debt instruments, net of tax (expense)/benefit		(814)		0			0		0		0		(814)				0		0		0		0				0		0
Foreign currency translation adjustments, net of tax (expense)/benefit	[5]	(152)		0			0		0		0		0				(152)		0		0		0				0		0
Effective portion of changes in fair value of cash flow hedges, net of tax (expense)/benefit		111		0			0		0		0		0				0		111		0		0				0		0
Actuarial gain on post-employment benefit obligations, net of tax (expense)/benefit		7		0			0		0		0		0				0		0		0		0				7		0
Total comprehensive income for the year		17,947		0			0		0		0		(814)				(152)		111		0		0				7		18,795
Transactions with owners of the Company
Issue of equity shares on exercise of options		0		0	[6]		420		0		(420)		0				0		0		0		0				0		0
Share-based payment expense		389		0			0		0		389		0				0		0		0		0				0		0
Purchase of treasury shares		(535)		0			0		(535)		0		0				0		0		0		0				0		0
Dividend paid		(4,002)		0			0		0		0		0				0		0		0		0				0		(4,002)
Total transactions with owners of the Company		(4,148)		0			420		(535)		(31)		0				0		0		0		0				0		(4,002)
Ending Balance at Mar. 31, 2019		140,197		830			8,210		(535)		990		(1,910)				4,032		156		173		0				(395)		128,646
Total comprehensive income
Profit for the year		19,498		0			0		0		0		0				0		0		0		0				0		19,498
Net change in fair value of equity and debt instruments, net of tax (expense)/benefit		(476)		0			0		0		0		(495)				0		0		0		0				0		19	[7]
Foreign currency translation adjustments, net of tax (expense)/benefit		311		0			0		0		0		0				311		0		0		0				0		0
Effective portion of changes in fair value of cash flow hedges, net of tax (expense)/benefit		(719)		0			0		0		0		0				0		(719)		0		0				0		0
Actuarial gain on post-employment benefit obligations, net of tax (expense)/benefit		35		0			0		0		0		0				0		0		0		0				35		0
Total comprehensive income for the year		18,649		0			0		0		0		(495)				(311)		(719)		0		0				35		19,517
Transactions with owners of the Company
Issue of equity shares on exercise of options		11		1			285		3		(278)		0				0		0		0		0				0		0
Share-based payment expense		521		0			0				521		0				0		0		0		0				0		0
Purchase of treasury shares		(474)		0			0		(474)		0		0				0		0		0		0				0		0
Dividend paid		(3,916)		0			0				0		0				0		0		0		0				0		(3,916)
Total transactions with owners of the Company		(3,858)		1			285		(471)		243		0				0		0		0		0				0		(3,916)
Ending Balance at Mar. 31, 2020		154,988		831			8,495		(1,006)		1,233		(2,405)				4,343		(563)		173		0				(360)		144,247
Total comprehensive income
Profit for the year		17,238	$ 236	0			0		0		0		0				0		0		0		0				0		17,238
Net change in fair value of equity and debt instruments, net of tax (expense)/benefit		3,956		0			0		0		0		3,945				0		0		0		0				0		11	[7]
Foreign currency translation adjustments, net of tax (expense)/benefit		706		0			0		0		0		0				706		0		0		0				0		0
Effective portion of changes in fair value of cash flow hedges, net of tax (expense)/benefit		804		0			0		0		0		0				0		804		0		0				0		0
Actuarial gain on post-employment benefit obligations, net of tax (expense)/benefit		(143)		0			0		0		0		0				0		0		0		0				(143)		0
Total comprehensive income for the year		22,561	308	0			0		0		0		3,945				706		804		0		0				(143)		17,249
Transactions with owners of the Company
Issue of equity shares on exercise of options		269		1			392		232		(356)		0				0		0		0		0				0		0
Share-based payment expense		584		0			0		0		584		0				0		0		0		0				0		0
Purchase of treasury shares		(1,193)		0			0		(1,193)		0		0				0		0		0		0				0		0
Dividend paid		(4,147)		0			0		0		0		0				0		0		0		0				0		(4,147)
Total transactions with owners of the Company		(4,487)		1			392		(961)		228		0				0		0		0		0				0		(4,147)
Transfer to special economic zone re-investment reserve, net of reversal of Rs.127		0		0			0		0		0		0				0		0		0		1,402				0		(1,402)
Transfer from special economic zone re-investment reserve on utilization		0		0			0		0		0		0				0		0		0		(76)				0		76
Total (D)		0		0			0		0		0		0				0		0		0		1,326				0		(1,326)
Ending Balance at Mar. 31, 2021		₨ 173,062	2,366	₨ 832			₨ 8,887		₨ (1,967)		₨ 1,461		₨ 1,540				₨ 5,049		₨ 241		₨ 173		₨ 1,326				₨ (503)		₨ 156,023
Transactions with owners of the Company
Convenience translation into U.S.$ (See note 2(d)) \| $			$ 2,366			$ 11		$ 122		$ (27)		$ 20			$ 21			$ 69		$ 3		$ 2			$ 18			$ (7)			$ 2,133

[1]	Represents mark to market gain or loss on financial assets classified as fair value through other comprehensive income (“FVTOCI”). Depending on the category and type of the financial asset, the mark to market gain or loss is either reclassified to the income statement or to retained earnings upon disposal of the investment.
[2]	The Company has created a Special Economic Zone (“SEZ”) Reinvestment Reserve out of profits of its eligible SEZ Units in accordance with the terms of Section 10AA(1) of the Indian Income Tax Act, 1961. This reserve is to be utilized by the Company for acquiring Plant and Machinery in accordance with Section 10AA(2) of such Act.
[3]	Consists of mark to market gains on mutual funds amounting to Rs.50, offset by an impairment loss of Rs.62 on trade receivables. The net impact of Rs.12 was recognized in retained earnings.
[4]	Represents mark to market gain or loss on available-for-sale financial instruments (under IAS 39) recognized in other comprehensive income (“OCI”). The amount will be retained in OCI and will be re-classified to retained earnings only on disposal of these investments.
[5]	Includes gain of Rs.113 re-classified from foreign currency translation reserve to the income statement on disposal of a foreign operation.
[6]	Rounded to the nearest million.
[7]	Represents gain on disposal of financial instruments classified as FVTOCI instruments re-classified to retained earnings.

CONSOLIDATED STATEMENTS OF CH_2

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - INR (₨) ₨ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Statement of changes in equity [abstract]
Tax on changes in fair value of equity and debt instruments	₨ (293)		₨ (411)
Tax effect on Foreign currency translation adjustments	0	₨ 0	14
Tax effect on effective portion of change in fair value of cash flow hedges	(319)	232	(69)
Tax effect on actuarial gain on post-employment benefit obligations	73	(22)	₨ (3)
Reversal from special economic zone reinvestment reserve	₨ 127

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS ₨ in Millions, $ in Millions	12 Months Ended
	Mar. 31, 2021INR (₨)		Mar. 31, 2021USD ($)		Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Cash flows from operating activities:
Profit for the year	₨ 17,238		$ 236		₨ 19,498	₨ 18,795
Adjustments for:
Tax expense/(benefit), net	9,175		125		(1,466)	3,648
Fair value changes and profit on sale of units of mutual funds, net	(557)		(8)		(929)	(773)
Depreciation and amortization	12,796		175		12,472	12,190
Impairment of non-current assets	8,588		117		16,767	210
Allowance for credit losses (on trade receivables and other advances)	230		3		190	420
Loss/(gain) on sale or de-recognition of non-current assets, net	42		1		68	(1,264)
Share of profit of equity accounted investees	(480)		(7)		(561)	(438)
Foreign exchange loss/(gain), net	1,856		25		(2,168)	(1,588)
Interest expense, net	144		2		95	119
Equity settled share-based payment expense	584		8		521	389
Dividend income		[1]		[1]	(5)
Changes in operating assets and liabilities:
Trade and other receivables	2,081		28		(12,446)	1,797
Inventories (Refer to Note 10 for inventory write downs)	(9,881)		(135)		(1,487)	(4,480)
Trade and other payables	2,861		39		1,576	398
Other assets and other liabilities, net	(3,258)		(45)		4,821	4,122
Cash generated from operations	41,419		566		36,946	33,545
Income tax paid, net	(5,716)		(78)		(7,105)	(4,841)
Net cash from operating activities	35,703		488		29,841	28,704
Cash flows used in investing activities:
Expenditures on property, plant and equipment	(9,741)		(133)		(4,846)	(6,955)
Proceeds from sale of property, plant and equipment	85		1		131	1,265
Expenditures on other intangible assets	(2,820)		(39)		(1,269)	(1,421)
Proceeds from sale of other intangible assets					259	885
Payment for acquisition of business (Refer to Note 6)	(15,514)		(212)
Purchase of other investments	(75,418)		(1,031)		(111,918)	(78,573)
Proceeds from sale of other investments	79,528		1,087		111,704	76,291
Dividends received from equity accounted investees					392
Interest and dividend received	1,220		17		624	781
Net cash used in investing activities	(22,660)		(310)		(4,923)	(7,727)
Cash flows used in financing activities:
Proceeds from issuance of equity shares (including treasury shares)	269		4		4		[1]
Purchase of treasury shares	(1,193)		(16)		(474)	(535)
Proceeds from/(repayment of) short-term borrowings, net (Refer to Note 17)	6,791		93		4,235	(15,126)
Proceeds from long-term borrowings (Refer to Note 17)	3,800		52
Repayment of long-term borrowings (Refer to Note 17)	(3,743)		(51)		(22,918)
Payment of principal portion of lease liabilities (Refer to Note 17)	(754)		(10)		(482)	(56)
Dividend paid (March 31, 2020 and 2019 including corporate dividend tax)	(4,147)		(57)		(3,916)	(4,002)
Interest paid	(1,321)		(18)		(1,608)	(1,607)
Net cash used in financing activities	(298)		(4)		(25,159)	(21,326)
Net increase/(decrease) in cash and cash equivalents	12,745		174		(241)	(349)
Effect of exchange rate changes on cash and cash equivalents	113		2		(25)	35
Cash and cash equivalents at the beginning of the year	1,962		27		2,228	2,542
Cash and cash equivalents at the end of the year (Refer to Note 7)	₨ 14,820		$ 203		₨ 1,962	₨ 2,228

[1]	Rounded to the nearest million.

Reporting entity

Reporting entity	12 Months Ended
Reporting entity	Mar. 31, 2021
Description Of Business [Abstract]
Disclosure Of Nature Of Business Explanatory	1. Reporting entity Dr. Reddy’s Laboratories Limited (the “parent company”), together with its subsidiaries and joint ventures (collectively, the “Company”), is a leading India-based pharmaceutical company headquartered and having its registered office in Hyderabad, Telangana, India. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products – the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (“APIs”), Custom Pharmaceutical Services (“CPS”), generics, biosimilars and differentiated formulations. The Company’s principal research and development facilities are located in the states of Telangana and Andhra Pradesh in India, Cambridge in the United Kingdom and Leiden in the Netherlands; its principal manufacturing facilities are located in the states of Telangana, Andhra Pradesh and Himachal Pradesh in India, Cuernavaca-Cuautla in Mexico, Mirfield in the United Kingdom, and Louisiana in the United States; and its principal markets are in India, Russia, the United States, the United Kingdom, and Germany. The Company’s shares trade on the Bombay Stock Exchange, the National Stock Exchange, the NSE IFSC Limited in India and on the New York Stock Exchange in the United States.

Basis of preparation of financi

Basis of preparation of financial statements	12 Months Ended
Basis of preparation of financial statements	Mar. 31, 2021
Basis of preparation of financial statements [Abstract]
Basis of preparation of financial statements	2. Basis of preparation of financial statements a. Statement of compliance These consolidated financial statements as of and for the year ended March 31, 2021 comply in all material aspects with the International Financial Reporting Standards and its interpretations (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). These consolidated financial statements have been prepared by the Company as a going concern on the basis of relevant IFRS that are effective or elected for early adoption at the Company’s annual reporting date, March 31, 2021. These consolidated financial statements were authorized for issuance by the Company’s Board of Directors on June 29 b. Basis of measurement These consolidated financial statements have been prepared on the historical cost convention and on an accrual basis, except for the following material items in the statement of financial position: · derivative financial instruments are measured at fair value; · financial assets are measured either at fair value or at amortized cost, depending on the classification; · employee defined benefit assets/(liabilities) are recognized as the net total of the fair value of plan assets, adjusted for actuarial gains/(losses) and the present value of the defined benefit obligation; · long-term borrowings are measured at amortized cost using the effective interest rate method; · share-based payments are measured at fair value; · investments in joint ventures are accounted for using the equity method; · assets held for sale are measured at fair value; · assets acquired and liabilities assumed as part of business combinations are measured at fair value; and · right-of-use the assets are recognized at the present value of lease payments that are not paid at that date. This amount is adjusted for any lease payments made at or before the commencement date, lease incentives received and initial direct costs, incurred, if any. c. Convenience translation (unaudited) These consolidated financial statements have been prepared in Indian rupees. Solely for the convenience of the reader, these consolidated financial statements as of and for the year ended March 31, 2021 have been translated into U.S. dollars at the certified foreign exchange rate of U.S.$1.00 = Rs.73.14, as published by the Federal Reserve Board of Governors on March 31, 2021. No representation is made that the Indian rupee amounts have been, could have been or could be converted into U.S. dollars at such a rate or any other rate. Such convenience translation is not subject to audit by the Company’s Independent Registered Public Accounting Firm. d. Use of estimates and judgments The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, information about significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes: · Note 3(b) — Assessment of functional currency; · Notes 3(a) and 15 — Evaluation of joint arrangements; · Notes 3(c), 31 and 32 — Financial instruments; · Notes 3(d) and 6 — Business combinations; · Notes 3(e) and (f) — Useful lives of property, plant and equipment and intangible assets; · Notes 3(g) – Determination of cost for right-of-use assets and lease term; · Notes 3(h) and 10— Valuation of inventories; · Notes 3(i), 12, 13 and 14— Measurement of recoverable amounts of cash-generating units; · Notes 3 (j) and 28 — Assets and obligations relating to employee benefits; · Notes 3 (j) and 29— Share-based payments; · Note 3(k) and 18 — Provisions and other accruals; · Note 3(l) — Measurement of transaction price in a revenue transaction (sales returns, rebates and chargeback provisions); · Note 3(o) and 25 — Evaluation of recoverability of deferred tax assets, and estimation of income tax payable and income tax expense in relation to uncertain tax positions; and · Note 33 — Contingencies. e. Current and non-current classification All assets and liabilities have been classified as current or non-current as per the Company’s normal operating cycle and other criteria set out in IAS 1, “Presentation of financial statements” Assets: An asset is classified as current when it satisfies any of the following criteria: a) it is expected to be realized in, or is intended for sale or consumption in, the Company’s normal operating cycle; b) it is held primarily for the purpose of being traded; c) it is expected to be realized within twelve months after the reporting date; or d) it is cash or a cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date. Liabilities: A liability is classified as current when it satisfies any of the following criteria: a) it is expected to be settled in the Company’s normal operating cycle; b) it is held primarily for the purpose of being traded; c) it is due to be settled within twelve months after the reporting date; or d) the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification. Current assets and liabilities include the current portion of non-current assets and liabilities respectively. All other assets and liabilities are classified as non-current. Deferred tax assets and liabilities are always classified as non-current. f. Prior period Prior period amounts have been reclassified to conform to the current year classification.

Significant accounting policies

Significant accounting policies	12 Months Ended
Significant accounting policies	Mar. 31, 2021
Disclosure Of Summary Of Significant Accounting Policies Explanatory [Abstract]
Significant accounting policies	3. Significant accounting policies New Standards adopted by the Company Amendments to IAS 1 and IAS 8: Definition of Material The amendments provided a new definition to the word “material” as follows: ‘Information is material if omitting, misstating or obscuring it could reasonably be expected to influence decisions that the primary users of general-purpose financial statements make on the basis of those financial statements, which provide financial information about a specific reporting entity.’ The amendments clarify that materiality will depend on the nature or magnitude of information, either individually or in combination with other information, in the context of the financial statements. A misstatement of information is material if it could reasonably be expected to influence decisions made by the primary users. An information is considered to be obscured if it is communicated in a way that would have a similar effect for primary users of financial statements to omitting or misstating that information. The amendments provided examples of circumstances that may result in information being obscured. An entity should apply the amendments prospectively for annual periods beginning on or after January 1, 2020. The amendments to the definition of material had no impact on the consolidated financial statements of the Company. Amendments to IFRS 3: Definition of a Business The amendments clarified the definition of a business for the purpose of identifying a business combination under IFRS 3, “Business Combinations” A related amendment has been made to the definition of ‘output’ as an element of business. The amendments include an election to use a ‘concentration test’. This is a simplified assessment that would cause an acquisition to qualify as an asset acquisition. The concentration test is met if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets. An entity is required to apply the amendments to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after January 1, 2020, and to asset acquisitions that occur on or after the beginning of that period. This amendment had no impact on the consolidated financial statements of the Company but may impact future periods should the Company enter into any business combinations. Amendments to IFRS 7 and IFRS 9: Interest Rate Benchmark Reform The IASB published “Interest Rate Benchmark Reform – Phase II (Amendments to IFRS 9, IAS 39 and IFRS 7)” representing the finalization of Phase II of the project on August 27, 2020 to address issues that might affect financial reporting when an existing interest rate benchmark is replaced with an alternative benchmark interest rate. The amendments to IFRS 9, “Financial Instruments” The amendments to IFRS 7, “Financial Instruments: Disclosures” These amendments are applicable for annual periods beginning on or after January 1, 2020. These amendments had no impact on the consolidated financial statements of the Company as it does not have any interest rate hedge relationships. Amendments to IFRS 16: COVID-19 related rent concessions IFRS 16, “Leases” The amendments provide a practical expedient that lessees may elect to not treat any rent concessions, provided by lessors as a direct consequence of COVID-19 pandemic, as lease modifications. However, to be eligible for this relief: · the revised consideration for the lease should be less than or equal to the lease consideration immediately before the change; · the rent concession should be for a period that does not extend beyond June 30, 2021 (for example, lease rents are reduced for a period up to June 30, 2021 and increased for periods thereafter); and · there should be no substantial modification to the other terms and conditions of the lease. Lessee should apply the amendments for annual reporting periods beginning on or after January 1, 2020. In case a lessee has not yet approved the financial statements for issue before the issuance of the amendments, then the same may be applied for annual reporting periods beginning on or after the January 1, 2019. The aforesaid amendments had no impact on the consolidated financial statements of the Company. a. Basis of consolidation Subsidiaries Subsidiaries are all entities (including special purpose entities) that are controlled by the Company. Control exists when the Company is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through power over the entity. In assessing control, potential voting rights are considered only if the rights are substantive. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases. Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of financial position, respectively. For the purpose of preparing these consolidated financial statements, the accounting policies of subsidiaries have been changed where necessary to align them with the policies adopted by the Company. Joint arrangements (equity accounted investees) Joint arrangements are those arrangements over which the parties have joint control, established by contractual agreement and requiring unanimous consent for strategic financial and operating decisions. A joint arrangement is either a joint operation or a joint venture. A joint operation is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the assets, and obligations for the liabilities, relating to the arrangement. A joint venture is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the arrangement. With respect to joint operations, the Company recognizes its direct right to the assets, liabilities, revenues and expenses of joint operations and its share of any jointly held or incurred assets, liabilities, revenues and expenses. Investments in joint ventures are accounted for using the equity method and are initially recognized at cost. The carrying value of the Company’s investment includes goodwill identified on acquisition, net of any accumulated impairment losses. The Company does not consolidate entities where the non-controlling interest (“NCI”) holders have certain significant participating rights that provide for effective involvement in significant decisions in the ordinary course of business of such entities. Investments in such entities are accounted by the equity method of accounting. When the Company’s share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest (including any long-term investments) is reduced to zero and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee. For the purpose of preparing these consolidated financial statements, the accounting policies of joint ventures have been changed where necessary to align them with the policies adopted by the Company. Furthermore, the financial statements of the joint ventures are prepared for the same reporting period as of the Company. Transactions eliminated on consolidation Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in full while preparing these consolidated financial statements. Unrealized gains or losses arising from transactions with equity accounted investees are eliminated against the investment to the extent of the Company’s interest in the investee. Changes in ownership interests Acquisition of some or all of the NCI is accounted for as a transaction with equity holders in their capacity as equity holders. Consequently, the difference arising between the fair value of the purchase consideration paid and the carrying value of the NCI is recorded as an adjustment to retained earnings that is attributable to the parent company. The associated cash flows are classified as financing activities. No goodwill is recognized as a result of such transactions. Loss of Control Upon loss of control, the Company derecognizes the assets and liabilities of the subsidiary, any NCIs and the other components of equity related to the subsidiary. Any surplus or deficit arising on the loss of control is recognized in the consolidated income statement. If the Company retains any interest in the previous subsidiary, then such interest is measured at fair value at the date that control is lost. Subsequently, depending on the level of influence retained, it is accounted for as an equity accounted investee or as an investment measured at fair value through other comprehensive income (“FVTOCI”) or fair value through profit or loss (“FVTPL”) under IFRS 9. b. Foreign currency Functional and presentation currency These consolidated financial statements are presented in Indian rupees, which is the functional currency of the parent company. All financial information presented in Indian rupees has been rounded to the nearest million. In respect of certain non-Indian subsidiaries that operate as marketing arms of the parent company in their respective countries/regions, the functional currency has been determined to be the functional currency of the parent company (i.e., the Indian rupee). The operations of these entities are largely restricted to importing of finished goods from the parent company in India, sales of these products in the foreign country and making of import payments to the parent company. The cash flows realized from sales of goods are available for making import payments to the parent company and cash is paid to the parent company on a regular basis. The costs incurred by these entities are primarily the cost of goods imported from the parent company. The financing of these subsidiaries is done directly or indirectly by the parent company. In respect of subsidiaries whose operations are self-contained and integrated within their respective countries/regions, the functional currency has been generally determined to be the local currency of those countries/regions, unless use of a different currency is considered appropriate. Foreign currency transactions Transactions in foreign currencies are translated to the respective functional currencies of entities within the Company at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated into the functional currency at the exchange rate at that date. Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured. Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements are recognized in the consolidated income statement in the period in which they arise. However, foreign currency differences arising from the translation of the following items are recognized in OCI: · certain debt instruments classified as measured at FVTOCI; · certain equity instruments where the Company had made an irrevocable election to present in OCI subsequent changes in the fair value; · a financial liability designated as a hedge of the net investment in a foreign operation, to the extent that the hedge is effective; and · qualifying cash flow hedges, to the extent that the hedges are effective. When several exchange rates are available, the rate used is that at which the future cash flows represented by the transaction or balance could have been settled if those cash flows had occurred at the measurement date. Foreign operations Foreign exchange gains and losses arising from a monetary item receivable from a foreign operation, the settlement of which is neither planned nor likely in the foreseeable future, are considered to form part of the net investment in the foreign operation and are recognized in OCI and presented within equity as foreign currency translation reserve (“FCTR”). In case of foreign operations whose functional currency is different from the parent company’s functional currency, the assets and liabilities of such foreign operations, including goodwill and fair value adjustments arising upon acquisition, are translated to the reporting currency at exchange rates at the reporting date. The income and expenses of such foreign operations are translated to the reporting currency at the monthly average exchange rates prevailing during the year. Resulting foreign currency differences are recognized in OCI and presented within equity as part of FCTR. When a foreign operation is disposed of, in part or in full, such that control, significant influence or joint control is lost, the relevant amount in the FCTR is reclassified to the consolidated income statement. c. Financial instruments A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial assets Initial recognition and measurement All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (e.g., regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the asset. Trade receivables are recognized initially at the amount of consideration that is unconditional unless they contain significant financing components, in which case they are recognized at fair value. The Company’s trade receivables do not contain any significant financing component and hence are measured at the transaction price measured under IFRS 15, “Revenue from Contracts with Customers” Subsequent measurement For purposes of subsequent measurement, financial assets are classified in four categories: · Debt instruments at amortized cost; · Debt instruments at FVTOCI; · Debt instruments, derivatives and equity instruments at FVTPL; and · Equity instruments measured at FVTOCI. Debt instruments at amortized cost A “debt instrument” is measured at the amortized cost if both the following conditions are met: a) the asset is held within a business model whose objective is to hold assets for collecting contractual cash flows; and b) contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (“SPPI”) on the principal amount outstanding. After initial measurement, such financial assets are subsequently measured at amortized cost using the effective interest rate method and are subject to impairment. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on de-recognition is recognized directly in the consolidated income statement and presented in other income/(losses),net. The losses arising from impairment are recognized in the consolidated income statement. This category generally applies to trade and other receivables. Debt instrument at FVTOCI A “debt instrument” is classified as at the FVTOCI if both of the following criteria are met: a) the objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets; and b) the asset’s contractual cash flows represent SPPI. Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in the OCI. However, the Company recognizes interest income, impairment losses and reversals and foreign exchange gain or loss in the consolidated income statement. On de-recognition of the asset, cumulative gain or loss previously recognized in OCI is reclassified to the consolidated income statement. Interest earned while holding a FVTOCI debt instrument is reported as interest income using the effective interest rate method. Debt instrument at FVTPL FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL. In addition, the Company may elect to designate a debt instrument, which otherwise meets amortized cost or FVTOCI criteria, as FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as an “accounting mismatch”). Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the consolidated income statement. Equity investments All equity investments within the scope of IFRS 9 are measured at fair value. Equity instruments which are held for trading and contingent consideration recognized by an acquirer in a business combination to which IFRS 3 applies, are classified as at FVTPL. For all other equity instruments, the Company may make an irrevocable election to present in OCI subsequent changes in the fair value. The Company makes such election on an instrument-by-instrument basis. The classification is made upon initial recognition and is irrevocable. If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to the consolidated income statement, even on sale of investment. However, on sale the Company may transfer the cumulative gain or loss within equity. Equity investments designated as FVTOCI are not subject to impairment assessment. Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the consolidated income statement. De-recognition A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company’s consolidated statement of financial position) when: · the rights to receive cash flows from the asset have expired; or · Both (1) the Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a “pass-through” arrangement; and (2) either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset. When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of the Company’s continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained. Impairment of trade receivables and other financial assets In accordance with IFRS 9, the Company applies the expected credit loss (“ECL”) model for measurement and recognition of impairment loss on trade receivables or any contractual right to receive cash or another financial asset. For this purpose, the Company follows a “simplified approach” for recognition of impairment loss allowance on the trade receivable balances. The application of this simplified approach does not require the Company to track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition. As a practical expedient, the Company uses a provision matrix to determine impairment loss allowance on portfolio of its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analyzed. Financial liabilities Initial recognition and measurement Financial liabilities are classified, at initial recognition, as financial liabilities at FVTPL, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Company’s financial liabilities include trade and other payables, loans and borrowings including bank overdrafts and derivative financial instruments. Subsequent measurement The measurement of financial liabilities depends on their classification, as described below: Financial liabilities at FVTPL Financial liabilities at FVTPL include financial liabilities held for trading and financial liabilities designated upon initial recognition as at FVTPL. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by IFRS 9. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments. Gains or losses on liabilities held for trading are recognized in the consolidated income statement. Financial liabilities designated upon initial recognition at FVTPL are designated as such at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains or losses are not subsequently transferred to the consolidated income statement. However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognized in the consolidated income statement. The Company has not designated any financial liability as FVTPL. Loans and borrowings Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in the consolidated income statement over the period of the borrowings using the effective interest method. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost using the effective interest rate method. Gains and losses are recognized in the consolidated income statement when the liabilities are derecognized as well as through the effective interest rate amortization process. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortization is included as finance costs in the consolidated income statement. De-recognition A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the consolidated income statement. Derivative financial instruments The Company is exposed to exchange rate risk which arises from its foreign exchange revenues and expenses, primarily in U.S. dollars, U.K. pounds sterling, Russian roubles, Brazilian reals, Swiss francs, South African rands, Kazakhstan tenges, Romanian new leus, Australian dollars and Euros, and foreign currency debt in U.S. dollars, Russian roubles, South African rands, Mexican pesos, Ukrainian hryvnias and Brazilian reals. The Company uses derivative financial instruments such as foreign exchange forward contracts, option contracts and swap contracts to mitigate its risk of changes in foreign currency exchange rates. The Company also uses non-derivative financial instruments as part of its foreign currency exposure risk mitigation strategy. Derivatives are classified as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. Hedges of highly probable forecasted transactions The Company classifies its derivative financial instruments that hedge foreign currency risk associated with highly probable forecasted transactions as cash flow hedges and measures them at fair value. The effective portion of such cash flow hedges is recorded in the Company’s hedging reserve as a component of equity and re-classified to the consolidated income statement as part of the hedged item in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion of such cash flow hedges is recorded in the consolidated income statement as finance costs immediately. The Company also designates certain non-derivative financial liabilities, such as foreign currency borrowings from banks, as hedging instruments for hedge of foreign currency risk associated with highly probable forecasted transactions. Accordingly, the Company applies cash flow hedge accounting to such relationships. Re-measurement gain or loss on such non-derivative financial liabilities is recorded in the Company’s hedging reserve as a component of equity and reclassified to the consolidated income statement as part of the hedged item in the period corresponding to the occurrence of the forecasted transactions. If the hedging instrument no longer meets the criteria for hedge accounting, expires or is sold, terminated or exercised, then hedge accounting is discontinued prospectively. The cumulative gain or loss previously recognized in OCI, remains there until the forecasted transaction occurs. If the forecasted transaction is no longer expected to occur, then the balance in OCI is recognized immediately in the consolidated income statement. Hedges of recognized assets and liabilities Changes in the fair value of derivative contracts that economically hedge monetary assets and liabilities in foreign currencies, and for which no hedge accounting is applied, are recognized in the consolidated income statement. The changes in fair value of such derivative contracts, as well as the foreign exchange gains and losses relating to the monetary items, are recognized in the consolidated income statement. If the hedged item is derecognized, the unamortized fair value is recognized immediately in the consolidated income statement. Hedges of changes in the interest rates Consistent with its risk management policy, the Company uses interest rate swaps to mitigate the risk of changes in interest rates. The Company does not use them for trading or speculative purposes. Cash and cash equivalents Cash and cash equivalents consist of cash on hand, demand deposits and short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value. For this purpose, “short-term” means investments having original maturities of three months or less from the date of investment. Bank overdrafts that are repayable on demand form an integral part of the Company’s cash management and are included as a component of cash and cash equivalents for the purpose of the consolidated statement of cash flows. d. Business combinations The acquisition method of accounting is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. The acquisition date is the date on which control is transferred to the acquirer. Judgment is applied in determining the acquisition date and determining whether control is transferred from one party to another. Control exists when the Company is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through power over the entity. In assessing control, potential voting rights are considered only if the rights are substantive. The Company determines that it has acquired a business when the acquired set of activities and assets include an input and a substantive process that together significantly contribute to the ability to create outputs. The acquired process is considered substantive if it is critical to the ability to continue producing outputs, and the inputs acquired include an organized workforce with the necessary skills, knowledge, or experience to perform that process or it significantly contributes to the ability to continue producing outputs and is considered unique or scarce or cannot be replaced without significant cost, effort, or delay in the ability to continue producing outputs. The consideration transferred for the acquisition of a subsidiary is comprised of: • fair values of the assets transferred; • liabilities incurred to the former owners of the acquired business; • equity interests issued by the Company; • fair value of any asset or liability resulting from a contingent consideration arrangement; and • fair value of any pre-existing equity interest in the subsidiary. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially at their fair values at the acquisition date. The Company recognizes any non-controlling interest in the acquired entity on an acquisition-by-acquisition basis either at fair value or at the non-controlling interest’s proportionate share of the acquired entity’s net identifiable assets. Acquisition related costs are expensed as incurred. The excess of the sum of: • the consideration transferred, • the amount of any non-controlling interest in the acquired entity, and • the acquisition date fair value of any previous equity interest in the acquired entity, over the fair value of the net identifiable assets acquired is recorded as goodwill. If those amounts are less than the fair value of the net identifiable assets of the business acquired, the difference is recognized directly in the consolidated income statement as a bargain purchase. Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity’s incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. Contingent consideration is classified either as equity or a financial liability. Contingent consideration classified as equity is not re-measured and its subsequent settlement is accounted for within equity. Amounts classified as a financial liability are subsequently re-measured to fair value, with changes in fair value recognized in the consolidated income statement. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer’s previously held equity interest in the acquiree is re-mea

Determination of fair values

Determination of fair values	12 Months Ended
Determination of fair values	Mar. 31, 2021
Disclosure Of Fair Value Measurement Of Assets And Liabilities [Abstract]
Determination of fair values	4. Determination of fair values The Company’s accounting policies and disclosures require the determination of fair value, for certain financial and non-financial assets and liabilities. Fair values have been determined for measurement and/or disclosure purposes based on the following methods. When applicable, further information about the assumptions made in determining fair values is disclosed in the notes specific to that asset or liability. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either in the principal market for the asset or liability or in the absence of a principal market, in the most advantageous market for the asset or liability. The principal or the most advantageous market must be accessible by the Company. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use. The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs. All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole: · Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities. · Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable. · Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable. For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Company determines whether transfers have occurred between levels in the hierarchy by re-assessing categorization (based on the lowest level input that is significant to the fair value measurement as a whole) at the end of each reporting period. External valuers are involved for valuation of significant assets, such as assets acquired in a business combination and significant liabilities, such as contingent consideration. Involvement of external valuers is determined by the Management, based on market knowledge, reputation, independence and whether professional standards are maintained. (i) Property, plant and equipment Property, plant and equipment, if acquired in a business combination or through an exchange of non-monetary assets, is measured at fair value on the acquisition date. For this purpose, fair value is based on appraised market values and replacement cost. (ii) Intangible assets The fair value of brands, technology related intangibles, and patents and trademarks acquired in a business combination is based on the discounted estimated royalty payments that have been avoided as a result of these brands, technology related intangibles, patents or trademarks being owned (the “relief of royalty method”). The fair value of customer related, product related and other intangibles acquired in a business combination has been determined using the multi-period excess earnings method. Under this method, value is estimated as the present value of the benefits anticipated from ownership of the intangible assets in excess of the returns required or the investment in the contributory assets necessary to realize those benefits. (iii) Inventories The fair value of inventories acquired in a business combination is determined based on its estimated selling price in the ordinary course of business less the estimated costs of completion and sale, and a reasonable profit margin based on the effort required to complete and sell the inventories. (iv) Investments in equity and debt securities and units of mutual funds The fair value of marketable equity and debt securities is determined by reference to their quoted market price at the reporting date. For debt securities where quoted market prices are not available, fair value is determined using pricing techniques such as discounted cash flow analysis. In respect of investments in mutual funds, the fair values represent net asset value as stated by the issuers of these mutual fund units in the published statements. Net asset values represent the price at which the issuer will issue further units in the mutual fund and the price at which issuers will redeem such units from the investors. Accordingly, such net asset values are analogous to fair market value with respect to these investments, as transactions of these mutual funds are carried out at such prices between investors and the issuers of these units of mutual funds. (v) Derivatives The fair value of foreign exchange forward contracts is estimated by discounting the difference between the contractual forward price and the current forward price for the residual maturity of the contract using a risk-free interest rate (based on government bonds). The fair value of foreign currency option and swap contracts and interest rate swap contracts is determined based on the appropriate valuation techniques, considering the terms of the contract. (vi) Non-derivative financial liabilities Fair value, which is determined for disclosure purposes, is calculated based on the present value of future principal and interest cash flows, discounted at the market rate of interest at the reporting date. For finance leases the market rate of interest is determined by reference to similar lease agreements. In respect of the Company’s borrowings that have floating rates of interest, their fair value approximates carrying value. (vii) Share-based payment transactions The fair value of employee stock options is measured using the Black-Scholes-Merton valuation model. Measurement inputs include share price on grant date, exercise price of the instrument, expected volatility (based on weighted average historical volatility), expected life of the instrument (based on historical experience), expected dividends, and the risk free interest rate (based on government bonds). (viii) Contingent consideration The fair value of the contingent consideration arising out of business combination is estimated by applying the income approach. The fair value measurement is based on significant inputs that are not observable in the market, which IFRS 13, “Fair Value Measurement”

Segment reporting

Segment reporting	12 Months Ended
Segment reporting	Mar. 31, 2021
Disclosure of operating segments [abstract]
Segment reporting	5. Segment reporting The Chief Operating Decision Maker (“CODM”) evaluates the Company’s performance and allocates resources based on an analysis of various performance indicators by operating segments. The CODM reviews revenue and gross profit as the performance indicator for all of the operating segments, and does not review the total assets and liabilities of an operating segment. The Co-Chairman and Managing Director was previously the CODM of the Company. Pursuant to certain organizational changes, effective December 1, 2020, the office of Chief Executive Officer (“CEO”) assumed the authority and responsibility for making decisions about resources to be allocated to various segments and assessing their performance. Consequently, the CEO is currently the CODM of the Company. The Company’s reportable operating segments are as follows: • Global Generics; • Pharmaceutical Services and Active Ingredients (“PSAI”); • Proprietary Products; and • Others. Global Generics. Pharmaceutical Services and Active Ingredients Proprietary Products. Others. The measurement of each segment’s revenues, expenses and assets is consistent with the accounting policies that are used in preparation of the Company’s consolidated financial statements. Segment information: For the Year Ended March 31, Reportable segments Global Generics PSAI Proprietary Products 2021 2020 2019 2021 2020 2019 2021 2020 2019 Revenues (1) Rs. 154,404 Rs. 138,123 Rs. 122,903 Rs. 31,982 Rs. 25,747 Rs. 24,140 Rs. 523 Rs. 7,949 Rs. 4,750 Gross profit Rs. 91,111 Rs. 78,449 Rs. 71,924 Rs. 9,426 Rs. 6,190 Rs. 6,128 Rs. 482 Rs. 7,744 Rs. 4,182 Selling, general and administrative expenses Research and development expenses Impairment of non-current assets Other income, net Results from operating activities Finance income, net Share of profit of equity accounted investees, net of tax Profit before tax Tax expense/(benefit), net Profit for the year [Continued on next page] [Continued from above table, first column repeated] Segment information: For the Year Ended March 31, Reportable segments Others Total 2021 2020 2019 2021 2020 2019 Revenues (1) Rs. 2,813 Rs. 2,781 Rs. 2,058 Rs. 189,722 Rs. 174,600 Rs. 153,851 Gross profit Rs. 2,058 Rs. 1,626 Rs. 1,196 Rs. 103,077 Rs. 94,009 Rs. 83,430 Selling, general and administrative expenses 54,650 50,129 48,680 Research and development expenses 16,541 15,410 15,607 Impairment of non-current assets 8,588 16,767 210 Other income, net (982 ) (4,290 ) (1,955 ) Results from operating activities Rs. 24,280 Rs. 15,993 Rs. 20,888 Finance income, net 1,653 1,478 1,117 Share of profit of equity accounted investees, net of tax 480 561 438 Profit before tax Rs. 26,413 Rs. 18,032 Rs. 22,443 Tax expense/(benefit), net 9,175 (1,466 ) 3,648 Profit for the yea r Rs. 17,238 Rs. 19,498 Rs. 18,795 (1) Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively). Analysis of revenues within the Global Generics segment: An analysis of revenues by therapeutic areas in the Company’s Global Generics segment is given below: For the Year Ended March 31, 2021 2020 2019 Nervous System Rs. 29,040 Rs. 26,825 Rs. 19,726 Gastrointestinal 21,132 19,394 19,250 Oncology 16,842 18,245 18,357 Cardiovascular 15,460 14,729 15,106 Pain Management 15,531 13,808 13,806 Anti-Infective 12,906 9,402 7,073 Respiratory 11,089 10,433 8,130 Others 32,404 25,287 21,455 Tota l Rs. 154,404 Rs. 138,123 Rs. 122,903 Analysis of revenues within the PSAI segment: An analysis of revenues by therapeutic areas in the Company’s PSAI segment is given below: For the Year Ended March 31, 2021 2020 2019 Cardiovascular Rs. 9,834 Rs. 8,567 Rs. 7,019 Pain Management 4,657 5,073 3,364 Anti-Infective 4,126 2,264 1,247 Nervous System 2,704 2,797 2,741 Oncology 2,385 1,798 2,212 Dermatology 768 1,370 1,622 Others 7,508 3,878 5,935 Total Rs. 31,982 Rs. 25,747 Rs. 24,140 Analysis of revenues by geography: The following table shows the distribution of the Company’s revenues by country, based on the location of the customers: For the Year Ended March 31, Country 2021 2020 2019 India Rs. 36,252 Rs. 32,089 Rs. 28,804 United States 76,702 76,028 69,299 Russia 15,816 16,900 15,299 Others (1) 60,952 49,583 40,449 Rs. 189,722 Rs. 174,600 Rs. 153,851 (1) Others include Germany, the United Kingdom, Ukraine, China, Canada and other countries across the world. Analysis of assets by geography: The following table shows the distribution of the Company’s non-current assets (other than financial instruments and deferred tax assets) by country, based on the location of assets: As of March 31, Country 2021 2020 India Rs. 75,284 Rs. 55,083 Switzerland 11,661 18,204 United States 7,627 7,065 Germany 1,087 1,435 Others 5,109 5,010 Rs. 100,768 Rs. 86,797 The following table shows the distribution of the Company’s property, plant and equipment including capital work in progress and intangible assets acquired during the year (other than goodwill arising on business combination) by country, based on the location of assets: For the Year Ended March 31, Country 2021 2020 India Rs. 27,882 Rs. 5,519 Switzerland 3,760 1,025 United States 2,158 241 Others 1,031 688 Rs. 34,831 Rs. 7,473 Analysis of depreciation and amortization, included in cost of revenues, by reportable segments: For the Year Ended March 31, 2021 2020 2019 Global Generics Rs. 3,435 Rs. 3,666 Rs. 3,791 PSAI 2,578 2,804 2,906 Proprietary Products - - - Others 48 71 71 Rs. 6,061 Rs. 6,541 Rs. 6,768 Information about major customers Revenues from two customers of the Company's Global Generics segment were Rs.19,341 and Rs.9,867, representing approximately 10% and 5%, respectively, of the Company’s total revenues for the year ended March 31, 2021. Revenues from two customers of the Company's Global Generics segment were Rs.14,164 and Rs.9,267, representing approximately 8% and 5%, respectively, of the Company’s total revenues for the year ended March 31, 2020. Revenues from two customers of the Company's Global Generics segment were Rs.10,639 and Rs.10,024, each representing approximately 7% of the Company’s total revenues for the year ended March 31, 2019.

Business Transfer Agreement wit

Business Transfer Agreement with Wockhardt Limited	12 Months Ended
Business Transfer Agreement with Wockhardt Limited	Mar. 31, 2021
Disclosure of Business Transfer Agreement with Wockhardt Limited [Abstract]
Business Transfer Agreement with Wockhardt Limited	6. Business Transfer Agreement with Wockhardt Limited In February 2020, the Company entered into a Business Transfer Agreement (“BTA”) with Wockhardt Limited (“Wockhardt”) to acquire select divisions of its branded generics business in India and the territories of Nepal, Sri Lanka, Bhutan and Maldives for a consideration of Rs.18,500. The business consists of a portfolio of 62 brands in multiple therapy areas, such as respiratory, neurology, venous malformations, dermatology, gastroenterology, pain and vaccines. This entire portfolio was to be transferred to the Company, along with related sales and marketing teams, the manufacturing plant located in Baddi, Himachal Pradesh and all plant employees (together the “Business Undertaking”). The transaction involved 2,051 employees engaged in operations of the acquired Business Undertaking. As of March 31, 2020, the acquisition of this Business Undertaking was subject to certain closing conditions, such as approval from shareholders and lenders of Wockhardt and other requisite approvals under applicable statutes. Hence, the transaction was not accounted for in the year ended March 31, 2020. Due to the COVID-19 pandemic and the consequent government restrictions, there was a reduction in the revenue from the sales of the products forming part of the Business Undertaking during March and April 2020. Accordingly, through an amendment to the BTA, the Company and Wockhardt agreed that the consideration would be up to Rs.18,500, to be paid as per the following terms: a) an amount of Rs.14,830 to be paid on the date of closing; b) an amount of Rs.670 to be deposited in an escrow account which shall be released subject to adjustments for, inter alia, net working capital, employee liabilities and certain other contractual and statutory liabilities; c) an amount of Rs.3,000 (the “Holdback Amount”) which shall be released as follows: · If the revenue from sales of the products forming part of the Business Undertaking during the twelve (12) months post-closing exceeds Rs.4,800, the Company will be required to pay to Wockhardt an amount equal to two (2) times the amount by which the revenue exceeds Rs. 4,800 The acquisition is in line with the Company's strategic focus on India and has paved a path for accelerated growth and leadership in the domestic Indian market. The Company believes that the acquired Business Undertaking offers to strengthen the Company’s pharmaceutical portfolio and products in the Indian market. The transaction was completed on June 10, 2020. The Company has accounted for the transaction under IFRS 3. As of June 30, 2020, the purchase price allocation was preliminary. During the three months ended September 30, 2020, the Company completed the purchase price allocation. Tabulated below are the fair values of the assets acquired, including goodwill, and liabilities assumed on the acquisition date: Particulars Amount Cash Rs. 14,990 Payment through Escrow account 564 Contingent consideration (Holdback Amount) 561 Total consideration Rs. 16,115 Assets acquired Goodwill Rs. 530 Property, plant and equipment 373 Product related intangibles 14,888 Inventories 466 Other assets 245 Liabilities assumed Employee benefits (Gratuity-Rs.70 and Compensated absences- Rs.75) (145 ) Refund liability (242 ) Total net assets Rs. 16,115 The total goodwill of Rs.530 consists largely of the synergies and economies of scale expected from the acquired business, together with the value of the workforce acquired and has been assigned to the Company’s Global Generics segment. The entire amount of goodwill is not deductible for tax purposes. Acquisition related costs amounted to Rs.60 and were excluded from the consideration transferred and were recognized as expense under “Selling, general and administrative expenses” in the consolidated income statements for the year ended March 31, 2021. The fair value of the contingent consideration of Rs.561 was estimated by applying the income approach. The fair value measurement is based on significant inputs that are not observable in the market, which IFRS 13 refers to as Level 3 inputs. The significant unobservable inputs in the valuation is the estimated sales forecast. During the three months ended March 31, 2021, the Company, after taking into account the revenue of the products until twelve months post-closing (June 9, 2021), re-measured the contingent consideration to Rs.420. The amount of revenue included in the consolidated income statements for the year ended March 31, 2021 pertaining to the acquired business since June 10, 2020 is Rs.3,887. The acquired business has been integrated into the Company’s existing activities and it is not practicable to identify the impact on the Company profit in the year.

Cash and cash equivalents

Cash and cash equivalents	12 Months Ended
Cash and cash equivalents	Mar. 31, 2021
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	7. Cash and cash equivalents Cash and cash equivalents consist of the following: As of March 31, 2021 2020 Cash on hand Rs.1 Rs.2 Balances with banks 14,324 1,807 Term deposits with banks (original maturities less than 3 months) 504 244 Cash and cash equivalents in the statements of financial position Rs. 14,829 Rs. 2,053 Bank overdrafts used for cash management purposes 9 91 Cash and cash equivalents in the statements of cash flow Rs. 14,820 Rs. 1,962 Restricted cash balances included above Balance in unclaimed dividend and debenture interest account Rs. 106 Rs. 111 Balances in Escrow account pursuant to the Business Transfer Agreement with Wockhardt Limited (Refer to Note 6 for details) 40 - Other restricted cash balances 82 15

Other investments

Other investments	12 Months Ended
Other investments	Mar. 31, 2021
Disclosure of investments other than investments accounted for using equity method [Abstract]
Other investments	8. Other investments Other investments consist of investments in units of mutual funds, equity securities, bonds, market linked debentures, commercial paper, limited liability partnership firm and term deposits with banks (i.e., certificates of deposit having an original maturity period exceeding 3 months). The details of such investments as of March 31, 2021 and 2020 are as follows: As of March 31, 2021 As of March 31, 2020 Cost Unrealized Fair value/ (2) Cost Unrealized Fair value/ (2) Current portion In units of mutual funds Rs. 13,197 Rs. 66 Rs. 13,263 Rs. 13,686 Rs. 146 Rs. 13,832 In bonds 522 - 522 1,851 - 1,851 In commercial paper - - - 967 - 967 In market linked debentures - - - 2,000 (7 ) 1,993 Term deposits with banks 5,959 - 5,959 5,044 - 5,044 Rs. 19,678 Rs. 66 Rs. 19,744 Rs. 23,548 Rs. 139 Rs. 23,687 Non-current portion In equity securities (1) Rs. 2,701 Rs. 1,832 Rs. 4,533 Rs. 2,701 Rs. (2,397 ) Rs. 304 In limited liability partnership firm 400 - 400 - - - Others 25 - 25 24 - 24 Rs. 3,126 Rs. 1,832 Rs. 4,958 Rs. 2,725 Rs. (2,397 ) Rs. 328 (1) Primarily represents the shares of Curis, Inc. Refer to Note 34 of these consolidated financial statements for further details. (2) Interest accrued but not due on bonds and debentures, commercial paper and term deposits with banks is included in other current assets. For the purpose of measurement, the aforesaid investments are classified as follows: Investments in units of mutual funds Fair value through profit and loss Investments in bonds, commercial paper, term deposits and others Amortized cost Investments in market linked debentures Fair value through other comprehensive income Investments in equity securities Fair value through other comprehensive income (on account of irrevocable option elected at time of transition) and fair value through profit and loss Investment in limited liability partnership firm Fair value through profit and loss

Trade and other receivables

Trade and other receivables	12 Months Ended
Trade and other receivables	Mar. 31, 2021
Trade and other receivables [abstract]
Trade and other receivables	9. Trade and other receivables As of March 31, 2021 2020 Current Trade and other receivables, gross Rs. 50,937 Rs. 51,480 Less: Allowance for credit losses (1,296 ) (1,202 ) Trade and other receivables, net Rs. 49,641 Rs. 50,278 Non-current Trade and other receivables, gross (1) Rs. 118 Rs. 1,737 Less: Allowance for credit losses - - Trade and other receivables, net Rs. 118 Rs. 1,737 (1) Represents amounts receivable pursuant to an out-licensing arrangement with a customer. As these amounts are not expected to be realized within twelve months from the end of the reporting date, they are disclosed as non-current. Pursuant to an arrangement with a bank, the Company sells to the bank certain of its trade receivables forming part of its Global Generics segment, on a non-recourse basis. The receivables sold were mutually agreed upon with the bank after considering the creditworthiness and contractual terms with the customer, including any gross to net adjustments (due to rebates, discounts etc.) from the contracted amounts. As a result, the receivables sold are generally lower than the total net amount of trade receivables. The Company has transferred substantially all the risks and rewards of ownership of such receivables sold to the bank, and accordingly, the same are derecognized in the statements of financial position. As on March 31, 2021 and March 31, 2020, the amount of trade receivables de-recognized pursuant to the aforesaid arrangement was Rs.9,254 and Rs.9,049, respectively. In accordance with IFRS 9, the Company uses the expected credit loss (“ECL”) model for measurement and recognition of impairment loss on its trade receivables or any contractual right to receive cash or another financial asset that result from transactions that are within the scope of IFRS 15. For this purpose, the Company uses a provision matrix to compute the expected credit loss amount for trade receivables. The provision matrix takes into account external and internal credit risk factors and historical data of credit losses from various customers. The details of changes in allowance for credit losses during the years ended March 31, 2021 and 2020, are as follows: For the Year Ended March 31, 2021 2020 Balance at the beginning of the year Rs. 1,202 Rs. 1,172 Provision made during the year, net of reversals 176 154 Trade and other receivables written off & exchange differences (82 ) (124 ) Balance at the end of the year Rs. 1,296 Rs. 1,202

Inventories

Inventories	12 Months Ended
Inventories	Mar. 31, 2021
Classes of current inventories [abstract]
Inventories	10. Inventories Inventories consist of the following: As of March 31, 2021 2020 Raw materials Rs. 12,287 Rs. 10,594 Work-in-progress 10,009 6,806 Finished goods (includes stock-in-trade) 19,829 15,126 Packing materials, stores and spares 3,287 2,540 Rs. 45,412 Rs. 35,066 Details of inventories recognized in the consolidated income statement are as follows: For the Year Ended March 31, 2021 2020 2019 Raw materials, consumables and changes in finished goods and work in progres s Rs. 58,268 Rs. 51,892 Rs. 40,932 Inventory write-downs (1) 2,521 3,652 4,016 (1) Following the Company’s decision to voluntarily recall all of its ranitidine medications sold in United States, due to confirmed contamination with N-Nitrosodimethylamine (“NDMA”) above levels established by the U.S. FDA, the Company recognized Rs.373 as inventory write downs of ranitidine during the year ended March 31, 2020. Furthermore, an amount of Rs.239 was recognized (as a reduction from revenue) as a provision for refund liabilities arising out of the Company’s recall decision.

Other assets

Other assets	12 Months Ended
Other assets	Mar. 31, 2021
Assets [Abstract]
Other assets	11. Other assets As of March 31, 2021 2020 Current Balances and receivables from statutory authorities (1) Rs. 7,227 Rs. 4,445 Export benefits receivable (2) 2,070 2,652 Prepaid expenses 1,141 950 Others (3) 4,071 5,755 Rs. 14,509 Rs. 13,802 Non-current Security deposits Rs. 666 Rs. 613 Others 168 231 Rs. 834 Rs. 844 (1) Balances and receivables from statutory authorities primarily consist of amounts recoverable towards the goods and service tax (“GST”), excise duty and value added tax, and from customs authorities of India. (2) Export benefits receivables primarily consist of amounts receivable from various government authorities of India towards incentives on export sales made by the Company. ( 3 Others primarily includes advances given to vendors and employees, security deposits, interest accrued but not due on investments, and claims receivable.

Property, plant and equipment

Property, plant and equipment	12 Months Ended
Property, plant and equipment	Mar. 31, 2021
Disclosure of detailed information about property, plant and equipment [abstract]
Property, plant and equipment	12. Property, plant and equipment The following is a summary of the changes in carrying value of property, plant and equipment. Particulars Land Buildings Plant and Furniture, Vehicles Total Gross carrying value Balance as of April 1, 2019 Rs. 4,192 Rs. 23,106 Rs. 70,940 Rs. 5,717 Rs. 775 Rs. 104,730 Recognition of right-of-use asset on initial application of IFRS 16 - 723 2 28 400 1,153 Adjusted balance as of April 1, 2019 Rs. 4,192 Rs. 23,829 Rs. 70,942 Rs. 5,745 Rs. 1,175 Rs. 105,883 Additions 4 997 4,278 497 295 6,071 Disposals - (55 ) (706 ) (253 ) (179 ) (1,193 ) Effect of changes in foreign exchange rates (73 ) 185 353 (24 ) (80 ) 361 Balance as of March 31, 2020 Rs. 4,123 Rs. 24,956 Rs. 74,867 Rs. 5,965 Rs. 1,211 Rs. 111,122 Balance as of April 1, 2020 Rs. 4,123 Rs. 24,956 Rs. 74,867 Rs. 5,965 Rs. 1,211 Rs. 111,122 Additions 13 2,720 4,544 437 220 7,934 Assets acquired through business combinations (1) 84 113 165 11 - 373 Disposals - (35 ) (852 ) (134 ) (182 ) (1,203 ) Assets held for sale (18 ) (245 ) (334 ) (58 ) - (655 ) Effect of changes in foreign exchange rates 26 11 244 31 8 320 Balance as of March 31, 2021 Rs. 4,228 Rs. 27,520 Rs. 78,634 Rs. 6,252 Rs. 1,257 Rs. 117,891 Accumulated Depreciation Balance as of April 1, 2019 Rs. - Rs. 6,873 Rs. 43,642 Rs. 4,603 Rs. 442 Rs. 55,560 Depreciation for the year - 1,306 6,404 562 368 8,640 Impairment - - - - - - Disposals - (36 ) (667 ) (251 ) (158 ) (1,112 ) Effect of changes in foreign exchange rates - 65 223 (11 ) (54 ) 223 Balance as of March 31, 2020 Rs. - Rs. 8,208 Rs. 49,602 Rs. 4,903 Rs. 598 Rs. 63,311 Balance as of April 1, 2020 Rs. - Rs. 8,208 Rs. 49,602 Rs. 4,903 Rs. 598 Rs. 63,311 Depreciation for the year - 1,697 5,935 554 341 8,527 Impairment 4 32 9 1 - 46 Disposals - (29 ) (773 ) (125 ) (136 ) (1,063 ) Assets held for sale (4 ) (140 ) (306 ) (54 ) - (504 ) Effect of changes in foreign exchange rates - 22 194 24 1 241 Balance as of March 31, 2021 Rs. - Rs. 9,790 Rs. 54,661 Rs. 5,303 Rs. 804 Rs. 70,558 Particulars Land Buildings Plant and Furniture, Vehicles Total Net carrying value As of April 1, 2019 Rs. 4,192 Rs. 16,233 Rs. 27,298 Rs. 1,114 Rs. 333 Rs. 49,170 As of March 31, 2020 Rs. 4,123 Rs. 16,748 Rs. 25,265 Rs. 1,062 Rs. 613 Rs. 47,811 Add: Capital-work-in-progress Rs. 4,521 Total as of March 31, 2020 Rs. 52,332 As of March 31, 2021 Rs. 4,228 Rs. 17,730 Rs. 23,973 Rs. 949 Rs. 453 Rs. 47,333 Add: Capital-work-in-progress Rs. 9,778 Total as of March 31, 2021 Rs. 57,111 (1) Refer to Note 6 of these consolidated financial statements for further details. Leases The Company has lease contracts for various items of plant and equipment, vehicles and other equipment used in its operations. Below are the carrying amounts of right-of-use assets recognized and the movements during the year included in the above property, plant and equipment. Particulars Land Buildings Plant and Furniture, Vehicles Total Gross carrying value Balance as of April 1, 2019 Rs. 73 Rs. 840 Rs. 12 Rs. - Rs. 37 Rs. 962 Recognition of right-of-use asset on initial application of IFRS 16 - 723 2 28 400 1,153 Adjusted balance as of April 1, 2019 Rs. 73 Rs. 1,563 Rs. 14 Rs. 28 Rs. 437 Rs. 2,115 Additions - 87 3 17 146 253 Disposals - (1 ) - - (56 ) (57 ) Effect of changes in foreign exchange rates 5 39 1 - 3 48 Balance as of March 31, 2020 Rs. 78 Rs. 1,688 Rs. 18 Rs. 45 Rs. 530 Rs. 2,359 Balance as of April 1, 2020 Rs. 78 Rs. 1,688 Rs. 18 Rs. 45 Rs. 530 Rs. 2,359 Additions (1) - 2,212 - 7 194 2,413 Disposals - - - (1 ) (120 ) (121 ) Effect of changes in foreign exchange rates 3 (14 ) - - - (11 ) Balance as of March 31, 2021 Rs. 81 Rs. 3,886 Rs. 18 Rs. 51 Rs. 604 Rs. 4,640 Accumulated Depreciation Balance as of April 1, 2019 Rs. - Rs. 454 Rs. 12 Rs. - Rs. 33 Rs. 499 Depreciation for the year - 267 1 13 210 491 Disposals - (1 ) - - (41 ) (42 ) Effect of changes in foreign exchange rates - 24 1 - (3 ) 22 Balance as of March 31, 2020 Rs. - Rs. 744 Rs. 14 Rs. 13 Rs. 199 Rs. 970 Balance as of April 1, 2020 Rs. - Rs. 744 Rs. 14 Rs. 13 Rs. 199 Rs. 970 Depreciation for the year - 616 1 12 202 831 Disposals - - - - (78 ) (78 ) Effect of changes in foreign exchange rates - (25 ) - - (2 ) (27 ) Balance as of March 31, 2021 Rs. - Rs. 1,335 Rs. 15 Rs. 25 Rs. 321 Rs. 1,696 Net carrying value As of March 31, 2020 Rs. 78 Rs. 944 Rs. 4 Rs. 32 Rs. 331 Rs. 1,389 As of March 31, 202 1 Rs. 81 Rs. 2,551 Rs. 3 Rs. 26 Rs. 283 Rs. 2,944 (1) Additions for the year ended March 31, 2021 include recognition of a right-of-use asset of Rs.1,852 relating to a warehousing services agreement in the United States. The following are the amounts recognized in income statement: For the Year Ended March 31, 2021 2020 Depreciation expense of right-of-use assets Rs. 831 Rs. 491 Interest expense on lease liabilities 227 230 The Company had total cash outflows for leases of Rs.1,252 and Rs.972 during the years ended March 31, 2021 and 2020, respectively. The maturity analysis of lease liabilities are disclosed in Note 17 of these consolidated financial statements. Capital commitments As of March 31, 2021 and 2020, the Company was committed to spend Rs.9,841 and Rs.4,888, respectively, under agreements to purchase property, plant and equipment. This amount is net of capital advances paid in respect of such purchase commitments. Interest capitalization During the years ended March 31, 2021 and 2020, the Company capitalized interest cost of Rs.149 and Rs.52, respectively, with respect to qualifying assets. The rate for capitalization of interest cost for the years ended March 31, 2021 and 2020 was approximately 4.25% and 4.22%, respectively.

Goodwill

Goodwill	12 Months Ended
Goodwill	Mar. 31, 2021
Disclosure of reconciliation of changes in goodwill [abstract]
Goodwill	13. Goodwill Goodwill arising upon business combinations is not amortized but tested for impairment at least annually or more frequently if there is any indication that the cash generating unit to which goodwill is allocated is impaired. The following table presents the changes in goodwill during the years ended March 31, 2021 and 2020: As of March 31, 2021 2020 Opening balance, gross Rs. 20,278 Rs. 20,176 Goodwill arising on business combinations (1) 530 - Effect of translation adjustments 44 102 Impairment loss (2) (16,284 ) (16,284 ) Closing balance Rs. 4,568 Rs. 3,994 (1) Refer to Note 6 of these consolidated financial statements for further details. (2) The impairment loss of Rs.16,284 includes Rs.16,003 pertaining to the Company’s German subsidiary, betapharm Arzneimittel GmbH, which is part of the Company’s Global Generics segment. This impairment loss was recorded for the years ended March 31, 2009 and 2010. For the purpose of impairment testing, goodwill is allocated to a cash generating unit, representing the lowest level within the Company at which goodwill is monitored for internal management purposes and which is not higher than the Company’s operating segment. The carrying amount of goodwill (other than those arising upon investment in a joint venture) was allocated to the cash generating units as follows: As of March 31, 2021 2020 PSAI-Active Pharmaceutical Operations Rs. 997 Rs. 997 Global Generics-Complex Injectables 1,421 1,372 Global Generics-North America Operations 1,015 1,021 Global Generics-Branded Formulations 1,021 491 Other s 114 113 Rs. 4,568 Rs. 3,994 The recoverable amounts of the above cash generating units have been assessed using a value-in-use model. Value in use is generally calculated as the net present value of the projected post-tax cash flows plus a terminal value of the cash generating unit to which the goodwill is allocated. Initially, a post-tax discount rate is applied to calculate the net present value of the post-tax cash flows. Key assumptions upon which the Company has based its determinations of value-in-use include: a) Estimated cash flows for five years, based on management’s projections. b) A terminal value arrived at by extrapolating the last forecasted year cash flows to perpetuity, using a constant long-term growth rate of 0- 2%. This long-term growth rate takes into consideration external macroeconomic sources of data. Such long-term growth rate considered does not exceed that of the relevant business and industry sector. c) The after tax discount rates used are based on the Company’s weighted average cost of capital. d) The after tax discount rates used range from 7.6% to 10.5% for various cash generating units. The pre-tax discount rates range from 9.1% to 15.7%. The Company believes that any reasonably possible change in the key assumptions on which a recoverable amount is based would not cause the aggregate carrying amount to exceed the aggregate recoverable amount of the cash-generating unit.

Other intangible assets

Other intangible assets	12 Months Ended
Other intangible assets	Mar. 31, 2021
Disclosure of detailed information about intangible assets [abstract]
Other intangible assets	14. Other intangible assets The following is a summary of changes in the carrying value of intangible assets: Product Others Total Gross carrying value Balance as of April 1, 2019 Rs. 81,971 Rs. 3,600 Rs. 85,571 Additions 1,641 165 1,806 Disposals/De-recognitions (814 ) (1 ) (815 ) Effect of changes in foreign exchange rates 4,532 2 4,534 Balance as of March 31, 2020 Rs. 87,330 Rs. 3,766 Rs. 91,096 Balance as of April 1, 2020 Rs. 87,330 Rs. 3,766 Rs. 91,096 Additions (1) 6,107 304 6,411 Assets acquired through business combinations (2) 14,888 - 14,888 Disposals/De-recognitions (192 ) - (192 ) Effect of changes in foreign exchange rates (900 ) - (900 ) Balance as of March 31, 2021 Rs. 107,233 Rs. 4,070 Rs. 111,303 Amortization/impairment loss Balance as of April 1, 2019 Rs. 39,577 Rs. 1,627 Rs. 41,204 Amortization for the year 3,554 278 3,832 Impairment loss 16,757 - 16,757 Disposals/De-recognitions (749 ) (1 ) (750 ) Effect of changes in foreign exchange rates 2,392 2 2,394 Balance as of March 31, 2020 Rs. 61,531 Rs. 1,906 Rs. 63,437 Balance as of April 1, 2020 Rs. 61,531 Rs. 1,906 Rs. 63,437 Amortization for the year 3,972 297 4,269 Impairment loss 8,542 - 8,542 Disposals/De-recognitions (192 ) - (192 ) Effect of changes in foreign exchange rates (401 ) - (401 ) Balance as of March 31, 2021 Rs. 73,452 Rs. 2,203 Rs. 75,655 Net carrying value As of April 1, 2019 Rs. 42,394 Rs. 1,973 Rs. 44,367 As of March 31, 2020 Rs. 25,799 Rs. 1,860 Rs. 27,659 As of March 31, 2021 Rs. 33,781 Rs. 1,867 Rs. 35,648 (1) The Company entered into a definitive agreement with Glenmark Pharmaceuticals Limited to acquire marketing authorizations and other rights of select brands in four “Emerging Markets” countries. The acquired brands represent two products, (a) a mometasone mono product and (b) a combination of mometasone with azelastine, and are indicated for the treatment of seasonal and perennial allergic rhinitis. The total consideration paid was Rs.1,516. Following the principles of IAS 38, the Company recognized the acquired brands at their acquisition cost. The acquisition pertains to the Company’s Global Generics segment. (2) Refer to Note 6 of these consolidated financial statements for further details. In-process research and development assets (“IPR&D”) Tabulated below is the reconciliation of amounts relating to in-process research and development assets as at the beginning and at the end of the year: As of March 31, 2021 2020 Opening balance Rs. 10,987 Rs. 24,610 Add (1) 3,557 950 Less (2) - (2,530 ) Less (8,099 ) (13,379 ) Effect of changes in exchange rates (332 ) 1,336 Closing balance Rs. 6,113 Rs. 10,987 (1) During the year ended March 31, 2021, the additions include expenditure During the year ended March 31, 2020, the Company acquired a portfolio of approved, non-marketed Abbreviated New Drug Applications (“ANDAs”) in the United States from Teva for a total consideration of Rs.277. (2) During the year ended March 31, 2020, the product ramelt e Interest capitalization During the years ended March 31, 2021 and 2020, the Company capitalized interest cost of Rs.266 and Rs.674, respectively, with respect to certain qualifying assets. The rate for capitalization of interest cost for the years ended March 31, 2021 and 2020 ranged from 3.95% to 4.74% and from 2.04% to 4.60% respectively. Impairment losses recorded for the year ended March 31, 2021 Total impairment charges for the year ended March 31, 2021 were Rs.8,542 which were recorded in impairment of non-current assets in the consolidated income statement, of which Rs.3,180 was attributable to impairment of gNuvaring, Rs.3,291 was attributable to impairment of Xeglyze® and the balance of Rs.2,071 was attributable to other product related intangibles. Impairment of gNuvaring During the year ended March 31, 2021, there were significant changes to the generics market for Ethinyl estradiol/Ethenogestral vaginal ring (a generic equivalent to Nuvaring®), one of the 8 ANDAs acquired from Teva in June 2016. The changes include the launch by a competitor of a generic version of the product in January 2021. Due to these adverse market developments, the Company tested the carrying value of this product at the product cash generating unit (“CGU”) level, being the smallest identifiable group of assets that generate cash inflows that are largely independent of the cash inflows from other assets or groups of assets. The recoverable amount was determined by reference to the product’s value-in-use or fair value less costs to sell, whichever is higher. This resulted in the value-in-use being the recoverable value of the product. Accordingly, the Company recorded an impairment loss of Rs.3,180 for the year ended March 31, 2021. This impairment loss pertained to the Company’s Global Generics segment. With this impairment, the carrying value of the asset has been reduced to Rs.Nil. Impairment of Xeglyze® Consequent to the decline in the market potential of the product Xeglyze® Rs.3,291 as impairment loss for the year ended March 31, 2021. Other intangible assets With respect to the saxagliptin/metformin (generic version of Kombiglyze®-XR) and phentermine and topiramate (generic version of Qsymia®), two of the 8 ANDAs acquired from Teva in June 2016, there has been a significant decrease in the market potential of these products, primarily due to higher than expected value erosion. Accordingly, the Company assessed the recoverable amount by revisiting market volume, share and price assumptions for these two products and recorded an amount of Rs.1,587 as impairment loss for the year ended March 31, 2021. This impairment loss pertained to the Company’s Global Generics segment. In view of the specific triggers occurring in the year with respect to some other product related intangible assets forming part of the Company's Global Generics segment, the Company determined that there was a decrease in the market potential of these products primarily due to higher than expected price erosion and increased competition leading to lower volumes. Consequently, the Company recorded an amount of Rs.484 as impairment loss for the year ended March 31, 2021. The Company used the discounted cash flow approach to calculate the value-in-use which considered assumptions such as revenue projections, rate of generic penetration, estimated price erosion, the useful life of the asset and the net cash flows have been discounted based on post tax discount rate. Impairment losses recorded for the year ended March 31, 2020 Total impairment charges for the year ended March 31, 2020 were Rs.16,757 which were recorded in impairment of non-current assets in the consolidated income statement, of which Rs.11,137 was attributable to impairment of gNuvaring and the balance of Rs.5,620 was attributable to other product related intangibles. Impairment of gNuvaring During the year ended March 31, 2020, there were significant changes to the generics market for Ethinyl estradiol / Ethenogestral vaginal ring (a generic equivalent to Nuvaring®), one of the 8 ANDAs acquired from Teva in June 2016. The changes include the launches by competitors of both generic and authorized generic versions of the product in December 2019. Due to these adverse market developments, as at December 31, 2019, the Company tested the carrying value of this product at the product cash generating unit (“CGU”) level, being the smallest identifiable group of assets that generate cash inflows that are largely independent of the cash inflows from other assets or groups of assets. The recoverable amount was determined by reference to the product’s value-in-use or fair value less costs to sell, whichever is higher. This resulted in the value-in-use being the recoverable value of the product. Accordingly, the Company recorded an impairment loss of Rs.11,137 for the year ended March 31, 2020. This impairment loss pertained to the Company’s Global Generics segment. The Company used the discounted cash flow approach to calculate the value in use, with the assistance of independent appraisers. The key assumptions considered in the calculation are as follows: a. Weighted average of probability adjusted revenue projections, which take into consideration different scenarios such as the base case, the upside case and the downside case; b. Rate of generic penetration and estimated price erosion throughout the period; c. Estimate of useful life over which the product is expected to generate cash flows; and d. the net cash flows have been discounted based on a post-tax discounting tax rate of 8%. Other intangible assets In June 2019, the Company launched tobramycin inhalation solution, USP, a therapeutic equivalent generic version of TOBI® (tobramycin) Inhalation Solution, and in July 2019 the Company launched ramelteon tablets, 8 mg, a therapeutically equivalent generic version of Rozerem® (ramelteon, 8 mg) Tablets. Subsequent to their respective launches, both products experienced adverse market conditions, such as increased competition and reduced selling prices by competitors. As a result, the performance of the products was significantly lower than the Company’s prior estimates. Furthermore, the Company decided to drop the launch of its planned imiquimod cream product. Accordingly, the Company assessed the recoverable amount of intangible assets associated with these three products, and recognized an impairment loss of Rs.4,385 for the year ended March 31, 2020. These impairment losses pertained to the Company’s Global Generics segment. In view of the specific triggers occurring in the year with respect to some other product related intangible assets forming part of the Company's Global Generics and Proprietary Products segments, the Company determined that there was a decrease in the market potential of these products primarily due to higher than expected price erosion and increased competition leading to lower volumes. Consequently, the Company recorded an amount of Rs.1,235 as impairment loss for the year ended March 31, 2020. Impairment losses recorded for the year ended March 31, 2019 As a result of the Company’s decision to discontinue a few products pertaining to its Global Generics segment, product related intangibles of Rs.116 was recorded as impairment loss for the year ended March 31, 2019 in the consolidated income statement. Consequent to the materiality of the amount involved, these impairment amounts have been disclosed separately in the consolidated income statements . Significant separately acquired intangible assets Details of significant separately acquired intangible assets as of March 31, 2021 are as follows: Particulars of the asset Acquired from Carrying cost Select portfolio of branded generics business Wockhardt Limited Rs. 14,241 Select portfolio of dermatology, respiratory and pediatric assets UCB India Private Limited and affiliates 4,568 Intellectual property rights relating to PPC-06 (tepilamide fumarate) Xenoport, Inc. 4,036 Various ANDAs Teva and an affiliate of Allergan 4,000 Commercialization rights for an anti-cancer biologic agent Eisai Company Limited 1,840 Select Anti-Allergy brands Glenmark Pharmaceuticals Limited 1,487 Habitrol® brand Novartis Consumer Health Inc. 1,181

Investment in equity accounted

Investment in equity accounted investees	12 Months Ended
Investment in equity accounted investees	Mar. 31, 2021
Share of profit (loss) of associates and joint ventures accounted for using equity method [abstract]
Investment in equity accounted investees	15. Investment in equity accounted investees As of March 31, 2021 2020 Equity shares held in Kunshan Rotam Reddy Pharmaceutical Company Limited, China Rs. 3,307 Rs. 2,714 Equity shares held in DRES Energy Private Limited, India 68 49 Rs. 3,375 Rs. 2,763 Details of the Company’s investment in Kunshan Rotam Reddy Pharmaceuticals Company Limited: Kunshan Rotam Reddy Pharmaceuticals Company Limited (“Reddy Kunshan”) is engaged in manufacturing and marketing of finished dosages in China. The Company’s interest in Reddy Kunshan was 51.3% as of March 31, 2021 and 2020. Four directors of the Company are on the board of Reddy Kunshan, which consists of eight directors. Under the terms of the joint venture agreement, all major decisions with respect to operating activities, significant financing and other activities are taken by the approval of at least five of the eight directors of Reddy Kunshan’s board. As the Company does not control Reddy Kunshan’s board and the other partners have significant participation rights, the Company’s interest in Reddy Kunshan has been accounted for under the equity method of accounting. Summary financial information of Reddy Kunshan, as translated into the reporting currency of the Company and not adjusted for the percentage ownership held by the Company, is as follows: As of/for the Year Ended March 31, 2021 2020 2019 Ownership 51.3 % 51.3 % 51.3 % Total current assets Rs. 8,778 Rs. 6,925 Rs. 6,195 Total non-current assets 892 732 374 Total assets Rs. 9,670 Rs. 7,657 Rs. 6,569 Equity Rs. 6,088 Rs. 4,931 Rs. 4,448 Total current liabilities 3,582 2,726 2,121 Total equity and liabilities Rs. 9,670 Rs. 7,657 Rs. 6,569 Revenues Rs. 9,017 Rs. 7,679 Rs. 7,436 Expenses 8,117 6,554 6,558 Profit for the year Rs. 900 Rs. 1,125 Rs. 878 Company’s share of profits for the year Rs. 461 Rs. 577 Rs. 449 Carrying value of the Company’s investment (1) Rs. 3,307 Rs. 2,714 Rs. 2,464 Translation adjustment arising out of translation of foreign currency balances Rs. 438 Rs. 306 Rs. 241 (1) Includes Rs.181 representing the goodwill on acquisition of investment. During the year ended March 31 2020, the Company recognized an amount of Rs.392, representing its share of dividend declared by the equity accounted investee, Reddy Kunshan. The amount of dividend is adjusted against the carrying amount of investment in the consolidated statement of financial position. Details of the Company’s investment in DRES Energy Private Limited: As of/for the Year Ended March 31, 2021 2020 2019 Carrying value of the Company’s investment Rs. 68 Rs. 49 Rs. 65 Company’s share of profits for the year 19 (16 ) (11 )

Trade and other payables

Trade and other payables	12 Months Ended
Trade and other payables	Mar. 31, 2021
Trade and other payables [abstract]
Trade and other payables	16. Trade and other payables Trade and other payables consist of the following: As of March 31, 2021 2020 Trade payables Rs. 12,696 Rs. 10,745 Due to creditors for expenses 5,413 4,503 Due to capital creditors 5,635 1,411 Rs. 23,744 Rs. 16,659 For details regarding the Company’s exposure to currency and liquidity risks, see Note 32 of these consolidated financial statements under “Liquidity risk”.

Loans and borrowings

Loans and borrowings	12 Months Ended
Loans and borrowings	Mar. 31, 2021
Borrowings [abstract]
Loans and borrowings	17. Loans and borrowings Short-term borrowings Short-term borrowings primarily consist of “pre-shipment credit” drawn by the parent company and other unsecured loans drawn by parent company and certain of its subsidiaries in Russia, Brazil, Mexico, Ukraine, Switzerland, the United States and South Africa which are repayable within 6 to 12 months from the date of drawdown. Short-term borrowings consist of the following: As of March 31, 2021 2020 Pre-shipment credit Rs. 10,300 Rs. 10,432 Other working capital borrowings 12,836 6,009 Rs. 23,136 Rs. 16,441 The interest rate profile of short-term borrowings from banks is given below: As of March 31, 2021 2020 Currency (1) Interest Rate (2) Currency (1) Interest Rate (2) Pre-shipment credit INR 3 Months T-bill + 30 bps INR 1 Month T-bill + 60 bps INR 5.75% - - - - U.S.$ 1 Month LIBOR + 12.5 to 16 bps Other working capital borrowings U.S.$ (2.2)% to (1.8)% U.S.$ 1Month/3 Months LIBOR + 55 to 78 bps RUB 3.00% to 3.40% and 5.55% RUB 7.05% MXN TIIE + 1.20% MXN TIIE + 1.25% INR 4.00% INR 7.75% BRL 4.00% BRL 7.25% UAH 4.75% - - - - ZAR 1Month JIBAR+120 bps (1) “INR” means Indian rupees, “U.S.$” means United States Dollars, “RUB” means Russian roubles, “MXN” means Mexican pesos, “UAH” means Ukrainian hryvnia, “BRL” means Brazilian reals and “ZAR” means South African rand. (2) “LIBOR” means the London Inter-bank Offered Rate, “TIIE” means the Equilibrium Inter-banking Interest Rate (Tasa de Interés Interbancaria de Equilibrio), “JIBAR” means the Johannesburg Interbank Average Rate and “T-bill” means India Treasury Bill. Long-term borrowings Long-term borrowings consist of the following: As of March 31, 2021 As of March 31, 2020 Non-current Current Non-current Current Foreign currency borrowing by the parent company Rs. - Rs. - Rs. - Rs. 3,783 Non-convertible debentures by the APSL subsidiary (1) 3,800 - - - Obligations under leases (2) 2,499 864 1,304 483 Rs. 6,299 Rs. 864 Rs. 1,304 Rs. 4,266 (1) “APSL subsidiary” refers to Aurigene Pharmaceutical Services Limited. (2) Additions for the year ended March 31, 2021 include right-of-use liability of Rs.1,878 relating to a warehousing services agreement in the United States. During the year ended March 31, 2021, the APSL subsidiary issued non-convertible debentures for Rs.3,800. The aforesaid non-convertible debentures are repayable at par after 3 years following the date of issue. The interest rate profiles of long-term borrowings (other than obligations under leases) as of March 31, 2021 and 2020 were as follows: As of March 31, 2021 2020 Currency (1) Interest Rate (2) Currency (1) Interest Rate (2) Foreign currency borrowings - - U.S.$ 1 Month LIBOR + 82.7 bps Non-convertible debentures INR 6.77% - - (1) “U.S.$” means United States Dollars and “INR” means Indian rupees. (2) “LIBOR” means the London Inter-bank Offered Rate. The aggregate maturities of long-term loans and borrowings, based on contractual maturities, as of March 31, 2021 were as follows: Maturing in the year ending Non- Obligations Total 2022 Rs. - Rs. 864 Rs. 864 2023 - 802 802 2024 3,800 745 4,545 2025 - 734 734 2026 - 118 118 Thereafter - 100 100 Rs. 3,800 Rs. 3,363 Rs. 7,163 The aggregate maturities of long-term loans and borrowings, based on contractual maturities, as of March 31, 2020 were as follows: Maturing in the year ending March 31, (1) Foreign Obligations Total 2021 Rs. 3,783 Rs. 483 Rs. 4,226 2022 - 359 359 2023 - 267 267 2024 - 249 249 2025 - 286 286 Thereafter - 143 143 Rs. 3,783 Rs. 1,787 Rs. 5,570 (1) Long-term debt obligations disclosed in the above table do not reflect any netting of transaction costs . Uncommitted lines of credit from banks The Company had uncommitted lines of credit of Rs.38,766 and Rs.39,374 as of March 31, 2021 and 2020, respectively, from its banks for working capital requirements. The Company draw upon these lines of credit based on its working capital requirements. Reconciliation of liabilities arising from financing activities during the year ended March 31, 2021: Particulars Long-term (1) Short-term Total Opening balance Rs. 5,570 Rs. 16,441 Rs. 22,011 Recognition of right-of-use liability during the year 2,393 - 2,393 Payment of principal portion of lease liabilities (754 ) - (754 ) Borrowings made during the year 3,800 44,469 48,269 Borrowings repaid during the year (3,743 ) (37,678 ) (41,421 ) Effect of changes in foreign exchange rates (103 ) (96 ) (199 ) Closing balance Rs. 7,163 Rs. 23,136 Rs. 30,299 Reconciliation of liabilities arising from financing activities during the year ended March 31, 2020: Particulars Long-term borrowing (1) Short-term borrowings Total Opening balance Rs. 26,256 Rs. 12,125 Rs. 38,381 Recognition of right-of-use liability on initial application of IFRS 16 1,335 - 1,335 Recognition of right-of-use liability during the year 238 - 238 Payment of principal portion of lease liabilities (482 ) - (482 ) Borrowings made during the year - 29,831 29,831 Borrowings repaid during the year (22,918 ) (25,596 ) (48,514 ) Effect of changes in foreign exchange rates 1,051 81 1,132 Others 90 - 90 Closing balance Rs. 5,570 Rs. 16,441 Rs. 22,011 (1) Includes current portion.

Provisions

Provisions	12 Months Ended
Provisions	Mar. 31, 2021
Disclosure of other provisions [abstract]
Provisions	18. Provisions The details of changes in provisions during the year ended March 31, 2021 are as follows: Particulars Refund (1) Environmental (2) Legal and (3) Total Balance as at beginning of the year Rs. 3,252 Rs. 54 Rs. 548 Rs. 3,854 Provision made during the year, net of reversals 2,934 - 63 2,997 Provision used during the year (3,309 ) - - (3,309 ) Effect of changes in foreign exchange rates (53 ) 4 - (49 ) Balance as at end of the year Rs. 2,824 Rs. 58 Rs. 611 Rs. 3,493 Current Rs. 2,824 Rs. - Rs. 611 Rs. 3,435 Non-current - 58 - 58 Rs. 2,824 Rs. 58 Rs. 611 Rs. 3,493 (1) Refund liability is accounted for by recording a provision based on the Company’s estimate of expected sales returns. See Note 3(l) of these consolidated financial statements for the Company’s accounting policy on refund liability. (2) As a result of the acquisition of a unit of The Dow Chemical Company in April 2008, the Company assumed a liability for contamination of the Mirfield site acquired of Rs.39 (carrying value Rs.58). The seller is required to indemnify the Company for this liability. Accordingly, a corresponding asset has also been recorded in the consolidated statements of financial position. (3) Primarily consists of provision recorded towards the potential liability arising out of a litigation relating to cardiovascular and anti-diabetic formulations. Refer to Note 33 (Contingencies) of these consolidated financial statements under “Product and patent related matters - Matters relating to National Pharmaceutical Pricing Authority - Litigation relating to Cardiovascular and Anti-diabetic formulations” for further details.

Other liabilities

Other liabilities	12 Months Ended
Other liabilities	Mar. 31, 2021
Disclosure of Other Liabilities [Abstract]
Other liabilities	19. Other liabilities Other liabilities consist of the following: As of March 31, 2021 2020 Current Accrued expenses Rs. 17,821 Rs. 18,025 Employee benefits payable 5,607 4,944 Statutory dues payable 2,968 980 Deferred revenue (1) 1,052 1,242 Advance from customers 981 668 Others 2,059 3,523 Rs. 30,488 Rs. 29,382 Non-current Deferred revenue (1) Rs. 1,531 Rs. 1,956 Others 812 850 Rs. 2,343 Rs. 2,806 (1) Refer to Note 22 for details of deferred revenue.

Share Capital

Share Capital	12 Months Ended
Share Capital	Mar. 31, 2021
Disclosure of Share Capital Explanatory [Abstract]
Share Capital	20. Share Capital For the Year Ended For the Year Ended Number Amount Number Amount Authorized share capital 240,000,000 Rs. 1,200 240,000,000 Rs. 1,200 Fully paid up share capital Opening number of equity shares/share capital 166,172,082 Rs. 831 166,065,948 Rs. 830 Add: Equity shares issued pursuant to employee stock option plan (1) 129,149 1 106,134 1 Closing number of equity shares/share capital 166,301,231 Rs. 832 166,172,082 Rs. 831 Treasury shares (2) 575,201 Rs. 1,967 395,950 Rs. 1,006 (1) During the years ended March 31, 2021 and 2020, equity shares were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy’s Employees Stock Option Scheme, 2002 and the Dr. Reddy’s Employees Stock Option Scheme, 2007. The options exercised had an exercise price of Rs.5, Rs.2,607 or Rs.2,814 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the "share based payment reserve”was transferred to“share premium” in the consolidated statements of changes in equity. (2) Pursuant to the special resolution approved by the shareholders in the Annual General Meeting held on July 27, 2018, the Dr. Reddy’s Employees ESOS Trust (the “ESOS Trust”) was formed to support the Dr. Reddy’s Employees Stock Option Scheme, 2018 by acquiring, from the Company or through secondary market acquisitions, equity shares which are used for issuance to eligible employees (as defined therein) upon exercise of stock options thereunder. During the years ended March 31, 2021 and 2020, an aggregate of 85,250 and 1,150 equity shares, respectively were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy’s Employees Stock Option Scheme, 2018. The options exercised had an exercise price of Rs.2,607 or Rs.2,814 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the “share based payment reserve” was transferred to “share premium” in the consolidated statements of changes in equity.In addition, any difference between the carrying amount of treasury shares and the consideration received was recognized in the “share premium”. As of March 31, 2021 and 2020, the ESOS Trust had outstanding 575,201 and 395,950 shares, respectively, which it purchased from the secondary market for an aggregate consideration of Rs.1,967 and Rs.1,006, respectively. Refer to Note 29 of these consolidated financial statements for further details on the Dr. Reddy’s Employees Stock Option Scheme, 2018. The Company has only one class of equity shares having a par value of Rs.5 per share. For all matters submitted to vote in a shareholders meeting of the Company, every holder of an equity share, as reflected in the records of the Company as on the record date set for the shareholders meeting, shall have one vote in respect of each share held. Should the Company declare and pay any dividends, such dividends will be paid in Indian rupees to each holder of equity shares in proportion to the number of shares held to the total equity shares outstanding as on that date. Indian law on foreign exchange governs the remittance of dividends outside India. In the event of liquidation of the Company, all preferential amounts, if any, shall be discharged by the Company. The remaining assets of the Company shall be distributed to the holders of equity shares in proportion to the number of shares held to the total equity shares outstanding as on that date . Final dividends on equity shares (including dividend tax on distribution of such dividends, if any) are recorded as a liability on the date of their approval by the shareholders and interim dividends are recorded as a liability on the date of declaration by the Company’s Board of Directors. The details of dividends paid by the Company are as follows: For the Year Ended March 31, 2021 2020 2019 Dividend per share (in absolute Rs.) Rs. 25 Rs. 20 Rs. 20 Dividend distribution tax on the dividend paid - 602 682 Dividend paid during the year 4,147 3,314 3,320 Proposed dividend At the Company’s Board of Directors’ meeting held on May 14, 2021, the Board proposed a dividend of Rs.25 per share and aggregating to Rs.4,158, which is subject to the approval of the Company’s shareholders.

Earnings per share

Earnings per share	12 Months Ended
Earnings per share	Mar. 31, 2021
Basic and diluted earnings per share [abstract]
Earnings per share	21. Earnings per share The calculation of basic and diluted earnings per share for the years ended March 31, 2021, 2020 and 2019 was based on the profit attributable to equity shareholders of the Company, being Rs.17,238, Rs.19,498 and Rs.18,795, respectively . The weighted average number of equity shares outstanding, used for calculating the basic earnings per share, are as follows: For the Year Ended March 31, 2021 2020 2019 Number of equity shares at the beginning of the year (excluding treasury shares) 165,776,132 165,847,972 165,910,907 Effect of treasury shares held during the year (56,014 ) (154,020 ) (100,672 ) Effect of equity shares issued on exercise of stock options 124,222 64,432 103,801 Weighted average number of equity shares – Basic 165,844,340 165,758,384 165,914,036 Earnings per share of par value Rs.5 – Basic Rs. 103.94 Rs. 117.63 Rs. 113.28 The weighted average number of equity shares outstanding, used for calculating the diluted earnings per share, are as follows: For the Year Ended March 31, 2021 2020 2019 Weighted average number of equity shares – Basic 165,844,340 165,758,384 165,914,036 Dilutive effect of stock options outstanding (1) 471,701 323,601 278,718 Weighted average number of equity shares – Diluted 166,316,041 166,081,985 166,192,754 Earnings per share of par value Rs.5 – Diluted Rs. 103.65 Rs. 117.40 Rs. 113.09 (1) As of March 31, 2021 and 2020, 235,460 and 475,575 options, respectively, were excluded from the diluted weighted average number of equity shares calculation because their effect would have been anti-dilutive. The average market value of the Company’s shares for the purpose of calculating the dilutive effect of stock options was based on quoted market prices for the year during which the options were outstanding.

Revenue from contracts with cus

Revenue from contracts with customers and trade receivables	12 Months Ended
Revenue from contracts with customers and trade receivables	Mar. 31, 2021
Revenue [abstract]
Revenue from contracts with customers and trade receivables	22. Revenue from contracts with customers and trade receivables Revenue from contracts with customers: For the Year Ended March 31, 2021 2020 2019 Sales Rs. 184,202 Rs. 163,574 Rs. 148,706 Service income 4,105 2,409 2,129 License fees (1)(2) 1,415 8,617 3,016 Rs. 189,722 Rs. 174,600 Rs. 153,851 (1) During the year ended March 31, 2020, the Company entered into a definitive agreement with Upsher-Smith Laboratories, LLC for the sale of its U.S. and select territory rights for ZEMBRACE ® ® ® (2) License fees for the year ended March 31, 2019 primarily includes out-licensing revenue of Rs.1,807 from Encore Dermatology Inc . Analysis of revenues by segments: For the Year Ended March 31, Segment 2021 2020 2019 Global Generics Rs. 154,404 Rs. 138,123 Rs. 122,903 PSAI 31,982 25,747 24,140 Proprietary products 523 7,949 4,750 Others 2,813 2,781 2,058 Rs. 189,722 Rs. 174,600 Rs. 153,851 Analysis of revenues within the Global Generics segment: An analysis of revenues by therapeutic areas in the Company’s Global Generics segment is given below: For the Year Ended March 31, 2021 2020 2019 Nervous System Rs. 29,040 Rs. 26,825 Rs. 19,726 Gastrointestinal 21,132 19,394 19,250 Oncology 16,842 18,245 18,357 Cardiovascular 15,460 14,729 15,106 Pain Management 15,531 13,808 13,806 Anti-Infective 12,906 9,402 7,073 Respiratory 11,089 10,433 8,130 Others 32,404 25,287 21,455 Tota l Rs. 154,404 Rs. 138,123 Rs. 122,903 Analysis of revenues within the PSAI segment: An analysis of revenues by therapeutic areas in the Company’s PSAI segment is given below: For the Year Ended March 31, 2021 2020 2019 Cardiovascular Rs. 9,834 Rs. 8,567 Rs. 7,019 Pain Management 4,657 5,073 3,364 Anti-Infective 4,126 2,264 1,247 Nervous System 2,704 2,797 2,741 Oncology 2,385 1,798 2,212 Dermatology 768 1,370 1,622 Others 7,508 3,878 5,935 Tota l Rs. 31,982 Rs. 25,747 Rs. 24,140 Analysis of revenues by geography: The following table shows the distribution of the Company’s revenues by country, based on the location of the customers: For the Year Ended March 31, Country 2021 2020 2019 India Rs. 36,252 Rs. 32,089 Rs. 28,804 United States 76,702 76,028 69,299 Russia 15,816 16,900 15,299 Others (1) 60,952 49,583 40,449 Rs. 189,722 Rs. 174,600 Rs. 153,851 (1) Others include Germany, the United Kingdom, Ukraine, China, Canada and other countries across the world. Information about major customers Revenues from two customers of the Company's Global Generics segment were Rs.19,341 and Rs.9,867, representing approximately 10% and 5%, respectively, of the Company’s total revenues for the year ended March 31, 2021. Revenues from two customers of the Company's Global Generics segment were Rs.14,164 and Rs.9,267, representing approximately 8% and 5%, respectively, of the Company’s total revenues for the year ended March 31, 2020. Revenues from two customers of the Company's Global Generics segment were Rs.10,639 and Rs.10,024, each representing approximately 7% of the Company’s total revenues for the year ended March 31, 2019 . Details of deferred revenue: Tabulated below is the reconciliation of deferred revenue for the years ended March 31, 2021 and 2020. For the Year Ended March 31, 2021 2020 Balance as of April 1 Rs. 3,198 Rs. 2,592 Revenue recognized during the year (1,089 ) (1,250 ) Milestone payment received during the year 474 1,856 Balance as of March 31 Rs. 2,583 Rs. 3,198 Current 1,052 1,242 Non-current 1,531 1,956 Details of significant gross to net adjustments relating to Company’s North America Generics business (amounts in U.S.$ millions) A roll-forward for each major accrual for the Company’s North America Generics business for the fiscal years ended March 31, 2019, 2020 and 2021 is as follows: Particulars Chargebacks Rebates Medicaid Refund Liability (3) (All values in U.S.$ millions) Beginning Balance: April 1, 2018 170 161 12 28 Current provisions relating to sales during the year 1,415 461 18 29 Provisions and adjustments relating to sales in prior years * - - - Credits and payments** (1,457 ) (530 ) (19 ) (27 ) Ending Balance: March 31, 2019 128 92 11 30 Beginning Balance: April 1, 2019 128 92 11 30 Current provisions relating to sales during the year ( 1 1,468 319 20 21 Provisions and adjustments relating to sales in prior years * - - - Credits and payments** (1,440 ) (331 ) (20 ) (27 ) Ending Balance: March 31, 2020 156 80 11 24 Beginning Balance: April 1, 2020 156 80 11 24 Current provisions relating to sales during the year ( 2 1,702 245 21 15 Provisions and adjustments relating to sales in prior years * - - - Credits and payments** (1,656 ) (247 ) (19 ) (20 ) Ending Balance: March 31, 2021 202 78 13 19 * Currently, the Company does not separately track provisions and adjustments, in each case to the extent relating to prior years for chargebacks. However, the adjustments are expected to be non-material. The volumes used to calculate the closing balance of chargebacks represent approximately 1.3 months equivalent of sales, which corresponds to the pending chargeback claims yet to be processed. ** Currently, the Company does not separately track the credits and payments, in each case to the extent relating to prior years for chargebacks, rebates, medicaid payments or refund liability. ( 1 Chargebacks provisions for the year ended March 31, 2020 were higher compared to the year ended March 31, 2019, primarily as a result of higher sales volumes, which were partially offset due to a lower pricing rates per unit for chargebacks. Such lower pricing was primarily on account of a reduction in the invoice price to wholesalers for certain of the Company’s products. The chargebacks payments for the year ended March 31, 2020 were lower compared to the year ended March 31, 2019, primarily as a result of higher pending chargebacks claims at March 31, 2020 as compared to March 31, 2019. The rebates provisions and the payments for the year ended March 31, 2020 were each lower as compared to the year ended March 31, 2019, primarily as a result of lower pricing rates per unit for rebates, due to a reduction in the invoice price to wholesalers for certain of the Company’s products, which were partially offset by higher sales volumes during the year ended March 31, 2020 as compared to the year ended March 31, 2019. (2) Chargebacks provisions and payments for the year ended March 31, 2021 were each higher as compared to the year ended March 31, 2020, primarily as a result of higher sales volumes and also due to higher pricing rates per unit for chargebacks, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company’s products. The rebates provisions and payments for the year ended March 31, 2021 were each lower as compared to the year ended March 31, 2020, primarily as a result of lower pricing rates per unit for rebates, due to a reduction in the invoice price to wholesalers for certain of the Company’s products and also due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company’s products, which were partially off-set by higher sales volumes during the year ended March 31, 2021 as compared to the year ended March 31, 2020. (3) The Company’s overall refund liability as of March 31, 2021 relating to its North America Generics business was U.S.$19, as compared to a liability of U.S.$24 as of March 31, 2020. This decrease in the Company’s liability was primarily attributable to a lower refund liability allowance for the year ended March 31, 2021 as compared to the year ended March 31, 2020. Such allowance change was primarily due to certain product mix changes and recent trends in actual sales returns, together with the Company’s historical experience and also the price reduction for certain products resulting into lower refund liability to be carried. The estimates of “gross-to-net” adjustments for the Company’s operations in India and other countries outside of the United States relate mainly to refund liability in all such operations, and certain rebates to healthcare insurance providers are specific to the Company’s German operations. The pattern of such refund liability is generally consistent with the Company’s gross sales. In Germany, the rebates to healthcare insurance providers mentioned above are contractually fixed in nature and do not involve significant estimations by the Company . Details of refund liabilities: For the Year Ended March 31, 2021 2020 Balance at the beginning of the year Rs. 3,252 Rs. 3,581 Provision made during the year, net of reversals 2,934 2,675 Provision used during the year (3,309 ) (3,224 ) Effect of changes in foreign exchange rates (53 ) 220 Balance at the closing of the year Rs. 2,824 Rs. 3,252 Current Rs. 2,824 Rs. 3,252 Non-current - - Details of contract asset: As mentioned in the accounting policies for refund liability set forth in Note 3.l. of these consolidated financial statements, the Company recognizes an asset (i.e., the right to the returned goods), which is included in inventories, for the products expected to be returned. The Company initially measures this asset at the former carrying amount of the inventory, less any expected costs to recover the goods, including any potential decreases in the value of the returned goods. Along with re-measuring the refund liability at the end of each reporting period, the Company updates the measurement of the asset recorded for any revisions to its expected level of returns, as well as any additional decreases in the value of the returned products. As of March 31, 2021 and 2020, the Company had Rs.37 and Rs.23, respectively, as contract assets representing the right to returned goods. Details of contract liabilities As of March 31, 2021 2020 Advance from customers Rs. 981 Rs. 668 Rs. 981 Rs. 668

Other income, net

Other income, net	12 Months Ended
Other income, net	Mar. 31, 2021
Other operating income expense [Abstract]
Other income, net	23. Other income, net Other income, net consists of the following: For the Year Ended March 31, 2021 2020 2019 Loss/(gain) on sale/disposal of non-current assets, net (1) Rs. 42 Rs. 10 Rs. (1,264 ) Sale of spent chemicals (270 ) (306 ) (356 ) Scrap sales (142 ) (167 ) (179 ) Miscellaneous income, net (2) (612 ) (3,827 ) (156 ) Rs. (982 ) Rs. (4,290 ) Rs. (1,955 ) (1) Gain on disposal of assets for the year ended March 31, 2019 includes: a) an amount of Rs.582 representing the profit on sale of intangible assets forming part of the Company’s Proprietary Products segment after adjusting associated cost; b) an amount of Rs.423 representing the profit on sale of an API manufacturing business unit located in Jeedimetla, Hyderabad; and c) an amount of Rs.110 representing the profit on sale of all the membership interests in Dr. Reddy’s Laboratories Tennessee, LLC. (2) Miscellaneous income, net includes Rs.3,457 received from Celgene pursuant to a settlement agreement entered into in April 2019. The agreement effectively settles any claim the Company or its affiliates may have had for damages under section 8 of the Canadian Patented Medicines (Notice of Compliance) Regulations in regard to the Company’s ANDS for a generic version of REVLIMID® brand capsules (Lenalidomide) pending before Health Canada.

Finance income, net

Finance income, net	12 Months Ended
Finance income, net	Mar. 31, 2021
Finance expense income [Abstract]
Finance income, net	24. Finance income, net Finance income, net consists of the following: For the Year Ended March 31, 2021 2020 2019 Interest income Rs. 826 Rs. 888 Rs. 770 Fair value changes and profit on sale of units of mutual funds, net 557 929 773 Foreign exchange gain 1,240 639 737 Miscellaneous income, net - * 5 - Finance income (A) Rs. 2,623 Rs. 2,461 Rs. 2,280 Interest expense Rs. (970 ) Rs. (983 ) Rs. (889 ) Foreign exchange loss - - (274 ) Finance expense (B) Rs. (970 ) Rs. (983 ) Rs. (1,163 ) Finance income, net [(A)+(B)] Rs. 1,653 Rs. 1,478 Rs. 1,117 * Rounded to the nearest million.

Income taxes

Income taxes	12 Months Ended
Income taxes	Mar. 31, 2021
Disclosure of income tax [Abstract]
Income taxes	25. Income taxes a. Income tax expense/(benefit) recognized in the consolidated income statement Income tax expense/(benefit) recognized in the consolidated income statement consists of the following: For the Year Ended March 31, 2021 2020 2019 Current taxes Domestic Rs. 5,849 Rs. 5,157 Rs. 3,003 Foreign 2,323 1,459 1,707 Rs. 8,172 Rs. 6,616 Rs. 4,710 Deferred taxes Domestic Rs. 2,736 Rs. (6,580 ) Rs. 244 Foreign (1,733 ) (1,502 ) (1,306 ) Rs. 1,003 Rs. (8,082 ) Rs. (1,062 ) Tax expense/(benefit), net Rs. 9,175 Rs. (1,466 ) Rs. 3,648 b. Income tax expense/(benefit) recognized directly in equity Income tax expense/(benefit) recognized directly in equity consists of the following: For the Year Ended March 31, 2021 2020 2019 Tax effect on changes in fair value of other investments Rs. 293 Rs. - Rs. 411 Tax effect on foreign currency translation differences - - (14 ) Tax effect on effective portion of change in fair value of cash flow hedges 319 (232 ) 69 Tax effect on actuarial gains/losses on defined benefit obligations (73 ) 22 3 Rs. 539 Rs. (210 ) Rs. 469 c. Reconciliation of effective tax rate The following is a reconciliation of the Company’s effective tax rates for the years ended March 31, 2021, 2020 and 2019: For the Year Ended March 31, 2021 2020 2019 Profit before income taxes Rs. 26,413 Rs. 18,032 Rs. 22,443 Enacted tax rate in India 34.94 % 34.94 % 34.94 % Computed expected tax expense Rs. 9,229 Rs. 6,301 Rs. 7,842 Effect of: Differences between Indian and foreign tax rates Rs. 810 Rs. 3,385 Rs. (734 ) Unrecognized deferred tax assets/(recognition of previously unrecognized deferred tax assets, net) 1,220 (6,478 ) 482 Expenses not deductible for tax purposes 230 155 340 Reversal of earlier years’ tax provisions - - (282 ) Income exempt from income taxes (1,807 ) (1,029 ) (1,282 ) Foreign exchange differences (18 ) (64 ) (470 ) Incremental deduction allowed for research and development costs (1) - (1,241 ) (1,134 ) Tax expense on distributed/undistributed earnings of subsidiary outside India - 254 - Write off of accounts receivables - - (1,294 ) Income from sale of capital assets - (2,620 ) - Effect of change in tax rate (333 ) (37 ) 3 Others (156 ) (92 ) 177 Income tax expense/(benefit) Rs. 9,175 Rs. (1,466 ) Rs.3,648 Effective tax rate 35 % (8 )% 16 % (1) India’s Finance Act, 2016 incorporated an amendment that reduc e . The Company’s effective tax rate for the year ended March 31, 202 1 higher 0 · de-recognition of deferred tax asset during the year ended March 31, 2021 due to non-availability of depreciation on goodwill pursuant to an amendment to section 2(11) of the Income Tax Act in the Finance Act, 2021; · recognition of a deferred tax asset related to the Minimum Alternate Tax (“MAT”) credits and planned restructuring activity between companies of our group during the year ended March 31, 2020; · weighted deduction on eligible research and development expenditure in Dr. Reddy’s Laboratories Limited, India for the year ended March 31, 2020; and · income from sale of capital assets during the year ended March 31, 2020, which was set off against the carried forward capital loss . d. Unrecognized deferred tax assets The details of unrecognized deferred tax assets are summarized below: As of March 31, 2021 2020 Deductible temporary differences, net Rs. 738 Rs. 394 Operating tax loss carry-forward 4,742 3,926 Rs. 5,480 Rs. 4,320 During the year ended March 31, 2021, the Company recognized deferred tax assets on operating tax losses pertaining primarily to Dr. Reddy’s Laboratories New York, Inc. as the Company believes that it is probable that there will be available taxable profits against which such tax losses can be utilized. During the year ended March 31, 2021, the Company did not recognize deferred tax assets on operating tax losses and other deductible temporary differences pertaining primarily to Dr. Reddy’s Laboratories SA, Switzerland and Dr. Reddy’s Research and Development B.V., Netherlands. Deferred income taxes are not provided on undistributed earnings of Rs.19,543 and Rs.22,988 as of March 31, 2021 and 2020, respectively of subsidiaries, where it is expected that earnings of the subsidiaries will not be distributed in the foreseeable future. Generally, the Company indefinitely reinvests all of the accumulated undistributed earnings of subsidiaries, and accordingly, has not recorded any deferred taxes in relation to such undistributed earnings of its subsidiaries. e. Deferred tax assets and liabilities The tax effects of significant temporary differences that resulted in deferred tax assets and liabilities and a description of the items that created these differences is given below: As of March 31, 2021 2020 Deferred tax assets/(liabilities): Inventory Rs. 3,997 Rs. 3,216 Minimum Alternate Tax* 4,748 6,246 Trade and other receivables 569 369 Operating/other tax loss carry-forward 2,593 3,399 Other current assets and other current liabilities, net 1,404 1,448 Property, plant and equipment (2,547 ) (2,361 ) Other intangible assets (283 ) (477 ) Others (189 ) 99 Net deferred tax assets Rs. 10,292 Rs. 11,939 * As per Indian tax laws, companies are liable for a Minimum Alternate Tax (“MAT”) when current tax, as computed under the provisions of the Income Tax Act, 1961 (“Tax Act”), is determined to be below the MAT computed under section 115JB of the Tax Act. If in any year the Company pays a MAT, then it is entitled to claim credit of the MAT paid over and above the normal tax liability in the subsequent years. The MAT credit is eligible to be carried forward and set-off in the future against the current tax liabilities over a period of 15 years starting from the succeeding fiscal year in which such credit was generated. In assessing whether the deferred income tax assets will be realized, management considers whether some portion or all of the deferred income tax assets will not be realized. The ultimate realization of the deferred income tax assets and tax loss carry-forwards is dependent upon the generation of future taxable income during the periods in which the temporary differences become deductible. Management considers the scheduled reversals of deferred tax liabilities, projected future taxable income and tax planning strategy in making this assessment. Based on the level of historical taxable income and projections of future taxable income over the periods in which the deferred tax assets are deductible, management believes that the Company will realize the benefits of those recognized deductible differences and tax loss carry-forwards. Recoverability of deferred tax assets is based on estimates of future taxable income. Any changes in such future taxable income would impact the recoverability of deferred tax assets. Operating loss carry-forward consists of business losses, unabsorbed depreciation and unabsorbed interest carry-forwards. A portion of this total loss can be carried indefinitely and the remaining amounts expire at various dates ranging from 2022 through 2037. f. Movement in deferred tax assets and liabilities during the years ended March 31, 2021 and 2020 As of March 31, Recognized in Recognized in As of March 31, Deferred tax assets/(liabilities): Inventory Rs. 3,216 Rs. 781 Rs. - Rs. 3,997 Minimum Alternate Tax 6,246 (1,498 ) - 4,748 Trade and other receivables 369 200 - 569 Operating/other tax loss carry-forward 3,399 (806 ) - 2,593 Other current assets and other current liabilities, net 1,448 (44 ) - 1,404 Property, plant and equipment (2,361 ) (187 ) - (2,548 ) Other intangible assets (477 ) 194 - (283 ) Others 99 252 (539 ) (188 ) Net deferred tax assets Rs. 11,939 Rs. (1,108 ) Rs. (539 ) Rs. 10,292 The details of movement in deferred tax assets and liabilities are summarized below: As of March 31, Recognized in Recognized in As of March 31, Deferred tax assets/(liabilities): Inventory Rs. 3,285 Rs. (69 ) Rs. - Rs. 3,216 Minimum Alternate Tax 1,630 4,616 - 6,246 Trade and other receivables: 316 53 - 369 Operating/other tax loss carry-forward 297 3,102 - 3,399 Other current assets and other current liabilities, net 1,315 133 - 1,448 Property, plant and equipment (2,665 ) 304 - (2,361 ) Other intangible assets (662 ) 185 - (477 ) Others 42 (153 ) 210 99 Net deferred tax assets Rs. 3,558 Rs. 8,171 Rs. 210 Rs. 11,939 The amounts recognized in the consolidated income statement for the years ended March 31, 2021 and 2020 include Rs.(105) and Rs.89, respectively, which represent exchange differences arising due to foreign currency translations . g. Uncertain tax positions The Company is contesting various disallowances by the Indian Income Tax authorities. The associated tax impact for disallowances being more likely than not to be accepted by Tax authorities is Rs.2,291, and accordingly, no provision is made in these consolidated financial statements as of March 31, 2021. During the years ended March 31, 2014, 2015 and 2016, Industrias Quimicas Falcon de Mexico, S.A. de CV, a wholly-owned subsidiary of the Company in Mexico, received a notice from Mexico's Tax Administration Service, Servicio de Administracion Tributaria

Nature of Expense

Nature of Expense	12 Months Ended
Nature of Expense	Mar. 31, 2021
Expenses by nature [abstract]
Nature of Expense	26. Nature of Expense The following table shows supplemental information related to certain “nature of expense” items for the years ended March 31, 2021, 2020 and 2019: For the Year Ended March 31, Employee benefits 2021 2020 2019 Cost of revenues Rs. 11,529 Rs. 10,643 Rs. 10,644 Selling, general and administrative expenses 20,052 18,658 18,291 Research and development expenses 4,718 4,501 4,627 Rs. 36,299 Rs. 33,802 Rs. 33,562 For the Year Ended March 31, Depreciation 2021 2020 2019 Cost of revenues Rs. 6,061 Rs. 6,366 Rs. 6,484 Selling, general and administrative expenses 1,491 1,294 801 Research and development expenses 975 980 1,077 Rs. 8,527 Rs. 8,640 Rs. 8,362 For the Year Ended March 31, Amortization 2021 2020 2019 Cost of revenues Rs. - Rs. 175 Rs. 284 Selling, general and administrative expenses 4,171 3,547 3,421 Research and development expenses 98 110 123 Rs. 4,269 Rs. 3,832 Rs. 3,828 In addition, for details relating to costs of material consumed, refer to Note 10 of these consolidated financial statements.

Operating leases

Operating leases	12 Months Ended
Operating leases	Mar. 31, 2021
Disclosure Of Finance Leases And Operating Leases By Lessee [Abstract]
Disclosure Of Operating Lease By Lessee Explanatory	27. Operating leases The Company has leased offices and vehicles under various operating lease agreements that are renewable on a periodic basis at the option of both the lessor and the lessee. Rental expense under these leases was Rs.905 for the year ended March 31, 2019. The schedule of future minimum rental payments in respect of non-cancellable operating leases is set out below: As of March 31, 2021 2020 2019 Less than one year Rs. - Rs. - Rs. 405 Between one and five years - - 797 More than five years - - 89 Rs. - Rs. - Rs. 1,291 Commencing April 1, 2019, upon adoption of IFRS 16, majority of leases for which the Company is a lessee are recognized as a lease liability with corresponding right-of-use assets recognized in the statement of financial position. Upon adoption of the new standard, a portion of the annual operating lease costs, which was previously fully recognized as a functional expense, is recorded as interest expense.

Employee benefits

Employee benefits	12 Months Ended
Employee benefits	Mar. 31, 2021
Disclosure of defined benefit plans [abstract]
Employee benefits	28. Employee benefits Total employee benefit expenses, including share-based payments, incurred during the years ended March 31, 2021, 2020 and 2019 amounted to Rs.36,299, Rs.33,802 and Rs.33,562, respectively. Gratuity benefits provided by the parent company In accordance with applicable Indian laws, the Company has a defined benefit plan which provides for gratuity payments (the “Gratuity Plan”) and covers certain categories of employees in India. The Gratuity Plan provides a lump sum gratuity payment to eligible employees at retirement or termination of their employment. The amount of the payment is based on the respective employee’s last drawn salary and the years of employment with the Company. Effective September 1, 1999, the Company established the Dr. Reddy’s Laboratories Gratuity Fund (the “Gratuity Fund”) to fund the Gratuity Plan. Liabilities in respect of the Gratuity Plan are determined by an actuarial valuation, based upon which the Company makes contributions to the Gratuity Fund. Trustees administer the contributions made to the Gratuity Fund. Amounts contributed to the Gratuity Fund are invested in bonds issued by the Government of India and in debt securities and equity securities of Indian companies. The components of gratuity cost recognized in the income statement for the years ended March 31, 2021, 2020 and 2019 consist of the following: For the Year Ended March 31, 2021 2020 2019 Current service cost Rs. 281 Rs. 276 Rs. 265 Interest on defined benefit liability 8 (4 ) (2 ) Gratuity cost recognized in income statement Rs. 289 Rs. 272 Rs. 263 Details of the employee benefits obligations and plan assets are provided below: As of March 31, 2021 2020 Present value of funded obligations Rs. 2,628 Rs. 2,349 Fair value of plan assets (1,997 ) (2,160 ) Net defined benefit liability recognized Rs. 631 Rs. 189 Details of changes in the present value of defined benefit obligations are as follows: As of March 31, 2021 2020 Defined benefit obligations at the beginning of the year Rs. 2,349 Rs. 2,200 Current service cost 281 276 Interest on defined obligations 140 152 Re-measurements due to: Actuarial loss/(gain) due to change in financial assumptions 153 (96 ) Actuarial loss/(gain) due to demographic assumptions (26 ) (48 ) Actuarial loss/(gain) due to experience changes 51 59 Benefits paid (345 ) (194 ) Liabilities assumed/(transferred) (1) 25 - Defined benefit obligations at the end of the year Rs. 2,628 Rs. 2,349 (1) a) Rs.70 increase in liabilities on account of the acquisition of employees pursuant to the Business Transfer Agreement with Wockhardt Limited. Refer to Note 6 of these consolidated financial statements for further details. b) Rs.45 transfer of liabilities on account of a restructuring of the pharmaceutical services business between the parent company and its subsidiary . Details of changes in the fair value of plan assets are as follows: As of March 31, 2021 2020 Fair value of plan assets at the beginning of the year Rs. 2,160 Rs. 2,174 Employer contributions 25 14 Interest on plan assets 132 156 Re-measurements due to: Return on plan assets excluding interest on plan assets (1 ) 10 Benefits paid (345 ) (194 ) Assets acquired/(transferred) (1) 26 - Plan assets at the end of the year Rs. 1,997 Rs. 2,160 (1) a) Rs.70 increase in assets on account of the acquisition of employees pursuant to the Business Transfer Agreement with Wockhardt Limited. Refer to Note 6 of these consolidated financial statements for further details . b) Rs.44 transfer of assets on account of a restructuring of the pharmaceutical services business between the parent company and its subsidiary . Sensitivity Analysis: As of Defined benefit obligation without effect of projected salary growth Rs. 1,795 Add: Effect of salary growth 833 Defined benefit obligation with projected salary growth 2,628 Defined benefit obligation, using discount rate minus 50 basis points 2,700 Defined benefit obligation, using discount rate plus 50 basis points 2,559 Defined benefit obligation, using salary growth rate plus 50 basis points 2,698 Defined benefit obligation, using salary growth rate minus 50 basis points 2,560 Summary of the actuarial assumptions: The assumptions used to determine benefit obligations: For the Year Ended March 31, 2021 2020 2019 Discount rate 6.00 % 6.65 % 7.45 % Rate of compensation increase 8.00 % 7.50 % 8% per annum for the first year and 9% per annum thereafter The assumptions used to determine gratuity cost: For the Year Ended March 31, 2021 2020 2019 Discount rate 6.65 % 7.45 % 7.75 % Rate of compensation increase 7.50 % 8% per annum for the first year and 9% per annum thereafter 7% per annum for the first year and 9% per annum thereafter Contributions: Disaggregation of plan assets: As of March 31, 2021 2020 Funds managed by insurers 100 % 99 % Others - 1 % The expected future cash flows in respect of gratuity as of March 31, 2021 were as follows: Expected contribution Amount During the year ended March 31, 2022 (estimated) Rs. 317 Expected future benefit payments March 31, 2022 452 March 31, 2023 390 March 31, 2024 361 March 31, 2025 339 March 31, 2026 308 Thereafter 1,971 Pension plan of the Company’s subsidiary, Industrias Quimicas Falcon de Mexico All employees of the Company’s Mexican subsidiary, Industrias Quimicas Falcon de Mexico (“Falcon”), are entitled to a pension benefit in the form of a defined benefit pension plan. The Falcon pension plan provides for payment to vested employees at retirement or termination of employment. Liabilities in respect of the pension plan are determined by an actuarial valuation, based on which the Company makes contributions to the pension plan fund. This fund is administered by a third party, who is provided guidance by a technical committee formed by senior employees of Falcon . The components of net pension cost recognized in the income statement for the years ended March 31, 2021, 2020 and 2019 consist of the following: For the Year Ended March 31, 2021 2020 2019 Current service cost Rs. 13 Rs. 11 Rs. 13 Interest on defined benefit liability 8 16 15 Total cost recognized in income statement Rs. 21 Rs. 27 Rs. 28 Details of the employee benefits obligations and plan assets are provided below: As of March 31, 2021 2020 Present value of funded obligations Rs. 307 Rs. 234 Fair value of plan assets (169 ) (128 ) Net defined benefit liability recognized Rs. 138 Rs. 106 Details of changes in the present value of defined benefit obligations are as follows: As of March 31, 2021 2020 Defined benefit obligations at the beginning of the year Rs. 234 Rs. 223 Current service cost 13 11 Interest on defined obligations 21 25 Re-measurements due to: Actuarial loss/(gain) due to change in financial assumptions 24 50 Actuarial loss/(gain) due to experience changes 19 (8 ) Benefits paid (32 ) (41 ) Foreign exchanges differences 28 (26 ) Defined benefit obligations at the end of the year Rs. 307 Rs. 234 Details of changes in the fair value of plan assets are as follows: As of March 31, 2021 2020 Fair value of plan assets at the beginning of the year Rs. 128 Rs. 70 Employer contributions 32 113 Interest on plan assets 13 9 Re-measurements due to: Return on plan assets excluding interest on plan assets 12 (7 ) Benefits paid (32 ) (41 ) Foreign exchanges differences 16 (16 ) Plan assets at the end of the year Rs. 169 Rs. 128 Sensitivity Analysis: As of March 31, 2021 Defined benefit obligation without effect of projected salary growth Rs. 209 Add: Effect of salary growth 98 Defined benefit obligation with projected salary growth 307 Defined benefit obligation, using discount rate minus 50 basis points 321 Defined benefit obligation, using discount rate plus 50 basis points 294 Defined benefit obligation, using salary growth rate plus 50 basis points 321 Defined benefit obligation, using salary growth rate minus 50 basis points 294 Summary of the actuarial assumptions: The assumptions used to determine benefit obligations: For the Year Ended March 31, 2021 2020 2019 Discount rate 7.75 % 8.75 % 11.25 % Rate of compensation increase 4.50 % 4.50 % 4.50 % The assumptions used to determine defined benefit cost: For the Year Ended March 31, 2021 2020 2019 Discount rate 8.75 % 11.25 % 9.00 % Rate of compensation increase 4.50 % 4.50 % 4.50 % Contributions: Disaggregation of plan assets: As of March 31, 2021 2020 Funds managed by insurers 51 % 51 % Others 49 % 49 % The expected future cash flows in respect of post-employment benefit plans in Mexico as of March 31, 2021 were as follows: Expected contribution Amount During the year ended March 31, 2022 (estimated) Rs. 36 Expected future benefit payments March 31, 2022 6 March 31, 2023 6 March 31, 2024 12 March 31, 2025 16 March 31, 2026 21 Thereafter 608 Provident fund benefits Certain categories of employees of the Company receive benefits from a provident fund, a defined contribution plan. Both the employee and employer each make monthly contributions to a government administered fund equal to 12% of the covered employee’s qualifying salary. The Company has no further obligations under the plan beyond its monthly contributions. The Company contributed Rs.906, Rs.812 and Rs.740 to the provident fund plan during the years ended March 31, 2021, 2020 and 2019, respectively. Superannuation benefits Certain categories of employees of the Company participate in superannuation, a defined contribution plan administered by the Life Insurance Corporation of India. The Company makes monthly contributions based on a specified percentage of each covered employee’s salary. The Company has no further obligations under the plan beyond its monthly contributions. The Company contributed Rs.84, Rs.82 and Rs.84 to the superannuation plan during the years ended March 31, 2021, 2020 and 2019, respectively. Other contribution plans In the United States, the Company sponsors a defined contribution 401(k) retirement savings plan for all eligible employees who meet minimum age and service requirements. The Company contributed Rs.139, Rs.177 and Rs.213 to the 401(k) retirement savings plan during the years ended March 31, 2021, 2020 and 2019, respectively. The Company has no further obligations under the plan beyond its monthly matching contributions. In the United Kingdom, certain social security benefits (such as pension, unemployment and disability) are funded by employers and employees through mandatory National Insurance contributions. The contribution amounts are determined based upon the employee’s salary. The Company has no further obligations under the plan beyond its monthly contributions. The Company contributed Rs.143, Rs.135 and Rs.148 to the National Insurance during the years ended March 31, 2021, 2020 and 2019, respectively. Compensated absences The Company provides for accumulation of compensated absences by certain categories of its employees. These employees can carry forward a portion of the unutilized compensated absences and utilize them in future periods or receive cash in lieu thereof as per the Company’s policy. The Company records a liability for compensated absences in the period in which the employee renders the services that increases this entitlement. The total liability recorded by the Company towards this obligation was Rs.1,130 and Rs.1,161 as of March 31, 2021 and 2020, respectively.

Employee stock incentive plans

Employee stock incentive plans	12 Months Ended
Employee stock incentive plans	Mar. 31, 2021
Disclosure Of Share based Payment Arrangement [Abstract]
Employee stock incentive plans	29. Employee stock incentive plans Dr. Reddy’s Employees Stock Option Scheme, 2002 (the “DRL 2002 Plan”): The Company instituted the DRL 2002 Plan for all eligible employees pursuant to the special resolution approved by the shareholders in the Annual General Meeting held on September 24, 2001. The DRL 2002 Plan covers all employees and directors (excluding promoter directors) of the parent company and its subsidiaries (collectively, “eligible employees”). The Nomination, Governance and Compensation Committee of the Board of the parent company (the “Committee”) administers the DRL 2002 Plan and grants stock options to eligible employees. The Committee determines which eligible employees will receive options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for all options issued on the date of grant. The options issued under the DRL 2002 Plan vest in periods ranging between one and four years and generally have a maximum contractual term of five years. The DRL 2002 Plan, as amended at annual general meetings of shareholders held on July 28, 2004 and on July 27, 2005, provides for stock option grants in two categories: Category A Category B Under the DRL 2002 Plan, the exercise price of the fair market value options granted under Category A above is determined based on the average closing price for 30 days prior to the grant in the stock exchange where there is highest trading volume during that period. Notwithstanding the foregoing, the Committee may, after obtaining the approval of the shareholders in the annual general meeting, grant options with a per share exercise price other than fair market value and par value of the equity shares. After the stock split effected in the form of a stock dividend issued by the Company in August 2006, the DRL 2002 Plan provides for stock option grants in the above two categories as follows: Particulars Number of Number of Total Options reserved under original Plan 300,000 1,995,478 2,295,478 Options exercised prior to stock dividend date (A) 94,061 147,793 241,854 Balance of shares that can be allotted on exercise of options (B) 205,939 1,847,685 2,053,624 Options arising from stock dividend (C) 205,939 1,847,685 2,053,624 Options reserved after stock dividend (A+B+C) 505,939 3,843,163 4,349,102 The term of the DRL 2002 plan was extended for a period of 10 years effective as of January 29, 2012 by the shareholders at the Company’s Annual General Meeting held on July 20, 2012. Stock option activity under the DRL 2002 Plan for the two categories of options during the years ended March 31, 2021 and 2020 is as follows: Category A — Fair Market Value Options: Category B — Par Value Options: For the Year Ended March 31, 2021 Category B — Par Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 232,837 Rs. 5.00 Rs. 5.00 69 Granted during the year 92,092 5.00 5.00 93 Expired/forfeited during the year (35,646 ) 5.00 5.00 - Exercised during the year (72,030 ) 5.00 5.00 - Outstanding at the end of the year 217,253 Rs. 5.00 Rs. 5.00 69 Exercisable at the end of the year 46,130 Rs. 5.00 Rs. 5.00 44 For the Year Ended March 31, 2020 Category B — Par Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 270,141 Rs. 5.00 Rs. 5.00 73 Granted during the year 49,796 5.00 5.00 90 Expired/forfeited during the year (14,934 ) 5.00 5.00 - Exercised during the year (72,166 ) 5.00 5.00 - Outstanding at the end of the year 232,837 Rs. 5.00 Rs. 5.00 69 Exercisable at the end of the year 40,548 Rs. 5.00 Rs. 5.00 43 The weighted average grant date fair value of options granted during the years ended March 31, 2021 and 2020 was Rs.3,677 and Rs.2,746 per option, respectively. The weighted average share price on the date of exercise of options during the years ended March 31, 2021 and 2020 . The aggregate intrinsic value of options exercised during the years ended March 31, 2021 and 2020 was Rs.328 and Rs.193, respectively. As of March 31, 2021, options outstanding had an aggregate intrinsic value of Rs.980 and options exercisable had an aggregate intrinsic value of Rs.208. Dr. Reddy’s Employees ADR Stock Option Scheme The Company instituted the DRL 2007 Plan for all eligible employees in pursuance of the special resolution approved by the shareholders in the Annual General Meeting held on July 27, 2005. The DRL 2007 Plan became effective upon its approval by the Board of Directors on January 22, 2007. The DRL 2007 Plan covers all employees and directors (excluding promoter directors) of DRL and its subsidiaries (collectively, “eligible employees”). The Committee administers the DRL 2007 Plan and grants stock options to eligible employees. The Committee determines which eligible employees will receive the options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for all options issued on the date of grant. The options issued under the DRL 2007 Plan vest in periods ranging between one and four years and generally have a maximum contractual term of five years. The DRL 2007 Plan provides for option grants in two categories: Category A Category B Stock options activity under the DRL 2007 Plan for the above two categories of options during the years ended March 31, 2021 and 2020 was as follows: For the Year Ended March 31, 2021 Category A — Fair Market Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 202,760 Rs.1,982.00 to Rs.2,353.62 72 Granted during the year 96,080 3,679.00 3,679.00 90 Expired/forfeited during the year (13,348 ) 2,607.00/ 2,678.03 - Exercised during the year (15,152 ) 2,607.00/ 2,643.48 - Outstanding at the end of the year 270,340 Rs.1,982.00 to Rs.3,679.00 Rs. 2,791.65 67 Exercisable at the end of the year 69,530 Rs.1,982.00 to Rs.2,814.00 Rs. 2,182.21 45 For the Year Ended March 31, 2020 Category A — Fair Market Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 146,060 Rs.1,982.00/ Rs.2,607.00 Rs. 2,166.00 81 Granted during the year 61,700 2,814.00 2,814.00 90 Expired/forfeited during the year (5,000 ) 2,607.00 2,607.00 - Exercised during the year - - - - Outstanding at the end of the year 202,760 Rs.1,982.00 to Rs.2,814.00 Rs. 2,353.62 72 Exercisable at the end of the yea r 35,265 Rs.1,982.00/ Rs.2,607.00 Rs. 2,150.81 51 The weighted average grant date fair value of options granted during the years ended March 31, 2021 and 2020 was Rs.1,255 and Rs.993 per option, respectively. The weighted average share price on the date of exercise of options during the year ended March 31, 2021 was Rs.4,506 per share . The aggregate intrinsic value of options exercised during the year ended March 31, 2021 was Rs.28. As of March 31, 2021, options outstanding had an aggregate intrinsic value of Rs.466 and options exercisable had an aggregate intrinsic value of Rs.120. For the Year Ended March 31, 2021 Category B — Par Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 151,583 Rs. 5.00 Rs. 5.00 73 Granted during the year 52,316 5.00 5.00 89 Expired/forfeited during the year (19,933 ) 5.00 5.00 - Exercised during the year (41,967 ) 5.00 5.00 - Outstanding at the end of the year 141,999 Rs. 5.00 Rs. 5.00 71 Exercisable at the end of the year 15,393 Rs. 5.00 Rs. 5.00 41 For the Year Ended March 31, 2020 Category B — Par Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 115,155 Rs. 5.00 Rs. 5.00 73 Granted during the year 89,282 5.00 5.00 90 Expired/forfeited during the year (18,886 ) 5.00 5.00 - Exercised during the year (33,968 ) 5.00 5.00 - Outstanding at the end of the year 151,583 Rs. 5.00 Rs. 5.00 73 Exercisable at the end of the year 14,166 Rs. 5.00 Rs. 5.00 44 The weighted average grant date fair value of options granted during the years ended March 31, 2021 and 2020 was Rs.3,631 and Rs.2,747, respectively. The weighted average share price on the date of exercise of options during the years ended March 31, 2021 and 2020 was Rs.4,334 and Rs.2,757, respectively. The aggregate intrinsic value of options exercised during the years ended March 31, 2021 and 2020 was Rs.182 and Rs.93, respectively. As of March 31, 2021, options outstanding had an aggregate intrinsic value of Rs.641 and options exercisable had an aggregate intrinsic value of Rs.69. Dr. Reddy’s Employees Stock Option Scheme, 2018 (the “DRL 2018 Plan”) The Company instituted the DRL 2018 Plan for all eligible employees pursuant to the special resolution approved by the shareholders at the Annual General Meeting held on July 27, 2018. The DRL 2018 Plan covers all employees and directors (excluding independent and promoter directors) of the parent company and its subsidiaries (collectively, “eligible employees”). Upon the exercise of options granted under the DRL 2018 Plan, the applicable equity shares may be issued directly by the Company to the eligible employee or may be transferred from the Dr. Reddy’s Employees ESOS Trust (the “ESOS Trust”) to the eligible employee. The ESOS Trust may acquire such equity shares through primary issuances by the Company and/or by way of secondary market acquisitions funded through loans from the Company. The Nomination, Governance and Compensation Committee of the Board of the parent company (the “Compensation Committee”) administers the DRL 2018 Plan and grants stock options to eligible employees, but may delegate functions and powers relating to the administration of the DRL 2018 Plan to the ESOS Trust. The Compensation Committee determines which eligible employees will receive the options, the number of options to be granted, the exercise price, the vesting period and the exercise period. The vesting period is determined for all options issued on the date of grant. The options issued under the DRL 2018 Plan vest in periods ranging between the end of one and five years, and generally have a maximum contractual term of five years. The DRL 2018 Plan provides for option grants having an exercise price equal to the fair market value of the underlying equity shares on the date of grant as follows: Particulars Number of securities Number of securities Total Options reserved against equity shares 2,500,000 1,500,000 4,000,000 Options reserved against ADRs - 1,000,000 1,000,000 Total 2,500,000 2,500,000 5,000,000 As of March 31, 2021, the outstanding shares purchased from secondary market are 575,201 shares for an aggregate consideration of Rs.1,967. Stock option activity under the DRL 2018 Plan during the years ended March 31, 2021 and 2020 was as follows: For the Year Ended March 31, 2021 Fair Market Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 375,775 Rs.2,607.00/ Rs.2,814.00 Rs. 2,697.12 75 Granted during the year 150,740 3,679. 3,679.00 90 Expired/forfeited during the year (55,335 ) 2,607.00 3,679. 2,904.51 - Exercised during the year (85,250 ) 2,607.00/ 2,814.00 2,671.71 - Outstanding at the end of the year 385,930 Rs.2,607.00 to Rs.3,679.00 Rs. 3,056.51 71 Exercisable at the end of the year 71,225 Rs.2,607.00/ Rs.2,814.00 Rs. 2,665.63 51 For the Year Ended March 31, 2020 Fair Market Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 229,600 Rs.2,607.00 Rs. 2,607.00 84 Granted during the year 169,900 2,814.00/ 2,817.07 90 Expired/forfeited during the year (22,575 ) 2,607.00 to 2,687.84 - Exercised during the year (1,150 ) 2,607.00 2,607.00 - Outstanding at the end of the year 375,775 Rs.2,607.00/ Rs.2814.00 Rs. 2,697.12 75 Exercisable at the end of the year 53,100 Rs.2,607.00 Rs. 2,607.00 53 The weighted average grant date fair value of options granted during the years ended March 31, 2021 and 2020 was Rs.1,255 and Rs.994 per option, respectively. The weighted average share price on the date of exercise of options during the years ended March 31, 2021 and 2020 was Rs.4,609 and Rs.2,914 per share, respectively. The aggregate intrinsic value of options exercised during the years ended March 31, 2021 and 2020 was Rs.165 and Rs.0.35, respectively. As of March 31, 2021, options outstanding had an aggregate intrinsic value of Rs.563 and options exercisable had an aggregate intrinsic value of Rs.104. Valuation of stock options: The fair value of services received in return for stock options granted to employees is measured by reference to the fair value of stock options granted. The fair value of stock options granted under the DRL 2002 Plan, DRL 2007 Plan and the DRL 2018 Plan has been measured using the Black–Scholes-Merton model at the date of the grant. The Black-Scholes-Merton model includes assumptions regarding dividend yields, expected volatility, expected terms and risk free interest rates. In respect of par value options granted, the expected term of an option (or “option life”) is estimated based on the vesting term and contractual term, as well as the expected exercise behavior of the employees receiving the option. In respect of fair market value options granted, the option life is estimated based on the simplified method. Expected volatility of the option is based on historical volatility, during a period equivalent to the option life, of the observed market prices of the Company’s publicly traded equity shares. Dividend yield of the options is based on recent dividend activity. Risk-free interest rates are based on the government securities yield in effect at the time of the grant. These assumptions reflect management’s best estimates, but these assumptions involve inherent market uncertainties based on market conditions generally outside of the Company’s control. As a result, if other assumptions had been used in the current period, stock-based compensation expense could have been materially impacted. Further, if management uses different assumptions in future periods, stock based compensation expense could be materially impacted in future years. The estimated fair value of stock options is recognized in the consolidated income statement on a straight-line basis over the requisite service period for each separately vesting portion of the award as if the award was, in substance, multiple awards. The weighted average inputs used in computing the fair value of options granted were as follows: Grants made on October 27, 2020 May 19, 2020 May 19, 2020 Expected volatility 30.81% 29.12% 30.47% Exercise price Rs.5.00 Rs.3,679.00 Rs.5.00 Option life 2.5 Years 5.0 Years 2.5 Years Risk-free interest rate 4.36% 5.67% 4.62% Expected dividends 0.49% 0.68% 0.68% Grant date share price Rs.5,009.00 Rs.3,700.00 Rs.3,700.00 Grants made on January 26, 2020 October 31, 2019 May 16, 2019 May 16, 2019 Expected volatility 27.00% 27.10% 28.25% 29.29% Exercise price Rs.3,031.00 Rs.5.00 Rs.2,814.00 Rs.5.00 Option life 5.00 Years 2.5 Years 5.0 Years 2.5 Years Risk-free interest rate 6.61% 5.72% 7.14% 6.76% Expected dividends 0.66% 0.72% 0.71% 0.71% Grant date share price Rs.3,031.00 Rs.2,783.20 Rs.2,801.00 Rs.2,801.00 Share-based payment expense For the Year Ended March 31, 2021 2020 2019 Equity settled share-based payment expense (1) Rs. 584 Rs. 521 Rs. 389 Cash settled share-based payment expense (2) 157 94 85 Rs. 741 Rs. 615 Rs. 474 (1) As of March 31, 2021 and 2020, there was Rs.612 and Rs.515, respectively, of total unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period of 1.95 years and 1.93 years, respectively. (2) Certain of the Company’s employees are eligible for share-based payment awards that are settled in cash. These awards entitle the employees to a cash payment, on the exercise date, subject to vesting upon satisfaction of certain service conditions which range from 1 to 4 years. The amount of cash payment is determined based on the price of the Company’s ADSs at the time of vesting. As of March 31, 2021 and 2020, there was Rs.126 and Rs.97, respectively of total unrecognized compensation cost related to unvested awards. This cost is expected to be recognized over a weighted-average period of 1.88 years and 1.93 years, respectively. This scheme does not involve dealing in or subscribing to or purchasing securities of the Company, directly or indirectly .

Related parties

Related parties	12 Months Ended
Related parties	Mar. 31, 2021
Disclosure of transactions between related parties [abstract]
Related parties	30. Related parties The Company has entered into transactions with the following related parties: · Green Park Hotel and Resorts Limited for hotel services; · Green Park Hospitality Services Private Limited for catering and other services; · Dr. Reddy’s Foundation towards contributions for social development; · Kunshan Rotam Reddy Pharmaceuticals Company Limited for sales of goods and for research and development services; · Pudami Educational Society towards contributions for social development; · Indus Projects Private Limited for engineering services relating to civil works; · CERG Advisory Private Limited for professional consulting services; · Dr. Reddy’s Institute of Life Sciences for research and development services; · AverQ Inc. for professional consulting services; · Shravya Publications Private Limited for professional consulting services; · Samarjita Management Consultancy Private Limited for professional consulting services; · Cancelled Plans LLP for the sale of scrap materials; · Araku Originals Private Limited for the purchase of coffee powder; · DRES Energy Private Limited for the purchase of solar power; and · Stamlo Industries Limited for hotel services. These are enterprises over which key management personnel have control or significant influence. “Key management personnel” consists of the Company’s Directors and members of the Company’s Management Council. The Company has also entered into cancellable operating lease transactions with key management personnel and close members of their families. Further, the Company contributes to the Dr. Reddy’s Laboratories Gratuity Fund, which maintains the plan assets of the Company’s Gratuity Plan for the benefit of its employees. See Note 28 of these consolidated financial statements for information on transactions between the Company and the Gratuity Fund. The following is a summary of significant related party transactions: For the Year Ended March 31, 2021 2020 2019 Research and development services received Rs. 105 Rs. 105 Rs. 97 Sale of goods 22 14 23 Lease rentals received 1 1 - Research and development services provided 93 58 103 Lease rentals paid 37 35 35 Catering expenses paid 301 344 270 Hotel expenses paid 8 22 26 Facility management services paid 36 24 - Purchase of solar power 127 108 - Civil works 55 101 106 Professional consultancy services paid 30 4 1 Contributions towards social development 232 233 220 Salaries to relatives of key management personnel 8 7 5 Others - - * - * Rounded to the nearest million. The Company had the following amounts due from related parties: As of March 31, 2021 2020 Key management personnel and close members of th e Rs. 8 Rs. 8 Other related parties 72 68 The Company had the following amounts due to related parties: As of March 31, 2021 2020 Due to related parties Rs. 93 Rs. 91 The following table describes the components of compensation paid or payable to key management personnel for the services rendered during the applicable year ended: For the Year Ended March 31, 2021 2020 2019 Salaries and other benefits Rs. 803 Rs. 684 Rs. 668 Contributions to defined contribution plans 34 34 35 Commission to directors 301 298 243 Share-based payments expense 259 165 99 Rs. 1,397 Rs. 1,181 Rs. 1,045 Some of the key management personnel of the Company are also covered under the Company’s Gratuity Plan along with the other employees of the Company. Proportionate amounts of gratuity accrued under the Company’s Gratuity Plan have not been separately computed or included in the above disclosure.

Financial instruments

Financial instruments	12 Months Ended
Financial instruments	Mar. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Financial instruments	31. Financial instruments Financial instruments by category The carrying value and fair value of financial instruments as of March 31, 2021 and 2020, respectively were as follows: As of March 31, 2021 As of March 31, 2020 Total carrying Total fair value Total carrying Total fair value Assets: Cash and cash equivalents Rs. 14,829 Rs. 14,829 Rs. 2,053 Rs. 2,053 Other investments (1) 24,702 24,702 24,015 24,015 Trade and other receivables 49,759 49,759 52,015 52,015 Derivative financial instruments 1,218 1,218 1,105 1,105 Other assets (2) 2,626 2,626 4,170 4,170 Total Rs. 93,134 Rs. 93,134 Rs. 83,358 Rs. 83,358 Liabilities: Trade and other payables Rs. 23,744 Rs. 23,744 Rs. 16,659 Rs. 16,659 Derivative financial instruments 326 326 1,602 1,602 Long-term borrowings 7,163 7,163 5,570 5,570 Short-term borrowings 23,136 23,136 16,441 16,441 Bank overdraft 9 9 91 91 Other liabilities and provisions (3) 23,233 23,233 25,317 25,317 Total Rs. 77,611 Rs. 77,611 Rs. 65,680 Rs. 65,680 (1) Interest accrued but not due on investments is included in other assets. (2) Other assets that are not financial assets (such as receivables from statutory authorities, export benefit receivables, prepaid expenses, advances paid and certain other receivables) of Rs.12,717 and Rs.10,476 as of March 31, 2021 and 2020, respectively, are not included. (3) Amounts as of March 31, 2021 includes contingent consideration of Other liabilities and provisions that are not financial liabilities (such as statutory dues payable, deferred revenue, advances from customers and certain other accruals) of Rs.13,091 and Rs.10,725 as of March 31, 2021 and 2020, respectively, are not included. Fair value hierarchy Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e., as prices) or indirectly (i.e., derived from prices). Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs). The following table presents the fair value hierarchy of assets and liabilities measured at fair value on a recurring basis as of March 31, 2021: Particulars Level 1 Level 2 Level 3 Total FVTPL - Financial asset - Investments in units of mutual funds Rs. 13,263 Rs. - Rs. - Rs. 13,263 FVTPL - Financial asset - Investment in limited liability partnership firm - - 400 400 FVTPL - Financial asset - Investments in equity securities - - 1 1 FVTOCI - Financial asset - Investments in equity securities 4,532 - - 4,532 Derivative financial instruments – net gain/(loss) on outstanding foreign exchange forward, option and swap contracts and interest rate swap contracts (1) - 892 - 892 FVTPL- Contingent consideration pursuant to the Business Transfer Agreement with Wockhardt Limited (Refer to Note 6 for details) - - 420 420 The following table presents the fair value hierarchy of assets and liabilities measured at fair value on a recurring basis as of March 31, 2020: Particulars Level 1 Level 2 Level 3 Total FVTPL - Financial asset - Investments in units of mutual funds Rs. 13,832 Rs. - Rs. - Rs. 13,832 FVTPL - Financial asset - Investments in equity securities - - 1 1 FVTOCI - Financial asset - Investments in equity securities 303 - - 303 FVTOCI - Financial asset - Investments in market linked debentures 1,993 - - 1,993 Derivative financial instruments – net gain/(loss) on outs t (1) - (497 ) - (497 ) (1) The Company enters into derivative financial instruments with various counterparties, principally financial institutions and banks. Derivatives valued using valuation techniques with market observable inputs are mainly interest rate swaps, foreign exchange forward option and swap contracts. The most frequently applied valuation techniques include forward pricing, swap models and Black-Scholes-Merton models (for option valuation), using present value calculations. The models incorporate various inputs, including foreign exchange forward rates, interest rate curves and forward rate curves. As of March 31, 2021 and 2020, the changes in counterparty credit risk had no material effect on the hedge effectiveness assessment for derivatives designated in hedge relationships and other financial instruments recognized at fair value. Derivative financial instruments The Company had a derivative financial asset and derivative financial liability of Rs.1,218 and Rs.326, respectively, as of March 31, 2021, as compared to derivative financial asset and derivative financial liability of Rs.1,105 and Rs.1,602, respectively, as of March 31, 2020, towards these derivative financial instruments. Details of gain/(loss) recognized in respect of derivative contracts The following table presents details in respect of the gain/(loss) recognized in respect of derivative contracts during the applicable year ended: For the Year Ended March 31, 2021 2020 2019 Net gain/(loss) recognized in finance costs in respect of foreign exchange derivative contracts and cross currency interest rate swaps contracts Rs. 2,619 Rs. 155 Rs. (257 ) Net gain/(loss) recognized in equity in respect of hedges of highly probable forecast transactions, net of amounts reclassified from equity and recognized as component of revenue 1,123 (951 ) 180 Net gain/(loss) reclassified from equity and recognized as component of revenue occurrence of forecasted transaction 340 (50 ) (524 ) The net carrying amount of the Company’s “hedging reserve” as a component of equity before adjusting for tax impact was a gain of Rs.401 as of March 31, 2021, as compared to a loss of Rs.722 as of March 31, 2020. Outstanding foreign exchange derivative contracts The following table gives details in respect of the notional amount of outstanding foreign exchange derivative contracts as of March 31, 2021. Category Instrument Currency (1) Cross Currency (1) Amounts Buy/Sell Hedges of recognized assets and li a Forward contract AUD INR AUD 7 Sell Forward contract CHF INR CHF 200 Sell Forward contract GBP INR GBP 8 Sell Forward contract RUB INR RUB 2,799 Sell Forward contract U.S.$ INR U.S.$ 353 Sell Forward contract U.S.$ MXN U.S.$ 10 Buy Forward contract U.S.$ UAH U.S.$ 14 Buy Forward contract ZAR INR ZAR 111 Sell Forward contract U.S.$ RUB U.S.$ 2 Buy Forward contract U.S.$ RON U.S.$ 12 Buy Forward contract U.S.$ AUD U.S.$ 3 Buy Forward contract GBP U.S.$ GBP 48 Buy Forward contract EUR GBP EUR 1 Sell Forward contract EUR U.S.$ EUR 16 Buy Forward contract CHF U.S.$ CHF200 Buy Forward contract U.S.$ KZT U.S.$ 4 Buy Forward contract U.S.$ CLP U.S.$ 3 Buy Forward contract U.S.$ COP U.S.$ 4 Buy Forward contract U.S.$ BRL U.S.$ 4 Buy Forward contract U.S.$ KZT U.S.$ 9 Buy Hedges of highly probable forecast transactions Forward contract AUD INR AUD 10 Sell Forward contract RUB INR RUB 6,850 Sell Option contract U.S.$ INR U.S.$ 645 Sell - Risk Reversal Forward contract ZAR INR ZAR 148 Sell The following table gives details in respect of the notional amount of outstanding foreign exchange derivative contracts as of March 31, 2020. Category Instrument Currency (1) Cross Currency (1) Amounts Buy/Sell Hedges of recognized assets and liabilities Forward contract U.S.$ INR U.S.$ 148 Sell Forward contract RUB INR RUB 5,968 Sell Forward contract GBP INR GBP 9 Sell Forward contract AUD INR AUD 4 Sell Forward contract CHF INR CHF 200 Sell Forward contract ZAR INR ZAR 71 Sell Forward contract CHF U.S.$ CHF 200 Buy Forward contract EUR GBP EUR 3 Sell Forward contract EUR U.S.$ EUR 6 Buy Forward contract GBP U.S.$ GBP 38 Buy Forward contract U.S.$ AUD U.S.$ 5 Buy Forward contract U.S.$ BRL U.S.$ 6 Buy Forward contract U.S.$ CLP U.S.$ 4 Buy Forward contract U.S.$ COP U.S.$ 4 Buy Forward contract U.S.$ KZT U.S.$ 11 Buy Forward contract U.S.$ MXN U.S.$ 2 Buy Forward contract U.S.$ RON U.S.$ 7 Buy Forward contract U.S.$ RUB U.S.$ 6 Buy Forward contract U.S.$ UAH U.S.$ 19 Buy Forward contract U.S.$ INR U.S.$ 140 Sell Hedges of highly probable forecast transactions Option contract U.S.$ INR U.S.$ 270 Sell (1) “INR” means Indian rupees, “U.S.$” means United States dollars, “RON” means Ro m The table below summarizes the periods when the cash flows associated with highly probable forecast transactions that are classified as cash flow hedges are expected to occur: As of March 31, 2021 2020 Cash flows in U.S dollars Not later than one month Rs. 3,656 Rs. 2,648 Later than one month and not later than three months 7,311 5,297 Later than three months and not later than six months 12,063 7,945 Later than six months and not later than one year 24,126 4,540 Rs. 47,156 Rs. 20,430 Cash flows in Russian roubles Not later than one month Rs. 437 Rs. - Later than one month and not later than three months 874 - Later than three months and not later than six months 1,748 - Later than six months and not later than one year 3,593 - Rs. 6,651 Rs. - Cash flows in Australian dollars Not later than one month Rs. 46 Rs. - Later than one month and not later than three months 92 - Later than three months and not later than six months 139 - Later than six months and not later than one year 277 - Rs. 555 Rs. - Cash flows in South African rands Not later than one month Rs. 61 Rs. - Later than one month and not later than three months 121 - Later than three months and not later than six months 182 - Later than six months and not later than one year 364 - Rs. 728 Rs. - Hedges of changes in the interest rates: Consistent with its risk management policy, the Company uses interest rate swaps (including cross currency interest rate swaps) to mitigate the risk of changes in interest rates. The Company does not use them for trading or speculative purposes. A net gain/(loss) of Rs. Nil 164 33 Rs.-* for for the years ended March 31, 2021, 2020 and 2019 respectively. The Company had outstanding cross currency swap against INR borrowing of Rs. 7,240 *

Financial risk management

Financial risk management	12 Months Ended
Financial risk management	Mar. 31, 2021
Financial risk management [Abstract]
Financial risk management	32. Financial risk management The Company’s activities expose it to a variety of financial risks, including market risk, credit risk and liquidity risk. The Company’s primary risk management focus is to minimize potential adverse effects of market risk on its financial performance. The Company’s risk management assessment and policies and processes are established to identify and analyze the risks faced by the Company, to set appropriate risk limits and controls, and to monitor such risks and compliance with the same. Risk assessment and management policies and processes are reviewed regularly to reflect changes in market conditions and the Company’s activities. The Board of Directors and the Audit Committee is responsible for overseeing the Company’s risk assessment and management policies and processes. a. Market risk Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from adverse changes in market rates and prices (such as interest rates, foreign currency exchange rates and commodity prices) or in the price of market risk-sensitive instruments as a result of such adverse changes in market rates and prices. Market risk is attributable to all market risk-sensitive financial instruments, all foreign currency receivables and payables and all short-term and long-term debt. The Company is exposed to market risk primarily related to foreign exchange rate risk, interest rate risk and the market value of its investments. Thus, the Company’s exposure to market risk is a function of investing and borrowing activities and revenue generating and operating activities in foreign currencies. Foreign exchange risk The Company is exposed to exchange rate risk which arises from its foreign exchange revenues and expenses, primarily in U.S. dollars, U.K. pounds sterling, Russian roubles, Brazilian reals, Swiss francs, South African rands, Kazakhstan tenges, Romanian new leus, Australian dollars and Euros, and foreign currency debt in U.S. dollars, Russian roubles, South African rands, Mexican pesos, Ukrainian hryvnias and Brazilian reals. A significant portion of the Company’s revenues are in these foreign currencies, while a significant portion of its costs are in Indian rupees. As a result, if the value of the Indian rupee appreciates relative to these foreign currencies, the Company’s revenues measured in Indian rupees may decrease. The exchange rate between the Indian rupee and these foreign currencies has changed substantially in recent periods and may continue to fluctuate substantially in the future. Consequently, the Company uses both derivative and non-derivative financial instruments, such as foreign exchange forward contracts, option contracts, currency swap contracts and foreign currency financial liabilities, to mitigate the risk of changes in foreign currency exchange rates in respect of its highly probable forecast transactions and recognized assets and liabilities. The details in respect of the outstanding foreign exchange forward and option contracts are given in Note 31 to these consolidated financial statements. In respect of the Company’s forward and option contracts, a 10% decrease/increase in the respective exchange rates of each of the currencies underlying such contracts would have resulted in: • a Rs. 4,824 4,195 2,658 2,658 • a Rs. 1,203 1,740 2,070 1,745 • a Rs. 1,872 1,349 1,789 1,873 The following table analyzes foreign currency risk from non-derivative financial instruments as of March 31, 2021: U.S. dollars Euro Russian roubles Others (1) Total Assets: Cash and cash equivalents Rs. 12,643 Rs. 129 Rs. 30 Rs 92 Rs. 12,894 Other investments 24 - - - 24 Trade and other receivables 30,247 841 721 101 31,910 Other assets 184 20 3 16 223 Total Rs. 43,098 Rs. 990 Rs. 754 Rs. 209 Rs. 45,051 Liabilities: Trade and other payables Rs. 4,207 Rs. 1,270 Rs. - * Rs. 210 Rs. 5,687 Long-term borrowings 2,216 52 18 43 2,329 Short-term borrowings 3,657 - 3,717 - 7,374 Other liabilities and provisions 4,665 65 81 292 5,103 Total Rs. 14,745 Rs. 1,387 Rs. 3,816 Rs. 545 Rs. 20,493 The following table analyzes foreign currency risk from non-derivative financial instruments as of March 31, 2020: U.S. dollars Euro Russian roubles Others (1) Total Assets: Cash and cash equivalents Rs. 365 Rs. 43 Rs. 4 Rs. 135 Rs. 547 Other investments 24 - - - 24 Trade and other receivables 31,931 705 989 317 33,942 Other assets 921 15 3 153 1,092 Total Rs. 33,241 Rs. 763 Rs. 996 Rs. 605 Rs. 35,605 Liabilities: Trade and other payables Rs. 1,857 Rs. 525 Rs. - * Rs. 73 Rs. 2,455 Long-term borrowings 4,401 2 3 77 4,483 Short-term borrowings 7,316 - - - 7,316 Other liabilities and provisions 5,534 60 52 400 6,046 Total Rs. 19,108 Rs. 587 Rs. 55 Rs. 550 Rs. 20,300 * Rounded to the nearest million. (1) Others primarily consists of U.K. pounds sterling, Swiss francs, Romanian new leus, Chinese yuans (Renminbi), Canadian dollars and Ukrainian hryvnia. For the years ended March 31, 2021 and 2020, every 10% depreciation/appreciation in the exchange rate between the Indian rupee and the respective currencies for the above mentioned financial assets/liabilities would affect the Company’s net profit by Rs.2,456 and Rs.1,531, respectively. Interest rate risk As of March 31, 2021, the Company had loans with floating interest rates as follows: Rs.8,800 of loans carrying a floating interest rate of the 3 Months India Treasury Bill plus 30 bps and Rs.1,896 of loans carrying a floating interest rate of TIIE+1.20%. As of March 31, 2020, the Company had loans with floating interest rates as follows: Rs.10,971 of loans carrying a floating interest rate ranging from 1 Month LIBOR plus 12.5 bps to 1 Month LIBOR plus 82.7 bps; Rs.4,000 of loans carrying a floating interest rate of 1 Month India Treasury Bill plus 60 bps; Rs.1,627 of loans carrying a floating interest rate of 3 Month LIBOR plus 55 bps; Rs.1,579 of loans carrying a floating interest rate of TIIE+1.25%; and Rs.63 of loans carrying a floating interest rate of 1 Month JIBAR plus 120 bps. For details of the Company’s short-term and long-term loans and borrowings, including interest rate profiles, refer to Note 17 of these consolidated financial statements. For the years ended March 31, 2021, 2020 and 2019, every 10% increase or decrease in the floating interest rate component (i.e., LIBOR, JIBAR, Indian Treasury Bill and TIIE) applicable to its loans and borrowings would affect the Company’s net profit by Rs.37, Rs.41 and Rs.93, respectively. The carrying value of the Company’s borrowings, interest component of which was designated in a cash flow hedge, was Rs.Nil as of March 31, 2021 and 2020. The Company’s investments in term deposits (i.e., certificates of deposit) with banks and short-term liquid mutual funds are for short durations, and therefore do not expose the Company to significant interest rates risk. Commodity rate risk Exposure to market risk with respect to commodity prices primarily arises from the Company’s purchases and sales of active pharmaceutical ingredients, including the raw material components for such active pharmaceutical ingredients. These are commodity products, whose prices may fluctuate significantly over short periods of time. The prices of the Company’s raw materials generally fluctuate in line with commodity cycles, although the prices of raw materials used in the Company’s active pharmaceutical ingredients business are generally more volatile. Cost of raw materials forms the largest portion of the Company’s cost of revenues. Commodity price risk exposure is evaluated and managed through operating procedures and sourcing policies. As of March 31, 2021, the Company had not entered into any material derivative contracts to hedge exposure to fluctuations in commodity prices. b. Credit risk Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company’s receivables from customers and investment securities. The Company establishes an allowance for doubtful debts and impairment that represents its estimate of expected losses in respect of trade and other receivables and investments. Trade and other receivables The Company’s exposure to credit risk is influenced mainly by the individual characteristics of each customer. The demographics of the customer, including the default risk of the industry and country in which the customer operates, also has an influence on credit risk assessment. Credit risk is managed through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business. Investments The Company limits its exposure to credit risk by generally investing in liquid securities and only with counterparties that have a good credit rating. The Company does not expect any losses from non-performance by these counter-parties, and does not have any significant concentration of exposures to specific industry sectors or specific country risks. Details of financial assets – not due, past due and impaired None of the Company’s cash equivalents, including term deposits (i.e., certificates of deposit) with banks, were past due or impaired as of March 31, 2021. The Company’s credit period for trade and other receivables payable by its customers generally ranges from 20 - 180 days. The aging of trade and other receivables is given below: As of March 31, Particulars 2021 2020 Neither past due nor impaired Rs. 41,350 Rs. 45,864 Past due but not impaired Less than 365 days 8,598 6,305 More than 36 5 1,107 1,048 Rs. 51,055 Rs. 53,217 Less : Allowance for credit losses (1,296 ) (1,202 ) Total Rs. 49,759 Rs. 52,015 See Note 9 of these consolidated financial statements for the activity in the allowance for credit losses on trade and other receivables. Other than trade and other receivables, the Company has no significant class of financial assets that is past due but not impaired. c. Liquidity risk Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by ensuring, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risk to the Company’s reputation. As of March 31, 2021 and 2020, the Company had uncommitted lines of credit from banks of Rs.38,766 and Rs.39,374, respectively. As of March 31, 2021, the Company had working capital of Rs.66,626 (excluding assets held for sale of Rs.151), including cash and cash equivalent s As of March 31, 2020, the Company had working capital of Rs.57,556, including cash and cash equivalents of Rs.2,053, investments in term deposits with banks, bonds and commercial paper of Rs.7,862, investments in marked linked debentures of Rs.1,993 and investments in units of mutual funds of Rs.13,832. The table below provides details regarding the contractual maturities of significant financial liabilities (other than long-term borrowings and obligations under leases, which have been disclosed in Note 17 to these consolidated financial statements) as of March 31, 2021: Particulars 2022 2023 2024 2025 Thereafter Total Trade and other payables Rs. 23,744 Rs. - Rs. - Rs. - Rs. - Rs. 23,744 Bank overdraft, short-term borrowings 23,145 - - - - 23,145 Derivative financial instruments 326 - - - - 326 Other liabilities and provisions 22,507 - - - 726 23,233 The table below provides details regarding the contractual maturities of significant financial liabilities (other than long-term borrowings and obligations under leases, which have been disclosed in Note 17 to these consolidated financial statements) as of March 31, 2020: Particulars 2021 2022 2023 2024 Thereafter Total Trade and other payables Rs. 16,659 Rs. - Rs. - Rs. - Rs. - Rs. 16,659 Bank overdraft, short-term borrowings 16,532 - - - - 16,532 Derivative financial instruments 1,602 - - - - 1,602 Other liabilities and provisions 24,566 - - - 751 25,317

Contingencies

Contingencies	12 Months Ended
Contingencies	Mar. 31, 2021
Disclosure of contingent liabilities [abstract]
Contingencies	33. Contingencies The Company is involved in disputes, lawsuits, claims, governmental and/or regulatory inspections, inquiries, investigations and proceedings, including patent and commercial matters that arise from time to time in the ordinary course of business. The more significant matters are discussed below. Most of the claims involve complex issues. Often, these issues are subject to uncertainties and therefore the probability of a loss, if any, being sustained and an estimate of the amount of any loss is difficult to ascertain. Consequently, for a majority of these claims, it is not possible to make a reasonable estimate of the expected financial effect, if any, that will result from ultimate resolution of the proceedings. This is due to a number of factors, including: the stage of the proceedings (in many cases trial dates have not been set) and the overall length and extent of pre-trial discovery; the entitlement of the parties to an action to appeal a decision; clarity as to theories of liability; damages and governing law; uncertainties in timing of litigation; and the possible need for further legal proceedings to establish the appropriate amount of damages, if any. In these cases, the Company based on internal and external legal advice discloses information with respect to the nature and facts of the case. The Company also believes that disclosure of the amount sought by plaintiffs, if that is known, would not be meaningful with respect to those legal proceedings. Although there can be no assurance regarding the outcome of any of the legal proceedings or investigations referred to in this Note, the Company does not expect them to have a materially adverse effect on its financial position, as it believes that the likelihood of loss in excess of amounts accrued (if any) is not probable. However, if one or more of such proceedings were to result in judgments against the Company, such judgments could be material to its results of operations in a given period. Product and patent related matters Launch of product On June 14, 2018, the U.S. FDA granted the Company final approval for buprenorphine and naloxone sublingual film, 2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg dosages, a therapeutic equivalent generic version of Suboxone® sublingual film. The U.S. FDA approval came after the conclusion of litigation in the U.S. District Court for the District of Delaware (the “Delaware District Court”), where the Delaware District Court held that patents covering Suboxone® sublingual film would not be infringed by the Company’s commercial launch of its generic sublingual film product. In light of the favorable decision from the Delaware District Court, the Company launched its generic sublingual film product in the United States immediately following the U.S. FDA approval on June 14, 2018. On July 12, 2019, the U.S. Court of Appeals for the Federal Circuit (“the Court of Appeals”) affirmed the Delaware District Court’s ruling that the Company’s generic version of Suboxone® sublingual films did not infringe the two remaining patents at issue in the Delaware District Court’s case (U.S. patent numbers 8,603,514 and 8,015,150). After the Delaware District Court’s decision, Indivior filed a second lawsuit against the Company alleging infringement of three additional U.S. patents (numbers 9,687,454, 9,855,221 and 9,931,305) in the U.S. District Court for the District of New Jersey (the “New Jersey District Court”), styled Indivior Inc. et al. v. Dr. Reddy’s Laboratories S.A., Civil Action No. 2:17-cv-07111 (D.N.J.). Following the launch, on June 15, 2018, Indivior filed an emergency application for a temporary restraining order and preliminary injunction against the Company in the New Jersey District Court. Indivior’s motion alleged that the Company’s generic sublingual film product infringed one of three U.S. patents (number 9,931,305) at issue in the New Jersey District Court. Pending a hearing and decision on the injunction application, the New Jersey District Court initially issued a temporary restraining order against the Company with respect to further sales, offer for sales, and imports of its generic sublingual film product in the United States. Subsequently, on July 14, 2018, the New Jersey District Court granted a preliminary injunction in favor of Indivior. Under the order, Indivior was required to and did post a bond of U.S.$72 to pay the costs and damages sustained by the Company if it was found to be wrongfully enjoined. The Company immediately appealed the decision, and the Court of Appeals agreed to expedite the appeal. On November 20, 2018, the Court of Appeals issued a decision vacating the preliminary injunction. The Court of Appeals denied Indivior’s petition for rehearing on February 4, 2019. Indivior subsequently filed two emergency motions in the Court of Appeals to stay issuance of the mandate and to keep the preliminary injunction in place, which the Court of Appeals denied. Indivior then petitioned the U.S. Supreme Court to stay issuance of the mandate. Indivior’s petition was denied by the Chief Justice of the U.S. Supreme Court on February 19, 2019, and the mandate was issued on the same day. The Company resumed sales of its generic sublingual film product after the mandate was issued. On February 19, 2019, the New Jersey District Court entered a stipulated order of dismissal of Indivior’s claims under U.S. patent number 9,855,221. On November 5, 2019, the New Jersey District Court issued its claim construction decision construing certain terms in U.S. patent numbers 9,931,305 and 9,687,454. After such claim construction decision, on January 8, 2020, the New Jersey District Court entered a stipulated order that the Company’s generic sublingual film product does not infringe the asserted claims in U.S. patent number 9,931,305. In the stipulated order, Indivior reserved the ability to appeal the New Jersey District Court’s claim construction order. The Company filed a motion requesting that the New Jersey District Court enter partial final judgment in the Company’s favor relating to the allegations of infringement of U.S. patent number 9,931,305, which the District Court denied without prejudice on August 24, 2020, pending resolution of Indivior’s allegations relating to U.S. patent number 9,687,454. On November 11, 2019, a Magistrate Judge in the District of New Jersey granted the Company leave to file a counterclaim against Indivior that alleges that Indivior engaged in anticompetitive conduct by making false or misleading statements to the New Jersey District Court during the preliminary injunction proceedings in violation of federal antitrust laws. Indivior appealed the Magistrate Judge’s ruling to the District Court Judge and, on August 24, 2020, the District Court Judge denied Indivior’s appeal. The District Court did grant Indivior’s motion to bifurcate the patent claims and the antitrust claims into two separate trials. Fact discovery closed on January 29, 2021. No trial date has been set and expert discovery on both the patent and antitrust claims is ongoing. Opening expert reports were submitted on March 24, 2021. Expert discovery is scheduled to close on or around September 1, 2021. In addition to the District Court proceeding, on November 13, 2018, the Company filed two petitions for inter-partes review challenging the validity of certain claims of U.S. patent number 9,687,454 before the Patent Trial and Appeal Board (“PTAB”). On June 13, 2019, the PTAB agreed to institute inter-partes review on one of the two petitions filed by the Company. The PTAB heard oral argument in the pending inter-partes review challenge on March 3, 2020. On June 2, 2020, the PTAB issued a final written decision in the Company’s favor finding that the Company had demonstrated that claims 1–5, 7, and 9–14 of U.S. patent number 9,687,454 were unpatentable. The PTAB upheld the validity of only one of the challenged claims, claim 8. Additionally, claim 6 was not at issue in the inter-partes review and therefore not subject to the final written decision. Claims 6 and 8 remain asserted against the Company in the New Jersey District Court litigation. Indivior filed a timely notice of appeal of the PTAB’s Final Written Decision (“ FWD”) for claims 1-5, 7, and 9-14, and the Company cross appealed the PTAB’s FWD on claim 8. In the PTAB appeal, Indivior submitted its principal appeal brief on December 9, 2020. Indivior did not challenge the Board’s decision on claims 5 and 12 in its appeal brief. The Company submitted its opening and response brief on February 18, 2021 and Indivior submitted its response and reply brief on March 30, 2021. The Company’s reply brief was submitted on April 20, 2021. The court of appeals has not y et ts The Company intends to vigorously defend its positions and pursue a claim for damages caused by the preliminary injunction. Matters relating to National Pharmaceutical Pricing Authority Norfloxacin, India litigation The Company manufactures and distributes Norfloxacin, a formulations product, and in limited quantities, the active pharmaceutical ingredient norfloxacin. Under the Drugs (Prices Control) Order (the “DPCO”), the National Pharmaceutical Pricing Authority (the “NPPA”) established by the Government of India had the authority to designate a pharmaceutical product as a “specified product” and fix the maximum selling price for such product. In 1995, the NPPA issued a notification and designated Norfloxacin as a “specified product” and fixed the maximum selling price. In 1996, the Company filed a statutory Form III before the NPPA for the upward revision of the maximum selling price and a writ petition in the Andhra Pradesh High Court (the “High Court”) challenging the validity of the designation on the grounds that the applicable rules of the DPCO were not complied with while fixing the maximum selling price. The High Court had previously granted an interim order in favor of the Company; however it subsequently dismissed the case in April 2004. The Company filed a review petition in the High Court in April 2004 which was also dismissed by the High Court in October 2004. Subsequently, the Company appealed to the Supreme Court of India, New Delhi (the “Supreme Court”) by filing a Special Leave Petition. During the year ended March 31, 2006, the Company received a notice from the NPPA demanding the recovery of the price charged by the Company for sales of Norfloxacin in excess of the maximum selling price fixed by the NPPA, which was Rs.285 including interest. The Company filed a writ petition in the High Court challenging this demand order. The High Court admitted the writ petition and granted an interim order, directing the Company to deposit 50% of the principal amount claimed by the NPPA, which was Rs.77. The Company deposited this amount with the NPPA in November 2005. In February 2008, the High Court directed the Company to deposit an additional amount of Rs.30, which was deposited by the Company in March 2008. In November 2010, the High Court allowed the Company’s application to include additional legal grounds that the Company believed strengthened its defense against the demand. For example, the Company added as grounds that trade margins should not be included in the computation of amounts overcharged, and that it was necessary for the NPPA to set the active pharmaceutical ingredient price before the process of determining the ceiling on the formulation price. In October 2013, the Company filed an additional writ petition before the Supreme Court challenging the inclusion of Norfloxacin as a “specified product” under the DPCO. In January 2015, the NPPA filed a counter affidavit stating that the inclusion of Norfloxacin was based upon the recommendation of a committee consisting of experts in the field. On July 20, 2016, the Supreme Court remanded the matters concerning the inclusion of Norfloxacin as a “specified product” under the DPCO back to the High Court for further proceedings. During the three months ended September 30, 2016, the Supreme Court dismissed the Special Leave Petition pertaining to the fixing of prices for Norfloxacin formulations. During the three months ended December 31, 2016, a writ petition pertaining to Norfloxacin was filed by the Company with the Delhi High Court. The matter has been adjourned to July 29, 2021 for hearing. Based on its best estimate, the Company has recorded a provision for potential liability for sale proceeds in excess of the notified selling prices, including the interest thereon, and believes that the likelihood of any further liability that may arise on account of penalties pursuant to this litigation is not probable. Litigation relating to Cardiovascular and Anti-diabetic formulations In July 2014, the NPPA, pursuant to the guidelines issued in May 2014 and the powers granted by the Government of India under the Drugs (Price Control) Order, 2013, issued certain notifications regulating the prices for 108 formulations in the cardiovascular and antidiabetic therapeutic areas. The Indian Pharmaceutical Alliance (“IPA”), in which the Company is a member, filed a writ petition in the Bombay High Court challenging the notifications issued by the NPPA on the grounds that they were ultra vires, ex facie and ab initio void. The Bombay High Court issued an order to stay the writ in July 2014. On September 26, 2016, the Bombay High Court dismissed the writ petition filed by the IPA and upheld the validity of the notifications/orders passed by the NPPA in July 2014. Further, on October 25, 2016, the IPA filed a Special Leave Petition with the Supreme Court, which was dismissed by the Supreme Court. During the three months ended December 31, 2016, the NPPA issued show-cause notices relating to allegations that the Company exceeded the notified maximum prices for 11 of its products. The Company has responded to these notices. On March 20, 2017, the IPA filed an application before the Bombay High Court for the recall of the judgment of the Bombay High Court dated September 26, 2016. This recall application filed by the IPA was dismissed by the Bombay High Court on October 4, 2017. Further, on December 13, 2017, the IPA filed a Special Leave Petition with the Supreme Court for the recall of the judgment of the Bombay High Court dated October 4, 2017, which was dismissed by Supreme Court on January 10, 2018. During the three months ended March 31, 2017, the NPPA issued notices to the Company demanding payments relating to the foregoing products for the allegedly overcharged amounts, along with interest. On July 13, 2017, in response to a writ petition which the Company had filed, the Delhi High Court set aside all the demand notices of the NPPA and directed the NPPA to provide a personal hearing to the Company and pass a speaking order. A personal hearing in this regard was held on July 21, 2017. On July 27, 2017, the NPPA passed a speaking order along with the demand notice directing the Company to pay an amount of Rs.776. On August 3, 2017, the Company filed a writ petition challenging the speaking order and the demand notice. Upon hearing the matter on August 8, 2017, the Delhi High Court stayed the operation of the demand order and directed the Company to deposit Rs.100 and furnish a bank guarantee for Rs.676. Pursuant to the order, the Company deposited Rs.100 on September 13, 2017 and submitted a bank guarantee of Rs.676 dated September 15, 2017 to the Registrar General, Delhi High Court. On November 22, 2017, the Delhi High Court directed the Union of India to file a final counter affidavit within six weeks, subsequent to which the Company could file a rejoinder. On May 10, 2018, the counter affidavit was filed by the Union of India. The Company subsequently filed a rejoinder and both were taken on record by the Delhi High Court. The matter has been adjourned to August 3, 2021 for hearing. Based on its best estimate, the Company has recorded a provision of Rs.310 under “Selling, general and administrative expenses” as a potential liability for sale proceeds in excess of the notified selling prices, including the interest thereon, and believes that the likelihood of any further liability that may arise on account of penalties pursuant to this litigation is not probable. However, if the Company is unsuccessful in such litigation, it will be required to remit the sale proceeds in excess of the notified selling prices to the Government of India with interest and could potentially include penalties, which amounts are not readily ascertainable. Other product and patent related matters Child resistant packaging matter complaint under the False Claims Act (“FCA”) In May 2012, the Consumer Product Safety Commission (the “CPSC”) requested that Dr. Reddy’s Laboratories Inc., a wholly-owned subsidiary of the Company in the United States, provide certain information with respect to compliance with requirements of special packaging for child resistant blister packs for 6 products sold by the Company in the United States during the period commencing in 2002 through 2011. The Company provided the requested information. The CPSC subsequently alleged in a letter dated April 30, 2014 that the Company had violated the Consumer Product Safety Act (the “CPSA”) and the Poison Prevention Packaging Act (the “PPPA”) and that the CPSC intended to seek civil penalties. Specifically, the CPSC asserted, among other things, that from or about August 14, 2008 through June 1, 2012, the Company sold prescription drugs having unit dose packaging that failed to comply with the CPSC's special child resistant packaging regulations under the PPPA and failed to issue general certificates of conformance. In addition, the CPSC asserted that the Company violated the CPSA by failing to immediately advise the CPSC of the alleged violations. The Company disagrees with the CPSC’s allegations. Simultaneously, the U.S. Department of Justice (the “DOJ”) began to investigate a sealed complaint which was filed in the United States District Court for the Eastern District of Pennsylvania under the Federal False Claims Act (“FCA”) related to these same issues (the “FCA Complaint”). The Company cooperated with the DOJ in its investigation. The DOJ and all States involved in the investigation declined to intervene in the FCA Complaint. On November 10, 2015, the FCA Complaint was unsealed and the plaintiff whistleblowers, who are two former employees of the Company, proceeded without the DOJ’s and applicable States’ involvement. The unsealed FCA Complaint relates to the 6 blister pack products originally subject to the investigation and also 38 of the Company’s generic prescription products sold in the U.S. in various bottle and cap packaging. The Company filed its response to the FCA Complaint on February 23, 2016 in the form of a motion to dismiss for failure to state a claim upon which relief can be granted. On March 26, 2017, the Court granted the Company’s motion to dismiss, dismissing the FCA Complaint and allowing the plaintiffs one more chance to refile this complaint in an attempt to plead sustainable allegations. On March 29, 2017, the plaintiffs filed their final amended FCA Complaint, which the Company opposed and during the three months ended March 31, 2018, the Company obtained dismissal of the FCA Complaint with prejudice. The plaintiffs filed a petition with the Court requesting that the Court reconsider its decision to dismiss the FCA Complaint with prejudice, and that request was denied. The parallel investigation by the CPSC under the CPSA and the PPPA was referred by the CPSC to the DOJ’s office in Washington, D.C. in April 2016, with the recommendation that the DOJ initiate a civil penalty action against the Company. The CPSC matter referred to the DOJ relates to five of the blister pack products. On January 18, 2018, the Company and the DOJ entered into a settlement of the action and agreed to a consent decree providing for a civil penalty of U.S.$5 (Rs.319), and injunctive relief. The settlement was without adjudication of any issue of fact or law, and the Company has not admitted any violations of law pursuant to this settlement. During the three months ended March 31, 2018, the Company obtained dismissal of the FCA Complaint with prejudice. The plaintiffs subsequently filed a petition with the Court requesting that the Court reconsider its decision to dismiss the FCA Complaint with prejudice, and that request was denied. In June 2018, the plaintiffs filed their Notice of Appeal to the Third Circuit Court of Appeals. During the three months ended September 2018, the plaintiffs and the DOJ settled and thus this appeal was dismissed. The plaintiffs then filed an application for recovery of attorneys' fees from the Company under the "alternative remedy doctrine." The Company made opposing filings to this and in response the plaintiffs withdrew their application. The Company believes that the likelihood of any liability that may arise on account of the FCA Complaint is not probable. Accordingly, no provision has been made in these consolidated financial statements. Namenda Litigation In August 2015, Sergeants Benevolent Assoc. Health & Welfare Fund (“Sergeants”) filed suit against the Company in the United States District Court for the Southern District of New York. Sergeants alleged that certain parties, including the Company, violated federal antitrust laws as a consequence of having settled patent litigation related to the Alzheimer’s drug Namenda® (memantine) tablets during a period from about 2009 until 2010. Sergeants seeks to represent a class of “end payor” purchasers of Namenda® tablets (i.e., insurers, other third-party payors and consumers). Sergeants seeks damages based upon an allegation made in the complaint that the defendants entered into patent settlements regarding Namenda® tablets for the purpose of delaying generic competition and facilitating the brand innovator’s attempt to shift sales from the original immediate release product to the more recently introduced extended release product. On August 23, 2020, the Company and certain other defendants entered into a settlement agreement. The settlement agreement calls for the dismissal with prejudice of the claims brought by the plaintiff on behalf of the putative class, in exchange for the payment of U.S.$0.4. The Company paid that amount into escrow. The Court preliminarily approved the settlement on October 5, 2020. The settlement agreement is contingent upon final court approval. The settlement agreement explicitly disclaims any liability or wrongdoing. Following the settlement agreement, the Company recognized such amount in the income statement for the three months ended September 30, 2020. On November 5, 2019 plaintiffs MSP Recovery Claims, Series LLC and MSPA Claims 1, LLC filed suit against the Company and other drug manufacturers in the United States District Court for the Southern District of New York. The claims in this complaint were similar in nature to the claims in the Sergeants lawsuit, and those cases were coordinated for discovery purposes. On April 14, 2020, with the consent of the Company and the other defendants, plaintiffs MSP Recovery Claims, Series LLC and MSPA Claims 1, LLC voluntarily dismissed their claims without prejudice. Other class action complaints containing similar allegations to the Sergeants complaint have also been filed in the U.S. District Court for the Southern District of New York. However, apart from the Sergeants case described above, there are no such class actions that are pending and that name the Company as a defendant. In addition, the State of New York filed an antitrust case in the U.S. District Court for the Southern District of New York. The case brought by the State of New York contained some (but not all) of the allegations set forth in the class action complaints, but the Company was not named as a party. The case brought by the State of New York was dismissed by stipulation on November 30, 2015. The Company believes that the likelihood of any liability, apart from the settlement payment described above, that may arise on account of alleged violation of federal antitrust laws is not probable. Accordingly, no provision has been made in these consolidated financial statements. Ranitidine r l On October 1, 2019, the Company initiated a voluntary nationwide retail (at the retail level for over-the-counter products and at the consumer level for prescription products) of its ranitidine medications sold in the United States due to the presence of N-Nitrosodimethylamine (“NDMA”) above levels established by the U.S. FDA. On November 1, 2019, the U.S. FDA issued a statement indicating that it had found levels of NDMA in ranitidine from its testing generally that were “similar to the levels you would expect to be exposed to if you ate common foods like grilled or smoked meats.” See https://www.fda.gov/news-events/press-announcements/statement-new-testing-results-including-low-levels-impurities-ranitidine-drugs Individual federal court personal injury lawsuits, as well as various class actions, have been transferred to the In re Zantac (Ranitidine) Products Liability Litigation Multidistrict Litigation in the Southern District of Florida, MDL-2924 (“MDL-2924”). The Company and/or one or more of its U.S. subsidiaries have been named as a defendant in over 250 lawsuits pending in the MDL-2924. A census registry established in the MDL-2924 includes tens of thousands of claimants who have not filed complaints but are presenting claims for consideration in the MDL-2924 against the many pharmaceutical manufacturers, distributors and retailers which are defendants in the MDL-2924. The MDL-2924 also involves a proposed nationwide consumer class action and a proposed nationwide class action for medical monitoring. A third-party payor class action was dismissed without prejudice and has been appealed by plaintiffs to the U.S. Court of Appeals for the Eleventh Circuit. On December 31, 2020, the MDL-2924 Court ruled on multiple motions to dismiss in the MDL-2924 and granted the generic manufacturers’ (the Company is a generic manufacturer) motion to dismiss based on federal preemption. The plaintiffs’ failure-to-warn and design defect claims against the Company were dismissed with prejudice, but the Court permitted plaintiffs to attempt to replead several claims/theories. Plaintiffs have filed their amended complaints and the defendants, including the Company, filed motions to dismiss seeking dismissal of all claims against them on March 24, 2021. The briefings and arguments as to the latest round of motions to dismiss were completed and the parties continue to engage in discovery consistent with orders from the MDL-2924 Court. There are three ranitidine-related actions currently pending against the Company in state courts. The New Mexico State Attorney General filed suit against the Company’s U.S. subsidiary, and multiple other manufacturers and retailers. The State of New Mexico asserted claims of statutory and common law public nuisance and negligence claims against the Company. The Company joined in an effort to transfer the case from the Santa Fe County Court to the MDL-2924, but the case was remanded by the MDL-2924 Court to the Santa Fe County Court. Plaintiff filed an amended complaint on April 16, 2021, and a briefing schedule has been entered pursuant to which the defendants will move to dismiss the case. In November 2020, the City of Baltimore filed a similar action against the Company’s U.S. subsidiary, and multiple other manufacturers and retailers. The City of Baltimore asserts public nuisance and negligence claims against the Company. The City of Baltimore action also was transferred to the MDL-2924 and subsequently was remanded to the Circuit Court of Maryland by the MDL-2924 Court. The City of Baltimore intends to file an amended complaint and the defendants will then move to dismiss the case. In January 2021, the Company was served in a Proposition 65 case filed by the Center for Environmental Health in the Superior Court of Alameda County, California. The plaintiff purports to bring the case on behalf of the people of California and alleges that the Company violated Proposition 65, a California law requiring manufacturers to disclose the presence of carcinogens in consumer products. The Company and other defendants have filed demurrers (motions to dismiss) in the case, and on May 7, 2021 the Court granted all such demurrers without leave to amend the pleadings. The People of California have the right to appeal this decision. The Company believes that all of the aforesaid complaints and asserted claims are without merit and it denies any wrongdoing and intends to vigorously defend itself against the allegations. Any liability that may arise on account of these claims is unascertainable at this time. Accordingly, no provision was made in these consolidated financial statements of the Company. Class Action and Other Civil Litigation on Pricing/Reimbursement Matters On December 30, 2015 and on February 4, 2016, respectively, a class action complaint (the “First Pricing Complaint”) and another complaint (not a class action) (the “Second Pricing Complaint”) were filed against the Company and eighteen other pharmaceutical defendants in State Court in the Commonwealth of Pennsylvania. In these actions, the class action plaintiffs allege that the Company and other defendants, individually or in some cases in concert with one another, have engaged in pricing and price reporting practices in violation of various Pennsylvania state laws. More specifically, the plaintiffs allege that: (1) the Company provided false and misleading pricing information to third party drug compendia companies for the Company’s generic drugs, and such information was relied upon by private third party payers that reimbursed for drugs sold by the Company in the United States, and (2) the Company acted in concert with certain other defendants to unfairly raise the prices of generic divalproex sodium ER (bottle of 80, 500 mg tablets ER 24H) and generic pravastatin sodium (bottle of 500, 10 mg tablets). The First Pricing Complaint was removed to the U.S. District Court for the Eastern District of Pennsylvania (the “E.D.P.A. Federal Court”) and, pending the outcome of the First Pricing Complaint, the Second Pricing Complaint was stayed. On September 25, 2017, the E.D.P.A. Federal Court dismissed all the claims of the plaintiffs in the First Pricing Complaint and denied leave to amend such complaint as futile. Subsequent to this decision, the plaintiffs’ right to appeal the dismissal of the First Pricing Complaint expired. Further, on November 17, 2016, certain class action complaints were filed against the Company and a number of other pharmaceutical companies as defendants in the E.D.P.A. Federal Court. Subsequently, these complaints were consolidated into one amended complaint as part of a multi-district, multi-product litigation pending with the E.D.P.A. Federal Court. These complaints allege that the Company and the other named defendants have engaged in a conspiracy to fix prices and to allocate bids and customers in the sale of pravastatin sodium tablets and divalproex sodium extended-release tablets in the United States. In March 2017, plaintiffs agreed by stipulation to dismiss Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Limited from the actions related to pravastatin sodium tablets without prejudice. The Company denies any wrongdoing and intends to vigorously defend against these allegations. In response to the consolidated new complaint, the Company filed a motion to dismiss in October 2017. The plaintiffs filed opposition to the motion to dismiss in December 2017 and a reply was filed by the Company in January 2018. In October 2018, the Court denied the motion to dismiss on the grounds that the allegations pled leave open the possibility of conspiracy. Therefore, discovery will proceed to look into this possibility. The Company believes that the asserted claims are without merit and intends to vigorously defend itself against the allegations. Also any liability that may arise on account of these claims is unascertainable. Accordingly, no provision was made in these consolidated financial statements of the Company. United States Antitrust Multi-District Litigation s The following cases against the Company’s U.S. subsidiary, Dr. Reddy’s Laboratories, Inc., have been filed and are pending and consolidated in In re Generic Pharmaceutical Pricing Antitrust Litigation, MDL 2724, 14-MD-272

Collaboration, License and Opti

Collaboration, License and Option Agreement with Curis, Inc	12 Months Ended
Collaboration, License and Option Agreement with Curis, Inc	Mar. 31, 2021
Curis, Inc. [Member]
Collaboration Agreement [Line Items]
Collaboration, License and Option Agreement with Curis, Inc	34. Collaboration, License and Option Agreement with Curis, Inc. On January 18, 2015, Aurigene Discovery Technologies Limited ("ADTL"), a wholly-owned subsidiary of the parent company, entered into a Collaboration, License and Option Agreement (as amended, the "Collaboration Agreement") with Curis, Inc. ("Curis") to discover, develop and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Under the Collaboration Agreement, ADTL has the responsibility for conducting all discovery and preclinical activities, including Investigational New Drug ("IND") enabling studies and providing Phase 1 clinical trial supply, and Curis is responsible for all clinical development, regulatory and commercialization efforts worldwide, excluding India and Russia. The Collaboration Agreement provides that the parties will collaborate exclusively in immuno-oncology for an initial period of approximately two years, with the option for Curis to extend the broad immuno-oncology exclusivity. Revenues under the Collaboration Agreement consist of upfront consideration (including shares of Curis common stock) and the development and commercial milestone payments (including royalties) which are deferred and recognized as revenue over the period for which ADTL has continuing performance obligations. As a partial consideration for the collaboration, the following shares of Number of Curis Fair value Pursuant to the collaboration agreement dated January 18, 2015 17.1 million Rs.1,452 (U.S.$23.5) Pursuant to an amendment to collaboration agreement dated S e 10.2 million Rs.1,247 (U.S.$18.8) The Company has classified all of the shares of Curis common stock received, as a partial consideration for the collaboration, as an investment in equity instruments measured at FVTOCI. In May 2018, Curis completed a 1-for-5 reverse stock split of its common stock. After giving effect to such stock split, the total number of Curis equity shares held by the Company is 5.47 million. The following table is a summary of the details of cost, fair value, and the amount recognized in OCI of the fair value changes: As of March 31, 2021 Cost Unrealized gain Fair value Received on January 18, 2015 Rs. 1,452 Rs. 1,382 Rs. 2,834 Received on September 7, 2016 1,247 442 1,689 Rs. 2,699 Rs. 1,824 Rs. 4,523

Merger of Dr. Reddy's Holdings

Merger of Dr. Reddy's Holdings Limited into Dr. Reddy's Laboratories Limited	12 Months Ended
	Mar. 31, 2021
Disclosure Merger Of Dr Reddys Holdings Limited Into Dr Reddys Laboratories Limited [Abstract]
Merger of Dr. Reddy's Holdings Limited into Dr. Reddy's Laboratories Limited	35. Merger of Dr. Reddy’s Holdings Limited into Dr. Reddy’s Laboratories Limited The Board of Directors, at its meeting held on July 29, 2019, has approved the amalgamation (the “Scheme”) of Dr. Reddy’s Holdings Limited (“DRHL”), an entity held by the Promoter Group, which holds 24.88% of Dr. Reddy’s Laboratories Limited (the “Company”) into the Company. This is subject to the approval of shareholders, stock exchanges, the National Company Law Tribunal (“NCLT”) and other relevant regulators. The Scheme will lead to simplification of the shareholding structure and reduction of shareholding tiers. The Promoter Group cumulatively would continue to hold the same number of shares in the Company, pre- and post the amalgamation. All costs, charges and expenses relating to the Scheme will be borne out of the surplus assets of DRHL. Further, any expense, if exceeding the surplus assets of DRHL, will be borne directly by the Promoters. The Scheme also provides that the Promoters of the Company will jointly and severally indemnify, defend and hold harmless the Company, its directors, employees, officers, representatives, or any other person authorized by the Company (excluding the Promoters) for any liability, claim, or demand, which may devolve upon the Company on account of this amalgamation. During year ended March 31, 2020, the Scheme was approved by the board of directors, members and unsecured creditors of the Company. The no-observation letters from the BSE Limited and National Stock Exchange of India Limited were received on the basis of no comments received from Securities and Exchange Board of India (“SEBI”). The petition for approval of the said Scheme was filed with the Hon’ble NCLT, Hyderabad Bench. T and

Secondary listing of the Compan

Secondary listing of the Company's ADR on NSE IFSC Limited	12 Months Ended
Secondary listing of the Company's ADR on NSE IFSC Limited	Mar. 31, 2021
Disclosure Of Secondary Listing of the Companys ADR on NSE IFSC Limited [Abstract]
Secondary listing of the Company's ADR on NSE IFSC Limited	36. Secondary listing of the Company’s ADR on NSE IFSC Limited The Company completed the secondary listing of its American Depository Receipts (“ADRs”) on NSE IFSC Limited under the symbol ’DRREDDY’ on December 9, 2020. NSE IFSC Limited is a recognized international stock exchange established in the International Financial Services Centre (“IFSC”) at Gujarat International Finance Tec (“GIFT”) City in Gujarat, India. IFSC is one of the permissible jurisdictions where Depository Receipts can be listed in India. This listing provides a secondary platform (other than NYSE Inc.) to overseas investors for trading in the Company’s ADRs. This is a secondary listing of ADRs that are currently issued by J.P. Morgan Chase Bank N.A. under its ADR Deposit Agreement with the Company, and no further capital raising or issuance of new securities is involved.

Impact of COVID-19

Impact of COVID-19	12 Months Ended
Impact of COVID-19	Mar. 31, 2021
Disclosure of Impact of COVID19 [Abstract]
Impact of COVID-19	37. Impact of COVID-19 The Company considered the uncertainty relating to the COVID-19 pandemic in assessing the recoverability of receivables, goodwill, intangible assets, investments and other assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these consolidated financial statements. The Company based on its judgments, estimates and assumptions including sensitivity analysis, expects to fully recover the carrying amount of receivables, goodwill, intangible assets, investments and other assets. The Company will continue to closely monitor any material changes to future economic conditions.

Update on Cyber Incident

Update on Cyber Incident	12 Months Ended
Update on Cyber Incident	Mar. 31, 2021
Disclosure of Update on Cyber Incident [Abstract]
Update on Cyber Incident	38. Update on Cyber Incident On October 22, 2020, the Company experienced a cybersecurity incident related to ransom-ware. The company employed two leading cyber security incident response firms to assist with the investigation process. The incident was contained in a timely fashion and an enterprise-wide remediation was undertaken to ensure all traces of infection are completely removed from the network. Since then, the Company has strength e

The Code on Social Security, 20

The Code on Social Security, 2020	12 Months Ended
The Code on Social Security, 2020	Mar. 31, 2021
Disclosure Of The Code on Social Security 2020 [Abstract]
The Code on Social Security, 2020	39. The Code on Social Security, 2020 India’s Code on Social Security, 2020, which aims to consolidate, codify and revise certain existing social security laws, received Presidential assent in September 2020 and has been published in the Gazette of India. However, the related final rules have not yet been issued and the date on which this Code will come into effect has not been announced. The Company will assess the impact of this Code and the rules thereunder when they come into effect.

Update on the warning letter fr

Update on the warning letter from the U.S. FDA	12 Months Ended
Update on the warning letter from the U.S. FDA	Mar. 31, 2021
Update on the warning letter from the US FDA [Line Items]
Disclosure of update on the warning letter from regulatory authority explanatory	40. Update on the warning letter from the U.S. FDA The Company received a warning letter dated November 5, 2015 from the U.S. FDA relating to current Good Manufacturing Practices (“cGMPs”) deviations at its active pharmaceutical ingredient (“API”) manufacturing facilities at Srikakulam, Andhra Pradesh and Miryalaguda, Telangana, as well as violations at its oncology formulation manufacturing facility at Duvvada, Visakhapatnam, Andhra Pradesh. The contents of the warning letter emanated from Form 483 observations that followed inspections of these sites by the U.S. FDA in November 2014, January 2015 and February-March 2015. Tabulated below are the further updates with respect to the aforementioned sites: Month and year Update February, March and April 2017 The U.S. FDA completed the re-inspection of the aforementioned manufacturing facilities. During the re-inspections, the U.S. FDA issued three observations with respect to the API manufacturing facility at Miryalaguda, two observations with respect to the API manufacturing facility at Srikakulam and thirteen observations with respect to the Company’s oncology formulation manufacturing facility at Duvvada. June 2017 The U.S. FDA issued an Establishment Inspection Report (“EIR”) which indicated that the inspection of the Company’s API manufacturing facility at Miryalaguda was successfully closed. November 2017 The Company received EIRs from the U.S. FDA for the oncology manufacturing facility at Duvvada which indicated that the inspection status of this facility remained unchanged. February 2018 The Company received EIRs from the U.S. FDA for API manufacturing facility at Srikakulam which indicated that the inspection status of this facility remained unchanged. June 2018 The Company requested the U.S. FDA to schedule a re-inspection of the oncology formulation manufacturing facility at Duvvada. October 2018 The re-inspection was completed for the oncology formulation manufacturing facility at Duvvada and the U.S. FDA issued a Form 483 with eight observations. November 2018 The Company responded to the observations identified by the U.S. FDA for the oncology formulation manufacturing facility at Duvvada in October 2018. February 2019 The U.S. FDA issued an EIR indicating successful closure of the audit of the oncology formulation manufacturing facility at Duvvada. With respect to the API manufacturing facility at Srikakulam, subsequent to the receipt of an EIR in February 2018, the Company was asked, in October 2018, to carry out certain detailed investigations and analyses and the Company submitted the results of the investigations and analyses. As part of the review of the response by the U.S. FDA, certain additional follow on queries were received by the Company, and the Company responded to all such queries in January 2019. In February 2019, the Company received certain other follow on questions from the U.S. FDA and the Company responded to these questions in March 2019. The U.S. FDA completed the audit on January 28, 2020. The Company was issued a Form 483 with 5 observations and responded to the observations in February 2020. In May 2020, the Company received an EIR from the U.S. FDA, for the above-referred facility, indicating closure of the audit and classifying the inspection of this facility as Voluntary Action Indicated (“VAI”). With this, all facilities under the 2015 warning letter are now determined as VAI. Inspection of other facilities: Tabulated below are the details of the U.S. FDA inspections carried out at other facilities of the Company: Located in India Month and year Unit Details of observations June 2018 API Srikakulam Plant (SEZ) No observations were noted. An EIR indicating the closure of audit for this facility was issued by the U.S. FDA in August 2018. November 2018 Formulations Srikakulam Plant (SEZ) Unit II No observations were noted. An EIR indicating the closure of audit for this facility was issued by the U.S. FDA in February 2019. January 2019 Formulations Srikakulam Plant (SEZ) Unit I Four observations were noted. The Company responded to the observations and an EIR indicating the closure of audit for this facility was issued by the U.S. FDA in April 2019. January 2019 API manufacturing Plant at Miryalaguda, Nalgonda One observation was noted. The Company responded to the observation. In May 2019, an EIR was issued by the U.S. FDA indicating the closure of audit and the inspection classification of the facility was determined as VAI. January 2019 Formulations manufacturing facility at Bachupally, Hyderabad Eleven observations were noted. The Company responded to the observations in January 2019. In April 2019, an EIR was issued by the U.S. FDA indicating the closure of audit and the inspection classification of the facility was determined as VAI. Month and year Unit Details of observations March 2019 Aurigene Discovery Technologies Limited, Hyderabad No observations noted. In June 2019, the Company received an EIR from the U.S. FDA indicating the closure of audit for this facility. June 2019 Formulations manufacturing plants, Duvvada {Vizag SEZ plant 1 (FTO VII) and Vizag SEZ plant 2(FTO IX)} Two observations were noted. The Company responded to the observations. In September 2019, an EIR was issued by the U.S. FDA indicating the closure of audit of these facilities. July 2019 API Hyderabad plant 2, Bollaram, Hyderabad Five observations were noted during U.S. FDA inspection. The Company responded to the observations in August 2019. In October 2019, an EIR was issued by the U.S. FDA indicating the closure of audit and the inspection classification of the facility was determined as VAI. August 2019 Formulations manufacturing plants, (Vizag SEZ plant 1), Duvvada, Visakhapatnam (FTO VII) Eight observations were noted. The Company responded to the observations in September 2019. In February 2020, an EIR was issued by the U.S. FDA indicating the closure of audit and the inspection classification of the facility was determined as VAI. August 2019 Formulations manufacturing facility at Shreveport, Louisiana, U.S.A No observations were noted. In October 2019, an EIR was issued by the U.S. FDA indicating the closure of the audit and the inspection classification of the facility was determined as No Action Initiated (“NAI”). October 2019 API Srikakulam plant (SEZ), Andhra Pradesh Four observations were noted. The Company responded to the observations in November 2019. In May 2020, an EIR was issued by the U.S. FDA indicating the closure of the audit. February 2020 Formulations Srikakulam Plant (SEZ) Unit I No observations were noted. In May 2020, an EIR was issued by the U.S. FDA indicating the closure of the audit and the inspection classification of the facility was determined as NAI. February 2020 Formulations manufacturing facility at Bachupally, Hyderabad (FTO Unit III) One observation was noted. The Company responded to the observation in March 2020. In May 2020, an EIR was issued by the U.S. FDA indicating the closure of the audit and the inspection classification of the facility was determined as VAI. February 2020 Integrated Product Development Organization (IPDO) at Bachupally, Hyderabad No observation was noted. In May 2020, an EIR was issued by the U.S. FDA indicating the closure of the audit and the inspection classification of the facility was determined as NAI. March 2020 API manufacturing Plant at Miryalaguda, Nalgonda Three observations were noted. The Company responded to the observations in March 2020. In April 2020, an EIR was issued by the U.S. FDA indicating the closure of the audit and the inspection classification of the facility was determined as VAI. No U.S. FDA audits were conducted during the year ended March 31, 2021.

Subsequent events

Subsequent events	12 Months Ended
Subsequent events	Mar. 31, 2021
Disclosure Of Events After Reporting Period [Abstract]
Subsequent events	41. Subsequent events Please refer to Notes 6, 20 and 33 of these consolidated financial statements for the details of subsequent events relating to the business transfer agreement with Wockhardt Limited, proposed dividend and contingencies, respectively. On June 3, 2021, the Company allotted 43,083 equity shares to various employees with an exercise price of Rs.5 each (34,610 equity shares for Rs.5 each pursuant to the DRL 2002 Plan and 8,473 equity shares for Rs.5 each underlying 8,473 ADRs pursuant to the DRL 2007 plan).

Organizational structure

Organizational structure	12 Months Ended
Organizational structure	Mar. 31, 2021
Disclosure Of Significant Investments In Subsidiaries Associates And Joint Ventures [Abstract]
Organizational structure	42. Organizational structure Dr. Reddy’s Laboratories Limited is the parent company. Tabulated below is the list of subsidiaries and joint ventures as of March 31, 2021: Name of the subsidiary/joint venture Country of Percentage of Direct/Indirect Aurigene Discovery Technologies (Malaysia) Sdn. Bhd. Malaysia 100% (3) Aurigene Discovery Technologies, Inc. U.S.A. 100% (3) Aurigene Discovery Technologies Limited India 100% Aurigene Pharmaceutical Services Limited (from September 16, 2019) India 100% (3) beta Institut gemeinnützige GmbH Germany 100% (8) betapharm Arzneimittel GmbH Germany 100% (8) Cheminor Investments Limited India 100% Cheminor Employees Welfare Trust India Refer to below footnote (16) Chirotech Technology Limited United Kingdom 100% (2)(5) Dr. Reddy’s Research Foundation India Refer to below footnote (16) Dr. Reddy's Employees ESOS Trust (from July 27, 2018) India Refer to below footnote (16) Dr. Reddy’s Farmaceutica Do Brasil Ltda. Brazil 100% Dr. Reddy’s Laboratories (EU) Limited United Kingdom 100% (10) Dr. Reddy’s Laboratories (Proprietary) Limited South Africa 100% (10) Dr. Reddy’s Laboratories (UK) Limited United Kingdom 100% (5) Dr. Reddy’s Laboratories Canada, Inc. Canada 100% (10) Dr. Reddy's Laboratories Chile SPA. Chile 100% (10) Dr. Reddy’s Laboratories, Inc. U.S.A. 100% (10) Dr. Reddy’s Laboratories Japan KK Japan 100% (10) Dr. Reddy’s Laboratories Kazakhstan LLP Kazakhstan 100% (10) Dr. Reddy’s Laboratories Louisiana, LLC U.S.A. 100% (6) Dr. Reddy’s Laboratories Malaysia Sdn. Bhd. Malaysia 100% (10) Dr. Reddy’s Laboratories New York, LLC U.S.A. 100% (1) Dr. Reddy's Laboratories Philippines Inc. (from May 9, 2018) Philippines 100% (10) Dr. Reddy’s Laboratories Romania S.R.L. Romania 100% (10) Dr. Reddy’s Laboratories SA Switzerland 100% Dr. Reddy's Laboratories Taiwan Limited Taiwan 100% (10) Dr. Reddy's Laboratories (Thailand) Limited (from June 13, 2018) Thailand 100% (10) Dr. Reddy’s Laboratories, LLC Ukraine 100% (10) Dr. Reddy’s New Zealand Limited New Zealand 100% (10) Dr. Reddy’s S.R.L. Italy 100% (11) Dr. Reddy's Bio-Sciences Limited India 100% Dr. Reddy's Laboratories (Australia) Pty. Limited Australia 100% (10) Dr. Reddy's Laboratories S.A.S. Colombia 100% (10) Dr. Reddy's Research and Development B.V. (formerly Octoplus B.V.) Netherlands 100% (12) Dr. Reddy's Venezuela, C.A. Venezuela 100% (10) Dr. Reddy’s (WUXI) Pharmaceutical Company Limited China 100% (10) Dr. Reddy’s (Beijing) Pharmaceutical Co. Limited (from August 19, 2020) China 100% (10) DRANU LLC U.S.A. 50% (14)(17) DRES Energy Private Limited India 26% (15) DRL Impex Limited India 100% (13) Dr. Reddy's Laboratories B.V. (formerly Eurobridge Consulting B.V.) Netherlands 100% (12) Dr. Reddy’s Formulations Limited (from March 11, 2021) India 100% Idea2Enterprises (India) Private Limited India 100% Imperial Credit Private Limited India 100% Industrias Quimicas Falcon de Mexico, S.A. de CV Mexico 100% Kunshan Rotam Reddy Pharmaceutical Co. Limited China 51.33% (4) Lacock Holdings Limited Cyprus 100% (10) OOO Dr. Reddy's Laboratories Limited Russia 100% (10) OOO DRS LLC Russia 100% (9) Promius Pharma, LLC U.S.A. 100% (6) Reddy Holding GmbH Germany 100% (10) Reddy Netherlands B.V. Netherlands 100% (10) Reddy Pharma Iberia S.A.U. Spain 100% (10) Reddy Pharma Italia S.R.L. Italy 100% (7) Reddy Pharma SAS France 100% (10) Svaas Wellness Limited (formerly Regkinetics Services Limited) India 100% (1) Indirectly owned through Dr. Reddy’s Laboratories, Inc. (from October 29, 2020), formerly a subsidiary of Dr. Reddy’s Laboratories SA. Also, conversion from corporation to limited liability company is effective October 30, 2020. (2) Entity under liquidation. (3) Indirectly owned through Aurigene Discovery Technologies Limited. (4) Kunshan Rotam Reddy Pharmaceutical Co. Limited is a subsidiary as per Indian Companies Act, 2013, as the Company holds a 51.33% stake. However, the Company accounts for this investment by the equity method and does not consolidate it in the Company’s financial statements. (5) Indirectly owned through Dr. Reddy’s Laboratories (EU) Limited. (6) Indirectly owned through Dr. Reddy’s Laboratories Inc. (7) Indirectly owned through Lacock Holdings Limited. (8) Indirectly owned through Reddy Holding GmbH. (9) Indirectly owned through OOO Dr. Reddy's Laboratories Limited. (10) Indirectly owned through Dr. Reddy’s Laboratories SA. (11) Indirectly owned through Reddy Pharma Italia S.R.L. (12) Indirectly owned through Reddy Netherlands B.V. (13) Indirectly owned through Idea2Enterprises (India) Pvt. Limited. (14) DRANU LLC is consolidated in accordance with guidance available in IFRS 10, “Consolidated Financial Statements” (15) Accounted in accordance with IFRS 11, “Joint Arrangements” (16) The Company does not have any equity interests in this entity, but has significant influence or control over it. (17) Pursuant to the sale of the membership interests in DRANU, LLC, it ceased to be a joint venture effective March 31, 2021.

Basis of preparation of finan_2

Basis of preparation of financial statements (Policies)	12 Months Ended
Basis of preparation of financial statements (Policies)	Mar. 31, 2021
Basis of preparation of financial statements [Abstract]
Statement of compliance	a. Statement of compliance These consolidated financial statements as of and for the year ended March 31, 2021 comply in all material aspects with the International Financial Reporting Standards and its interpretations (“IFRS”) as issued by the International Accounting Standards Board (“IASB”). These consolidated financial statements have been prepared by the Company as a going concern on the basis of relevant IFRS that are effective or elected for early adoption at the Company’s annual reporting date, March 31, 2021. These consolidated financial statements were authorized for issuance by the Company’s Board of Directors on June 29
Basis of measurement	b. Basis of measurement These consolidated financial statements have been prepared on the historical cost convention and on an accrual basis, except for the following material items in the statement of financial position: · derivative financial instruments are measured at fair value; · financial assets are measured either at fair value or at amortized cost, depending on the classification; · employee defined benefit assets/(liabilities) are recognized as the net total of the fair value of plan assets, adjusted for actuarial gains/(losses) and the present value of the defined benefit obligation; · long-term borrowings are measured at amortized cost using the effective interest rate method; · share-based payments are measured at fair value; · investments in joint ventures are accounted for using the equity method; · assets held for sale are measured at fair value; · assets acquired and liabilities assumed as part of business combinations are measured at fair value; and · right-of-use the assets are recognized at the present value of lease payments that are not paid at that date. This amount is adjusted for any lease payments made at or before the commencement date, lease incentives received and initial direct costs, incurred, if any.
Convenience translation (unaudited)	c. Convenience translation (unaudited) These consolidated financial statements have been prepared in Indian rupees. Solely for the convenience of the reader, these consolidated financial statements as of and for the year ended March 31, 2021 have been translated into U.S. dollars at the certified foreign exchange rate of U.S.$1.00 = Rs.73.14, as published by the Federal Reserve Board of Governors on March 31, 2021. No representation is made that the Indian rupee amounts have been, could have been or could be converted into U.S. dollars at such a rate or any other rate. Such convenience translation is not subject to audit by the Company’s Independent Registered Public Accounting Firm.
Use of estimates and judgments	d. Use of estimates and judgments The preparation of financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. In particular, information about significant areas of estimation uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes: · Note 3(b) — Assessment of functional currency; · Notes 3(a) and 15 — Evaluation of joint arrangements; · Notes 3(c), 31 and 32 — Financial instruments; · Notes 3(d) and 6 — Business combinations; · Notes 3(e) and (f) — Useful lives of property, plant and equipment and intangible assets; · Notes 3(g) – Determination of cost for right-of-use assets and lease term; · Notes 3(h) and 10— Valuation of inventories; · Notes 3(i), 12, 13 and 14— Measurement of recoverable amounts of cash-generating units; · Notes 3 (j) and 28 — Assets and obligations relating to employee benefits; · Notes 3 (j) and 29— Share-based payments; · Note 3(k) and 18 — Provisions and other accruals; · Note 3(l) — Measurement of transaction price in a revenue transaction (sales returns, rebates and chargeback provisions); · Note 3(o) and 25 — Evaluation of recoverability of deferred tax assets, and estimation of income tax payable and income tax expense in relation to uncertain tax positions; and · Note 33 — Contingencies.
Current and non-current classification	e. Current and non-current classification All assets and liabilities have been classified as current or non-current as per the Company’s normal operating cycle and other criteria set out in IAS 1, “Presentation of financial statements” Assets: An asset is classified as current when it satisfies any of the following criteria: a) it is expected to be realized in, or is intended for sale or consumption in, the Company’s normal operating cycle; b) it is held primarily for the purpose of being traded; c) it is expected to be realized within twelve months after the reporting date; or d) it is cash or a cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting date. Liabilities: A liability is classified as current when it satisfies any of the following criteria: a) it is expected to be settled in the Company’s normal operating cycle; b) it is held primarily for the purpose of being traded; c) it is due to be settled within twelve months after the reporting date; or d) the Company does not have an unconditional right to defer settlement of the liability for at least twelve months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification. Current assets and liabilities include the current portion of non-current assets and liabilities respectively. All other assets and liabilities are classified as non-current. Deferred tax assets and liabilities are always classified as non-current.
Prior period	f. Prior period Prior period amounts have been reclassified to conform to the current year classification.

Significant accounting polici_2

Significant accounting policies (Policies)	12 Months Ended
Significant accounting policies (Policies)	Mar. 31, 2021
Significant accounting policies [Abstract]
Basis of consolidation	a. Basis of consolidation Subsidiaries Subsidiaries are all entities (including special purpose entities) that are controlled by the Company. Control exists when the Company is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through power over the entity. In assessing control, potential voting rights are considered only if the rights are substantive. The financial statements of subsidiaries are included in these consolidated financial statements from the date that control commences until the date that control ceases. Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated income statement, consolidated statement of comprehensive income, consolidated statement of changes in equity and consolidated statement of financial position, respectively. For the purpose of preparing these consolidated financial statements, the accounting policies of subsidiaries have been changed where necessary to align them with the policies adopted by the Company. Joint arrangements (equity accounted investees) Joint arrangements are those arrangements over which the parties have joint control, established by contractual agreement and requiring unanimous consent for strategic financial and operating decisions. A joint arrangement is either a joint operation or a joint venture. A joint operation is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the assets, and obligations for the liabilities, relating to the arrangement. A joint venture is a joint arrangement whereby the parties that have joint control of the arrangement have rights to the net assets of the arrangement. With respect to joint operations, the Company recognizes its direct right to the assets, liabilities, revenues and expenses of joint operations and its share of any jointly held or incurred assets, liabilities, revenues and expenses. Investments in joint ventures are accounted for using the equity method and are initially recognized at cost. The carrying value of the Company’s investment includes goodwill identified on acquisition, net of any accumulated impairment losses. The Company does not consolidate entities where the non-controlling interest (“NCI”) holders have certain significant participating rights that provide for effective involvement in significant decisions in the ordinary course of business of such entities. Investments in such entities are accounted by the equity method of accounting. When the Company’s share of losses exceeds its interest in an equity accounted investee, the carrying amount of that interest (including any long-term investments) is reduced to zero and the recognition of further losses is discontinued except to the extent that the Company has an obligation or has made payments on behalf of the investee. For the purpose of preparing these consolidated financial statements, the accounting policies of joint ventures have been changed where necessary to align them with the policies adopted by the Company. Furthermore, the financial statements of the joint ventures are prepared for the same reporting period as of the Company. Transactions eliminated on consolidation Intra-group balances and transactions, and any unrealized income and expenses arising from intra-group transactions, are eliminated in full while preparing these consolidated financial statements. Unrealized gains or losses arising from transactions with equity accounted investees are eliminated against the investment to the extent of the Company’s interest in the investee. Changes in ownership interests Acquisition of some or all of the NCI is accounted for as a transaction with equity holders in their capacity as equity holders. Consequently, the difference arising between the fair value of the purchase consideration paid and the carrying value of the NCI is recorded as an adjustment to retained earnings that is attributable to the parent company. The associated cash flows are classified as financing activities. No goodwill is recognized as a result of such transactions. Loss of Control Upon loss of control, the Company derecognizes the assets and liabilities of the subsidiary, any NCIs and the other components of equity related to the subsidiary. Any surplus or deficit arising on the loss of control is recognized in the consolidated income statement. If the Company retains any interest in the previous subsidiary, then such interest is measured at fair value at the date that control is lost. Subsequently, depending on the level of influence retained, it is accounted for as an equity accounted investee or as an investment measured at fair value through other comprehensive income (“FVTOCI”) or fair value through profit or loss (“FVTPL”) under IFRS 9.
Foreign currency	b. Foreign currency Functional and presentation currency These consolidated financial statements are presented in Indian rupees, which is the functional currency of the parent company. All financial information presented in Indian rupees has been rounded to the nearest million. In respect of certain non-Indian subsidiaries that operate as marketing arms of the parent company in their respective countries/regions, the functional currency has been determined to be the functional currency of the parent company (i.e., the Indian rupee). The operations of these entities are largely restricted to importing of finished goods from the parent company in India, sales of these products in the foreign country and making of import payments to the parent company. The cash flows realized from sales of goods are available for making import payments to the parent company and cash is paid to the parent company on a regular basis. The costs incurred by these entities are primarily the cost of goods imported from the parent company. The financing of these subsidiaries is done directly or indirectly by the parent company. In respect of subsidiaries whose operations are self-contained and integrated within their respective countries/regions, the functional currency has been generally determined to be the local currency of those countries/regions, unless use of a different currency is considered appropriate. Foreign currency transactions Transactions in foreign currencies are translated to the respective functional currencies of entities within the Company at exchange rates at the dates of the transactions. Monetary assets and liabilities denominated in foreign currencies at the reporting date are translated into the functional currency at the exchange rate at that date. Non-monetary items that are measured based on historical cost in a foreign currency are translated at the exchange rate at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was measured. Exchange differences arising on the settlement of monetary items or on translating monetary items at rates different from those at which they were translated on initial recognition during the period or in previous financial statements are recognized in the consolidated income statement in the period in which they arise. However, foreign currency differences arising from the translation of the following items are recognized in OCI: · certain debt instruments classified as measured at FVTOCI; · certain equity instruments where the Company had made an irrevocable election to present in OCI subsequent changes in the fair value; · a financial liability designated as a hedge of the net investment in a foreign operation, to the extent that the hedge is effective; and · qualifying cash flow hedges, to the extent that the hedges are effective. When several exchange rates are available, the rate used is that at which the future cash flows represented by the transaction or balance could have been settled if those cash flows had occurred at the measurement date. Foreign operations Foreign exchange gains and losses arising from a monetary item receivable from a foreign operation, the settlement of which is neither planned nor likely in the foreseeable future, are considered to form part of the net investment in the foreign operation and are recognized in OCI and presented within equity as foreign currency translation reserve (“FCTR”). In case of foreign operations whose functional currency is different from the parent company’s functional currency, the assets and liabilities of such foreign operations, including goodwill and fair value adjustments arising upon acquisition, are translated to the reporting currency at exchange rates at the reporting date. The income and expenses of such foreign operations are translated to the reporting currency at the monthly average exchange rates prevailing during the year. Resulting foreign currency differences are recognized in OCI and presented within equity as part of FCTR. When a foreign operation is disposed of, in part or in full, such that control, significant influence or joint control is lost, the relevant amount in the FCTR is reclassified to the consolidated income statement.
Financial instruments	c. Financial instruments A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Financial assets Initial recognition and measurement All financial assets are recognized initially at fair value plus, in the case of financial assets not recorded at fair value through profit or loss, transaction costs that are attributable to the acquisition of the financial asset. Purchases or sales of financial assets that require delivery of assets within a time frame established by regulation or convention in the market place (e.g., regular way trades) are recognized on the trade date, i.e., the date that the Company commits to purchase or sell the asset. Trade receivables are recognized initially at the amount of consideration that is unconditional unless they contain significant financing components, in which case they are recognized at fair value. The Company’s trade receivables do not contain any significant financing component and hence are measured at the transaction price measured under IFRS 15, “Revenue from Contracts with Customers” Subsequent measurement For purposes of subsequent measurement, financial assets are classified in four categories: · Debt instruments at amortized cost; · Debt instruments at FVTOCI; · Debt instruments, derivatives and equity instruments at FVTPL; and · Equity instruments measured at FVTOCI. Debt instruments at amortized cost A “debt instrument” is measured at the amortized cost if both the following conditions are met: a) the asset is held within a business model whose objective is to hold assets for collecting contractual cash flows; and b) contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (“SPPI”) on the principal amount outstanding. After initial measurement, such financial assets are subsequently measured at amortized cost using the effective interest rate method and are subject to impairment. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on de-recognition is recognized directly in the consolidated income statement and presented in other income/(losses),net. The losses arising from impairment are recognized in the consolidated income statement. This category generally applies to trade and other receivables. Debt instrument at FVTOCI A “debt instrument” is classified as at the FVTOCI if both of the following criteria are met: a) the objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets; and b) the asset’s contractual cash flows represent SPPI. Debt instruments included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in the OCI. However, the Company recognizes interest income, impairment losses and reversals and foreign exchange gain or loss in the consolidated income statement. On de-recognition of the asset, cumulative gain or loss previously recognized in OCI is reclassified to the consolidated income statement. Interest earned while holding a FVTOCI debt instrument is reported as interest income using the effective interest rate method. Debt instrument at FVTPL FVTPL is a residual category for debt instruments. Any debt instrument, which does not meet the criteria for categorization as at amortized cost or as FVTOCI, is classified as at FVTPL. In addition, the Company may elect to designate a debt instrument, which otherwise meets amortized cost or FVTOCI criteria, as FVTPL. However, such election is allowed only if doing so reduces or eliminates a measurement or recognition inconsistency (referred to as an “accounting mismatch”). Debt instruments included within the FVTPL category are measured at fair value with all changes recognized in the consolidated income statement. Equity investments All equity investments within the scope of IFRS 9 are measured at fair value. Equity instruments which are held for trading and contingent consideration recognized by an acquirer in a business combination to which IFRS 3 applies, are classified as at FVTPL. For all other equity instruments, the Company may make an irrevocable election to present in OCI subsequent changes in the fair value. The Company makes such election on an instrument-by-instrument basis. The classification is made upon initial recognition and is irrevocable. If the Company decides to classify an equity instrument as at FVTOCI, then all fair value changes on the instrument, excluding dividends, are recognized in the OCI. There is no recycling of the amounts from OCI to the consolidated income statement, even on sale of investment. However, on sale the Company may transfer the cumulative gain or loss within equity. Equity investments designated as FVTOCI are not subject to impairment assessment. Equity instruments included within the FVTPL category are measured at fair value with all changes recognized in the consolidated income statement. De-recognition A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e., removed from the Company’s consolidated statement of financial position) when: · the rights to receive cash flows from the asset have expired; or · Both (1) the Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a “pass-through” arrangement; and (2) either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset. When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognize the transferred asset to the extent of the Company’s continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained. Impairment of trade receivables and other financial assets In accordance with IFRS 9, the Company applies the expected credit loss (“ECL”) model for measurement and recognition of impairment loss on trade receivables or any contractual right to receive cash or another financial asset. For this purpose, the Company follows a “simplified approach” for recognition of impairment loss allowance on the trade receivable balances. The application of this simplified approach does not require the Company to track changes in credit risk. Rather, it recognizes impairment loss allowance based on lifetime ECLs at each reporting date, right from its initial recognition. As a practical expedient, the Company uses a provision matrix to determine impairment loss allowance on portfolio of its trade receivables. The provision matrix is based on its historically observed default rates over the expected life of the trade receivables and is adjusted for forward-looking estimates. At every reporting date, the historical observed default rates are updated and changes in the forward-looking estimates are analyzed. Financial liabilities Initial recognition and measurement Financial liabilities are classified, at initial recognition, as financial liabilities at FVTPL, loans and borrowings, payables, or as derivatives designated as hedging instruments in an effective hedge, as appropriate. All financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables, net of directly attributable transaction costs. The Company’s financial liabilities include trade and other payables, loans and borrowings including bank overdrafts and derivative financial instruments. Subsequent measurement The measurement of financial liabilities depends on their classification, as described below: Financial liabilities at FVTPL Financial liabilities at FVTPL include financial liabilities held for trading and financial liabilities designated upon initial recognition as at FVTPL. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered into by the Company that are not designated as hedging instruments in hedge relationships as defined by IFRS 9. Separated embedded derivatives are also classified as held for trading unless they are designated as effective hedging instruments. Gains or losses on liabilities held for trading are recognized in the consolidated income statement. Financial liabilities designated upon initial recognition at FVTPL are designated as such at the initial date of recognition, and only if the criteria in IFRS 9 are satisfied. For liabilities designated as FVTPL, fair value gains/ losses attributable to changes in own credit risk are recognized in OCI. These gains or losses are not subsequently transferred to the consolidated income statement. However, the Company may transfer the cumulative gain or loss within equity. All other changes in fair value of such liability are recognized in the consolidated income statement. The Company has not designated any financial liability as FVTPL. Loans and borrowings Borrowings are initially recognized at fair value, net of transaction costs incurred. Borrowings are subsequently measured at amortized cost. Any difference between the proceeds (net of transaction costs) and the redemption amount is recognized in the consolidated income statement over the period of the borrowings using the effective interest method. After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortized cost using the effective interest rate method. Gains and losses are recognized in the consolidated income statement when the liabilities are derecognized as well as through the effective interest rate amortization process. Amortized cost is calculated by taking into account any discount or premium on acquisition and fees or costs that are an integral part of the effective interest rate. The effective interest rate amortization is included as finance costs in the consolidated income statement. De-recognition A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the consolidated income statement. Derivative financial instruments The Company is exposed to exchange rate risk which arises from its foreign exchange revenues and expenses, primarily in U.S. dollars, U.K. pounds sterling, Russian roubles, Brazilian reals, Swiss francs, South African rands, Kazakhstan tenges, Romanian new leus, Australian dollars and Euros, and foreign currency debt in U.S. dollars, Russian roubles, South African rands, Mexican pesos, Ukrainian hryvnias and Brazilian reals. The Company uses derivative financial instruments such as foreign exchange forward contracts, option contracts and swap contracts to mitigate its risk of changes in foreign currency exchange rates. The Company also uses non-derivative financial instruments as part of its foreign currency exposure risk mitigation strategy. Derivatives are classified as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. Hedges of highly probable forecasted transactions The Company classifies its derivative financial instruments that hedge foreign currency risk associated with highly probable forecasted transactions as cash flow hedges and measures them at fair value. The effective portion of such cash flow hedges is recorded in the Company’s hedging reserve as a component of equity and re-classified to the consolidated income statement as part of the hedged item in the period corresponding to the occurrence of the forecasted transactions. The ineffective portion of such cash flow hedges is recorded in the consolidated income statement as finance costs immediately. The Company also designates certain non-derivative financial liabilities, such as foreign currency borrowings from banks, as hedging instruments for hedge of foreign currency risk associated with highly probable forecasted transactions. Accordingly, the Company applies cash flow hedge accounting to such relationships. Re-measurement gain or loss on such non-derivative financial liabilities is recorded in the Company’s hedging reserve as a component of equity and reclassified to the consolidated income statement as part of the hedged item in the period corresponding to the occurrence of the forecasted transactions. If the hedging instrument no longer meets the criteria for hedge accounting, expires or is sold, terminated or exercised, then hedge accounting is discontinued prospectively. The cumulative gain or loss previously recognized in OCI, remains there until the forecasted transaction occurs. If the forecasted transaction is no longer expected to occur, then the balance in OCI is recognized immediately in the consolidated income statement. Hedges of recognized assets and liabilities Changes in the fair value of derivative contracts that economically hedge monetary assets and liabilities in foreign currencies, and for which no hedge accounting is applied, are recognized in the consolidated income statement. The changes in fair value of such derivative contracts, as well as the foreign exchange gains and losses relating to the monetary items, are recognized in the consolidated income statement. If the hedged item is derecognized, the unamortized fair value is recognized immediately in the consolidated income statement. Hedges of changes in the interest rates Consistent with its risk management policy, the Company uses interest rate swaps to mitigate the risk of changes in interest rates. The Company does not use them for trading or speculative purposes. Cash and cash equivalents Cash and cash equivalents consist of cash on hand, demand deposits and short-term, highly liquid investments that are readily convertible into known amounts of cash and which are subject to insignificant risk of changes in value. For this purpose, “short-term” means investments having original maturities of three months or less from the date of investment. Bank overdrafts that are repayable on demand form an integral part of the Company’s cash management and are included as a component of cash and cash equivalents for the purpose of the consolidated statement of cash flows.
Business combinations	d. Business combinations The acquisition method of accounting is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. The acquisition date is the date on which control is transferred to the acquirer. Judgment is applied in determining the acquisition date and determining whether control is transferred from one party to another. Control exists when the Company is exposed to, or has rights to variable returns from its involvement with the entity and has the ability to affect those returns through power over the entity. In assessing control, potential voting rights are considered only if the rights are substantive. The Company determines that it has acquired a business when the acquired set of activities and assets include an input and a substantive process that together significantly contribute to the ability to create outputs. The acquired process is considered substantive if it is critical to the ability to continue producing outputs, and the inputs acquired include an organized workforce with the necessary skills, knowledge, or experience to perform that process or it significantly contributes to the ability to continue producing outputs and is considered unique or scarce or cannot be replaced without significant cost, effort, or delay in the ability to continue producing outputs. The consideration transferred for the acquisition of a subsidiary is comprised of: • fair values of the assets transferred; • liabilities incurred to the former owners of the acquired business; • equity interests issued by the Company; • fair value of any asset or liability resulting from a contingent consideration arrangement; and • fair value of any pre-existing equity interest in the subsidiary. Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are, with limited exceptions, measured initially at their fair values at the acquisition date. The Company recognizes any non-controlling interest in the acquired entity on an acquisition-by-acquisition basis either at fair value or at the non-controlling interest’s proportionate share of the acquired entity’s net identifiable assets. Acquisition related costs are expensed as incurred. The excess of the sum of: • the consideration transferred, • the amount of any non-controlling interest in the acquired entity, and • the acquisition date fair value of any previous equity interest in the acquired entity, over the fair value of the net identifiable assets acquired is recorded as goodwill. If those amounts are less than the fair value of the net identifiable assets of the business acquired, the difference is recognized directly in the consolidated income statement as a bargain purchase. Where settlement of any part of cash consideration is deferred, the amounts payable in the future are discounted to their present value as at the date of exchange. The discount rate used is the entity’s incremental borrowing rate, being the rate at which a similar borrowing could be obtained from an independent financier under comparable terms and conditions. Contingent consideration is classified either as equity or a financial liability. Contingent consideration classified as equity is not re-measured and its subsequent settlement is accounted for within equity. Amounts classified as a financial liability are subsequently re-measured to fair value, with changes in fair value recognized in the consolidated income statement. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer’s previously held equity interest in the acquiree is re-measured to fair value at the acquisition date. Any gains or losses arising from such re-measurement are recognized in the consolidated income statement.
Property, plant and equipment	e. Property, plant and equipment Recognition and measurement Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditures that are directly attributable to the acquisition of the asset. The cost of self-constructed assets includes the cost of materials and other costs directly attributable to bringing the asset to a working condition for its intended use. Borrowing costs that are directly attributable to the construction or production of a qualifying asset are capitalized as part of the cost of that asset. When parts of an item of property, plant and equipment have different useful lives, they are accounted for as separate items (major components) of property, plant and equipment. Gains and losses upon disposal of an item of property, plant and equipment are determined by comparing the proceeds from disposal with the carrying amount of property, plant and equipment and are recognized net within “Other (income)/expense, net” in the consolidated income statement. The cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. The costs of repairs and maintenance are recognized in the consolidated income statement as incurred. Items of property, plant and equipment acquired through exchange of non-monetary assets are measured at fair value, unless the exchange transaction lacks commercial substance or the fair value of either the asset received or asset given up is not reliably measurable, in which case the asset exchanged is recorded at the carrying amount of the asset given up. Depreciation Depreciation is recognized in the consolidated income statement on a straight line basis over the estimated useful lives of property, plant and equipment. The depreciation expense is included in the costs of the functions using the asset. Land is not depreciated but subject to impairment. Depreciation methods, useful lives and residual values are reviewed at each reporting date and any changes are considered prospectively. The estimated useful lives are as follows: Buildings - Factory and administrative buildings 20 - 50 years - Ancillary structures 3 - 15 years Plant and equipment 3 - 15 years Furniture, fixtures and office equipment 3 - 10 years Vehicles 4 - 5 years Software for internal use, which is primarily acquired from third-party vendors and which is an integral part of a tangible asset, including consultancy charges for implementing the software, is capitalized as part of the related tangible asset. Subsequent costs associated with maintaining such software are recognized as expense as incurred. The capitalized costs are amortized over the estimated useful life of the software or the remaining useful life of the tangible fixed asset, whichever is lower. Advances paid towards the acquisition of property, plant and equipment outstanding at each reporting date and the cost of property, plant and equipment not ready to use before such date are disclosed under capital work-in-progress. Assets not ready for use are not depreciated but are tested for impairment.
Goodwill and other intangible assets	f. Goodwill and other intangible assets Recognition and measurement Goodwill Goodwill represents the excess of consideration transferred, together with the amount of non-controlling interest in the acquiree, over the fair value of the Company’s share of identifiable net assets acquired. Goodwill is measured at cost less accumulated impairment losses. In respect of equity accounted investees, the carrying amount of goodwill is included in the carrying amount of the investment, and any impairment loss on such an investment is not allocated to any asset, including goodwill, that forms part of the carrying value of the equity accounted investee. Other intangible assets Other intangible assets that are acquired by the Company and that have finite useful lives are measured at cost less accumulated amortization and accumulated impairment losses. The cost of intangible assets acquired in a business combination is their fair value at the date of acquisition. Research and development Expenditures on research activities undertaken with the prospect of gaining new scientific or technical knowledge and understanding are recognized in the consolidated income statement when incurred. Development activities involve a plan or design for the production of new or substantially improved products and processes. Development expenditures are capitalized only if: · development costs can be measured reliably; · the product or process is technically and commercially feasible; · future economic benefits are probable; and · the Company intends to, and has sufficient resources, to complete development and to use or sell the asset. The expenditures to be capitalized include the cost of materials and other costs directly attributable to preparing the asset for its intended use. Other development expenditures are recognized in the consolidated income statement as incurred. As of March 31, 2021, none of the development expenditure amounts has met the aforesaid recognition criteria. Separate acquisition of intangible assets Payments to third parties that generally take the form of up-front payments and milestones for in-licensed products, compounds and intellectual property are capitalized. The Company’s criteria for capitalization of such assets are consistent with the guidance given in paragraph 25 of IAS 38, “ Intangible Assets” In-Process Research and Development assets Acquired research and development intangible assets that are under development are recognized as In-Process Research and Development (“IPR&D”) assets. IPR&D assets are not amortized, but evaluated for potential impairment on an annual basis or when there are indications that the carrying value may not be recoverable. Any impairment charge on such IPR&D assets is recorded in the consolidated income statement under “Impairment of non-current assets”. Subsequent expenditure Other intangible assets Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other expenditures, including expenditures on internally generated goodwill and brands, is recognized in the consolidated income statement as incurred. IPR&D assets Subsequent expenditure on an IPR&D project acquired separately or in a business combination and recognized as an intangible asset is: · recognized as an expense when incurred, if it is a research expenditure; · recognized as an expense when incurred, if it is a development expenditure that does not satisfy the criteria for recognition as an intangible asset in paragraph 57 of IAS 38; and · added to the carrying amount of the acquired IPR&D project, if it is a development expenditure that satisfies the recognition criteria in paragraph 57 of IAS 38. Amortization Amortization is recognized in the consolidated income statement on a straight-line basis over the estimated useful lives of intangible assets. The amortization expense is recognized in the income statement in the expense category that is consistent with the function of the intangible asset. Intangible assets that are not available for use are amortized from the date they are available for use. The estimated useful lives are as follows: Product related intangibles 3 – 20 years Other intangibles 3 - 15 years The amortization period and the amortization method for intangible assets with a finite useful life are reviewed at each reporting date. Changes in the expected useful lives or expected pattern of consumption of future economic benefits embodied in the assets are considered to modify the amortization period or method, as appropriate and are treated as change in accounting estimate. Goodwill, intangible assets relating to products in development, other intangible assets not available for use and intangible assets having indefinite useful life are subject to impairment testing at each reporting date. All other intangible assets are tested for impairment when there are indications that the carrying value may not be recoverable. All impairment losses are recognized immediately in the consolidated income statement under “Impairment of non-current assets”. De-recognition of intangible assets Intangible assets are de-recognized either on their disposal or where no future economic benefits are expected from their use. Losses arising on such de-recognition are recorded in the consolidated income statement, and are measured as the difference between the net disposal proceeds, if any, and the carrying amount of respective intangible assets as at the date of de-recognition.
Leases	g. Leases Accounting policies relating to leases for periods ending on or after April 1, 2019 The Company's accounting policies relating to leases for periods ending on or after April 1, 2019 are as follows: The Company assesses at contract inception whether a contract is or contains a lease, which applies if the contract conveys the right to control the use of the identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset at the commencement date of the lease - i.e., the date the underlying asset is available for use. Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments to be made over the lease term: · fixed payments (including in-substance fixed payments), less any lease incentives receivable; · variable lease payment that are based on an index or a rate, initially measured using the index or rate as at the commencement date; · amounts expected to be payable by the Company under residual value guarantees; · the exercise price of a purchase option if the Company is reasonably certain to exercise that option; and · payments of penalties for terminating the lease, if the lease term reflects the Company exercising that option. The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Company, then the lessee’s incremental borrowing rate is used. Such borrowing rate is calculated as the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions. The Company’s lease liabilities are included in borrowings. Lease payments are allocated between principal and interest cost. The interest cost is charged to consolidated income statement over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period. Right-of-use assets are measured at cost less accumulated depreciation and accumulated impairment, comprised of the following: · the amount of the initial measurement of lease liability; · any lease payments made at or before the commencement date less any lease incentives received; · any initial direct costs; and · restoration costs. Right-of-use assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis. Payments associated with short-term leases of equipment and vehicles and all leases of low-value assets are recognized on a straight-line basis as an expense in the consolidated income statement. Short-term leases are leases with a lease term of 12 months or less. Low-value assets comprise IT equipment and small items of office furniture. The right-of-use assets are initially recognized on the statement of financial position at cost, which is calculated as the amount of the initial measurement of the corresponding lease liability, adjusted for any lease payments made at or prior to the commencement date of the lease, any lease incentive received and any initial direct costs incurred by the Company. Accounting policies relating to leases for periods ending on or prior to March 31, 2019 The Company’s accounting policies relating to leases for periods ending on or prior to March 31, 2019 are as follows: At the inception of each lease, the lease arrangement is classified as either a finance lease or an operating lease, based on the substance of the lease arrangement. Finance leases A finance lease is recognized as an asset and a liability at the commencement of the lease, at the lower of the fair value of the asset and the present value of the minimum lease payments. Initial direct costs, if any, are also capitalized and, subsequent to initial recognition, the asset is accounted for in accordance with the accounting policy applicable to that asset. Minimum lease payments made under finance leases are apportioned between the finance expense and the reduction of the outstanding lease liability. The finance expense is allocated to each period during the lease term so as to produce a constant periodic rate of interest on the remaining balance of the liability. Operating leases Other leases are operating leases, and the leased assets are not recognized on the Company’s statement of financial position. Payments made under operating leases are recognized in the consolidated income statement on a straight-line basis over the term of the lease. Operating lease incentives received from the landlord are recognized as a reduction of rental expense on a straight line basis over the lease term.
Inventories	h. Inventories Inventories consist of raw materials, stores and spares, work in progress and finished goods and are measured at the lower of cost and net realizable value. The cost of all categories of inventories is based on the weighted average method. Cost includes expenditures incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. In the case of finished goods and work in progress, cost includes an appropriate share of overheads based on normal operating capacity. Stores and spares consists of packing materials, engineering spares (such as machinery spare parts) and consumables (such as lubricants, cotton waste and oils), which are used in operating machines or consumed as indirect materials in the manufacturing process. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and selling expenses. The factors that the Company considers in determining the provision for slow moving, obsolete and other non-saleable inventory include estimated shelf life, planned product discontinuances, price changes, aging of inventory and introduction of competitive new products, to the extent each of these factors impact the Company’s business and markets. The Company considers all these factors and adjusts the inventory provision to reflect its actual experience on a periodic basis.
Impairment	i. Impairment Non-financial assets The carrying amounts of the Company’s non-financial assets, other than inventories and deferred tax assets are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, then the asset’s recoverable amount is estimated. For goodwill and intangible assets that have indefinite lives or that are not yet available for use, an impairment test is performed each year at March 31. The recoverable amount of an asset or cash-generating unit (as defined below) is the greater of its value in use and its fair value less costs to sell. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or the cash-generating unit. For the purpose of impairment testing, assets are grouped together into the smallest group of assets that generate cash inflows from continuing use that are largely independent of the cash inflows of other assets or groups of assets (the “cash-generating unit”). The goodwill acquired in a business combination is, for the purpose of impairment testing, allocated to cash-generating units that are expected to benefit from the synergies of the combination. An impairment loss is recognized in the consolidated income statement if the estimated recoverable amount of an asset or its cash-generating unit is lower than its carrying amount. Impairment losses recognized in respect of cash-generating units are allocated first to reduce the carrying amount of any goodwill allocated to the units and then to reduce the carrying amount of the other assets in the unit on a pro-rata basis. An impairment loss in respect of goodwill is not reversed. In respect of other assets, impairment losses recognized in prior periods are assessed at each reporting date for any indications that the loss has decreased or no longer exists. An impairment loss is reversed if there has been a change in the estimates used to determine the recoverable amount. An impairment loss is reversed only to the extent that the asset’s carrying amount does not exceed its recoverable amount, nor exceed the carrying amount that would have been determined, net of depreciation or amortization, if no impairment loss had been recognized. Goodwill that forms part of the carrying amount of an investment in a joint venture is not recognized separately, and therefore is not tested for impairment separately. Instead, the entire amount of the investment in a joint venture is tested for impairment as a single asset when there is objective evidence that the investment in a joint venture may be impaired. An impairment loss in respect of equity accounted investee is measured by comparing the recoverable amount of investment with its carrying amount. An impairment loss is recognized in the consolidated income statement, and reversed if there has been a favorable change in the estimates used to determine the recoverable amount.
Employee benefits	j. Employee benefits Short-term employee benefits Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably. Defined contribution plans The Company’s contributions to defined contribution plans are charged to the consolidated income statement as and when the services are received from the employees. Defined benefit plans The liability in respect of defined benefit plans and other post-employment benefits is calculated using the projected unit credit method consistent with the advice of qualified actuaries. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of the related defined benefit obligation. In countries where there is no deep market in such bonds, the market interest rates on government bonds are used. The current service cost of the defined benefit plan, recognized in the consolidated income statement, reflects the increase in the defined benefit obligation resulting from employee service in the current year, benefit changes, curtailments and settlements. Past service costs are recognized immediately in the consolidated income statement. The net interest cost is calculated by applying the discount rate to the net balance of the defined benefit obligation and the fair value of plan assets. This cost is included in the consolidated income statement. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions for defined benefit obligation and plan assets are recognized in OCI in the period in which they arise. When the benefits under a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognized immediately in the consolidated income statement. The Company recognizes gains or losses on the settlement of a defined benefit plan obligation when the settlement occurs. Termination benefits Termination benefits are recognized as an expense in the consolidated income statement when the Company is demonstrably committed, without realistic possibility of withdrawal, to a formal detailed plan to either terminate employment before the normal retirement date, or to provide termination benefits as a result of an offer made to encourage voluntary redundancy. Termination benefits for voluntary redundancies are recognized as an expense in the consolidated income statement if the Company has made an offer encouraging voluntary redundancy, it is probable that the offer will be accepted, and the number of acceptances can be estimated reliably. Other long-term employee benefits The Company’s net obligation in respect of other long-term employee benefits is the amount of future benefit that employees have earned in return for their service in the current and previous periods. That benefit is discounted to determine its present value. Re-measurements are recognized in the consolidated income statement in the period in which they arise. Compensated absences The Company’s current policies permit certain categories of its employees to accumulate and carry forward a portion of their unutilized compensated absences and utilize them in future periods or receive cash in lieu thereof in accordance with the terms of such policies. The Company measures the expected cost of accumulating compensated absences as the additional amount that the Company incurs as a result of the unused entitlement that has accumulated at the reporting date. Such measurement is based on actuarial valuation as at the reporting date carried out by a qualified actuary. Equity settled share-based payment transactions The grant date fair value of options granted to employees is recognized as an expense in the consolidated income statement, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the options. The amount recognized as an expense is adjusted to reflect the number of awards for which the related service and performance conditions are expected to be met, such that the amount ultimately recognized is based on the number of awards that meet the related service and performance conditions at the vesting date. The expense is recorded for each separately vesting portion of the award as if the award was, in substance, multiple awards. The increase in equity recognized in connection with share-based payment transaction is presented as a separate component in equity under “share-based payment reserve”. The amount recognized as an expense is adjusted to reflect the actual number of stock options that vest. Cash settled share-based payment transactions The fair value of the amount payable to employees in respect of share-based payment transactions which are settled in cash is recognized as an expense, with a corresponding increase in liabilities, over the period during which the employees become unconditionally entitled to payment. The liability is re-measured at each reporting date and at the settlement date based on the fair value of the share-based payment transaction. Any changes in the liability are recognized in the consolidated income statement.
Provisions	k. Provisions A provision is recognized in the consolidated income statement if, as a result of a past event, the Company has a present legal or constructive obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. If the effect of the time value of money is material, provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. Where discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost. Restructuring A provision for restructuring is recognized in the consolidated income statement when the Company has approved a detailed and formal restructuring plan, and the restructuring either has commenced or has been announced publicly. Future operating costs are not provided. Onerous contracts A provision for onerous contracts is recognized in the consolidated income statement when the expected benefits to be derived by the Company from a contract are lower than the unavoidable cost of meeting its obligations under the contract. The provision is measured at the present value of the lower of the expected cost of terminating the contract and the expected net cost of continuing with the contract. Before a provision is established, the Company recognizes any impairment loss on the assets associated with that contract. Reimbursement rights Expected reimbursements for expenditures required to settle a provision are recognized in the consolidated income statement only when receipt of such reimbursements is virtually certain. Such reimbursements are recognized as a separate asset in the statement of financial position, with a corresponding credit to the specific expense for which the provision has been made. Contingent liabilities and contingent assets A disclosure for a contingent liability is made when there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources. Where there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision or disclosure is made. Contingent assets are not recognized in the financial statements. A contingent asset is disclosed where an inflow of economic benefits is probable. Contingent assets are assessed continually and, if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognized in the period in which the change occurs.
Revenue	l. Revenue The Company’s revenue is derived from sales of goods, service income and income from licensing arrangements. Most of such revenue is generated from the sale of goods. The Company has generally concluded that it is the principal in its revenue arrangements. Sale of goods Revenue is recognized when the control of the goods has been transferred to a third party. This is usually when the title passes to the customer, either upon shipment or upon receipt of goods by the customer. At that point, the customer has full discretion over the channel and price to sell the products, and there are no unfulfilled obligations that could affect the customer’s acceptance of the product. Revenue from the sale of goods is measured at the transaction price which is the consideration received or receivable, net of returns, taxes and applicable trade discounts and allowances. Revenue includes shipping and handling costs billed to the customer. In arriving at the transaction price, the Company considers the terms of the contract with the customers and its customary business practices. The transaction price is the amount of consideration the Company is entitled to receive in exchange for transferring promised goods or services, excluding amounts collected on behalf of third parties. The amount of consideration varies because of estimated rebates, returns and chargebacks, which are considered to be key estimates. Any amount of variable consideration is recognized as revenue only to the extent that it is highly probable that a significant reversal will not occur. The Company estimates the amount of variable consideration using the expected value method. Presented below are the points of recognition of revenue with respect to the Company’s sale of goods: Particulars Point of recognition of revenue Sales of generic products in India Upon delivery of products to distributors by clearing and forwarding agents of the Company. Control over the generic products is transferred by the Company when the goods are delivered to distributors from clearing and forwarding agents. Sales of active pharmaceutical ingredients and intermediates in India Upon delivery of products to customers (generally formulation manufacturers), from the factories of the Company. Export sales and other sales outside of India Upon delivery of the products to the customers unless the terms of the applicable contract provide for specific revenue generating activities to be completed, in which case revenue is recognized once all such activities are completed. Profit share revenues The Company from time to time enters into marketing arrangements with certain business partners for the sale of its products in certain markets. Under such arrangements, the Company sells its products to the business partners at a non-refundable base purchase price agreed upon in the arrangement and is also entitled to a profit share which is over and above the base purchase price. The profit share is typically dependent on the business partner’s ultimate net sale proceeds or net profits, subject to any reductions or adjustments that are required by the terms of the arrangement. Such arrangements typically require the business partner to provide confirmation of units sold and net sales or net profit computations for the products covered under the arrangement. Revenue in an amount equal to the base sale price is recognized in these transactions upon delivery of products to the business partners. An additional amount representing the profit share component is recognized as revenue only to the extent that it is highly probable that a significant reversal will not occur. At the end of each reporting period, the Company updates the estimated transaction price (including updating its assessment of whether an estimate of variable consideration is constrained) to represent faithfully the circumstances present at the end of the reporting period and the changes in circumstances during the reporting period. Out licensing arrangements, milestone payments and royalties Revenues include amounts derived from product out-licensing agreements. These arrangements typically consist of an initial up-front payment on inception of the license and subsequent payments dependent on achieving certain milestones in accordance with the terms prescribed in the agreement. In cases where the transaction has two or more components, the Company accounts for the delivered item (for example, the transfer of title to the intangible asset) as a separate unit of accounting and record revenue upon delivery of that component, provided that the Company can make a reasonable estimate of the fair value of the undelivered component. Otherwise, non-refundable up-front license fees received in connection with product out-licensing agreements are deferred and recognized over the balance period in which the Company has pending performance obligations. Milestone payments which are contingent on achieving certain clinical milestones are recognized as revenues either on achievement of such milestones, over the performance period depending on the terms of the contract. If milestone payments are creditable against future royalty payments, the milestones are deferred and released over the period in which the royalties are anticipated to be paid. Royalty income earned through a license is recognized when the underlying sales have occurred. Provision for chargeback, rebates and discounts Provisions for chargeback, rebates, discounts and Medicaid payments are estimated and provided for in the year of sales and recorded as reduction of revenue. A chargeback claim is a claim made by the wholesaler for the difference between the price at which the product is initially invoiced to the wholesaler and the net price at which it is agreed to be procured from the Company. Provisions for such chargebacks are accrued and estimated based on historical average chargeback rate actually claimed over a period of time, current contract prices with wholesalers/other customers and estimated inventory holding by the wholesaler. Shelf stock adjustments Shelf stock adjustments are credits issued to customers to reflect decreases in the selling price of products sold by the Company, and are accrued when the prices of certain products decline as a result of increased competition or otherwise. These credits are customary in the pharmaceutical industry, and are intended to reduce the customer inventory cost to better reflect the current market prices. The determination to grant a shelf stock adjustment to a customer is based on the terms of the applicable contract, which may or may not specifically limit the age of the stock on which a credit would be offered. Refund Liability The Company accounts for sales returns accrual by recording refund liability concurrent with the recognition of revenue at the time of a product sale. This liability is based on the Company’s estimate of expected sales returns. The Company deals in various products and operates in various markets. Accordingly, the estimate of sales returns is determined primarily by the Company’s historical experience in the markets in which the Company operates. With respect to established products, the Company considers its historical experience of actual sales returns, levels of inventory in the distribution channel, estimated shelf life, any revision in the shelf life of the product, product discontinuances, price changes of competitive products, and the introduction of competitive new products, to the extent each of these factors impact the Company’s business and markets. With respect to new products introduced by the Company, such products have historically been either extensions of an existing line of product where the Company has historical experience or in therapeutic categories where established products exist and are sold either by the Company or the Company’s competitors. At the time of recognizing the refund liability, the Company also recognizes an asset, (i.e., the right to the returned goods) which is included in inventories for the products expected to be returned. The Company initially measures this asset at the former carrying amount of the inventory, less any expected costs to recover the goods, including any potential decreases in the value of the returned goods. Along with re-measuring the refund liability at the end of each reporting period, the Company updates the measurement of the asset recorded for any revisions to its expected level of returns, as well as any additional decreases in the value of the returned products. Services Revenue from services rendered, which primarily relate to contract research, is recognized in the consolidated income statement as the underlying services are performed. Upfront non-refundable payments received under these arrangements are deferred and recognized as revenue over the expected period over which the related services are expected to be performed. License fees License fees primarily consist of income from the out-licensing of intellectual property, and other licensing and supply arrangements with various parties. Revenue from license fees is recognized when control transfers to the third party and the Company’s performance obligations are satisfied. Some of these arrangements include certain performance obligations by the Company. Revenue from such arrangements is recognized in the period in which the Company completes all its performance obligations.
Shipping and handling costs	m. Shipping and handling costs Shipping and handling costs incurred to transport products to customers, and internal transfer costs incurred to transport the products from the Company’s factories to its various points of sale, are included in selling, general and administrative expenses.
Finance income and expense	n. Finance income and expense Finance income consists of interest income on funds invested, dividend income and gains on the disposal of financial assets. Interest income is recognized in the consolidated income statement as it accrues, using the effective interest method. Dividend income is recognized in the consolidated income statement on the date that the Company’s right to receive payment is established. The associated cash flows are classified as investing activities in the statement of cash flows. Finance expenses consist of interest expense on loans and borrowings. Borrowing costs are recognized in the consolidated income statement using the effective interest method. The associated cash flows are classified as financing activities in the statement of cash flows. Foreign currency gains and losses are reported on a net basis within finance income and expense. These primarily include: exchange differences arising on the settlement or translation of monetary items; changes in the fair value of derivative contracts that economically hedge monetary assets and liabilities in foreign currencies and for which no hedge accounting is applied; and the ineffective portion of cash flow hedges.
Income tax	o. Income tax Income tax expense consists of current and deferred tax. Income tax expense is recognized in the consolidated income statement except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is recognized using the balance sheet method, providing for temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is not recognized for the following temporary differences: · temporary differences on the initial recognition of assets or liabilities in a transaction that is not a business combination and that affects neither accounting nor taxable profit; · temporary differences relating to investments in subsidiaries and jointly controlled entities to the extent that it is probable that they will not reverse in the foreseeable future; and · taxable temporary differences arising upon the initial recognition of goodwill. Deferred tax is measured at the tax rates that are expected to be applied to the temporary differences when they reverse, based on the laws that have been enacted or substantively enacted at the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related deferred tax asset will be utilized. Unrecognized deferred tax assets are reassessed at each reporting date and are recognized to the extent that it has become probable that the future taxable profits will allow the deferred tax assets to be recovered. Any deferred tax asset or liability arising from deductible or taxable temporary differences in respect of unrealized inter-company profit or loss on inventories held by the Company in different tax jurisdictions is recognized using the tax rate of the jurisdiction in which such inventories are held. Withholding tax arising out of payment of dividends to shareholders under the Indian Income tax regulations is not considered as tax expense for the Company and all such taxes are recognized in the statement of changes in equity as part of the associated dividend payment. Current and deferred tax is recognized in the consolidated income statement, except to the extent that it relates to items recognized in OCI or directly in equity. In this case, the tax is also recognized in OCI or directly in equity, respectively. Accruals for uncertain tax positions require management to make judgments of potential exposures. Accruals for uncertain tax positions are measured using either the most likely amount or the expected value amount, depending on which method the entity expects to better predict the resolution of the uncertainty. Tax benefits are not recognized unless the tax positions will probably be accepted by the tax authorities. This is based upon management’s interpretation of applicable laws and regulations and the expectation of how the tax authority will resolve the matter. Once considered probable of not being accepted, management reviews each material tax benefit and reflects the effect of the uncertainty in determining the related taxable amounts.
Earnings per share	p. Earnings per share The Company presents basic and diluted earnings per share (“EPS”) data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the Company by the weighted average number of ordinary shares outstanding during the period. Diluted EPS is determined by adjusting the profit or loss attributable to ordinary shareholders and the weighted average number of ordinary shares outstanding for the effects of all dilutive potential ordinary shares, which includes all stock options granted to employees.
Government grants and incentives	q. Government grants and incentives The Company recognizes government grants only when there is reasonable assurance that the conditions attached to them will be complied with, and the grants will be received. Government grants received in relation to assets are presented as a reduction to the carrying amount of the related asset. Grants related to income are deducted in reporting the related expense in the consolidated income statement. Export entitlements from government authorities are recognized in the consolidated income statement as a reduction from “Cost of Revenues” when the right to receive credit as per the terms of the scheme is established in respect of the exports made by the Company, and where there is no significant uncertainty regarding the ultimate collection of the relevant export proceeds.
Segment Reporting	r. Segment reporting Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The Chief Executive Officer of the Company is responsible for allocating resources and assessing performance of the operating segments and accordingly is identified as the chief operating decision maker.
Treasury shares	s. Treasury shares Own equity instruments that are reacquired (treasury shares) are recognized at cost and deducted from equity. No gain or loss is recognized in the consolidated income statement on the purchase, sale, issue or cancellation of the Company’s own equity instruments. Any difference between the carrying amount and the consideration, if reissued, is recognized in the share premium.
Non-currents assets held for sale	t. Non-currents assets held for sale The Company classifies non-current assets and disposal groups as held for sale if their carrying amounts will be recovered principally through a sale transaction rather than through continuing use. Non-current assets classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell. Costs to sell are the incremental costs directly attributable to the disposal of an asset, excluding finance costs and income tax expense. The criteria for held for sale classification is regarded as met only when the sale is highly probable, and the asset or disposal group is available for immediate sale in its present condition. Property, plant and equipment are not depreciated or amortized once classified as held for sale. Assets classified as held for sale are presented separately as current items in the statement of financial position.
Rounding of amounts	u. Rounding of amounts All amounts disclosed in the consolidated financial statements and notes have been rounded off to the nearest million currency units unless otherwise stated.

Significant accounting polici_3

Significant accounting policies (Tables)	12 Months Ended
Significant accounting policies (Tables)	Mar. 31, 2021
Significant Of accounting policies [Abstract]
Disclosure of useful lives or depreciation rates, property, plant and equipment [Table Text Block]	Depreciation methods, useful lives and residual values are reviewed at each reporting date and any changes are considered prospectively. The estimated useful lives are as follows: Buildings - Factory and administrative buildings 20 - 50 years - Ancillary structures 3 - 15 years Plant and equipment 3 - 15 years Furniture, fixtures and office equipment 3 - 10 years Vehicles 4 - 5 years
Disclosure of useful lives or amortisation rates, intangible assets other than goodwill [Table Text Block]	The estimated useful lives are as follows: Product related intangibles 3 – 20 years Other intangibles 3 - 15 years

Segment reporting (Tables)

Segment reporting (Tables)	12 Months Ended
Segment reporting (Tables)	Mar. 31, 2021
Disclosure of operating segments [line items]
Analysis of revenues within the Global Generics segment [Table Text Block]	Analysis of revenues within the Global Generics segment: An analysis of revenues by therapeutic areas in the Company’s Global Generics segment is given below: For the Year Ended March 31, 2021 2020 2019 Nervous System Rs. 29,040 Rs. 26,825 Rs. 19,726 Gastrointestinal 21,132 19,394 19,250 Oncology 16,842 18,245 18,357 Cardiovascular 15,460 14,729 15,106 Pain Management 15,531 13,808 13,806 Anti-Infective 12,906 9,402 7,073 Respiratory 11,089 10,433 8,130 Others 32,404 25,287 21,455 Tota l Rs. 154,404 Rs. 138,123 Rs. 122,903
Analysis of revenues within the PSAI segment [Table Text Block]	Analysis of revenues within the PSAI segment: An analysis of revenues by therapeutic areas in the Company’s PSAI segment is given below: For the Year Ended March 31, 2021 2020 2019 Cardiovascular Rs. 9,834 Rs. 8,567 Rs. 7,019 Pain Management 4,657 5,073 3,364 Anti-Infective 4,126 2,264 1,247 Nervous System 2,704 2,797 2,741 Oncology 2,385 1,798 2,212 Dermatology 768 1,370 1,622 Others 7,508 3,878 5,935 Tota l Rs. 31,982 Rs. 25,747 Rs. 24,140
Analysis of revenues by geography [Table Text block]	Analysis of revenues by geography: The following table shows the distribution of the Company’s revenues by country, based on the location of the customers: For the Year Ended March 31, Country 2021 2020 2019 India Rs. 36,252 Rs. 32,089 Rs. 28,804 United States 76,702 76,028 69,299 Russia 15,816 16,900 15,299 Others (1) 60,952 49,583 40,449 Rs. 189,722 Rs. 174,600 Rs. 153,851 (1) Others include Germany, the United Kingdom, Ukraine, China, Canada and other countries across the world.
Reportable segments [member]
Disclosure of operating segments [line items]
Disclosure of operating segments [Table Text Block]	The measurement of each segment’s revenues, expenses and assets is consistent with the accounting policies that are used in preparation of the Company’s consolidated financial statements. Segment information: For the Year Ended March 31, Reportable segments Global Generics PSAI Proprietary Products 2021 2020 2019 2021 2020 2019 2021 2020 2019 Revenues (1) Rs. 154,404 Rs. 138,123 Rs. 122,903 Rs. 31,982 Rs. 25,747 Rs. 24,140 Rs. 523 Rs. 7,949 Rs. 4,750 Gross profit Rs. 91,111 Rs. 78,449 Rs. 71,924 Rs. 9,426 Rs. 6,190 Rs. 6,128 Rs. 482 Rs. 7,744 Rs. 4,182 Selling, general and administrative expenses Research and development expenses Impairment of non-current assets Other income, net Results from operating activities Finance income, net Share of profit of equity accounted investees, net of tax Profit before tax Tax expense/(benefit), net Profit for the year [Continued on next page] [Continued from above table, first column repeated] Segment information: For the Year Ended March 31, Reportable segments Others Total 2021 2020 2019 2021 2020 2019 Revenues (1) Rs. 2,813 Rs. 2,781 Rs. 2,058 Rs. 189,722 Rs. 174,600 Rs. 153,851 Gross profit Rs. 2,058 Rs. 1,626 Rs. 1,196 Rs. 103,077 Rs. 94,009 Rs. 83,430 Selling, general and administrative expenses 54,650 50,129 48,680 Research and development expenses 16,541 15,410 15,607 Impairment of non-current assets 8,588 16,767 210 Other income, net (982 ) (4,290 ) (1,955 ) Results from operating activities Rs. 24,280 Rs. 15,993 Rs. 20,888 Finance income, net 1,653 1,478 1,117 Share of profit of equity accounted investees, net of tax 480 561 438 Profit before tax Rs. 26,413 Rs. 18,032 Rs. 22,443 Tax expense/(benefit), net 9,175 (1,466 ) 3,648 Profit for the yea r Rs. 17,238 Rs. 19,498 Rs. 18,795 (1) Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).
Analysis of revenues within the Global Generics segment [Table Text Block]	Analysis of revenues within the Global Generics segment: An analysis of revenues by therapeutic areas in the Company’s Global Generics segment is given below: For the Year Ended March 31, 2021 2020 2019 Nervous System Rs. 29,040 Rs. 26,825 Rs. 19,726 Gastrointestinal 21,132 19,394 19,250 Oncology 16,842 18,245 18,357 Cardiovascular 15,460 14,729 15,106 Pain Management 15,531 13,808 13,806 Anti-Infective 12,906 9,402 7,073 Respiratory 11,089 10,433 8,130 Others 32,404 25,287 21,455 Tota l Rs. 154,404 Rs. 138,123 Rs. 122,903
Analysis of revenues within the PSAI segment [Table Text Block]	Analysis of revenues within the PSAI segment: An analysis of revenues by therapeutic areas in the Company’s PSAI segment is given below: For the Year Ended March 31, 2021 2020 2019 Cardiovascular Rs. 9,834 Rs. 8,567 Rs. 7,019 Pain Management 4,657 5,073 3,364 Anti-Infective 4,126 2,264 1,247 Nervous System 2,704 2,797 2,741 Oncology 2,385 1,798 2,212 Dermatology 768 1,370 1,622 Others 7,508 3,878 5,935 Total Rs. 31,982 Rs. 25,747 Rs. 24,140
Analysis of revenues by geography [Table Text block]	Analysis of revenues by geography: The following table shows the distribution of the Company’s revenues by country, based on the location of the customers: For the Year Ended March 31, Country 2021 2020 2019 India Rs. 36,252 Rs. 32,089 Rs. 28,804 United States 76,702 76,028 69,299 Russia 15,816 16,900 15,299 Others (1) 60,952 49,583 40,449 Rs. 189,722 Rs. 174,600 Rs. 153,851 (1) Others include Germany, the United Kingdom, Ukraine, China, Canada and other countries across the world.
Disclosure of analysis of Company's non-current assets (other than financial instruments and deferred tax assets)[Table Text Block]	The following table shows the distribution of the Company’s non-current assets (other than financial instruments and deferred tax assets) by country, based on the location of assets: As of March 31, Country 2021 2020 India Rs. 75,284 Rs. 55,083 Switzerland 11,661 18,204 United States 7,627 7,065 Germany 1,087 1,435 Others 5,109 5,010 Rs. 100,768 Rs. 86,797
Disclosure of analysis of distribution of the Company's property, plant and equipment including capital work in progress and intangible assets acquired during the year (other than goodwill arising on business combination) [Table Text Block]	The following table shows the distribution of the Company’s property, plant and equipment including capital work in progress and intangible assets acquired during the year (other than goodwill arising on business combination) by country, based on the location of assets: For the Year Ended March 31, Country 2021 2020 India Rs. 27,882 Rs. 5,519 Switzerland 3,760 1,025 United States 2,158 241 Others 1,031 688 Rs. 34,831 Rs. 7,473
Disclosure of Analysis of depreciation and amortization, included in cost of revenues [Table Text Block]	Analysis of depreciation and amortization, included in cost of revenues, by reportable segments: For the Year Ended March 31, 2021 2020 2019 Global Generics Rs. 3,435 Rs. 3,666 Rs. 3,791 PSAI 2,578 2,804 2,906 Proprietary Products - - - Others 48 71 71 Rs. 6,061 Rs. 6,541 Rs. 6,768

Business Transfer Agreement w_2

Business Transfer Agreement with Wockhardt Limited (Tables)	12 Months Ended
Business Transfer Agreement with Wockhardt Limited (Tables)	Mar. 31, 2021
Disclosure of detailed information about business combination [abstract]
Summary of fair values of the assets acquired, including goodwill, and liabilities	During the three months ended September 30, 2020, the Company completed the purchase price allocation. Tabulated below are the fair values of the assets acquired, including goodwill, and liabilities assumed on the acquisition date: Particulars Amount Cash Rs. 14,990 Payment through Escrow account 564 Contingent consideration (Holdback Amount) 561 Total consideration Rs. 16,115 Assets acquired Goodwill Rs. 530 Property, plant and equipment 373 Product related intangibles 14,888 Inventories 466 Other assets 245 Liabilities assumed Employee benefits (Gratuity-Rs.70 and Compensated absences- Rs.75) (145 ) Refund liability (242 ) Total net assets Rs. 16,115

Cash and cash equivalents (Tabl

Cash and cash equivalents (Tables)	12 Months Ended
Cash and cash equivalents (Tables)	Mar. 31, 2021
Cash and Cash Equivalents [Abstract]
Cash And Cash Equivalents [Text Block]	Cash and cash equivalents consist of the following: As of March 31, 2021 2020 Cash on hand Rs.1 Rs.2 Balances with banks 14,324 1,807 Term deposits with banks (original maturities less than 3 months) 504 244 Cash and cash equivalents in the statements of financial position Rs. 14,829 Rs. 2,053 Bank overdrafts used for cash management purposes 9 91 Cash and cash equivalents in the statements of cash flow Rs. 14,820 Rs. 1,962 Restricted cash balances included above Balance in unclaimed dividend and debenture interest account Rs. 106 Rs. 111 Balances in Escrow account pursuant to the Business Transfer Agreement with Wockhardt Limited (Refer to Note 6 for details) 40 - Other restricted cash balances 82 15

Other investments (Tables)

Other investments (Tables)	12 Months Ended
Other investments (Tables)	Mar. 31, 2021
Disclosure of investments other than investments accounted for using equity method [Abstract]
Disclosure of investments other than investments accounted for using equity method [Table Text Block]	The details of such investments as of March 31, 2021 and 2020 are as follows: As of March 31, 2021 As of March 31, 2020 Cost Unrealized Fair value/ (2) Cost Unrealized Fair value/ (2) Current portion In units of mutual funds Rs. 13,197 Rs. 66 Rs. 13,263 Rs. 13,686 Rs. 146 Rs. 13,832 In bonds 522 - 522 1,851 - 1,851 In commercial paper - - - 967 - 967 In market linked debentures - - - 2,000 (7 ) 1,993 Term deposits with banks 5,959 - 5,959 5,044 - 5,044 Rs. 19,678 Rs. 66 Rs. 19,744 Rs. 23,548 Rs. 139 Rs. 23,687 Non-current portion In equity securities (1) Rs. 2,701 Rs. 1,832 Rs. 4,533 Rs. 2,701 Rs. (2,397 ) Rs. 304 In limited liability partnership firm 400 - 400 - - - Others 25 - 25 24 - 24 Rs. 3,126 Rs. 1,832 Rs. 4,958 Rs. 2,725 Rs. (2,397 ) Rs. 328 (1) Primarily represents the shares of Curis, Inc. Refer to Note 34 of these consolidated financial statements for further details. (2) Interest accrued but not due on bonds and debentures, commercial paper and term deposits with banks is included in other current assets. For the purpose of measurement, the aforesaid investments are classified as follows: Investments in units of mutual funds Fair value through profit and loss Investments in bonds, commercial paper, term deposits and others Amortized cost Investments in market linked debentures Fair value through other comprehensive income Investments in equity securities Fair value through other comprehensive income (on account of irrevocable option elected at time of transition) and fair value through profit and loss Investment in limited liability partnership firm Fair value through profit and loss

Trade and other receivables (Ta

Trade and other receivables (Tables)	12 Months Ended
Trade and other receivables (Tables)	Mar. 31, 2021
Trade and other receivables [abstract]
Trade And Other Receivables [Table Text Block]	As of March 31, 2021 2020 Current Trade and other receivables, gross Rs. 50,937 Rs. 51,480 Less: Allowance for credit losses (1,296 ) (1,202 ) Trade and other receivables, net Rs. 49,641 Rs. 50,278 Non-current Trade and other receivables, gross (1) Rs. 118 Rs. 1,737 Less: Allowance for credit losses - - Trade and other receivables, net Rs. 118 Rs. 1,737 (1) Represents amounts receivable pursuant to an out-licensing arrangement with a customer. As these amounts are not expected to be realized within twelve months from the end of the reporting date, they are disclosed as non-current.
Allowance For Credit Losses [Table Text Block]	The details of changes in allowance for credit losses during the years ended March 31, 2021 and 2020, are as follows: For the Year Ended March 31, 2021 2020 Balance at the beginning of the year Rs. 1,202 Rs. 1,172 Provision made during the year, net of reversals 176 154 Trade and other receivables written off & exchange differences (82 ) (124 ) Balance at the end of the year Rs. 1,296 Rs. 1,202

Inventories (Tables)

Inventories (Tables)	12 Months Ended
Inventories (Tables)	Mar. 31, 2021
Classes of current inventories [abstract]
Disclosure of detailed information about inventories [Text Block]	Inventories consist of the following: As of March 31, 2021 2020 Raw materials Rs. 12,287 Rs. 10,594 Work-in-progress 10,009 6,806 Finished goods (includes stock-in-trade) 19,829 15,126 Packing materials, stores and spares 3,287 2,540 Rs. 45,412 Rs. 35,066
Disclosure of detail information about of inventories recognized in consolidated income statement [Text Block]	Details of inventories recognized in the consolidated income statement are as follows: For the Year Ended March 31, 2021 2020 2019 Raw materials, consumables and changes in finished goods and work in progres s Rs. 58,268 Rs. 51,892 Rs. 40,932 Inventory write-downs (1) 2,521 3,652 4,016 (1) Following the Company’s decision to voluntarily recall all of its ranitidine medications sold in United States, due to confirmed contamination with N-Nitrosodimethylamine (“NDMA”) above levels established by the U.S. FDA, the Company recognized Rs.373 as inventory write downs of ranitidine during the year ended March 31, 2020. Furthermore, an amount of Rs.239 was recognized (as a reduction from revenue) as a provision for refund liabilities arising out of the Company’s recall decision.

Other assets (Tables)

Other assets (Tables)	12 Months Ended
Other assets (Tables)	Mar. 31, 2021
Assets [Abstract]
Disclosure Of Detailed Information About Other Assets [Text Block]	As of March 31, 2021 2020 Current Balances and receivables from statutory authorities (1) Rs. 7,227 Rs. 4,445 Export benefits receivable (2) 2,070 2,652 Prepaid expenses 1,141 950 Others (3) 4,071 5,755 Rs. 14,509 Rs. 13,802 Non-current Security deposits Rs. 666 Rs. 613 Others 168 231 Rs. 834 Rs. 844 (1) Balances and receivables from statutory authorities primarily consist of amounts recoverable towards the goods and service tax (“GST”), excise duty and value added tax, and from customs authorities of India. (2) Export benefits receivables primarily consist of amounts receivable from various government authorities of India towards incentives on export sales made by the Company. ( 3 Others primarily includes advances given to vendors and employees, security deposits, interest accrued but not due on investments, and claims receivable.

Property, plant and equipment (

Property, plant and equipment (Tables)	12 Months Ended
Property, plant and equipment (Tables)	Mar. 31, 2021
Disclosure of detailed information about property, plant and equipment [abstract]
Summary of detailed information about property plant and equipment explanatory	The following is a summary of the changes in carrying value of property, plant and equipment. Particulars Land Buildings Plant and Furniture, Vehicles Total Gross carrying value Balance as of April 1, 2019 Rs. 4,192 Rs. 23,106 Rs. 70,940 Rs. 5,717 Rs. 775 Rs. 104,730 Recognition of right-of-use asset on initial application of IFRS 16 - 723 2 28 400 1,153 Adjusted balance as of April 1, 2019 Rs. 4,192 Rs. 23,829 Rs. 70,942 Rs. 5,745 Rs. 1,175 Rs. 105,883 Additions 4 997 4,278 497 295 6,071 Disposals - (55 ) (706 ) (253 ) (179 ) (1,193 ) Effect of changes in foreign exchange rates (73 ) 185 353 (24 ) (80 ) 361 Balance as of March 31, 2020 Rs. 4,123 Rs. 24,956 Rs. 74,867 Rs. 5,965 Rs. 1,211 Rs. 111,122 Balance as of April 1, 2020 Rs. 4,123 Rs. 24,956 Rs. 74,867 Rs. 5,965 Rs. 1,211 Rs. 111,122 Additions 13 2,720 4,544 437 220 7,934 Assets acquired through business combinations (1) 84 113 165 11 - 373 Disposals - (35 ) (852 ) (134 ) (182 ) (1,203 ) Assets held for sale (18 ) (245 ) (334 ) (58 ) - (655 ) Effect of changes in foreign exchange rates 26 11 244 31 8 320 Balance as of March 31, 2021 Rs. 4,228 Rs. 27,520 Rs. 78,634 Rs. 6,252 Rs. 1,257 Rs. 117,891 Accumulated Depreciation Balance as of April 1, 2019 Rs. - Rs. 6,873 Rs. 43,642 Rs. 4,603 Rs. 442 Rs. 55,560 Depreciation for the year - 1,306 6,404 562 368 8,640 Impairment - - - - - - Disposals - (36 ) (667 ) (251 ) (158 ) (1,112 ) Effect of changes in foreign exchange rates - 65 223 (11 ) (54 ) 223 Balance as of March 31, 2020 Rs. - Rs. 8,208 Rs. 49,602 Rs. 4,903 Rs. 598 Rs. 63,311 Balance as of April 1, 2020 Rs. - Rs. 8,208 Rs. 49,602 Rs. 4,903 Rs. 598 Rs. 63,311 Depreciation for the year - 1,697 5,935 554 341 8,527 Impairment 4 32 9 1 - 46 Disposals - (29 ) (773 ) (125 ) (136 ) (1,063 ) Assets held for sale (4 ) (140 ) (306 ) (54 ) - (504 ) Effect of changes in foreign exchange rates - 22 194 24 1 241 Balance as of March 31, 2021 Rs. - Rs. 9,790 Rs. 54,661 Rs. 5,303 Rs. 804 Rs. 70,558 Particulars Land Buildings Plant and Furniture, Vehicles Total Net carrying value As of April 1, 2019 Rs. 4,192 Rs. 16,233 Rs. 27,298 Rs. 1,114 Rs. 333 Rs. 49,170 As of March 31, 2020 Rs. 4,123 Rs. 16,748 Rs. 25,265 Rs. 1,062 Rs. 613 Rs. 47,811 Add: Capital-work-in-progress Rs. 4,521 Total as of March 31, 2020 Rs. 52,332 As of March 31, 2021 Rs. 4,228 Rs. 17,730 Rs. 23,973 Rs. 949 Rs. 453 Rs. 47,333 Add: Capital-work-in-progress Rs. 9,778 Total as of March 31, 2021 Rs. 57,111 (1) Refer to Note 6 of these consolidated financial statements for further details.
Summary of detailed information about Right-of-Use Assets	The Company has lease contracts for various items of plant and equipment, vehicles and other equipment used in its operations. Below are the carrying amounts of right-of-use assets recognized and the movements during the year included in the above property, plant and equipment. Particulars Land Buildings Plant and Furniture, Vehicles Total Gross carrying value Balance as of April 1, 2019 Rs. 73 Rs. 840 Rs. 12 Rs. - Rs. 37 Rs. 962 Recognition of right-of-use asset on initial application of IFRS 16 - 723 2 28 400 1,153 Adjusted balance as of April 1, 2019 Rs. 73 Rs. 1,563 Rs. 14 Rs. 28 Rs. 437 Rs. 2,115 Additions - 87 3 17 146 253 Disposals - (1 ) - - (56 ) (57 ) Effect of changes in foreign exchange rates 5 39 1 - 3 48 Balance as of March 31, 2020 Rs. 78 Rs. 1,688 Rs. 18 Rs. 45 Rs. 530 Rs. 2,359 Balance as of April 1, 2020 Rs. 78 Rs. 1,688 Rs. 18 Rs. 45 Rs. 530 Rs. 2,359 Additions (1) - 2,212 - 7 194 2,413 Disposals - - - (1 ) (120 ) (121 ) Effect of changes in foreign exchange rates 3 (14 ) - - - (11 ) Balance as of March 31, 2021 Rs. 81 Rs. 3,886 Rs. 18 Rs. 51 Rs. 604 Rs. 4,640 Accumulated Depreciation Balance as of April 1, 2019 Rs. - Rs. 454 Rs. 12 Rs. - Rs. 33 Rs. 499 Depreciation for the year - 267 1 13 210 491 Disposals - (1 ) - - (41 ) (42 ) Effect of changes in foreign exchange rates - 24 1 - (3 ) 22 Balance as of March 31, 2020 Rs. - Rs. 744 Rs. 14 Rs. 13 Rs. 199 Rs. 970 Balance as of April 1, 2020 Rs. - Rs. 744 Rs. 14 Rs. 13 Rs. 199 Rs. 970 Depreciation for the year - 616 1 12 202 831 Disposals - - - - (78 ) (78 ) Effect of changes in foreign exchange rates - (25 ) - - (2 ) (27 ) Balance as of March 31, 2021 Rs. - Rs. 1,335 Rs. 15 Rs. 25 Rs. 321 Rs. 1,696 Net carrying value As of March 31, 2020 Rs. 78 Rs. 944 Rs. 4 Rs. 32 Rs. 331 Rs. 1,389 As of March 31, 202 1 Rs. 81 Rs. 2,551 Rs. 3 Rs. 26 Rs. 283 Rs. 2,944 (1) Additions for the year ended March 31, 2021 include recognition of a right-of-use asset of Rs.1,852 relating to a warehousing services agreement in the United States.
Summary of detailed information about amounts recognized in Income statement for Right-of-Use Assets	The following are the amounts recognized in income statement: For the Year Ended March 31, 2021 2020 Depreciation expense of right-of-use assets Rs. 831 Rs. 491 Interest expense on lease liabilities 227 230

Goodwill (Tables)

Goodwill (Tables)	12 Months Ended
Goodwill (Tables)	Mar. 31, 2021
Disclosure of reconciliation of changes in goodwill [abstract]
Disclosure of reconciliation of changes in goodwill [Table Text Block]	The following table presents the changes in goodwill during the years ended March 31, 2021 and 2020: As of March 31, 2021 2020 Opening balance, gross Rs. 20,278 Rs. 20,176 Goodwill arising on business combinations (1) 530 - Effect of translation adjustments 44 102 Impairment loss (2) (16,284 ) (16,284 ) Closing balance Rs. 4,568 Rs. 3,994 (1) Refer to Note 6 of these consolidated financial statements for further details. (2) The impairment loss of Rs.16,284 includes Rs.16,003 pertaining to the Company’s German subsidiary, betapharm Arzneimittel GmbH, which is part of the Company’s Global Generics segment. This impairment loss was recorded for the years ended March 31, 2009 and 2010.
Disclosure of Information for Cash generating Units [Table Text Block]	The carrying amount of goodwill (other than those arising upon investment in a joint venture) was allocated to the cash generating units as follows: As of March 31, 2021 2020 PSAI-Active Pharmaceutical Operations Rs. 997 Rs. 997 Global Generics-Complex Injectables 1,421 1,372 Global Generics-North America Operations 1,015 1,021 Global Generics-Branded Formulations 1,021 491 Other s 114 113 Rs. 4,568 Rs. 3,994

Other intangible assets (Tables

Other intangible assets (Tables)	12 Months Ended
Other intangible assets (Tables)	Mar. 31, 2021
Disclosure of detailed information about intangible assets [abstract]
Disclosure of detailed information about intangible assets explanatory [text block]	The following is a summary of changes in the carrying value of intangible assets: Product Others Total Gross carrying value Balance as of April 1, 2019 Rs. 81,971 Rs. 3,600 Rs. 85,571 Additions 1,641 165 1,806 Disposals/De-recognitions (814 ) (1 ) (815 ) Effect of changes in foreign exchange rates 4,532 2 4,534 Balance as of March 31, 2020 Rs. 87,330 Rs. 3,766 Rs. 91,096 Balance as of April 1, 2020 Rs. 87,330 Rs. 3,766 Rs. 91,096 Additions (1) 6,107 304 6,411 Assets acquired through business combinations (2) 14,888 - 14,888 Disposals/De-recognitions (192 ) - (192 ) Effect of changes in foreign exchange rates (900 ) - (900 ) Balance as of March 31, 2021 Rs. 107,233 Rs. 4,070 Rs. 111,303 Amortization/impairment loss Balance as of April 1, 2019 Rs. 39,577 Rs. 1,627 Rs. 41,204 Amortization for the year 3,554 278 3,832 Impairment loss 16,757 - 16,757 Disposals/De-recognitions (749 ) (1 ) (750 ) Effect of changes in foreign exchange rates 2,392 2 2,394 Balance as of March 31, 2020 Rs. 61,531 Rs. 1,906 Rs. 63,437 Balance as of April 1, 2020 Rs. 61,531 Rs. 1,906 Rs. 63,437 Amortization for the year 3,972 297 4,269 Impairment loss 8,542 - 8,542 Disposals/De-recognitions (192 ) - (192 ) Effect of changes in foreign exchange rates (401 ) - (401 ) Balance as of March 31, 2021 Rs. 73,452 Rs. 2,203 Rs. 75,655 Net carrying value As of April 1, 2019 Rs. 42,394 Rs. 1,973 Rs. 44,367 As of March 31, 2020 Rs. 25,799 Rs. 1,860 Rs. 27,659 As of March 31, 2021 Rs. 33,781 Rs. 1,867 Rs. 35,648 (1) The Company entered into a definitive agreement with Glenmark Pharmaceuticals Limited to acquire marketing authorizations and other rights of select brands in four “Emerging Markets” countries. The acquired brands represent two products, (a) a mometasone mono product and (b) a combination of mometasone with azelastine, and are indicated for the treatment of seasonal and perennial allergic rhinitis. The total consideration paid was Rs.1,516. Following the principles of IAS 38, the Company recognized the acquired brands at their acquisition cost. The acquisition pertains to the Company’s Global Generics segment. (2) Refer to Note 6 of these consolidated financial statements for further details.
Disclosure Of Detailed Information About Intangible Assets Under Development [Text Block]	Tabulated below is the reconciliation of amounts relating to in-process research and development assets as at the beginning and at the end of the year: As of March 31, 2021 2020 Opening balance Rs. 10,987 Rs. 24,610 Add (1) 3,557 950 Less (2) - (2,530 ) Less (8,099 ) (13,379 ) Effect of changes in exchange rates (332 ) 1,336 Closing balance Rs. 6,113 Rs. 10,987 (1) During the year ended March 31, 2021, the additions include expenditure During the year ended March 31, 2020, the Company acquired a portfolio of approved, non-marketed Abbreviated New Drug Applications (“ANDAs”) in the United States from Teva for a total consideration of Rs.277. (2) During the year ended March 31, 2020, the product ramelt e
Description of significant separately acquired Intangible Assets [text block]	Details of significant separately acquired intangible assets as of March 31, 2021 are as follows: Particulars of the asset Acquired from Carrying cost Select portfolio of branded generics business Wockhardt Limited Rs. 14,241 Select portfolio of dermatology, respiratory and pediatric assets UCB India Private Limited and affiliates 4,568 Intellectual property rights relating to PPC-06 (tepilamide fumarate) Xenoport, Inc. 4,036 Various ANDAs Teva and an affiliate of Allergan 4,000 Commercialization rights for an anti-cancer biologic agent Eisai Company Limited 1,840 Select Anti-Allergy brands Glenmark Pharmaceuticals Limited 1,487 Habitrol® brand Novartis Consumer Health Inc. 1,181

Investment in equity accounte_2

Investment in equity accounted investees (Tables)	12 Months Ended
Investment in equity accounted investees (Tables)	Mar. 31, 2021
Investments accounted for using equity method [Line Items]
Disclosure Of Equity Shares Held In Equity Accounted Investees [Table Text Block]	As of March 31, 2021 2020 Equity shares held in Kunshan Rotam Reddy Pharmaceutical Company Limited, China Rs. 3,307 Rs. 2,714 Equity shares held in DRES Energy Private Limited, India 68 49 Rs. 3,375 Rs. 2,763
Kunshan Rotam Reddy Pharmaceuticals Co. Limited [Member]
Investments accounted for using equity method [Line Items]
Disclosure of detailed information about joint venture [Table Text Block]	Summary financial information of Reddy Kunshan, as translated into the reporting currency of the Company and not adjusted for the percentage ownership held by the Company, is as follows: As of/for the Year Ended March 31, 2021 2020 2019 Ownership 51.3 % 51.3 % 51.3 % Total current assets Rs. 8,778 Rs. 6,925 Rs. 6,195 Total non-current assets 892 732 374 Total assets Rs. 9,670 Rs. 7,657 Rs. 6,569 Equity Rs. 6,088 Rs. 4,931 Rs. 4,448 Total current liabilities 3,582 2,726 2,121 Total equity and liabilities Rs. 9,670 Rs. 7,657 Rs. 6,569 Revenues Rs. 9,017 Rs. 7,679 Rs. 7,436 Expenses 8,117 6,554 6,558 Profit for the year Rs. 900 Rs. 1,125 Rs. 878 Company’s share of profits for the year Rs. 461 Rs. 577 Rs. 449 Carrying value of the Company’s investment (1) Rs. 3,307 Rs. 2,714 Rs. 2,464 Translation adjustment arising out of translation of foreign currency balances Rs. 438 Rs. 306 Rs. 241 (1) Includes Rs.181 representing the goodwill on acquisition of investment.
DRES energy private limited [Member]
Investments accounted for using equity method [Line Items]
Disclosure of detailed information about joint venture [Table Text Block]	Details of the Company’s investment in DRES Energy Private Limited: As of/for the Year Ended March 31, 2021 2020 2019 Carrying value of the Company’s investment Rs. 68 Rs. 49 Rs. 65 Company’s share of profits for the year 19 (16 ) (11 )

Trade and other payables (Table

Trade and other payables (Tables)	12 Months Ended
Trade and other payables (Tables)	Mar. 31, 2021
Trade and other payables [abstract]
Trade And Other Payables [Table Text Block]	Trade and other payables consist of the following: As of March 31, 2021 2020 Trade payables Rs. 12,696 Rs. 10,745 Due to creditors for expenses 5,413 4,503 Due to capital creditors 5,635 1,411 Rs. 23,744 Rs. 16,659

Loans and borrowings (Tables)

Loans and borrowings (Tables)	12 Months Ended
Loans and borrowings (Tables)	Mar. 31, 2021
Disclosure of detailed information about borrowings [abstract]
Disclosure of Short Term Borrowings [Table Text Block]	Short-term borrowings consist of the following: As of March 31, 2021 2020 Pre-shipment credit Rs. 10,300 Rs. 10,432 Other working capital borrowings 12,836 6,009 Rs. 23,136 Rs. 16,441
Disclosure of Interest Rate Profile of Short-term Borrowings [Table Text Block]	The interest rate profile of short-term borrowings from banks is given below: As of March 31, 2021 2020 Currency (1) Interest Rate (2) Currency (1) Interest Rate (2) Pre-shipment credit INR 3 Months T-bill + 30 bps INR 1 Month T-bill + 60 bps INR 5.75% - - - - U.S.$ 1 Month LIBOR + 12.5 to 16 bps Other working capital borrowings U.S.$ (2.2)% to (1.8)% U.S.$ 1Month/3 Months LIBOR + 55 to 78 bps RUB 3.00% to 3.40% and 5.55% RUB 7.05% MXN TIIE + 1.20% MXN TIIE + 1.25% INR 4.00% INR 7.75% BRL 4.00% BRL 7.25% UAH 4.75% - - - - ZAR 1Month JIBAR+120 bps (1) “INR” means Indian rupees, “U.S.$” means United States Dollars, “RUB” means Russian roubles, “MXN” means Mexican pesos, “UAH” means Ukrainian hryvnia, “BRL” means Brazilian reals and “ZAR” means South African rand. (2) “LIBOR” means the London Inter-bank Offered Rate, “TIIE” means the Equilibrium Inter-banking Interest Rate (Tasa de Interés Interbancaria de Equilibrio), “JIBAR” means the Johannesburg Interbank Average Rate and “T-bill” means India Treasury Bill.
Disclosure of Long-term Borrowings [Table Text Block]	Long-term borrowings consist of the following: As of March 31, 2021 As of March 31, 2020 Non-current Current Non-current Current Foreign currency borrowing by the parent company Rs. - Rs. - Rs. - Rs. 3,783 Non-convertible debentures by the APSL subsidiary (1) 3,800 - - - Obligations under leases (2) 2,499 864 1,304 483 Rs. 6,299 Rs. 864 Rs. 1,304 Rs. 4,266 (1) “APSL subsidiary” refers to Aurigene Pharmaceutical Services Limited. (2) Additions for the year ended March 31, 2021 include right-of-use liability of Rs.1,878 relating to a warehousing services agreement in the United States.
Disclosure of interest rate profile of long-term borrowings [Table Text Block]	The interest rate profiles of long-term borrowings (other than obligations under leases) as of March 31, 2021 and 2020 were as follows: As of March 31, 2021 2020 Currency (1) Interest Rate (2) Currency (1) Interest Rate (2) Foreign currency borrowings - - U.S.$ 1 Month LIBOR + 82.7 bps Non-convertible debentures INR 6.77% - - (1) “U.S.$” means United States Dollars and “INR” means Indian rupees. (2) “LIBOR” means the London Inter-bank Offered Rate.
Disclosure of Contractual maturities of Long-term Borrowings [Table Text Block]	The aggregate maturities of long-term loans and borrowings, based on contractual maturities, as of March 31, 2021 were as follows: Maturing in the year ending Non- Obligations Total 2022 Rs. - Rs. 864 Rs. 864 2023 - 802 802 2024 3,800 745 4,545 2025 - 734 734 2026 - 118 118 Thereafter - 100 100 Rs. 3,800 Rs. 3,363 Rs. 7,163 The aggregate maturities of long-term loans and borrowings, based on contractual maturities, as of March 31, 2020 were as follows: Maturing in the year ending March 31, (1) Foreign Obligations Total 2021 Rs. 3,783 Rs. 483 Rs. 4,226 2022 - 359 359 2023 - 267 267 2024 - 249 249 2025 - 286 286 Thereafter - 143 143 Rs. 3,783 Rs. 1,787 Rs. 5,570 (1) Long-term debt obligations disclosed in the above table do not reflect any netting of transaction costs .
Disclosure of reconciliation of liabilities arising from financing activities [text block]	Reconciliation of liabilities arising from financing activities during the year ended March 31, 2021: Particulars Long-term (1) Short-term Total Opening balance Rs. 5,570 Rs. 16,441 Rs. 22,011 Recognition of right-of-use liability during the year 2,393 - 2,393 Payment of principal portion of lease liabilities (754 ) - (754 ) Borrowings made during the year 3,800 44,469 48,269 Borrowings repaid during the year (3,743 ) (37,678 ) (41,421 ) Effect of changes in foreign exchange rates (103 ) (96 ) (199 ) Closing balance Rs. 7,163 Rs. 23,136 Rs. 30,299 Reconciliation of liabilities arising from financing activities during the year ended March 31, 2020: Particulars Long-term borrowing (1) Short-term borrowings Total Opening balance Rs. 26,256 Rs. 12,125 Rs. 38,381 Recognition of right-of-use liability on initial application of IFRS 16 1,335 - 1,335 Recognition of right-of-use liability during the year 238 - 238 Payment of principal portion of lease liabilities (482 ) - (482 ) Borrowings made during the year - 29,831 29,831 Borrowings repaid during the year (22,918 ) (25,596 ) (48,514 ) Effect of changes in foreign exchange rates 1,051 81 1,132 Others 90 - 90 Closing balance Rs. 5,570 Rs. 16,441 Rs. 22,011 (1) Includes current portion.

Provisions (Tables)

Provisions (Tables)	12 Months Ended
Provisions (Tables)	Mar. 31, 2021
Disclosure of other provisions [abstract]
Disclosure of Provision [Table Text Block]	The details of changes in provisions during the year ended March 31, 2021 are as follows: Particulars Refund (1) Environmental (2) Legal and (3) Total Balance as at beginning of the year Rs. 3,252 Rs. 54 Rs. 548 Rs. 3,854 Provision made during the year, net of reversals 2,934 - 63 2,997 Provision used during the year (3,309 ) - - (3,309 ) Effect of changes in foreign exchange rates (53 ) 4 - (49 ) Balance as at end of the year Rs. 2,824 Rs. 58 Rs. 611 Rs. 3,493 Current Rs. 2,824 Rs. - Rs. 611 Rs. 3,435 Non-current - 58 - 58 Rs. 2,824 Rs. 58 Rs. 611 Rs. 3,493 (1) Refund liability is accounted for by recording a provision based on the Company’s estimate of expected sales returns. See Note 3(l) of these consolidated financial statements for the Company’s accounting policy on refund liability. (2) As a result of the acquisition of a unit of The Dow Chemical Company in April 2008, the Company assumed a liability for contamination of the Mirfield site acquired of Rs.39 (carrying value Rs.58). The seller is required to indemnify the Company for this liability. Accordingly, a corresponding asset has also been recorded in the consolidated statements of financial position. (3) Primarily consists of provision recorded towards the potential liability arising out of a litigation relating to cardiovascular and anti-diabetic formulations. Refer to Note 33 (Contingencies) of these consolidated financial statements under “Product and patent related matters - Matters relating to National Pharmaceutical Pricing Authority - Litigation relating to Cardiovascular and Anti-diabetic formulations” for further details.

Other liabilities (Tables)

Other liabilities (Tables)	12 Months Ended
Other liabilities (Tables)	Mar. 31, 2021
Disclosure of Other Liabilities [Abstract]
Schedule Of Other Liabilities [Table Text Block]	Other liabilities consist of the following: As of March 31, 2021 2020 Current Accrued expenses Rs. 17,821 Rs. 18,025 Employee benefits payable 5,607 4,944 Statutory dues payable 2,968 980 Deferred revenue (1) 1,052 1,242 Advance from customers 981 668 Others 2,059 3,523 Rs. 30,488 Rs. 29,382 Non-current Deferred revenue (1) Rs. 1,531 Rs. 1,956 Others 812 850 Rs. 2,343 Rs. 2,806 (1) Refer to Note 22 for details of deferred revenue.

Share Capital (Tables)

Share Capital (Tables)	12 Months Ended
Share Capital (Tables)	Mar. 31, 2021
Disclosure of classes of share capital [abstract]
Disclosure Of Classes Of Share Capital [Text Block]	For the Year Ended For the Year Ended Number Amount Number Amount Authorized share capital 240,000,000 Rs. 1,200 240,000,000 Rs. 1,200 Fully paid up share capital Opening number of equity shares/share capital 166,172,082 Rs. 831 166,065,948 Rs. 830 Add: Equity shares issued pursuant to employee stock option plan (1) 129,149 1 106,134 1 Closing number of equity shares/share capital 166,301,231 Rs. 832 166,172,082 Rs. 831 Treasury shares (2) 575,201 Rs. 1,967 395,950 Rs. 1,006 (1) During the years ended March 31, 2021 and 2020, equity shares were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy’s Employees Stock Option Scheme, 2002 and the Dr. Reddy’s Employees Stock Option Scheme, 2007. The options exercised had an exercise price of Rs.5, Rs.2,607 or Rs.2,814 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the "share based payment reserve”was transferred to“share premium” in the consolidated statements of changes in equity. (2) Pursuant to the special resolution approved by the shareholders in the Annual General Meeting held on July 27, 2018, the Dr. Reddy’s Employees ESOS Trust (the “ESOS Trust”) was formed to support the Dr. Reddy’s Employees Stock Option Scheme, 2018 by acquiring, from the Company or through secondary market acquisitions, equity shares which are used for issuance to eligible employees (as defined therein) upon exercise of stock options thereunder. During the years ended March 31, 2021 and 2020, an aggregate of 85,250 and 1,150 equity shares, respectively were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy’s Employees Stock Option Scheme, 2018. The options exercised had an exercise price of Rs.2,607 or Rs.2,814 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the “share based payment reserve” was transferred to “share premium” in the consolidated statements of changes in equity.In addition, any difference between the carrying amount of treasury shares and the consideration received was recognized in the “share premium”. As of March 31, 2021 and 2020, the ESOS Trust had outstanding 575,201 and 395,950 shares, respectively, which it purchased from the secondary market for an aggregate consideration of Rs.1,967 and Rs.1,006, respectively. Refer to Note 29 of these consolidated financial statements for further details on the Dr. Reddy’s Employees Stock Option Scheme, 2018.
Disclosure of detailed information about dividends [Table Text Block]	Final dividends on equity shares (including dividend tax on distribution of such dividends, if any) are recorded as a liability on the date of their approval by the shareholders and interim dividends are recorded as a liability on the date of declaration by the Company’s Board of Directors. The details of dividends paid by the Company are as follows: For the Year Ended March 31, 2021 2020 2019 Dividend per share (in absolute Rs.) Rs. 25 Rs. 20 Rs. 20 Dividend distribution tax on the dividend paid - 602 682 Dividend paid during the year 4,147 3,314 3,320

Earnings per share (Tables)

Earnings per share (Tables)	12 Months Ended
Earnings per share (Tables)	Mar. 31, 2021
Basic and diluted earnings per share [abstract]
Basic Earnings Per Share [Table Text Block]	The weighted average number of equity shares outstanding, used for calculating the basic earnings per share, are as follows: For the Year Ended March 31, 2021 2020 2019 Number of equity shares at the beginning of the year (excluding treasury shares) 165,776,132 165,847,972 165,910,907 Effect of treasury shares held during the year (56,014 ) (154,020 ) (100,672 ) Effect of equity shares issued on exercise of stock options 124,222 64,432 103,801 Weighted average number of equity shares – Basic 165,844,340 165,758,384 165,914,036 Earnings per share of par value Rs.5 – Basic Rs. 103.94 Rs. 117.63 Rs. 113.28
Diluted Earnings Per Share [Table Text Block]	The weighted average number of equity shares outstanding, used for calculating the diluted earnings per share, are as follows: For the Year Ended March 31, 2021 2020 2019 Weighted average number of equity shares – Basic 165,844,340 165,758,384 165,914,036 Dilutive effect of stock options outstanding (1) 471,701 323,601 278,718 Weighted average number of equity shares – Diluted 166,316,041 166,081,985 166,192,754 Earnings per share of par value Rs.5 – Diluted Rs. 103.65 Rs. 117.40 Rs. 113.09 (1) As of March 31, 2021 and 2020, 235,460 and 475,575 options, respectively, were excluded from the diluted weighted average number of equity shares calculation because their effect would have been anti-dilutive. The average market value of the Company’s shares for the purpose of calculating the dilutive effect of stock options was based on quoted market prices for the year during which the options were outstanding.

Revenue from contracts with c_2

Revenue from contracts with customers and trade receivables (Tables)	12 Months Ended
	Mar. 31, 2021
Revenue [abstract]
Schedule of Revenue from contracts with customers [Table Text Block]	Revenue from contracts with customers: For the Year Ended March 31, 2021 2020 2019 Sales Rs. 184,202 Rs. 163,574 Rs. 148,706 Service income 4,105 2,409 2,129 License fees (1)(2) 1,415 8,617 3,016 Rs. 189,722 Rs. 174,600 Rs. 153,851 (1) During the year ended March 31, 2020, the Company entered into a definitive agreement with Upsher-Smith Laboratories, LLC for the sale of its U.S. and select territory rights for ZEMBRACE ® ® ® (2) License fees for the year ended March 31, 2019 primarily includes out-licensing revenue of Rs.1,807 from Encore Dermatology Inc .
Analysis of revenues by segments [Table Text Block]	Analysis of revenues by segments: For the Year Ended March 31, Segment 2021 2020 2019 Global Generics Rs. 154,404 Rs. 138,123 Rs. 122,903 PSAI 31,982 25,747 24,140 Proprietary products 523 7,949 4,750 Others 2,813 2,781 2,058 Rs. 189,722 Rs. 174,600 Rs. 153,851
Analysis of revenues within the Global Generics segment [Table Text Block]	Analysis of revenues within the Global Generics segment: An analysis of revenues by therapeutic areas in the Company’s Global Generics segment is given below: For the Year Ended March 31, 2021 2020 2019 Nervous System Rs. 29,040 Rs. 26,825 Rs. 19,726 Gastrointestinal 21,132 19,394 19,250 Oncology 16,842 18,245 18,357 Cardiovascular 15,460 14,729 15,106 Pain Management 15,531 13,808 13,806 Anti-Infective 12,906 9,402 7,073 Respiratory 11,089 10,433 8,130 Others 32,404 25,287 21,455 Tota l Rs. 154,404 Rs. 138,123 Rs. 122,903
Analysis of revenues within the PSAI segment [Table Text Block]	Analysis of revenues within the PSAI segment: An analysis of revenues by therapeutic areas in the Company’s PSAI segment is given below: For the Year Ended March 31, 2021 2020 2019 Cardiovascular Rs. 9,834 Rs. 8,567 Rs. 7,019 Pain Management 4,657 5,073 3,364 Anti-Infective 4,126 2,264 1,247 Nervous System 2,704 2,797 2,741 Oncology 2,385 1,798 2,212 Dermatology 768 1,370 1,622 Others 7,508 3,878 5,935 Tota l Rs. 31,982 Rs. 25,747 Rs. 24,140
Analysis of revenues by geography [Table Text block]	Analysis of revenues by geography: The following table shows the distribution of the Company’s revenues by country, based on the location of the customers: For the Year Ended March 31, Country 2021 2020 2019 India Rs. 36,252 Rs. 32,089 Rs. 28,804 United States 76,702 76,028 69,299 Russia 15,816 16,900 15,299 Others (1) 60,952 49,583 40,449 Rs. 189,722 Rs. 174,600 Rs. 153,851 (1) Others include Germany, the United Kingdom, Ukraine, China, Canada and other countries across the world.
Details of deferred revenue [Table Text Block]	Details of deferred revenue: Tabulated below is the reconciliation of deferred revenue for the years ended March 31, 2021 and 2020. For the Year Ended March 31, 2021 2020 Balance as of April 1 Rs. 3,198 Rs. 2,592 Revenue recognized during the year (1,089 ) (1,250 ) Milestone payment received during the year 474 1,856 Balance as of March 31 Rs. 2,583 Rs. 3,198 Current 1,052 1,242 Non-current 1,531 1,956
Details of significant gross to net adjustments relating to Company's North America Generics business [Table Text Block]	Details of significant gross to net adjustments relating to Company’s North America Generics business (amounts in U.S.$ millions) A roll-forward for each major accrual for the Company’s North America Generics business for the fiscal years ended March 31, 2019, 2020 and 2021 is as follows: Particulars Chargebacks Rebates Medicaid Refund Liability (3) (All values in U.S.$ millions) Beginning Balance: April 1, 2018 170 161 12 28 Current provisions relating to sales during the year 1,415 461 18 29 Provisions and adjustments relating to sales in prior years * - - - Credits and payments** (1,457 ) (530 ) (19 ) (27 ) Ending Balance: March 31, 2019 128 92 11 30 Beginning Balance: April 1, 2019 128 92 11 30 Current provisions relating to sales during the year ( 1 1,468 319 20 21 Provisions and adjustments relating to sales in prior years * - - - Credits and payments** (1,440 ) (331 ) (20 ) (27 ) Ending Balance: March 31, 2020 156 80 11 24 Beginning Balance: April 1, 2020 156 80 11 24 Current provisions relating to sales during the year ( 2 1,702 245 21 15 Provisions and adjustments relating to sales in prior years * - - - Credits and payments** (1,656 ) (247 ) (19 ) (20 ) Ending Balance: March 31, 2021 202 78 13 19 * Currently, the Company does not separately track provisions and adjustments, in each case to the extent relating to prior years for chargebacks. However, the adjustments are expected to be non-material. The volumes used to calculate the closing balance of chargebacks represent approximately 1.3 months equivalent of sales, which corresponds to the pending chargeback claims yet to be processed. ** Currently, the Company does not separately track the credits and payments, in each case to the extent relating to prior years for chargebacks, rebates, medicaid payments or refund liability. ( 1 Chargebacks provisions for the year ended March 31, 2020 were higher compared to the year ended March 31, 2019, primarily as a result of higher sales volumes, which were partially offset due to a lower pricing rates per unit for chargebacks. Such lower pricing was primarily on account of a reduction in the invoice price to wholesalers for certain of the Company’s products. The chargebacks payments for the year ended March 31, 2020 were lower compared to the year ended March 31, 2019, primarily as a result of higher pending chargebacks claims at March 31, 2020 as compared to March 31, 2019. The rebates provisions and the payments for the year ended March 31, 2020 were each lower as compared to the year ended March 31, 2019, primarily as a result of lower pricing rates per unit for rebates, due to a reduction in the invoice price to wholesalers for certain of the Company’s products, which were partially offset by higher sales volumes during the year ended March 31, 2020 as compared to the year ended March 31, 2019. (2) Chargebacks provisions and payments for the year ended March 31, 2021 were each higher as compared to the year ended March 31, 2020, primarily as a result of higher sales volumes and also due to higher pricing rates per unit for chargebacks, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company’s products. The rebates provisions and payments for the year ended March 31, 2021 were each lower as compared to the year ended March 31, 2020, primarily as a result of lower pricing rates per unit for rebates, due to a reduction in the invoice price to wholesalers for certain of the Company’s products and also due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company’s products, which were partially off-set by higher sales volumes during the year ended March 31, 2021 as compared to the year ended March 31, 2020. (3) The Company’s overall refund liability as of March 31, 2021 relating to its North America Generics business was U.S.$19, as compared to a liability of U.S.$24 as of March 31, 2020. This decrease in the Company’s liability was primarily attributable to a lower refund liability allowance for the year ended March 31, 2021 as compared to the year ended March 31, 2020. Such allowance change was primarily due to certain product mix changes and recent trends in actual sales returns, together with the Company’s historical experience and also the price reduction for certain products resulting into lower refund liability to be carried.
Details of refund liabilities [Table Text Block]	Details of refund liabilities: For the Year Ended March 31, 2021 2020 Balance at the beginning of the year Rs. 3,252 Rs. 3,581 Provision made during the year, net of reversals 2,934 2,675 Provision used during the year (3,309 ) (3,224 ) Effect of changes in foreign exchange rates (53 ) 220 Balance at the closing of the year Rs. 2,824 Rs. 3,252 Current Rs. 2,824 Rs. 3,252 Non-current - -
Details of contract liabilities [Table Text Block]	Details of contract liabilities As of March 31, 2021 2020 Advance from customers Rs. 981 Rs. 668 Rs. 981 Rs. 668

Other income, net (Tables)

Other income, net (Tables)	12 Months Ended
Other income, net (Tables)	Mar. 31, 2021
Other operating income expense [Abstract]
Other income, net	Other income, net consists of the following: For the Year Ended March 31, 2021 2020 2019 Loss/(gain) on sale/disposal of non-current assets, net (1) Rs. 42 Rs. 10 Rs. (1,264 ) Sale of spent chemicals (270 ) (306 ) (356 ) Scrap sales (142 ) (167 ) (179 ) Miscellaneous income, net (2) (612 ) (3,827 ) (156 ) Rs. (982 ) Rs. (4,290 ) Rs. (1,955 ) (1) Gain on disposal of assets for the year ended March 31, 2019 includes: a) an amount of Rs.582 representing the profit on sale of intangible assets forming part of the Company’s Proprietary Products segment after adjusting associated cost; b) an amount of Rs.423 representing the profit on sale of an API manufacturing business unit located in Jeedimetla, Hyderabad; and c) an amount of Rs.110 representing the profit on sale of all the membership interests in Dr. Reddy’s Laboratories Tennessee, LLC. (2) Miscellaneous income, net includes Rs.3,457 received from Celgene pursuant to a settlement agreement entered into in April 2019. The agreement effectively settles any claim the Company or its affiliates may have had for damages under section 8 of the Canadian Patented Medicines (Notice of Compliance) Regulations in regard to the Company’s ANDS for a generic version of REVLIMID® brand capsules (Lenalidomide) pending before Health Canada.

Finance income, net (Tables)

Finance income, net (Tables)	12 Months Ended
Finance income, net (Tables)	Mar. 31, 2021
Finance expense income [Abstract]
Finance income, net	Finance income, net consists of the following: For the Year Ended March 31, 2021 2020 2019 Interest income Rs. 826 Rs. 888 Rs. 770 Fair value changes and profit on sale of units of mutual funds, net 557 929 773 Foreign exchange gain 1,240 639 737 Miscellaneous income, net - * 5 - Finance income (A) Rs. 2,623 Rs. 2,461 Rs. 2,280 Interest expense Rs. (970 ) Rs. (983 ) Rs. (889 ) Foreign exchange loss - - (274 ) Finance expense (B) Rs. (970 ) Rs. (983 ) Rs. (1,163 ) Finance income, net [(A)+(B)] Rs. 1,653 Rs. 1,478 Rs. 1,117 * Rounded to the nearest million.

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
Income taxes (Tables)	Mar. 31, 2021	Mar. 31, 2020
Disclosure of income tax [Abstract]
Disclosure of income tax [Table Text Block]	Income tax expense/(benefit) recognized in the consolidated income statement consists of the following: For the Year Ended March 31, 2021 2020 2019 Current taxes Domestic Rs. 5,849 Rs. 5,157 Rs. 3,003 Foreign 2,323 1,459 1,707 Rs. 8,172 Rs. 6,616 Rs. 4,710 Deferred taxes Domestic Rs. 2,736 Rs. (6,580 ) Rs. 244 Foreign (1,733 ) (1,502 ) (1,306 ) Rs. 1,003 Rs. (8,082 ) Rs. (1,062 ) Tax expense/(benefit), net Rs. 9,175 Rs. (1,466 ) Rs. 3,648
Current and deferred tax relating to items charged or credited directly to equity [Table Text Block]	Income tax expense/(benefit) recognized directly in equity consists of the following: For the Year Ended March 31, 2021 2020 2019 Tax effect on changes in fair value of other investments Rs. 293 Rs. - Rs. 411 Tax effect on foreign currency translation differences - - (14 ) Tax effect on effective portion of change in fair value of cash flow hedges 319 (232 ) 69 Tax effect on actuarial gains/losses on defined benefit obligations (73 ) 22 3 Rs. 539 Rs. (210 ) Rs. 469
Reconciliation Between Enacted and Effective Tax Rates [Table Text Block]		The following is a reconciliation of the Company’s effective tax rates for the years ended March 31, 2021, 2020 and 2019: For the Year Ended March 31, 2021 2020 2019 Profit before income taxes Rs. 26,413 Rs. 18,032 Rs. 22,443 Enacted tax rate in India 34.94 % 34.94 % 34.94 % Computed expected tax expense Rs. 9,229 Rs. 6,301 Rs. 7,842 Effect of: Differences between Indian and foreign tax rates Rs. 810 Rs. 3,385 Rs. (734 ) Unrecognized deferred tax assets/(recognition of previously unrecognized deferred tax assets, net) 1,220 (6,478 ) 482 Expenses not deductible for tax purposes 230 155 340 Reversal of earlier years’ tax provisions - - (282 ) Income exempt from income taxes (1,807 ) (1,029 ) (1,282 ) Foreign exchange differences (18 ) (64 ) (470 ) Incremental deduction allowed for research and development costs (1) - (1,241 ) (1,134 ) Tax expense on distributed/undistributed earnings of subsidiary outside India - 254 - Write off of accounts receivables - - (1,294 ) Income from sale of capital assets - (2,620 ) - Effect of change in tax rate (333 ) (37 ) 3 Others (156 ) (92 ) 177 Income tax expense/(benefit) Rs. 9,175 Rs. (1,466 ) Rs.3,648 Effective tax rate 35 % (8 )% 16 % (1) India’s Finance Act, 2016 incorporated an amendment that reduc e .
Disclosure of Unrecognised Deferred Tax Assets and Liabilities [Table Text Block]	The details of unrecognized deferred tax assets are summarized below: As of March 31, 2021 2020 Deductible temporary differences, net Rs. 738 Rs. 394 Operating tax loss carry-forward 4,742 3,926 Rs. 5,480 Rs. 4,320
Disclosure of Tax Effects of Significant Temporary Differences That Resulted In Deferred Tax [Table Text Block]	The tax effects of significant temporary differences that resulted in deferred tax assets and liabilities and a description of the items that created these differences is given below: As of March 31, 2021 2020 Deferred tax assets/(liabilities): Inventory Rs. 3,997 Rs. 3,216 Minimum Alternate Tax* 4,748 6,246 Trade and other receivables 569 369 Operating/other tax loss carry-forward 2,593 3,399 Other current assets and other current liabilities, net 1,404 1,448 Property, plant and equipment (2,547 ) (2,361 ) Other intangible assets (283 ) (477 ) Others (189 ) 99 Net deferred tax assets Rs. 10,292 Rs. 11,939 * As per Indian tax laws, companies are liable for a Minimum Alternate Tax (“MAT”) when current tax, as computed under the provisions of the Income Tax Act, 1961 (“Tax Act”), is determined to be below the MAT computed under section 115JB of the Tax Act. If in any year the Company pays a MAT, then it is entitled to claim credit of the MAT paid over and above the normal tax liability in the subsequent years. The MAT credit is eligible to be carried forward and set-off in the future against the current tax liabilities over a period of 15 years starting from the succeeding fiscal year in which such credit was generated.
Disclosure Of Movement in deferred tax assets and liabilities [Table Text Block]	As of March 31, Recognized in Recognized in As of March 31, Deferred tax assets/(liabilities): Inventory Rs. 3,216 Rs. 781 Rs. - Rs. 3,997 Minimum Alternate Tax 6,246 (1,498 ) - 4,748 Trade and other receivables 369 200 - 569 Operating/other tax loss carry-forward 3,399 (806 ) - 2,593 Other current assets and other current liabilities, net 1,448 (44 ) - 1,404 Property, plant and equipment (2,361 ) (187 ) - (2,548 ) Other intangible assets (477 ) 194 - (283 ) Others 99 252 (539 ) (188 ) Net deferred tax assets Rs. 11,939 Rs. (1,108 ) Rs. (539 ) Rs. 10,292 The details of movement in deferred tax assets and liabilities are summarized below: As of March 31, Recognized in Recognized in As of March 31, Deferred tax assets/(liabilities): Inventory Rs. 3,285 Rs. (69 ) Rs. - Rs. 3,216 Minimum Alternate Tax 1,630 4,616 - 6,246 Trade and other receivables: 316 53 - 369 Operating/other tax loss carry-forward 297 3,102 - 3,399 Other current assets and other current liabilities, net 1,315 133 - 1,448 Property, plant and equipment (2,665 ) 304 - (2,361 ) Other intangible assets (662 ) 185 - (477 ) Others 42 (153 ) 210 99 Net deferred tax assets Rs. 3,558 Rs. 8,171 Rs. 210 Rs. 11,939

Nature of Expense (Tables)

Nature of Expense (Tables)	12 Months Ended
Nature of Expense (Tables)	Mar. 31, 2021
Expenses by nature [abstract]
Supplemental Information About Expense By Nature [Text Block]	The following table shows supplemental information related to certain “nature of expense” items for the years ended March 31, 2021, 2020 and 2019: For the Year Ended March 31, Employee benefits 2021 2020 2019 Cost of revenues Rs. 11,529 Rs. 10,643 Rs. 10,644 Selling, general and administrative expenses 20,052 18,658 18,291 Research and development expenses 4,718 4,501 4,627 Rs. 36,299 Rs. 33,802 Rs. 33,562 For the Year Ended March 31, Depreciation 2021 2020 2019 Cost of revenues Rs. 6,061 Rs. 6,366 Rs. 6,484 Selling, general and administrative expenses 1,491 1,294 801 Research and development expenses 975 980 1,077 Rs. 8,527 Rs. 8,640 Rs. 8,362 For the Year Ended March 31, Amortization 2021 2020 2019 Cost of revenues Rs. - Rs. 175 Rs. 284 Selling, general and administrative expenses 4,171 3,547 3,421 Research and development expenses 98 110 123 Rs. 4,269 Rs. 3,832 Rs. 3,828

Operating leases (Tables)

Operating leases (Tables)	12 Months Ended
Operating leases (Tables)	Mar. 31, 2021
Disclosure Of Finance Leases And Operating Leases By Lessee [Abstract]
Minimum Rental Payments Payable Under Noncancellable Operating Lease [Table Text Block]	The schedule of future minimum rental payments in respect of non-cancellable operating leases is set out below: As of March 31, 2021 2020 2019 Less than one year Rs. - Rs. - Rs. 405 Between one and five years - - 797 More than five years - - 89 Rs. - Rs. - Rs. 1,291

Employee benefits (Tables)

Employee benefits (Tables)	12 Months Ended
Employee benefits (Tables)	Mar. 31, 2021
Parent Company Gratuity plan [Member]
Disclosure of net defined benefit liability (asset) [abstract]
Cost Recognized in the Income Statement [Text Block]	The components of gratuity cost recognized in the income statement for the years ended March 31, 2021, 2020 and 2019 consist of the following: For the Year Ended March 31, 2021 2020 2019 Current service cost Rs. 281 Rs. 276 Rs. 265 Interest on defined benefit liability 8 (4 ) (2 ) Gratuity cost recognized in income statement Rs. 289 Rs. 272 Rs. 263
Disclosure of net defined benefit liability (asset) [Table Text Block]	Details of the employee benefits obligations and plan assets are provided below: As of March 31, 2021 2020 Present value of funded obligations Rs. 2,628 Rs. 2,349 Fair value of plan assets (1,997 ) (2,160 ) Net defined benefit liability recognized Rs. 631 Rs. 189
Disclosure of changes in the present value of defined benefit obligations [Text Block]	Details of changes in the present value of defined benefit obligations are as follows: As of March 31, 2021 2020 Defined benefit obligations at the beginning of the year Rs. 2,349 Rs. 2,200 Current service cost 281 276 Interest on defined obligations 140 152 Re-measurements due to: Actuarial loss/(gain) due to change in financial assumptions 153 (96 ) Actuarial loss/(gain) due to demographic assumptions (26 ) (48 ) Actuarial loss/(gain) due to experience changes 51 59 Benefits paid (345 ) (194 ) Liabilities assumed/(transferred) (1) 25 - Defined benefit obligations at the end of the year Rs. 2,628 Rs. 2,349 (1) a) Rs.70 increase in liabilities on account of the acquisition of employees pursuant to the Business Transfer Agreement with Wockhardt Limited. Refer to Note 6 of these consolidated financial statements for further details. b) Rs.45 transfer of liabilities on account of a restructuring of the pharmaceutical services business between the parent company and its subsidiary .
Disclosure of fair value of plan assets [text block]	Details of changes in the fair value of plan assets are as follows: As of March 31, 2021 2020 Fair value of plan assets at the beginning of the year Rs. 2,160 Rs. 2,174 Employer contributions 25 14 Interest on plan assets 132 156 Re-measurements due to: Return on plan assets excluding interest on plan assets (1 ) 10 Benefits paid (345 ) (194 ) Assets acquired/(transferred) (1) 26 - Plan assets at the end of the year Rs. 1,997 Rs. 2,160 (1) a) Rs.70 increase in assets on account of the acquisition of employees pursuant to the Business Transfer Agreement with Wockhardt Limited. Refer to Note 6 of these consolidated financial statements for further details . b) Rs.44 transfer of assets on account of a restructuring of the pharmaceutical services business between the parent company and its subsidiary .
Disclosure of sensitivity analysis for actuarial assumptions [text block]	Sensitivity Analysis: As of Defined benefit obligation without effect of projected salary growth Rs. 1,795 Add: Effect of salary growth 833 Defined benefit obligation with projected salary growth 2,628 Defined benefit obligation, using discount rate minus 50 basis points 2,700 Defined benefit obligation, using discount rate plus 50 basis points 2,559 Defined benefit obligation, using salary growth rate plus 50 basis points 2,698 Defined benefit obligation, using salary growth rate minus 50 basis points 2,560
Disclosure of assumptions used to determine benefit obligations [Table Text Block]	The assumptions used to determine benefit obligations: For the Year Ended March 31, 2021 2020 2019 Discount rate 6.00 % 6.65 % 7.45 % Rate of compensation increase 8.00 % 7.50 % 8% per annum for the first year and 9% per annum thereafter
Disclosure of assumptions used to determine the defined benefit cost [Table Text Block]	The assumptions used to determine gratuity cost: For the Year Ended March 31, 2021 2020 2019 Discount rate 6.65 % 7.45 % 7.75 % Rate of compensation increase 7.50 % 8% per annum for the first year and 9% per annum thereafter 7% per annum for the first year and 9% per annum thereafter
Disclosure of Disaggregation of Plan Assets [Table Text Block]	Disaggregation of plan assets: As of March 31, 2021 2020 Funds managed by insurers 100 % 99 % Others - 1 %
Disclosure Of Expected Future Cash Flows In Respect Of Post-employment Benefits [Text Block]	The expected future cash flows in respect of gratuity as of March 31, 2021 were as follows: Expected contribution Amount During the year ended March 31, 2022 (estimated) Rs. 317 Expected future benefit payments March 31, 2022 452 March 31, 2023 390 March 31, 2024 361 March 31, 2025 339 March 31, 2026 308 Thereafter 1,971
Industrias Quimicas Falcon de Mexico Pension plan [Member]
Disclosure of net defined benefit liability (asset) [abstract]
Cost Recognized in the Income Statement [Text Block]	The components of net pension cost recognized in the income statement for the years ended March 31, 2021, 2020 and 2019 consist of the following: For the Year Ended March 31, 2021 2020 2019 Current service cost Rs. 13 Rs. 11 Rs. 13 Interest on defined benefit liability 8 16 15 Total cost recognized in income statement Rs. 21 Rs. 27 Rs. 28
Disclosure of net defined benefit liability (asset) [Table Text Block]	Details of the employee benefits obligations and plan assets are provided below: As of March 31, 2021 2020 Present value of funded obligations Rs. 307 Rs. 234 Fair value of plan assets (169 ) (128 ) Net defined benefit liability recognized Rs. 138 Rs. 106
Disclosure of changes in the present value of defined benefit obligations [Text Block]	Details of changes in the present value of defined benefit obligations are as follows: As of March 31, 2021 2020 Defined benefit obligations at the beginning of the year Rs. 234 Rs. 223 Current service cost 13 11 Interest on defined obligations 21 25 Re-measurements due to: Actuarial loss/(gain) due to change in financial assumptions 24 50 Actuarial loss/(gain) due to experience changes 19 (8 ) Benefits paid (32 ) (41 ) Foreign exchanges differences 28 (26 ) Defined benefit obligations at the end of the year Rs. 307 Rs. 234
Disclosure of fair value of plan assets [text block]	Details of changes in the fair value of plan assets are as follows: As of March 31, 2021 2020 Fair value of plan assets at the beginning of the year Rs. 128 Rs. 70 Employer contributions 32 113 Interest on plan assets 13 9 Re-measurements due to: Return on plan assets excluding interest on plan assets 12 (7 ) Benefits paid (32 ) (41 ) Foreign exchanges differences 16 (16 ) Plan assets at the end of the year Rs. 169 Rs. 128
Disclosure of sensitivity analysis for actuarial assumptions [text block]	Sensitivity Analysis: As of March 31, 2021 Defined benefit obligation without effect of projected salary growth Rs. 209 Add: Effect of salary growth 98 Defined benefit obligation with projected salary growth 307 Defined benefit obligation, using discount rate minus 50 basis points 321 Defined benefit obligation, using discount rate plus 50 basis points 294 Defined benefit obligation, using salary growth rate plus 50 basis points 321 Defined benefit obligation, using salary growth rate minus 50 basis points 294
Disclosure of assumptions used to determine benefit obligations [Table Text Block]	The assumptions used to determine benefit obligations: For the Year Ended March 31, 2021 2020 2019 Discount rate 7.75 % 8.75 % 11.25 % Rate of compensation increase 4.50 % 4.50 % 4.50 %
Disclosure of assumptions used to determine the defined benefit cost [Table Text Block]	The assumptions used to determine defined benefit cost: For the Year Ended March 31, 2021 2020 2019 Discount rate 8.75 % 11.25 % 9.00 % Rate of compensation increase 4.50 % 4.50 % 4.50 %
Disclosure of Disaggregation of Plan Assets [Table Text Block]	Disaggregation of plan assets: As of March 31, 2021 2020 Funds managed by insurers 51 % 51 % Others 49 % 49 %
Disclosure Of Expected Future Cash Flows In Respect Of Post-employment Benefits [Text Block]	The expected future cash flows in respect of post-employment benefit plans in Mexico as of March 31, 2021 were as follows: Expected contribution Amount During the year ended March 31, 2022 (estimated) Rs. 36 Expected future benefit payments March 31, 2022 6 March 31, 2023 6 March 31, 2024 12 March 31, 2025 16 March 31, 2026 21 Thereafter 608

Employee stock incentive plans

Employee stock incentive plans (Tables)	12 Months Ended
Employee stock incentive plans (Tables)	Mar. 31, 2021
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Schedule of weighted average inputs of fair value of options granted [Text Block]	The weighted average inputs used in computing the fair value of options granted were as follows: Grants made on October 27, 2020 May 19, 2020 May 19, 2020 Expected volatility 30.81% 29.12% 30.47% Exercise price Rs.5.00 Rs.3,679.00 Rs.5.00 Option life 2.5 Years 5.0 Years 2.5 Years Risk-free interest rate 4.36% 5.67% 4.62% Expected dividends 0.49% 0.68% 0.68% Grant date share price Rs.5,009.00 Rs.3,700.00 Rs.3,700.00 Grants made on January 26, 2020 October 31, 2019 May 16, 2019 May 16, 2019 Expected volatility 27.00% 27.10% 28.25% 29.29% Exercise price Rs.3,031.00 Rs.5.00 Rs.2,814.00 Rs.5.00 Option life 5.00 Years 2.5 Years 5.0 Years 2.5 Years Risk-free interest rate 6.61% 5.72% 7.14% 6.76% Expected dividends 0.66% 0.72% 0.71% 0.71% Grant date share price Rs.3,031.00 Rs.2,783.20 Rs.2,801.00 Rs.2,801.00
Disclosure of detailed information about share based payment expense [Text Block]	Share-based payment expense For the Year Ended March 31, 2021 2020 2019 Equity settled share-based payment expense (1) Rs. 584 Rs. 521 Rs. 389 Cash settled share-based payment expense (2) 157 94 85 Rs. 741 Rs. 615 Rs. 474 (1) As of March 31, 2021 and 2020, there was Rs.612 and Rs.515, respectively, of total unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period of 1.95 years and 1.93 years, respectively. (2) Certain of the Company’s employees are eligible for share-based payment awards that are settled in cash. These awards entitle the employees to a cash payment, on the exercise date, subject to vesting upon satisfaction of certain service conditions which range from 1 to 4 years. The amount of cash payment is determined based on the price of the Company’s ADSs at the time of vesting. As of March 31, 2021 and 2020, there was Rs.126 and Rs.97, respectively of total unrecognized compensation cost related to unvested awards. This cost is expected to be recognized over a weighted-average period of 1.88 years and 1.93 years, respectively. This scheme does not involve dealing in or subscribing to or purchasing securities of the Company, directly or indirectly .
Disclosure And Details About 2018 Plan Table Text Block	The DRL 2018 Plan provides for option grants having an exercise price equal to the fair market value of the underlying equity shares on the date of grant as follows: Particulars Number of securities Number of securities Total Options reserved against equity shares 2,500,000 1,500,000 4,000,000 Options reserved against ADRs - 1,000,000 1,000,000 Total 2,500,000 2,500,000 5,000,000
DRL 2018 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Disclosure Of Number Of Share Options, Weighted Average Exercise Price, Range Of Exercise Prices And Weighted Average Remaining Contractual Life [Text Block]	Stock option activity under the DRL 2018 Plan during the years ended March 31, 2021 and 2020 was as follows: For the Year Ended March 31, 2021 Fair Market Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 375,775 Rs.2,607.00/ Rs.2,814.00 Rs. 2,697.12 75 Granted during the year 150,740 3,679. 3,679.00 90 Expired/forfeited during the year (55,335 ) 2,607.00 3,679. 2,904.51 - Exercised during the year (85,250 ) 2,607.00/ 2,814.00 2,671.71 - Outstanding at the end of the year 385,930 Rs.2,607.00 to Rs.3,679.00 Rs. 3,056.51 71 Exercisable at the end of the year 71,225 Rs.2,607.00/ Rs.2,814.00 Rs. 2,665.63 51 For the Year Ended March 31, 2020 Fair Market Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 229,600 Rs.2,607.00 Rs. 2,607.00 84 Granted during the year 169,900 2,814.00/ 2,817.07 90 Expired/forfeited during the year (22,575 ) 2,607.00 to 2,687.84 - Exercised during the year (1,150 ) 2,607.00 2,607.00 - Outstanding at the end of the year 375,775 Rs.2,607.00/ Rs.2814.00 Rs. 2,697.12 75 Exercisable at the end of the year 53,100 Rs.2,607.00 Rs. 2,607.00 53
DRL 2002 Plan [Member]
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Disclosure of Number of Options Reserved [Text Block]	After the stock split effected in the form of a stock dividend issued by the Company in August 2006, the DRL 2002 Plan provides for stock option grants in the above two categories as follows: Particulars Number of Number of Total Options reserved under original Plan 300,000 1,995,478 2,295,478 Options exercised prior to stock dividend date (A) 94,061 147,793 241,854 Balance of shares that can be allotted on exercise of options (B) 205,939 1,847,685 2,053,624 Options arising from stock dividend (C) 205,939 1,847,685 2,053,624 Options reserved after stock dividend (A+B+C) 505,939 3,843,163 4,349,102
Disclosure Of Number Of Share Options, Weighted Average Exercise Price, Range Of Exercise Prices And Weighted Average Remaining Contractual Life [Text Block]	Category A — Fair Market Value Options: Category B — Par Value Options: For the Year Ended March 31, 2021 Category B — Par Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 232,837 Rs. 5.00 Rs. 5.00 69 Granted during the year 92,092 5.00 5.00 93 Expired/forfeited during the year (35,646 ) 5.00 5.00 - Exercised during the year (72,030 ) 5.00 5.00 - Outstanding at the end of the year 217,253 Rs. 5.00 Rs. 5.00 69 Exercisable at the end of the year 46,130 Rs. 5.00 Rs. 5.00 44 For the Year Ended March 31, 2020 Category B — Par Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 270,141 Rs. 5.00 Rs. 5.00 73 Granted during the year 49,796 5.00 5.00 90 Expired/forfeited during the year (14,934 ) 5.00 5.00 - Exercised during the year (72,166 ) 5.00 5.00 - Outstanding at the end of the year 232,837 Rs. 5.00 Rs. 5.00 69 Exercisable at the end of the year 40,548 Rs. 5.00 Rs. 5.00 43
DRL 2007 Plans [Member]
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Disclosure Of Number Of Share Options, Weighted Average Exercise Price, Range Of Exercise Prices And Weighted Average Remaining Contractual Life [Text Block]	For the Year Ended March 31, 2021 Category B — Par Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 151,583 Rs. 5.00 Rs. 5.00 73 Granted during the year 52,316 5.00 5.00 89 Expired/forfeited during the year (19,933 ) 5.00 5.00 - Exercised during the year (41,967 ) 5.00 5.00 - Outstanding at the end of the year 141,999 Rs. 5.00 Rs. 5.00 71 Exercisable at the end of the year 15,393 Rs. 5.00 Rs. 5.00 41 For the Year Ended March 31, 2020 Category B — Par Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 115,155 Rs. 5.00 Rs. 5.00 73 Granted during the year 89,282 5.00 5.00 90 Expired/forfeited during the year (18,886 ) 5.00 5.00 - Exercised during the year (33,968 ) 5.00 5.00 - Outstanding at the end of the year 151,583 Rs. 5.00 Rs. 5.00 73 Exercisable at the end of the year 14,166 Rs. 5.00 Rs. 5.00 44
DRL 2007 Plans [Member] \| Category A [Member]
Disclosure of terms and conditions of share-based payment arrangement [abstract]
Disclosure Of Number Of Share Options, Weighted Average Exercise Price, Range Of Exercise Prices And Weighted Average Remaining Contractual Life [Text Block]	Stock options activity under the DRL 2007 Plan for the above two categories of options during the years ended March 31, 2021 and 2020 was as follows: For the Year Ended March 31, 2021 Category A — Fair Market Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 202,760 Rs.1,982.00 to Rs.2,353.62 72 Granted during the year 96,080 3,679.00 3,679.00 90 Expired/forfeited during the year (13,348 ) 2,607.00/ 2,678.03 - Exercised during the year (15,152 ) 2,607.00/ 2,643.48 - Outstanding at the end of the year 270,340 Rs.1,982.00 to Rs.3,679.00 Rs. 2,791.65 67 Exercisable at the end of the year 69,530 Rs.1,982.00 to Rs.2,814.00 Rs. 2,182.21 45 For the Year Ended March 31, 2020 Category A — Fair Market Value Options Shares arising out Range of exercise Weighted average Weighted average Outstanding at the beginning of the year 146,060 Rs.1,982.00/ Rs.2,607.00 Rs. 2,166.00 81 Granted during the year 61,700 2,814.00 2,814.00 90 Expired/forfeited during the year (5,000 ) 2,607.00 2,607.00 - Exercised during the year - - - - Outstanding at the end of the year 202,760 Rs.1,982.00 to Rs.2,814.00 Rs. 2,353.62 72 Exercisable at the end of the yea r 35,265 Rs.1,982.00/ Rs.2,607.00 Rs. 2,150.81 51

Related parties (Tables)

Related parties (Tables)	12 Months Ended
Related parties (Tables)	Mar. 31, 2021
Disclosure of transactions between related parties [abstract]
Disclosure of transactions between related parties [text block]	The following is a summary of significant related party transactions: For the Year Ended March 31, 2021 2020 2019 Research and development services received Rs. 105 Rs. 105 Rs. 97 Sale of goods 22 14 23 Lease rentals received 1 1 - Research and development services provided 93 58 103 Lease rentals paid 37 35 35 Catering expenses paid 301 344 270 Hotel expenses paid 8 22 26 Facility management services paid 36 24 - Purchase of solar power 127 108 - Civil works 55 101 106 Professional consultancy services paid 30 4 1 Contributions towards social development 232 233 220 Salaries to relatives of key management personnel 8 7 5 Others - - * - * Rounded to the nearest million.
Schedule of outstanding balances for related party transactions [Table Text Block]	The Company had the following amounts due from related parties: As of March 31, 2021 2020 Key management personnel and close members of th e Rs. 8 Rs. 8 Other related parties 72 68 The Company had the following amounts due to related parties: As of March 31, 2021 2020 Due to related parties Rs. 93 Rs. 91
Disclosure Of Compensation Paid Or Payable To Key Management Personnel [Table Text Block]	The following table describes the components of compensation paid or payable to key management personnel for the services rendered during the applicable year ended: For the Year Ended March 31, 2021 2020 2019 Salaries and other benefits Rs. 803 Rs. 684 Rs. 668 Contributions to defined contribution plans 34 34 35 Commission to directors 301 298 243 Share-based payments expense 259 165 99 Rs. 1,397 Rs. 1,181 Rs. 1,045

Financial instruments (Tables)

Financial instruments (Tables)	12 Months Ended
Financial instruments (Tables)	Mar. 31, 2021
Disclosure of detailed information about financial instruments [abstract]
Carrying value and fair value of financial instruments [Table Text Block]	Financial instruments by category The carrying value and fair value of financial instruments as of March 31, 2021 and 2020, respectively were as follows: As of March 31, 2021 As of March 31, 2020 Total carrying Total fair value Total carrying Total fair value Assets: Cash and cash equivalents Rs. 14,829 Rs. 14,829 Rs. 2,053 Rs. 2,053 Other investments (1) 24,702 24,702 24,015 24,015 Trade and other receivables 49,759 49,759 52,015 52,015 Derivative financial instruments 1,218 1,218 1,105 1,105 Other assets (2) 2,626 2,626 4,170 4,170 Total Rs. 93,134 Rs. 93,134 Rs. 83,358 Rs. 83,358 Liabilities: Trade and other payables Rs. 23,744 Rs. 23,744 Rs. 16,659 Rs. 16,659 Derivative financial instruments 326 326 1,602 1,602 Long-term borrowings 7,163 7,163 5,570 5,570 Short-term borrowings 23,136 23,136 16,441 16,441 Bank overdraft 9 9 91 91 Other liabilities and provisions (3) 23,233 23,233 25,317 25,317 Total Rs. 77,611 Rs. 77,611 Rs. 65,680 Rs. 65,680 (1) Interest accrued but not due on investments is included in other assets. (2) Other assets that are not financial assets (such as receivables from statutory authorities, export benefit receivables, prepaid expenses, advances paid and certain other receivables) of Rs.12,717 and Rs.10,476 as of March 31, 2021 and 2020, respectively, are not included. (3) Amounts as of March 31, 2021 includes contingent consideration of
Disclosure of detailed information about Fair Value Measurement Of Assets And Liabilities [Table Text Block]	The following table presents the fair value hierarchy of assets and liabilities measured at fair value on a recurring basis as of March 31, 2021: Particulars Level 1 Level 2 Level 3 Total FVTPL - Financial asset - Investments in units of mutual funds Rs. 13,263 Rs. - Rs. - Rs. 13,263 FVTPL - Financial asset - Investment in limited liability partnership firm - - 400 400 FVTPL - Financial asset - Investments in equity securities - - 1 1 FVTOCI - Financial asset - Investments in equity securities 4,532 - - 4,532 Derivative financial instruments – net gain/(loss) on outstanding foreign exchange forward, option and swap contracts and interest rate swap contracts (1) - 892 - 892 FVTPL- Contingent consideration pursuant to the Business Transfer Agreement with Wockhardt Limited (Refer to Note 6 for details) - - 420 420 The following table presents the fair value hierarchy of assets and liabilities measured at fair value on a recurring basis as of March 31, 2020: Particulars Level 1 Level 2 Level 3 Total FVTPL - Financial asset - Investments in units of mutual funds Rs. 13,832 Rs. - Rs. - Rs. 13,832 FVTPL - Financial asset - Investments in equity securities - - 1 1 FVTOCI - Financial asset - Investments in equity securities 303 - - 303 FVTOCI - Financial asset - Investments in market linked debentures 1,993 - - 1,993 Derivative financial instruments – net gain/(loss) on outs t (1) - (497 ) - (497 ) (1) The Company enters into derivative financial instruments with various counterparties, principally financial institutions and banks. Derivatives valued using valuation techniques with market observable inputs are mainly interest rate swaps, foreign exchange forward option and swap contracts. The most frequently applied valuation techniques include forward pricing, swap models and Black-Scholes-Merton models (for option valuation), using present value calculations. The models incorporate various inputs, including foreign exchange forward rates, interest rate curves and forward rate curves.
Disclosure of detailed information about of gain/loss recognized in Respect of derivative contracts [Text Block]	The following table presents details in respect of the gain/(loss) recognized in respect of derivative contracts during the applicable year ended: For the Year Ended March 31, 2021 2020 2019 Net gain/(loss) recognized in finance costs in respect of foreign exchange derivative contracts and cross currency interest rate swaps contracts Rs. 2,619 Rs. 155 Rs. (257 ) Net gain/(loss) recognized in equity in respect of hedges of highly probable forecast transactions, net of amounts reclassified from equity and recognized as component of revenue 1,123 (951 ) 180 Net gain/(loss) reclassified from equity and recognized as component of revenue occurrence of forecasted transaction 340 (50 ) (524 )
Disclosure of notional amount of outstanding foreign exchange derivative contracts [Table Text Block]	The following table gives details in respect of the notional amount of outstanding foreign exchange derivative contracts as of March 31, 2021. Category Instrument Currency (1) Cross Currency (1) Amounts Buy/Sell Hedges of recognized assets and li a Forward contract AUD INR AUD 7 Sell Forward contract CHF INR CHF 200 Sell Forward contract GBP INR GBP 8 Sell Forward contract RUB INR RUB 2,799 Sell Forward contract U.S.$ INR U.S.$ 353 Sell Forward contract U.S.$ MXN U.S.$ 10 Buy Forward contract U.S.$ UAH U.S.$ 14 Buy Forward contract ZAR INR ZAR 111 Sell Forward contract U.S.$ RUB U.S.$ 2 Buy Forward contract U.S.$ RON U.S.$ 12 Buy Forward contract U.S.$ AUD U.S.$ 3 Buy Forward contract GBP U.S.$ GBP 48 Buy Forward contract EUR GBP EUR 1 Sell Forward contract EUR U.S.$ EUR 16 Buy Forward contract CHF U.S.$ CHF200 Buy Forward contract U.S.$ KZT U.S.$ 4 Buy Forward contract U.S.$ CLP U.S.$ 3 Buy Forward contract U.S.$ COP U.S.$ 4 Buy Forward contract U.S.$ BRL U.S.$ 4 Buy Forward contract U.S.$ KZT U.S.$ 9 Buy Hedges of highly probable forecast transactions Forward contract AUD INR AUD 10 Sell Forward contract RUB INR RUB 6,850 Sell Option contract U.S.$ INR U.S.$ 645 Sell - Risk Reversal Forward contract ZAR INR ZAR 148 Sell The following table gives details in respect of the notional amount of outstanding foreign exchange derivative contracts as of March 31, 2020. Category Instrument Currency (1) Cross Currency (1) Amounts Buy/Sell Hedges of recognized assets and liabilities Forward contract U.S.$ INR U.S.$ 148 Sell Forward contract RUB INR RUB 5,968 Sell Forward contract GBP INR GBP 9 Sell Forward contract AUD INR AUD 4 Sell Forward contract CHF INR CHF 200 Sell Forward contract ZAR INR ZAR 71 Sell Forward contract CHF U.S.$ CHF 200 Buy Forward contract EUR GBP EUR 3 Sell Forward contract EUR U.S.$ EUR 6 Buy Forward contract GBP U.S.$ GBP 38 Buy Forward contract U.S.$ AUD U.S.$ 5 Buy Forward contract U.S.$ BRL U.S.$ 6 Buy Forward contract U.S.$ CLP U.S.$ 4 Buy Forward contract U.S.$ COP U.S.$ 4 Buy Forward contract U.S.$ KZT U.S.$ 11 Buy Forward contract U.S.$ MXN U.S.$ 2 Buy Forward contract U.S.$ RON U.S.$ 7 Buy Forward contract U.S.$ RUB U.S.$ 6 Buy Forward contract U.S.$ UAH U.S.$ 19 Buy Forward contract U.S.$ INR U.S.$ 140 Sell Hedges of highly probable forecast transactions Option contract U.S.$ INR U.S.$ 270 Sell (1) “INR” means Indian rupees, “U.S.$” means United States dollars, “RON” means Ro m
Disclosure Of Detailed Information About Highly Probable Forecast Transactions Hedged Items [Table Text Block]	The table below summarizes the periods when the cash flows associated with highly probable forecast transactions that are classified as cash flow hedges are expected to occur: As of March 31, 2021 2020 Cash flows in U.S dollars Not later than one month Rs. 3,656 Rs. 2,648 Later than one month and not later than three months 7,311 5,297 Later than three months and not later than six months 12,063 7,945 Later than six months and not later than one year 24,126 4,540 Rs. 47,156 Rs. 20,430 Cash flows in Russian roubles Not later than one month Rs. 437 Rs. - Later than one month and not later than three months 874 - Later than three months and not later than six months 1,748 - Later than six months and not later than one year 3,593 - Rs. 6,651 Rs. - Cash flows in Australian dollars Not later than one month Rs. 46 Rs. - Later than one month and not later than three months 92 - Later than three months and not later than six months 139 - Later than six months and not later than one year 277 - Rs. 555 Rs. - Cash flows in South African rands Not later than one month Rs. 61 Rs. - Later than one month and not later than three months 121 - Later than three months and not later than six months 182 - Later than six months and not later than one year 364 - Rs. 728 Rs. -

Financial risk management (Tabl

Financial risk management (Tables)	12 Months Ended
Financial risk management (Tables)	Mar. 31, 2021
Disclosure Of Financial Risk Management [Abstract]
Disclosure of foreign currency risk from non-derivative financial instruments [Table Text Block]	The following table analyzes foreign currency risk from non-derivative financial instruments as of March 31, 2021: U.S. dollars Euro Russian roubles Others (1) Total Assets: Cash and cash equivalents Rs. 12,643 Rs. 129 Rs. 30 Rs 92 Rs. 12,894 Other investments 24 - - - 24 Trade and other receivables 30,247 841 721 101 31,910 Other assets 184 20 3 16 223 Total Rs. 43,098 Rs. 990 Rs. 754 Rs. 209 Rs. 45,051 Liabilities: Trade and other payables Rs. 4,207 Rs. 1,270 Rs. - * Rs. 210 Rs. 5,687 Long-term borrowings 2,216 52 18 43 2,329 Short-term borrowings 3,657 - 3,717 - 7,374 Other liabilities and provisions 4,665 65 81 292 5,103 Total Rs. 14,745 Rs. 1,387 Rs. 3,816 Rs. 545 Rs. 20,493 The following table analyzes foreign currency risk from non-derivative financial instruments as of March 31, 2020: U.S. dollars Euro Russian roubles Others (1) Total Assets: Cash and cash equivalents Rs. 365 Rs. 43 Rs. 4 Rs. 135 Rs. 547 Other investments 24 - - - 24 Trade and other receivables 31,931 705 989 317 33,942 Other assets 921 15 3 153 1,092 Total Rs. 33,241 Rs. 763 Rs. 996 Rs. 605 Rs. 35,605 Liabilities: Trade and other payables Rs. 1,857 Rs. 525 Rs. - * Rs. 73 Rs. 2,455 Long-term borrowings 4,401 2 3 77 4,483 Short-term borrowings 7,316 - - - 7,316 Other liabilities and provisions 5,534 60 52 400 6,046 Total Rs. 19,108 Rs. 587 Rs. 55 Rs. 550 Rs. 20,300 * Rounded to the nearest million. (1) Others primarily consists of U.K. pounds sterling, Swiss francs, Romanian new leus, Chinese yuans (Renminbi), Canadian dollars and Ukrainian hryvnia.
Analysis of Age of Trade And Other Receivables [Table Text Block]	The aging of trade and other receivables is given below: As of March 31, Particulars 2021 2020 Neither past due nor impaired Rs. 41,350 Rs. 45,864 Past due but not impaired Less than 365 days 8,598 6,305 More than 36 5 1,107 1,048 Rs. 51,055 Rs. 53,217 Less : Allowance for credit losses (1,296 ) (1,202 ) Total Rs. 49,759 Rs. 52,015
Maturity Analysis For Financial Liabilities [Table Text Block]	The table below provides details regarding the contractual maturities of significant financial liabilities (other than long-term borrowings and obligations under leases, which have been disclosed in Note 17 to these consolidated financial statements) as of March 31, 2021: Particulars 2022 2023 2024 2025 Thereafter Total Trade and other payables Rs. 23,744 Rs. - Rs. - Rs. - Rs. - Rs. 23,744 Bank overdraft, short-term borrowings 23,145 - - - - 23,145 Derivative financial instruments 326 - - - - 326 Other liabilities and provisions 22,507 - - - 726 23,233 The table below provides details regarding the contractual maturities of significant financial liabilities (other than long-term borrowings and obligations under leases, which have been disclosed in Note 17 to these consolidated financial statements) as of March 31, 2020: Particulars 2021 2022 2023 2024 Thereafter Total Trade and other payables Rs. 16,659 Rs. - Rs. - Rs. - Rs. - Rs. 16,659 Bank overdraft, short-term borrowings 16,532 - - - - 16,532 Derivative financial instruments 1,602 - - - - 1,602 Other liabilities and provisions 24,566 - - - 751 25,317

Contingencies (Tables)

Contingencies (Tables)	12 Months Ended
Contingencies (Tables)	Mar. 31, 2021
Disclosure of contingent liabilities [abstract]
Disclosure of the show cause notices issued by Commercial Taxes Department regarding VAT input credit [Table Text Block]	The below table shows the details of each of such demand notice, the amount demanded and the current status of the Company’s responsive actions. Period covered under the notice Amount demanded Status April 2006 to March 2009 Rs.66 plus 10% penalty The State VAT Appellate Tribunal has remanded the matter to the assessing authority to re-compute the eligibility and penalty orders are set-aside. The Company filed appeal against the same with the High Court, Telangana. April 2009 to March 2011 Rs.59 plus 10% penalty The Company has filed an appeal before the Sales Tax Appellate Tribunal. The matter was remanded to the original adjudicating authority with a direction to re-calculate the eligibility for the year ended March 31, 2010. April 2011 to March 2014 Rs.27 plus 10% penalty The Appellate Deputy Commissioner issued an order partially in favor of the Company

Collaboration, License and Op_2

Collaboration, License and Option Agreement with Curis, Inc (Tables)	12 Months Ended
	Mar. 31, 2021
Collaboration Agreement [Line Items]
Summary of partail consideration received under collaboration license and option agreement	As a partial consideration for the collaboration, the following shares of Number of Curis Fair value Pursuant to the collaboration agreement dated January 18, 2015 17.1 Rs.1,452 (U.S.$23.5) Pursuant to an amendment to collaboration agreement dated S e 24.5 10.2 Rs.1,247 (U.S.$18.8)
Curis, Inc. [Member]
Collaboration Agreement [Line Items]
Summary of the details of cost, fair value, and the amount recognized in OCI of the fair value changes	The following table is a summary of the details of cost, fair value, and the amount recognized in OCI of the fair value changes: As of March 31, 2021 Cost Unrealized gain Fair value Received on January 18, 2015 Rs. 1,452 Rs. 1,382 Rs. 2,834 Received on September 7, 2016 1,247 442 1,689 Rs. 2,699 Rs. 1,824 Rs. 4,523

Organizational structure (Table

Organizational structure (Tables)	12 Months Ended
Organizational structure (Tables)	Mar. 31, 2021
Interests in other entities [Abstract]
Disclosure of interests in other entities [text block]	Dr. Reddy’s Laboratories Limited is the parent company. Tabulated below is the list of subsidiaries and joint ventures as of March 31, 2021: Name of the subsidiary/joint venture Country of Percentage of Direct/Indirect Aurigene Discovery Technologies (Malaysia) Sdn. Bhd. Malaysia 100% (3) Aurigene Discovery Technologies, Inc. U.S.A. 100% (3) Aurigene Discovery Technologies Limited India 100% Aurigene Pharmaceutical Services Limited (from September 16, 2019) India 100% (3) beta Institut gemeinnützige GmbH Germany 100% (8) betapharm Arzneimittel GmbH Germany 100% (8) Cheminor Investments Limited India 100% Cheminor Employees Welfare Trust India Refer to below footnote (16) Chirotech Technology Limited United Kingdom 100% (2)(5) Dr. Reddy’s Research Foundation India Refer to below footnote (16) Dr. Reddy's Employees ESOS Trust (from July 27, 2018) India Refer to below footnote (16) Dr. Reddy’s Farmaceutica Do Brasil Ltda. Brazil 100% Dr. Reddy’s Laboratories (EU) Limited United Kingdom 100% (10) Dr. Reddy’s Laboratories (Proprietary) Limited South Africa 100% (10) Dr. Reddy’s Laboratories (UK) Limited United Kingdom 100% (5) Dr. Reddy’s Laboratories Canada, Inc. Canada 100% (10) Dr. Reddy's Laboratories Chile SPA. Chile 100% (10) Dr. Reddy’s Laboratories, Inc. U.S.A. 100% (10) Dr. Reddy’s Laboratories Japan KK Japan 100% (10) Dr. Reddy’s Laboratories Kazakhstan LLP Kazakhstan 100% (10) Dr. Reddy’s Laboratories Louisiana, LLC U.S.A. 100% (6) Dr. Reddy’s Laboratories Malaysia Sdn. Bhd. Malaysia 100% (10) Dr. Reddy’s Laboratories New York, LLC U.S.A. 100% (1) Dr. Reddy's Laboratories Philippines Inc. (from May 9, 2018) Philippines 100% (10) Dr. Reddy’s Laboratories Romania S.R.L. Romania 100% (10) Dr. Reddy’s Laboratories SA Switzerland 100% Dr. Reddy's Laboratories Taiwan Limited Taiwan 100% (10) Dr. Reddy's Laboratories (Thailand) Limited (from June 13, 2018) Thailand 100% (10) Dr. Reddy’s Laboratories, LLC Ukraine 100% (10) Dr. Reddy’s New Zealand Limited New Zealand 100% (10) Dr. Reddy’s S.R.L. Italy 100% (11) Dr. Reddy's Bio-Sciences Limited India 100% Dr. Reddy's Laboratories (Australia) Pty. Limited Australia 100% (10) Dr. Reddy's Laboratories S.A.S. Colombia 100% (10) Dr. Reddy's Research and Development B.V. (formerly Octoplus B.V.) Netherlands 100% (12) Dr. Reddy's Venezuela, C.A. Venezuela 100% (10) Dr. Reddy’s (WUXI) Pharmaceutical Company Limited China 100% (10) Dr. Reddy’s (Beijing) Pharmaceutical Co. Limited (from August 19, 2020) China 100% (10) DRANU LLC U.S.A. 50% (14)(17) DRES Energy Private Limited India 26% (15) DRL Impex Limited India 100% (13) Dr. Reddy's Laboratories B.V. (formerly Eurobridge Consulting B.V.) Netherlands 100% (12) Dr. Reddy’s Formulations Limited (from March 11, 2021) India 100% Idea2Enterprises (India) Private Limited India 100% Imperial Credit Private Limited India 100% Industrias Quimicas Falcon de Mexico, S.A. de CV Mexico 100% Kunshan Rotam Reddy Pharmaceutical Co. Limited China 51.33% (4) Lacock Holdings Limited Cyprus 100% (10) OOO Dr. Reddy's Laboratories Limited Russia 100% (10) OOO DRS LLC Russia 100% (9) Promius Pharma, LLC U.S.A. 100% (6) Reddy Holding GmbH Germany 100% (10) Reddy Netherlands B.V. Netherlands 100% (10) Reddy Pharma Iberia S.A.U. Spain 100% (10) Reddy Pharma Italia S.R.L. Italy 100% (7) Reddy Pharma SAS France 100% (10) Svaas Wellness Limited (formerly Regkinetics Services Limited) India 100% (1) Indirectly owned through Dr. Reddy’s Laboratories, Inc. (from October 29, 2020), formerly a subsidiary of Dr. Reddy’s Laboratories SA. Also, conversion from corporation to limited liability company is effective October 30, 2020. (2) Entity under liquidation. (3) Indirectly owned through Aurigene Discovery Technologies Limited. (4) Kunshan Rotam Reddy Pharmaceutical Co. Limited is a subsidiary as per Indian Companies Act, 2013, as the Company holds a 51.33% stake. However, the Company accounts for this investment by the equity method and does not consolidate it in the Company’s financial statements. (5) Indirectly owned through Dr. Reddy’s Laboratories (EU) Limited. (6) Indirectly owned through Dr. Reddy’s Laboratories Inc. (7) Indirectly owned through Lacock Holdings Limited. (8) Indirectly owned through Reddy Holding GmbH. (9) Indirectly owned through OOO Dr. Reddy's Laboratories Limited. (10) Indirectly owned through Dr. Reddy’s Laboratories SA. (11) Indirectly owned through Reddy Pharma Italia S.R.L. (12) Indirectly owned through Reddy Netherlands B.V. (13) Indirectly owned through Idea2Enterprises (India) Pvt. Limited. (14) DRANU LLC is consolidated in accordance with guidance available in IFRS 10, “Consolidated Financial Statements” (15) Accounted in accordance with IFRS 11, “Joint Arrangements” (16) The Company does not have any equity interests in this entity, but has significant influence or control over it. (17) Pursuant to the sale of the membership interests in DRANU, LLC, it ceased to be a joint venture effective March 31, 2021.

Basis of preparation of finan_3

Basis of preparation of financial statements (Details Textual)	Mar. 31, 2021INRPerUSD
Basis of preparation of financial statements [Abstract]
Convenience Translation rate	73.14

Significant accounting polici_4

Significant accounting policies (Details 1)	12 Months Ended
Significant accounting policies (Details 1)	Mar. 31, 2021
Factory and administrative buildings [Member] \| Bottom of range [member]
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	20 years
Factory and administrative buildings [Member] \| Top of range [member]
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	50 years
Ancillary structures [Member] \| Bottom of range [member]
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	3 years
Ancillary structures [Member] \| Top of range [member]
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	15 years
Plant and equipment [member] \| Bottom of range [member]
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	3 years
Plant and equipment [member] \| Top of range [member]
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	15 years
Furniture, fixtures and office equipment [Member] \| Bottom of range [member]
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	3 years
Furniture, fixtures and office equipment [Member] \| Top of range [member]
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	10 years
Vehicles [Member] \| Bottom of range [member]
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	4 years
Vehicles [Member] \| Top of range [member]
Disclosure of detailed information about property, plant and equipment [line items]
Useful life measured as period of time, property, plant and equipment	5 years

Significant accounting polici_5

Significant accounting policies (Details 2)	12 Months Ended
Significant accounting policies (Details 2)	Mar. 31, 2021
Product related intangibles [member] \| Bottom of range [member]
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	3 years
Product related intangibles [member] \| Top of range [member]
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	20 years
Other intangibles [Member] \| Bottom of range [member]
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	3 years
Other intangibles [Member] \| Top of range [member]
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	15 years

Segment reporting (Details)

Segment reporting (Details) ₨ in Millions, $ in Millions		12 Months Ended
Segment reporting (Details) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Disclosure of operating segments [line items]
Revenues	[1]	₨ 189,722	$ 2,594	₨ 174,600	₨ 153,851
Gross Profit		103,077	1,409	94,009	83,430
Selling, general and administrative expenses		54,650	747	50,129	48,680
Research and development expenses		16,541	226	15,410	15,607
Impairment of non-current assets		8,588	117	16,767	210
Other income, net		(982)	(13)	(4,290)	(1,955)
Results from operating activities		24,280	332	15,993	20,888
Finance income, net		1,653	23	1,478	1,117
Share of profit of equity accounted investees, net of tax		480	7	561	438
Profit before tax		26,413	361	18,032	22,443
Tax (expense)/benefit, net		9,175	125	(1,466)	3,648
Profit for the year		17,238	$ 236	19,498	18,795
Global Generics [Member]
Disclosure of operating segments [line items]
Revenues	[1]	154,404		138,123	122,903
Gross Profit		91,111		78,449	71,924
Pharmaceutical Services and Active Ingredients [Member]
Disclosure of operating segments [line items]
Revenues	[1]	31,982		25,747	24,140
Gross Profit		9,426		6,190	6,128
Proprietary Product [Member]
Disclosure of operating segments [line items]
Revenues	[1]	523		7,949	4,750
Gross Profit		482		7,744	4,182
Other segment [Member]
Disclosure of operating segments [line items]
Revenues	[1]	2,813		2,781	2,058
Gross Profit		₨ 2,058		₨ 1,626	₨ 1,196

[1]	Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).

Segment reporting (Details 2)

Segment reporting (Details 2) ₨ in Millions, $ in Millions		12 Months Ended
Segment reporting (Details 2) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Disclosure of operating segments [line items]
Revenue	[1]	₨ 189,722	$ 2,594	₨ 174,600	₨ 153,851
Global Generic [Member]
Disclosure of operating segments [line items]
Revenue		154,404		138,123	122,903
Global Generic [Member] \| Nervous System [Member]
Disclosure of operating segments [line items]
Revenue		29,040		26,825	19,726
Global Generic [Member] \| Gastrointestinal [Member]
Disclosure of operating segments [line items]
Revenue		21,132		19,394	19,250
Global Generic [Member] \| Oncology [Member]
Disclosure of operating segments [line items]
Revenue		16,842		18,245	18,357
Global Generic [Member] \| Cardiovascular [Member]
Disclosure of operating segments [line items]
Revenue		15,460		14,729	15,106
Global Generic [Member] \| Pain Management [Member]
Disclosure of operating segments [line items]
Revenue		15,531		13,808	13,806
Global Generic [Member] \| Anti-Infective [Member]
Disclosure of operating segments [line items]
Revenue		12,906		9,402	7,073
Global Generic [Member] \| Respiratory [Member]
Disclosure of operating segments [line items]
Revenue		11,089		10,433	8,130
Global Generic [Member] \| Others
Disclosure of operating segments [line items]
Revenue		₨ 32,404		₨ 25,287	₨ 21,455

[1]	Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).

Segment reporting (Details 3)

Segment reporting (Details 3) ₨ in Millions, $ in Millions		12 Months Ended
Segment reporting (Details 3) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Disclosure Of Operating Segment [Line Items]
Revenue	[1]	₨ 189,722	$ 2,594	₨ 174,600	₨ 153,851
Pharmaceutical Services and Active Ingredient [Member]
Disclosure Of Operating Segment [Line Items]
Revenue		31,982		25,747	24,140
Pharmaceutical Services and Active Ingredient [Member] \| Cardiovascular [Member]
Disclosure Of Operating Segment [Line Items]
Revenue		9,834		8,567	7,019
Pharmaceutical Services and Active Ingredient [Member] \| Pain Management [Member]
Disclosure Of Operating Segment [Line Items]
Revenue		4,657		5,073	3,364
Pharmaceutical Services and Active Ingredient [Member] \| Anti-Infective [Member]
Disclosure Of Operating Segment [Line Items]
Revenue		4,126		2,264	1,247
Pharmaceutical Services and Active Ingredient [Member] \| Nervous System [Member]
Disclosure Of Operating Segment [Line Items]
Revenue		2,704		2,797	2,741
Pharmaceutical Services and Active Ingredient [Member] \| Oncology [Member]
Disclosure Of Operating Segment [Line Items]
Revenue		2,385		1,798	2,212
Pharmaceutical Services and Active Ingredient [Member] \| Dermatology [Member]
Disclosure Of Operating Segment [Line Items]
Revenue		768		1,370	1,622
Pharmaceutical Services and Active Ingredient [Member] \| Others [Member]
Disclosure Of Operating Segment [Line Items]
Revenue		₨ 7,508		₨ 3,878	₨ 5,935

[1]	Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).

Segment reporting (Details 4)

Segment reporting (Details 4) ₨ in Millions, $ in Millions		12 Months Ended
Segment reporting (Details 4) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Disclosures Of Geographical Areas [Line Items]
Revenue	[1]	₨ 189,722	$ 2,594	₨ 174,600	₨ 153,851
India [Member]
Disclosures Of Geographical Areas [Line Items]
Revenue		36,252		32,089	28,804
United States Country [Member]
Disclosures Of Geographical Areas [Line Items]
Revenue		76,702		76,028	69,299
Russia [Member]
Disclosures Of Geographical Areas [Line Items]
Revenue		15,816		16,900	15,299
Others [Member]
Disclosures Of Geographical Areas [Line Items]
Revenue	[2]	₨ 60,952		₨ 49,583	₨ 40,449

[1]	Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).
[2]	Others include Germany, the United Kingdom, Ukraine, China, Canada and other countries across the world.

Segment reporting (Details 5)

Segment reporting (Details 5) - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020
Disclosure of geographical areas [line items]
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts	₨ 100,768	₨ 86,797
India Country [Member]
Disclosure of geographical areas [line items]
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts	75,284	55,083
Switzerland Country [Member]
Disclosure of geographical areas [line items]
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts	11,661	18,204
United States Country [Member
Disclosure of geographical areas [line items]
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts	7,627	7,065
Germany Country [Member]
Disclosure of geographical areas [line items]
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts	1,087	1,435
Others [Member]
Disclosure of geographical areas [line items]
Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts	₨ 5,109	₨ 5,010

Segment reporting (Details 6)

Segment reporting (Details 6) - INR (₨) ₨ in Millions	12 Months Ended
Segment reporting (Details 6) - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020
Disclosure of geographical areas [line items]
Property, plant and equipments including capital work in progress and intangible assets acquired, other than goodwill arising on business combination	₨ 34,831	₨ 7,473
India Country [Member]
Disclosure of geographical areas [line items]
Property, plant and equipments including capital work in progress and intangible assets acquired, other than goodwill arising on business combination	27,882	5,519
Switzerland Country [Member]
Disclosure of geographical areas [line items]
Property, plant and equipments including capital work in progress and intangible assets acquired, other than goodwill arising on business combination	3,760	1,025
United States Country [Member]
Disclosure of geographical areas [line items]
Property, plant and equipments including capital work in progress and intangible assets acquired, other than goodwill arising on business combination	2,158	241
Others [Member]
Disclosure of geographical areas [line items]
Property, plant and equipments including capital work in progress and intangible assets acquired, other than goodwill arising on business combination	₨ 1,031	₨ 688

Segment reporting (Details 7)

Segment reporting (Details 7) - Cost of Revenues [Member] - INR (₨) ₨ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of operating segments [line items]
Depreciation and amortisation expense	₨ 6,061	₨ 6,541	₨ 6,768
Global Generic [Member]
Disclosure of operating segments [line items]
Depreciation and amortisation expense	3,435	3,666	3,791
PSAI [Member]
Disclosure of operating segments [line items]
Depreciation and amortisation expense	2,578	2,804	2,906
Proprietary Products [Member]
Disclosure of operating segments [line items]
Depreciation and amortisation expense	0	0	0
Others [Member]
Disclosure of operating segments [line items]
Depreciation and amortisation expense	₨ 48	₨ 71	₨ 71

Segment reporting (Details Text

Segment reporting (Details Textual) ₨ in Millions, $ in Millions		12 Months Ended
		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Disclosure of major customers [line items]
Revenue	[1]	₨ 189,722	$ 2,594	₨ 174,600	₨ 153,851
Inter-segment revenues from PSAI to Global Generic		6,905		5,910	5,785
Major Customer 1 [Member]
Disclosure of major customers [line items]
Revenue		₨ 19,341		₨ 14,164	₨ 10,639
Percentage of entity's revenue		10.00%	10.00%	8.00%	7.00%
Major Customer 2 [Member]
Disclosure of major customers [line items]
Revenue		₨ 9,867		₨ 9,267	₨ 10,024
Percentage of entity's revenue		5.00%	5.00%	5.00%	7.00%

[1]	Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).

Business Transfer Agreement w_3

Business Transfer Agreement with Wockhardt Limited (Details Textual) - Wockhardt Limited [Member] ₨ in Millions	Feb. 12, 2020INR (₨)BrandEmployees	Mar. 31, 2021INR (₨)
Disclosure of Business Transfer Agreement with Wockhardt Limited [Line Items]
Consideration on acquisition date	₨ 18,500	₨ 16,115
Number of brands \| Brand	62
Business combination contingent consideration payable		420
Gratuity payable		70
Compensation absence liability		75
Number of employees engaged in operations of the acquired Business Undertaking \| Employees	2,051
Goodwill recognized as of acquisition date		530
Revenue of acquiree since acquisition date		3,887
Selling general and administrative expenses [member]
Disclosure of Business Transfer Agreement with Wockhardt Limited [Line Items]
Acquisition-related costs recognised as expense for transaction recognised separately from acquisition of assets and assumption of liabilities in business combination		60
Level 3 of fair value hierarchy [member]
Disclosure of Business Transfer Agreement with Wockhardt Limited [Line Items]
Business combination contingent consideration payable		₨ 561
Major business combination [member]
Disclosure of Business Transfer Agreement with Wockhardt Limited [Line Items]
Consideration on acquisition date	₨ 18,500
Business combination payment of consideration	14,830
Acquisition date consideration payable for working capital adjustments and other statutory dues	670
Business combination contingent consideration payable	₨ 3,000
Number of times and the product of excess of minimum threshold revenue of the acquiree	2
Major business combination [member] \| Bottom of range [member] \| Scenario Forecast One [Member]
Disclosure of Business Transfer Agreement with Wockhardt Limited [Line Items]
Estimated revenue from sales of the acquiree post business combination	₨ 4,800

Business Transfer Agreement w_4

Business Transfer Agreement with Wockhardt Limited (Details) - Wockhardt Limited [Member] - INR (₨) ₨ in Millions	12 Months Ended
	Mar. 31, 2021	Feb. 12, 2020
Disclosure of detailed information about business combination [line items]
Cash	₨ 14,990
Payment through Escrow account	564
Contingent consideration (Holdback Amount)	561
Total consideration	16,115	₨ 18,500
Assets acquired
Goodwill	530
Property, plant and equipment	373
Product related intangibles	14,888
Inventories	466
Other assets	245
Employee benefits (Gratuity-Rs.70 and Compensated absences- Rs.75)	(145)
Refund liability	(242)
Total net assets	₨ 16,115

Cash and cash equivalents (Deta

Cash and cash equivalents (Details) ₨ in Millions, $ in Millions	Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)		Mar. 31, 2020INR (₨)	Mar. 31, 2020USD ($)	Mar. 31, 2019INR (₨)	Mar. 31, 2018INR (₨)
Cash and Cash Equivalents [Abstract]
Cash on hand	₨ 1			₨ 2
Balances with banks	14,324			1,807
Term deposits with banks (original maturities less than 3 months)	504			244
Cash and cash equivalents in the statement of financial position	14,829	$ 203		2,053
Bank overdrafts used for cash management purposes	9	0	[1]	91
Cash and cash equivalents in the statement of cash flow	14,820	$ 203		1,962	$ 27	₨ 2,228	₨ 2,542
Balance in unclaimed dividend and debenture interest account	106			111
Balances in Escrow account pursuant to the Business Transfer Agreement with Wockhardt Limited	40			0
Other restricted cash balances	₨ 82			₨ 15

[1]	Rounded to the nearest million.

Other investments (Details)

Other investments (Details) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)
Other Investments [Line Items]
Current portion		₨ 19,744	$ 270	₨ 23,687
Non-current portion		4,958	$ 68	328
Cost [member]
Other Investments [Line Items]
Current portion		19,678		23,548
Non-current portion		3,126		2,725
Cost [member] \| Investment in mutual funds [member]
Other Investments [Line Items]
Current portion		13,197		13,686
Cost [member] \| Investment in Bonds [Member]
Other Investments [Line Items]
Current portion		522		1,851
Cost [member] \| Investment in commercial paper [Member]
Other Investments [Line Items]
Current portion		0		967
Cost [member] \| Investment in market linked debentures [Member]
Other Investments [Line Items]
Current portion		0		2,000
Cost [member] \| Term deposits with banks [Member]
Other Investments [Line Items]
Current portion		5,959		5,044
Cost [member] \| Investment in equity securities [Member]
Other Investments [Line Items]
Non-current portion	[1]	2,701		2,701
Cost [member] \| Investment in limited liability partnership [Member]
Other Investments [Line Items]
Non-current portion		400		0
Cost [member] \| Investment in others [Member]
Other Investments [Line Items]
Non-current portion		25		24
Unrealised gain/(loss) [member]
Other Investments [Line Items]
Current portion		66		139
Non-current portion		1,832		2,397
Unrealised gain/(loss) [member] \| Investment in mutual funds [member]
Other Investments [Line Items]
Current portion		66		146
Unrealised gain/(loss) [member] \| Investment in Bonds [Member]
Other Investments [Line Items]
Current portion		0		0
Unrealised gain/(loss) [member] \| Investment in commercial paper [Member]
Other Investments [Line Items]
Current portion		0		0
Unrealised gain/(loss) [member] \| Investment in market linked debentures [Member]
Other Investments [Line Items]
Current portion		0		7
Unrealised gain/(loss) [member] \| Term deposits with banks [Member]
Other Investments [Line Items]
Current portion		0		0
Unrealised gain/(loss) [member] \| Investment in equity securities [Member]
Other Investments [Line Items]
Non-current portion	[1]	1,832		2,397
Unrealised gain/(loss) [member] \| Investment in limited liability partnership [Member]
Other Investments [Line Items]
Non-current portion		0		0
Unrealised gain/(loss) [member] \| Investment in others [Member]
Other Investments [Line Items]
Non-current portion		0		0
Fair value / amortized cost [Member]
Other Investments [Line Items]
Current portion	[2]	19,744		23,687
Non-current portion	[2]	4,958		328
Fair value / amortized cost [Member] \| Investment in mutual funds [member]
Other Investments [Line Items]
Current portion	[2]	13,263		13,832
Fair value / amortized cost [Member] \| Investment in Bonds [Member]
Other Investments [Line Items]
Current portion	[2]	522		1,851
Fair value / amortized cost [Member] \| Investment in commercial paper [Member]
Other Investments [Line Items]
Current portion	[2]	0		967
Fair value / amortized cost [Member] \| Investment in market linked debentures [Member]
Other Investments [Line Items]
Current portion	[2]	0		1,993
Fair value / amortized cost [Member] \| Term deposits with banks [Member]
Other Investments [Line Items]
Current portion	[2]	5,959		5,044
Fair value / amortized cost [Member] \| Investment in equity securities [Member]
Other Investments [Line Items]
Non-current portion	[1],[2]	4,533		304
Fair value / amortized cost [Member] \| Investment in limited liability partnership [Member]
Other Investments [Line Items]
Non-current portion	[1]	400		0
Fair value / amortized cost [Member] \| Investment in others [Member]
Other Investments [Line Items]
Non-current portion	[2]	₨ 25		₨ 24

[1]	Primarily represents the shares of Curis, Inc. Refer to Note 34 of these consolidated financial statements for further details.
[2]	Interest accrued but not due on bonds and debentures, commercial paper and term deposits with banks is included in other current assets.

Trade and other receivables (De

Trade and other receivables (Details) - INR (₨) ₨ in Millions		Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Current [Abstract]
Current Trade And Other Receivable Gross		₨ 50,937	₨ 51,480
Less: Allowance for credit losses		(1,296)	(1,202)	₨ (1,172)
Current trade receivables		49,641	50,278
Non-current [Abstract]
Non Current Trade And Other Receivable Gross	[1]	118	1,737
Less: Allowance for credit losses		0	0
Non-current trade receivables		₨ 118	₨ 1,737

[1]	Represents amounts receivable pursuant to an out-licensing arrangement with a customer. As these amounts are not expected to be realized within twelve months from the end of the reporting date, they are disclosed as non-current.

Trade and other receivables (_2

Trade and other receivables (Details 1) - INR (₨) ₨ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Reconciliation of changes in allowance account for credit losses of financial assets [abstract]
Balance at the beginning of the year	₨ 1,202	₨ 1,172
Provision made during the year, net of reversals	176	154
Trade and other receivables written off & exchange differences	(82)	(124)
Balance at the end of the year	₨ 1,296	₨ 1,202

Trade and other receivables (_3

Trade and other receivables (Details Textual) - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020
Factoring of receivables [member]
Factoring of receivables [Line Items]
Trade Receivables Derecognised Pursuant To Sale To The Bank	₨ 9,254	₨ 9,049

Inventories (Details)

Inventories (Details) ₨ in Millions, $ in Millions	Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)
Classes of current inventories [abstract]
Raw materials	₨ 12,287		₨ 10,594
Work-in-progress	10,009		6,806
Finished goods (includes stock-in-trade)	19,829		15,126
Packing materials, stores and spares	3,287		2,540
Total Inventories	₨ 45,412	$ 621	₨ 35,066

Inventories (Details 1)

Inventories (Details 1) - INR (₨) ₨ in Millions		12 Months Ended
Inventories (Details 1) - INR (₨) ₨ in Millions		Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Classes of current inventories [abstract]
Raw materials, consumables and changes in finished goods and work in progress		₨ 58,268	₨ 51,892	₨ 40,932
Inventory write-downs	[1]	₨ 2,521	₨ 3,652	₨ 4,016

[1]	Following the Company’s decision to voluntarily recall all of its ranitidine medications sold in United States, due to confirmed contamination with N-Nitrosodimethylamine (“NDMA”) above levels established by the U.S. FDA, the Company recognized Rs.373 as inventory write downs of ranitidine during the year ended March 31, 2020. Furthermore, an amount of Rs.239 was recognized (as a reduction from revenue) as a provision for refund liabilities arising out of the Company’s recall decision.

Inventories - (Details Textual)

Inventories - (Details Textual) - INR (₨) ₨ in Millions		12 Months Ended
Inventories - (Details Textual) - INR (₨) ₨ in Millions		Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of Inventories [Line Items]
Inventory write-downs	[1]	₨ 2,521	₨ 3,652	₨ 4,016
Ranitidine [Member]
Disclosure of Inventories [Line Items]
Inventory write-downs			373
Refunds provision			₨ 239

[1]	Following the Company’s decision to voluntarily recall all of its ranitidine medications sold in United States, due to confirmed contamination with N-Nitrosodimethylamine (“NDMA”) above levels established by the U.S. FDA, the Company recognized Rs.373 as inventory write downs of ranitidine during the year ended March 31, 2020. Furthermore, an amount of Rs.239 was recognized (as a reduction from revenue) as a provision for refund liabilities arising out of the Company’s recall decision.

Other assets (Details)

Other assets (Details) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)
Current
Other Assets		₨ 14,509	$ 198	₨ 13,802
Non-current
Other non-current assets		834	$ 11	844
Current
Current
Balances and receivables from statutory authorities	[1]	7,227		4,445
Export benefits receivable	[2]	2,070		2,652
Prepaid expenses		1,141		950
Others	[3]	4,071		5,755
Other Assets		14,509		13,802
Non-current
Non-current
Security deposits		666		613
Others		168		231
Other non-current assets		₨ 834		₨ 844

[1]	Balances and receivables from statutory authorities primarily consist of amounts recoverable towards the goods and service tax (“GST”), excise duty and value added tax, and from customs authorities of India.
[2]	Export benefits receivables primarily consist of amounts receivable from various government authorities of India towards incentives on export sales made by the Company.
[3]	Others primarily includes advances given to vendors and employees, security deposits, interest accrued but not due on investments, and claims receivable.

Property, plant and equipment_2

Property, plant and equipment (Details) ₨ in Millions, $ in Millions		12 Months Ended
		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		₨ 52,332
Ending Balance		57,111	$ 781	₨ 52,332
Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		111,122		104,730
Recognition of right of use asset on initial application of IFRS 16				1,153
Adjusted balance				105,883
Additions		7,934		6,071
Assets acquired through business combinations	[1]	373
Disposals		(1,203)		(1,193)
Assets held for sale		(655)
Effect of changes in foreign exchange rates		320		361
Ending Balance		117,891		111,122
Accumulated depreciation and impairment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		63,311		55,560
Depreciation for the year		8,527		8,640
Impairment		46		0
Disposals		(1,063)		(1,112)
Assets held for sale		(504)
Effect of changes in foreign exchange rates		241		223
Ending Balance		70,558		63,311
Excluding Capital-work-in-progress [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		47,811		49,170
Ending Balance		47,333		47,811
Capital-work-in-progress [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance				4,521
Ending Balance		9,778
Land [Member] \| Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		4,123		4,192
Recognition of right of use asset on initial application of IFRS 16				0
Adjusted balance				4,192
Additions		13		4
Assets acquired through business combinations	[1]	84
Disposals		0		0
Assets held for sale		(18)
Effect of changes in foreign exchange rates		26		(73)
Ending Balance		4,228		4,123
Land [Member] \| Accumulated depreciation and impairment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		0		0
Depreciation for the year		0		0
Impairment		4		0
Disposals		0		0
Assets held for sale		(4)
Effect of changes in foreign exchange rates		0		0
Ending Balance		0		0
Land [Member] \| Excluding Capital-work-in-progress [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		4,123		4,192
Ending Balance		4,228		4,123
Buildings [member] \| Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		24,956		23,106
Recognition of right of use asset on initial application of IFRS 16				723
Adjusted balance				23,829
Additions		2,720		997
Assets acquired through business combinations	[1]	113
Disposals		(35)		(55)
Assets held for sale		(245)
Effect of changes in foreign exchange rates		11		185
Ending Balance		27,520		24,956
Buildings [member] \| Accumulated depreciation and impairment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		8,208		6,873
Depreciation for the year		1,697		1,306
Impairment		32		0
Disposals		(29)		(36)
Assets held for sale		(140)
Effect of changes in foreign exchange rates		22		65
Ending Balance		9,790		8,208
Buildings [member] \| Excluding Capital-work-in-progress [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		16,748		16,233
Ending Balance		17,730		16,748
Plant and equipment [member] \| Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		74,867		70,940
Recognition of right of use asset on initial application of IFRS 16				2
Adjusted balance				70,942
Additions		4,544		4,278
Assets acquired through business combinations	[1]	165
Disposals		(852)		(706)
Assets held for sale		(334)
Effect of changes in foreign exchange rates		244		353
Ending Balance		78,634		74,867
Plant and equipment [member] \| Accumulated depreciation and impairment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		49,602		43,642
Depreciation for the year		5,935		6,404
Impairment		9		0
Disposals		(773)		(667)
Assets held for sale		(306)
Effect of changes in foreign exchange rates		194		223
Ending Balance		54,661		49,602
Plant and equipment [member] \| Excluding Capital-work-in-progress [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		25,265		27,298
Ending Balance		23,973		25,265
Furniture, fixtures and office equipment [member] \| Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		5,965		5,717
Recognition of right of use asset on initial application of IFRS 16				28
Adjusted balance				5,745
Additions		437		497
Assets acquired through business combinations	[1]	11
Disposals		(134)		(253)
Assets held for sale		(58)
Effect of changes in foreign exchange rates		31		(24)
Ending Balance		6,252		5,965
Furniture, fixtures and office equipment [member] \| Accumulated depreciation and impairment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		4,903		4,603
Depreciation for the year		554		562
Impairment		1		0
Disposals		(125)		(251)
Assets held for sale		(54)
Effect of changes in foreign exchange rates		24		(11)
Ending Balance		5,303		4,903
Furniture, fixtures and office equipment [member] \| Excluding Capital-work-in-progress [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		1,062		1,114
Ending Balance		949		1,062
Vehicles [Member] \| Gross carrying amount [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		1,211		775
Recognition of right of use asset on initial application of IFRS 16				400
Adjusted balance				1,175
Additions		220		295
Assets acquired through business combinations	[1]	0
Disposals		(182)		(179)
Assets held for sale		0
Effect of changes in foreign exchange rates		8		(80)
Ending Balance		1,257		1,211
Vehicles [Member] \| Accumulated depreciation and impairment [member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		598		442
Depreciation for the year		341		368
Impairment		0		0
Disposals		(136)		(158)
Assets held for sale		0
Effect of changes in foreign exchange rates		1		(54)
Ending Balance		804		598
Vehicles [Member] \| Excluding Capital-work-in-progress [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Beginning Balance		613		333
Ending Balance		₨ 453		₨ 613

[1]	Refer to Note 6 of these consolidated financial statements for further details.

Property, plant and equipment_3

Property, plant and equipment (Details 1) - INR (₨) ₨ in Millions	12 Months Ended
	Mar. 31, 2021		Mar. 31, 2020
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	₨ 1,389
Depreciation for the year	831		₨ 491
Ending balance	2,944		1,389
Gross carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	2,359		962
Recognition of right of use asset on initial application of IFRS 16			1,153
Adjusted balance as at April 1, 2019			2,115
Additions	2,413	[1]	253
Disposals	(121)		(57)
Effect of changes in foreign exchange rates	(11)		48
Ending balance	4,640		2,359
Accumulated depreciation [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	970		499
Depreciation for the year	831		491
Disposals	(78)		(42)
Effect of changes in foreign exchange rates	(27)		22
Ending balance	1,696		970
Land [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	78
Ending balance	81		78
Land [Member] \| Gross carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	78		73
Recognition of right of use asset on initial application of IFRS 16			0
Adjusted balance as at April 1, 2019			73
Additions	0	[1]	0
Disposals	0		0
Effect of changes in foreign exchange rates	3		5
Ending balance	81		78
Land [Member] \| Accumulated depreciation [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	0		0
Depreciation for the year	0		0
Disposals	0		0
Effect of changes in foreign exchange rates	0		0
Ending balance	0		0
Buildings [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	944
Ending balance	2,551		944
Buildings [member] \| Gross carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	1,688		840
Recognition of right of use asset on initial application of IFRS 16			723
Adjusted balance as at April 1, 2019			1,563
Additions	2,212	[1]	87
Disposals	0		(1)
Effect of changes in foreign exchange rates	(14)		39
Ending balance	3,886		1,688
Buildings [member] \| Accumulated depreciation [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	744		454
Depreciation for the year	616		267
Disposals	0		(1)
Effect of changes in foreign exchange rates	(25)		24
Ending balance	1,335		744
Plant and equipment [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	4
Ending balance	3		4
Plant and equipment [member] \| Gross carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	18		12
Recognition of right of use asset on initial application of IFRS 16			2
Adjusted balance as at April 1, 2019			14
Additions	0	[1]	3
Disposals	0		0
Effect of changes in foreign exchange rates	0		1
Ending balance	18		18
Plant and equipment [member] \| Accumulated depreciation [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	14		12
Depreciation for the year	1		1
Disposals	0		0
Effect of changes in foreign exchange rates	0		1
Ending balance	15		14
Furniture Fixtures And Office Equipment [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	32
Ending balance	26		32
Furniture Fixtures And Office Equipment [Member] \| Gross carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	45		0
Recognition of right of use asset on initial application of IFRS 16			28
Adjusted balance as at April 1, 2019			28
Additions	7	[1]	17
Disposals	(1)		0
Effect of changes in foreign exchange rates	0		0
Ending balance	51		45
Furniture Fixtures And Office Equipment [Member] \| Accumulated depreciation [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	13		0
Depreciation for the year	12		13
Disposals	0		0
Effect of changes in foreign exchange rates	0		0
Ending balance	25		13
Vehicles [Member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	331
Ending balance	283		331
Vehicles [Member] \| Gross carrying amount [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	530		37
Recognition of right of use asset on initial application of IFRS 16			400
Adjusted balance as at April 1, 2019			437
Additions	194	[1]	146
Disposals	(120)		(56)
Effect of changes in foreign exchange rates	0		3
Ending balance	604		530
Vehicles [Member] \| Accumulated depreciation [member]
Disclosure of quantitative information about right-of-use assets [line items]
Beginning balance	199		33
Depreciation for the year	202		210
Disposals	(78)		(41)
Effect of changes in foreign exchange rates	(2)		(3)
Ending balance	₨ 321		₨ 199

[1]	Additions for the year ended March 31, 2021 include recognition of a right-of-use asset of Rs.1,852 relating to a warehousing services agreement in the United States.

Property, plant and equipment_4

Property, plant and equipment (Details 2) - INR (₨) ₨ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disclosure of detailed information about property, plant and equipment [abstract]
Depreciation expense of right-of-use assets	₨ 831	₨ 491
Interest expense on lease liabilities	₨ 227	₨ 230

Property, plant and equipment_5

Property, plant and equipment (Details Textual) - INR (₨) ₨ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disclosure of detailed information about property, plant and equipment [line items]
Contractual commitments for acquisition of property, plant and equipment	₨ 9,841	₨ 4,888
Cash outflow for leases	1,252	972
Buildings [member] \| UNITED STATES \| Warehousing Agreement [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Additions to right-of-use assets	1,852
Property, Plant and Equipment [Member]
Disclosure of detailed information about property, plant and equipment [line items]
Interest costs capitalised	₨ 149	₨ 52
Capitalisation rate of borrowing costs eligible for capitalisation	4.25%	4.22%

Goodwill (Details)

Goodwill (Details) ₨ in Millions, $ in Millions		12 Months Ended
Goodwill (Details) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2020INR (₨)	Mar. 31, 2021USD ($)
Disclosure of reconciliation of changes in goodwill [abstract]
Opening balance, gross		₨ 20,278	₨ 20,176
Goodwill arising on business combinations	[1]	530	0
Effect of translation adjustments		44	102
Impairment loss	[2]	(16,284)	(16,284)
Closing balance		₨ 4,568	₨ 3,994	$ 62

[1]	Refer to Note 6 of these consolidated financial statements for further details.
[2]	The impairment loss of Rs.16,284 includes Rs.16,003 pertaining to the Company’s German subsidiary, betapharm Arzneimittel GmbH, which is part of the Company’s Global Generics segment. This impairment loss was recorded for the years ended March 31, 2009 and 2010.

Goodwill (Details 1)

Goodwill (Details 1) ₨ in Millions, $ in Millions	Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)
Disclosure of information for cash-generating units [line items]
Goodwill	₨ 4,568	$ 62	₨ 3,994
Cash-generating units [member]
Disclosure of information for cash-generating units [line items]
Goodwill	4,568		3,994
Cash-generating units [member] \| PSAI- Active Pharmaceutical Operations [Member]
Disclosure of information for cash-generating units [line items]
Goodwill	997		997
Cash-generating units [member] \| Global Generics-Complex Injectables [Member]
Disclosure of information for cash-generating units [line items]
Goodwill	1,421		1,372
Cash-generating units [member] \| Global Generics-North America Operations [Member]
Disclosure of information for cash-generating units [line items]
Goodwill	1,015		1,021
Cash-generating units [member] \| Global Generics-Branded Formulations [Member]
Disclosure of information for cash-generating units [line items]
Goodwill	1,021		491
Cash-generating units [member] \| Other Cash-generating units [Member]
Disclosure of information for cash-generating units [line items]
Goodwill	₨ 114		₨ 113

Goodwill (Details Textual)

Goodwill (Details Textual) - INR (₨) ₨ in Millions		Mar. 31, 2021	Mar. 31, 2020
Disclosure of reconciliation of changes in goodwill [line items]
Impairment Loss Recorded In Goodwill Till Date	[1]	₨ 16,284	₨ 16,284
Impairment Loss Recorded In Goodwill Pertaining To A Subsidiary Till Date		₨ 16,003	₨ 16,003
Bottom of range [member]
Disclosure of reconciliation of changes in goodwill [line items]
Growth rate used to extrapolate cash flow projections		0.00%
Top of range [member]
Disclosure of reconciliation of changes in goodwill [line items]
Growth rate used to extrapolate cash flow projections		2.00%
Before tax [Member] \| Bottom of range [member] \| Intangibles [Member]
Disclosure of reconciliation of changes in goodwill [line items]
Discount rate applied to cash flow projections		9.10%
Before tax [Member] \| Top of range [member] \| Intangibles [Member]
Disclosure of reconciliation of changes in goodwill [line items]
Discount rate applied to cash flow projections		15.70%
After tax [Member] \| Bottom of range [member] \| Intangibles [Member]
Disclosure of reconciliation of changes in goodwill [line items]
Discount rate applied to cash flow projections		7.60%
After tax [Member] \| Top of range [member] \| Intangibles [Member]
Disclosure of reconciliation of changes in goodwill [line items]
Discount rate applied to cash flow projections		10.50%

[1]	The impairment loss of Rs.16,284 includes Rs.16,003 pertaining to the Company’s German subsidiary, betapharm Arzneimittel GmbH, which is part of the Company’s Global Generics segment. This impairment loss was recorded for the years ended March 31, 2009 and 2010.

Other intangible assets (Detail

Other intangible assets (Details) ₨ in Millions, $ in Millions		12 Months Ended
		Mar. 31, 2021INR (₨)		Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)
Disclosure of detailed information about intangible assets [line items]
Beginning balance		₨ 27,659			₨ 44,367
Ending balance		35,648		$ 487	27,659
Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance		91,096			85,571
Additions		6,411	[1]		1,806
Assets acquired through business combinations	[2]	14,888
Disposals/De-recognitions		(192)			(815)
Effect of changes in foreign exchange rates		(900)			4,534
Ending balance		111,303			91,096
Accumulated amortization and impairment [member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance		(63,437)			(41,204)
Amortization for the year		4,269			3,832
Impairment loss		8,542			16,757
Disposals/De-recognitions		192			750
Effect of changes in foreign exchange rates		(401)			2,394
Ending balance		(75,655)			(63,437)
Product related intangibles [member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance		25,799			42,394
Ending balance		33,781			25,799
Product related intangibles [member] \| Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance		87,330			81,971
Additions		6,107	[1]		1,641
Assets acquired through business combinations	[2]	14,888
Disposals/De-recognitions		(192)			(814)
Effect of changes in foreign exchange rates		(900)			4,532
Ending balance		107,233			87,330
Product related intangibles [member] \| Accumulated amortization and impairment [member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance		(61,531)			(39,577)
Amortization for the year		3,972			3,554
Impairment loss		8,542			16,757
Disposals/De-recognitions		192			749
Effect of changes in foreign exchange rates		(401)			2,392
Ending balance		(73,452)			(61,531)
Others [Member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance		1,860			1,973
Ending balance		1,867			1,860
Others [Member] \| Gross carrying amount [member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance		3,766			3,600
Additions		304	[1]		165
Disposals/De-recognitions		0			(1)
Effect of changes in foreign exchange rates		0			2
Ending balance		4,070			3,766
Others [Member] \| Accumulated amortization and impairment [member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance		(1,906)			(1,627)
Amortization for the year		297			278
Impairment loss		0			0
Disposals/De-recognitions					1
Effect of changes in foreign exchange rates		0			2
Ending balance		₨ (2,203)			₨ (1,906)

[1]	The Company entered into a definitive agreement with Glenmark Pharmaceuticals Limited to acquire marketing authorizations and other rights of select brands in four “Emerging Markets” countries. The acquired brands represent two products, (a) a mometasone mono product and (b) a combination of mometasone with azelastine, and are indicated for the treatment of seasonal and perennial allergic rhinitis. The total consideration paid was Rs.1,516. Following the principles of IAS 38, the Company recognized the acquired brands at their acquisition cost. The acquisition pertains to the Company’s Global Generics segment.
[2]	Refer to Note 6 of these consolidated financial statements for further details.

Other intangible assets (Deta_2

Other intangible assets (Details 1) ₨ in Millions, $ in Millions		12 Months Ended
		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)
Disclosure of detailed information about intangible assets [line items]
Beginning balance		₨ 27,659		₨ 44,367
Ending balance		35,648	$ 487	27,659
In-process research and development assets [member]
Disclosure of detailed information about intangible assets [line items]
Beginning balance		10,987		24,610
Add: Additions during the year	[1]	3,557		950
Less: Capitalizations during the year	[2]	0		(2,530)
Less: Impairments during the year		(8,099)		(13,379)
Effect of changes in exchange rates		(332)		1,336
Ending balance		₨ 6,113		₨ 10,987

[1]	During the year ended March 31, 2021, the additions include Rs.3,291 representing the expenditure for purchase of intellectual property rights relating to Xeglyze® forming part of the Company’s Proprietary Products segment. During the year ended March 31, 2020, the Company acquired a portfolio of approved, non-marketed Abbreviated New Drug Applications (“ANDAs”) in the United States from Teva for a total consideration of Rs.277. The Company recognized these ANDAs acquired as product related intangibles.
[2]	During the year ended March 31, 2020, the product ramelteon was available for use and are subject to amortization. Accordingly, the Company reclassified the amount from IPR&D to product related intangibles.

Other intangible assets (Deta_3

Other intangible assets (Details 2) ₨ in Millions	12 Months Ended
Other intangible assets (Details 2) ₨ in Millions	Mar. 31, 2021INR (₨)
Wockhardt Limited [Member]
Disclosure of intangible assets material to entity [line items]
Description of intangible assets material to entity	Select portfolio of branded generics business
Intangible assets material to entity	₨ 14,241
UCB India Private Limited and affiliates [Member]
Disclosure of intangible assets material to entity [line items]
Description of intangible assets material to entity	Select portfolio of dermatology, respiratory and pediatric assets
Intangible assets material to entity	₨ 4,568
XenoPort, Inc. [Member]
Disclosure of intangible assets material to entity [line items]
Description of intangible assets material to entity	Intellectual property rights relating to PPC-06 (tepilamide fumarate)
Intangible assets material to entity	₨ 4,036
Teva and an affiliate of Allergan [Member]
Disclosure of intangible assets material to entity [line items]
Description of intangible assets material to entity	Various ANDAs
Intangible assets material to entity	₨ 4,000
Eisai Company Limited [Member]
Disclosure of intangible assets material to entity [line items]
Description of intangible assets material to entity	Commercialization rights for an anti-cancer biologic agent
Intangible assets material to entity	₨ 1,840
Glenmark Pharmaceuticals Limited [Member]
Disclosure of intangible assets material to entity [line items]
Description of intangible assets material to entity	Select Anti-Allergy brands
Intangible assets material to entity	₨ 1,487
Novartis Consumer Health Inc [Member]
Disclosure of intangible assets material to entity [line items]
Description of intangible assets material to entity	Habitrol® brand
Intangible assets material to entity	₨ 1,181

Other intangible assets (Deta_4

Other intangible assets (Details Textual) ₨ in Millions, $ in Millions		12 Months Ended
		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Disclosure of detailed information about intangible assets [line items]
Impairment loss		₨ 8,542		₨ 16,757	₨ 116
Consideration transferred for acquisition of asset		1,516
Payment for the purchase of intellectual property rights		2,820	$ 39	1,269	₨ 1,421
gNuvaring [Member] \| Global Generics [Member]
Disclosure of detailed information about intangible assets [line items]
Impairment loss		3,180		11,137
Carrying value of the asset		0		3,269
Xeglyze [Member]
Disclosure of detailed information about intangible assets [line items]
Impairment loss		3,291
Xeglyze [Member] \| Global Generics and Properietary Products [Member]
Disclosure of detailed information about intangible assets [line items]
Impairment loss		3,291
Saxagliptin/metformin and phentermine and topiramate [Member] \| Global Generics [Member]
Disclosure of detailed information about intangible assets [line items]
Impairment loss		1,587
Tobramycin Inhalation Solution Ramelteon And Imiquimod Cream Product [Member] \| Global Generics [Member]
Disclosure of detailed information about intangible assets [line items]
Impairment loss				4,385
Other Intangible Assets [Member]
Disclosure of detailed information about intangible assets [line items]
Interest costs capitalised		₨ 266		₨ 674
Other Intangible Assets [Member] \| Bottom of range [member]
Disclosure of detailed information about intangible assets [line items]
Capitalisation rate of borrowing costs eligible for capitalisation		3.95%	3.95%	2.04%
Other Intangible Assets [Member] \| Top of range [member]
Disclosure of detailed information about intangible assets [line items]
Capitalisation rate of borrowing costs eligible for capitalisation		4.74%	4.74%	4.60%
Other Intangible Assets [Member] \| Global Generics and Properietary Products [Member]
Disclosure of detailed information about intangible assets [line items]
Impairment loss		₨ 2,071		₨ 5,620
Other Intangible Assets [Member] \| Global Generics and Properietary Products [Member] \| Higher Than Expected Price Erosion And Increased Competition [Member]
Disclosure of detailed information about intangible assets [line items]
Impairment loss		484		1,235
Intangible assets under development [member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets acquired during the year	[1]	3,557		950
Payment for the purchase of intellectual property rights		₨ 3,291
Intangible assets under development [member] \| Abbreviated New Drug Applications [Member]
Disclosure of detailed information about intangible assets [line items]
Intangible assets acquired during the year				₨ 277

[1]	During the year ended March 31, 2021, the additions include Rs.3,291 representing the expenditure for purchase of intellectual property rights relating to Xeglyze® forming part of the Company’s Proprietary Products segment. During the year ended March 31, 2020, the Company acquired a portfolio of approved, non-marketed Abbreviated New Drug Applications (“ANDAs”) in the United States from Teva for a total consideration of Rs.277. The Company recognized these ANDAs acquired as product related intangibles.

Investment in equity accounte_3

Investment in equity accounted investees (Details) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Investments accounted for using equity method [Line Items]
Investments accounted for using equity method		₨ 3,375	$ 46	₨ 2,763
Kunshan Rotam Reddy Pharmaceuticals Co. Limited [Member]
Investments accounted for using equity method [Line Items]
Investments accounted for using equity method	[1]	3,307		2,714	₨ 2,464
DRES energy private limited [Member]
Investments accounted for using equity method [Line Items]
Investments accounted for using equity method		₨ 68		₨ 49	₨ 65

[1]	Includes Rs.181 representing the goodwill on acquisition of investment.

Investment in equity accounte_4

Investment in equity accounted investees (Details 1) ₨ in Millions, $ in Millions		12 Months Ended
		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2018INR (₨)
Investments accounted for using equity method [Line Items]
Total current assets		₨ 148,249		₨ 130,370		$ 2,027
Total non-current assets		117,242		101,871		1,603
Total assets		265,491		232,241		3,630
Equity		173,062		154,988	₨ 140,197	2,366	₨ 126,460
Total current liabilities		83,391		72,814		1,140
Total equity and liabilities		265,491		232,241		3,630
Revenues	[1]	189,722	$ 2,594	174,600	153,851
Profit for the year		17,238	236	19,498	18,795
Company's share of profits for the year		480	$ 7	561	₨ 438
Carrying value of the Company's investment		₨ 3,375		₨ 2,763		$ 46
Kunshan Rotam Reddy Pharmaceuticals Co. Limited [Member]
Investments accounted for using equity method [Line Items]
Ownership		51.30%	51.30%	51.30%	51.30%
Total current assets		₨ 8,778		₨ 6,925	₨ 6,195
Total non-current assets		892		732	374
Total assets		9,670		7,657	6,569
Equity		6,088		4,931	4,448
Total current liabilities		3,582		2,726	2,121
Total equity and liabilities		9,670		7,657	6,569
Revenues		9,017		7,679	7,436
Expenses		8,117		6,554	6,558
Profit for the year		900		1,125	878
Company's share of profits for the year		461		577	449
Carrying value of the Company's investment	[2]	3,307		2,714	2,464
Translation adjustment arising out of translation of foreign currency balances		₨ 438		₨ 306	₨ 241

[1]	Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).
[2]	Includes Rs.181 representing the goodwill on acquisition of investment.

Investment in equity accounte_5

Investment in equity accounted investees (Details 2) ₨ in Millions, $ in Millions	12 Months Ended
	Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)	Mar. 31, 2021USD ($)
Investments accounted for using equity method [Line Items]
Carrying value of the Company's investment	₨ 3,375		₨ 2,763		$ 46
Company's share of profits for the year	480	$ 7	561	₨ 438
DRES energy private limited [Member]
Investments accounted for using equity method [Line Items]
Carrying value of the Company's investment	68		49	65
Company's share of profits for the year	₨ 19		₨ (16)	₨ (11)

Investment in equity accounte_6

Investment in equity accounted investees (Details Textual) ₨ in Millions	12 Months Ended
	Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Investments accounted for using equity method [Line Items]
Dividends received from investments accounted for using equity method			₨ 392
Kunshan Rotam Reddy Pharmaceuticals Co. Limited [Member]
Investments accounted for using equity method [Line Items]
Proportion of ownership interest in joint venture	51.30%	51.30%	51.30%	51.30%
Goodwill arising on investment in an joint venture	₨ 181		₨ 181	₨ 181

Trade and other payables (Detai

Trade and other payables (Details) ₨ in Millions, $ in Millions	Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)
Trade and other current payables [abstract]
Trade payables	₨ 12,696		₨ 10,745
Due to creditors for expenses	5,413		4,503
Due to capital creditors	5,635		1,411
Trade and other current payables	₨ 23,744	$ 325	₨ 16,659

Loans and borrowings (Details)

Loans and borrowings (Details) ₨ in Millions, $ in Millions	Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)
Disclosure of Short Term Borrowings [Line Items]
Current borrowings	₨ 23,136	$ 316	₨ 16,441
Pre-shipment credit [Member]
Disclosure of Short Term Borrowings [Line Items]
Current borrowings	10,300		10,432
Other working capital borrowings [Member]
Disclosure of Short Term Borrowings [Line Items]
Current borrowings	₨ 12,836		₨ 6,009

Loans and borrowings (Details 1

Loans and borrowings (Details 1)		12 Months Ended
Loans and borrowings (Details 1)		Mar. 31, 2021	Mar. 31, 2020
Pre-Shipment Credit Borrowings USD [Member]
Disclosure Interest Rate of Short Term Borrowings [Line Items]
Borrowings, original currency	[1]		U.S
Borrowings, interest rate basis	[2]		1 Month LIBOR + 12.5 to 16 bps
Pre-Shipment Credit borrowings INR [Member]
Disclosure Interest Rate of Short Term Borrowings [Line Items]
Borrowings, original currency	[1]	INR	INR
Borrowings, interest rate basis	[2]	3 Months T-bill + 30 bps	1 Month T-bill + 60 bps
Pre-Shipment Credit borrowings INR [Member]
Disclosure Interest Rate of Short Term Borrowings [Line Items]
Borrowings, original currency	[1]	INR
Borrowings, interest rate basis	[2]	5.75%
Other Working Capital Borrowings UAH [Member]
Disclosure Interest Rate of Short Term Borrowings [Line Items]
Borrowings, original currency	[1]	UAH
Borrowings, interest rate basis	[2]	4.75%
Other Working Capital Borrowings USD [Member]
Disclosure Interest Rate of Short Term Borrowings [Line Items]
Borrowings, original currency	[1]	U.S	U.S
Borrowings, interest rate basis	[2]	(2.2)% to (1.8)%	1Month/3 Months LIBOR + 55 to 78 bps
Other Working Capital Borrowings RUB [Member]
Disclosure Interest Rate of Short Term Borrowings [Line Items]
Borrowings, original currency	[1]	RUB	RUB
Borrowings, interest rate basis	[2]	3.00% to 3.40% and 5.55%	7.05%
Other Working Capital Borrowings ZAR [Member]
Disclosure Interest Rate of Short Term Borrowings [Line Items]
Borrowings, original currency	[1]		ZAR
Borrowings, interest rate basis	[2]		1Month JIBAR+120 bps
Other Working Capital Borrowings MXN [Member]
Disclosure Interest Rate of Short Term Borrowings [Line Items]
Borrowings, original currency	[1]	MXN	MXN
Borrowings, interest rate basis	[2]	TIIE + 1.20%	TIIE + 1.25%
Other Working Capital Borrowings INR [Member]
Disclosure Interest Rate of Short Term Borrowings [Line Items]
Borrowings, original currency	[1]	INR	INR
Borrowings, interest rate basis	[2]	4.00%	7.75%
Other Working Capital Borrowings BRL [Member]
Disclosure Interest Rate of Short Term Borrowings [Line Items]
Borrowings, original currency	[1]	BRL	BRL
Borrowings, interest rate basis	[2]	4.00%	7.25%

[1]	“INR” means Indian rupees, “U.S.$” means United States Dollars, “RUB” means Russian roubles, “MXN” means Mexican pesos, “UAH” means Ukrainian hryvnia, “BRL” means Brazilian reals and “ZAR” means South African rand.
[2]	“LIBOR” means the London Inter-bank Offered Rate, “TIIE” means the Equilibrium Inter-banking Interest Rate (Tasa de Interés Interbancaria de Equilibrio), “JIBAR” means the Johannesburg Interbank Average Rate and “T-bill” means India Treasury Bill.

Loans and borrowings (Details 2

Loans and borrowings (Details 2) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)
Current portion
Current portion of non-current borrowings		₨ 864	$ 12	₨ 4,266
Non-current portion
Non-current portion of non-current borrowings		6,299	$ 86	1,304
Foreign currency borrowing by the parent company [Member]
Current portion
Current portion of non-current borrowings		0		3,783
Non-current portion
Non-current portion of non-current borrowings		0		0
Obligations Under Leases [Member]
Current portion
Current lease liabilities	[1]	864		483
Non-current portion
Non-current lease liabilities	[1]	2,499		1,304
Non-convertible debentures by the APSL subsidiary [Member]
Current portion
Current portion of non-current borrowings	[2]	0		0
Non-current portion
Non-current portion of non-current borrowings	[2]	₨ 3,800		₨ 0

[1]	Additions for the year ended March 31, 2021 include right-of-use liability of Rs.1,878 relating to a warehousing services agreement in the United States.
[2]	“APSL subsidiary” refers to Aurigene Pharmaceutical Services Limited.

Loans and borrowings (Details 3

Loans and borrowings (Details 3)		12 Months Ended
Loans and borrowings (Details 3)		Mar. 31, 2021	Mar. 31, 2020
USD
Disclosure of Interest Rate Profile of Long Term Borrowings [Line Items]
Borrowings, interest rate basis	[1]		1 Month LIBOR + 82.7 bps
Borrowings, original currency	[2]		U.S
Non Convertible Debentures \| INR
Disclosure of Interest Rate Profile of Long Term Borrowings [Line Items]
Borrowings, interest rate basis	[1]	6.77%
Borrowings, original currency	[2]	INR

[1]	“LIBOR” means the London Inter-bank Offered Rate.
[2]	“U.S.$” means United States Dollars and “INR” means Indian rupees.

Loans and borrowings (Details 4

Loans and borrowings (Details 4) - INR (₨) ₨ in Millions		Mar. 31, 2021	Mar. 31, 2020
Disclosure of Contractual maturities of Long Term Borrowings [Line Items]
Non-convertible debentures		₨ 3,800
Foreign currency loans	[1]		₨ 3,783
Obligations under leases		3,363	1,787
Borrowings		7,163	5,570	[1]
2021
Disclosure of Contractual maturities of Long Term Borrowings [Line Items]
Foreign currency loans	[1]		3,783
Obligations under leases	[1]		483
Borrowings	[1]		4,226
2022
Disclosure of Contractual maturities of Long Term Borrowings [Line Items]
Non-convertible debentures		0
Foreign currency loans	[1]		0
Obligations under leases		864	359	[1]
Borrowings		864	359	[1]
2023
Disclosure of Contractual maturities of Long Term Borrowings [Line Items]
Non-convertible debentures		0
Foreign currency loans	[1]		0
Obligations under leases		802	267	[1]
Borrowings		802	267	[1]
2024
Disclosure of Contractual maturities of Long Term Borrowings [Line Items]
Non-convertible debentures		3,800
Foreign currency loans	[1]		0
Obligations under leases		745	249	[1]
Borrowings		4,545	249	[1]
2025
Disclosure of Contractual maturities of Long Term Borrowings [Line Items]
Non-convertible debentures		0
Foreign currency loans	[1]		0
Obligations under leases		734	286	[1]
Borrowings		734	286	[1]
2026
Disclosure of Contractual maturities of Long Term Borrowings [Line Items]
Non-convertible debentures		0
Obligations under leases		118
Borrowings		118
Thereafter
Disclosure of Contractual maturities of Long Term Borrowings [Line Items]
Non-convertible debentures		0
Foreign currency loans	[1]		0
Obligations under leases		100	143	[1]
Borrowings		₨ 100	₨ 143	[1]

[1]	Long-term debt obligations disclosed in the above table do not reflect any netting of transaction costs.

Loans and borrowings (Details 5

Loans and borrowings (Details 5) - INR (₨) ₨ in Millions		12 Months Ended
Loans and borrowings (Details 5) - INR (₨) ₨ in Millions		Mar. 31, 2021	Mar. 31, 2020
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Opening balance		₨ 22,011	₨ 38,381
Recognition of right-of-use liability on initial application of IFRS 16			1,335
Recognition of right-of-use liability during the year		2,393	238
Payment of principal portion of lease liabilities		(754)	(482)
Borrowings made during the year		48,269	29,831
Borrowings repaid during the year		(41,421)	(48,514)
Effect of changes in foreign exchange rates		(199)	1,132
Others			90
Closing balance		30,299	22,011
Long-term borrowings [member]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Opening balance	[1]	5,570	26,256
Recognition of right-of-use liability on initial application of IFRS 16	[1]		1,335
Recognition of right-of-use liability during the year	[1]	2,393	238
Payment of principal portion of lease liabilities	[1]	(754)	(482)
Borrowings made during the year	[1]	3,800	0
Borrowings repaid during the year	[1]	(3,743)	(22,918)
Effect of changes in foreign exchange rates	[1]	(103)	1,051
Others	[1]		90
Closing balance	[1]	7,163	5,570
Short-term borrowings [member]
Disclosure of reconciliation of liabilities arising from financing activities [line items]
Opening balance		16,441	12,125
Recognition of right-of-use liability on initial application of IFRS 16			0
Recognition of right-of-use liability during the year		0	0
Payment of principal portion of lease liabilities		0	0
Borrowings made during the year		44,469	29,831
Borrowings repaid during the year		(37,678)	(25,596)
Effect of changes in foreign exchange rates		(96)	81
Others			0
Closing balance		₨ 23,136	₨ 16,441

[1]	Includes current portion.

Loans and borrowings (Details T

Loans and borrowings (Details Textual) - INR (₨) ₨ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disclosure of detailed information about borrowings [line items]
Undrawn borrowing facilities	₨ 38,766	₨ 39,374
Buildings [member] \| US [member] \| Warehousing Agreement [Member]
Disclosure of detailed information about borrowings [line items]
Additions to right of use liability	1,878
Non Convertible Debentures [Member] \| Aurigene Pharmaceutical Services Limited [Member]
Disclosure of detailed information about borrowings [line items]
Non current debentures issued	₨ 3,800
Borrowings maturity	3 years

Provisions (Details)

Provisions (Details) ₨ in Millions, $ in Millions		12 Months Ended
Provisions (Details) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)
Disclosure of other provisions [line items]
Beginning Balance		₨ 3,854
Provision made during the year, net of reversals		2,997
Provision used during the year		(3,309)
Effect of changes in foreign exchange rates		(49)
Ending Balance		3,493		₨ 3,854
Current		3,435	$ 47	3,800
Non-current		58	$ 1	54
Refund Liability [member]
Disclosure of other provisions [line items]
Beginning Balance	[1]	3,252
Provision made during the year, net of reversals	[1]	2,934
Provision used during the year	[1]	(3,309)
Effect of changes in foreign exchange rates	[1]	(53)
Ending Balance	[1]	2,824		3,252
Current	[1]	2,824
Non-current	[1]	0
Environmental liability provisions [Member]
Disclosure of other provisions [line items]
Beginning Balance	[2]	54
Provision made during the year, net of reversals	[2]	0
Provision used during the year	[2]	0
Effect of changes in foreign exchange rates	[2]	4
Ending Balance	[2]	58		54
Current	[2]	0
Non-current	[2]	58
Legal and others provision [Member]
Disclosure of other provisions [line items]
Beginning Balance	[3]	548
Provision made during the year, net of reversals	[3]	63
Provision used during the year	[3]	0
Effect of changes in foreign exchange rates	[3]	0
Ending Balance	[3]	611		₨ 548
Current	[3]	611
Non-current	[3]	₨ 0

[1]	Refund liability is accounted for by recording a provision based on the Company’s estimate of expected sales returns. See Note 3(l) of these consolidated financial statements for the Company’s accounting policy on refund liability.
[2]	As a result of the acquisition of a unit of The Dow Chemical Company in April 2008, the Company assumed a liability for contamination of the Mirfield site acquired of Rs.39 (carrying value Rs.58). The seller is required to indemnify the Company for this liability. Accordingly, a corresponding asset has also been recorded in the consolidated statements of financial position.
[3]	Primarily consists of provision recorded towards the potential liability arising out of a litigation relating to cardiovascular and anti-diabetic formulations. Refer to Note 33 (Contingencies) of these consolidated financial statements under “Product and patent related matters - Matters relating to National Pharmaceutical Pricing Authority - Litigation relating to Cardiovascular and Anti-diabetic formulations” for further details.

Provisions (Details Textual)

Provisions (Details Textual) - INR (₨) ₨ in Millions		Mar. 31, 2021	Mar. 31, 2020
Disclosure of other provisions [line items]
Carrying value		₨ 3,493	₨ 3,854
Other environment related provision [member]
Disclosure of other provisions [line items]
Initial liability assumed		39
Carrying value	[1]	₨ 58	₨ 54

[1]	As a result of the acquisition of a unit of The Dow Chemical Company in April 2008, the Company assumed a liability for contamination of the Mirfield site acquired of Rs.39 (carrying value Rs.58). The seller is required to indemnify the Company for this liability. Accordingly, a corresponding asset has also been recorded in the consolidated statements of financial position.

Other liabilities (Details)

Other liabilities (Details) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)
Current
Accrued expenses		₨ 17,821		₨ 18,025
Employee benefits payable		5,607		4,944
Statutory dues payable		2,968		980
Deferred revenue	[1]	1,052		1,242
Advance from customers		981		668
Others		2,059		3,523
Current liabilities		30,488	$ 417	29,382
Non-current
Deferred revenue	[1]	1,531		1,956
Others		812		850
Non-current liabilities		₨ 2,343	$ 32	₨ 2,806

[1]	Refer to Note 22 for details of deferred revenue.

Share Capital (Details)

Share Capital (Details) ₨ in Millions, $ in Millions		12 Months Ended
Share Capital (Details) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)shares		Mar. 31, 2021USD ($)shares	Mar. 31, 2020INR (₨)shares		Mar. 31, 2021USD ($)shares
Disclosure of classes of share capital [line items]
Authorized share capital		240,000,000			240,000,000		240,000,000
Amount of shares authorised \| ₨		₨ 1,200			₨ 1,200
Fully Paid Up Share Capital
Opening number of equity shares/share capital \| ₨		831			830
Increase (decrease) through exercise of options, equity \| ₨	[1]	1			1
Closing number of equity shares/share capital		₨ 832		$ 11	₨ 831
Opening number of equity shares/share capital		166,172,082		166,172,082	166,065,948
Add: Equity shares issued pursuant to employee stock option plan	[1]	129,149		129,149	106,134
Closing number of equity shares/share capital		166,301,231		166,301,231	166,172,082
Number Of Treasury Shares Issued	[2]	575,201		575,201	395,950
Treasury shares		₨ 1,967	[2]		₨ 1,006	[2]	$ 27

[1]	During the years ended March 31, 2021 and 2020, equity shares were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy’s Employees Stock Option Scheme, 2002 and the Dr. Reddy’s Employees Stock Option Scheme, 2007. The options exercised had an exercise price of Rs.5, Rs.2,607 or Rs.2,814 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the "share based payment reserve”was transferred to“share premium” in the consolidated statements of changes in equity.
[2]	Pursuant to the special resolution approved by the shareholders in the Annual General Meeting held on July 27, 2018, the Dr. Reddy’s Employees ESOS Trust (the “ESOS Trust”) was formed to support the Dr. Reddy’s Employees Stock Option Scheme, 2018 by acquiring, from the Company or through secondary market acquisitions, equity shares which are used for issuance to eligible employees (as defined therein) upon exercise of stock options thereunder. During the years ended March 31, 2021 and 2020, an aggregate of 85,250 and 1,150 equity shares, respectively were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy’s Employees Stock Option Scheme, 2018. The options exercised had an exercise price of Rs.2,607 or Rs.2,814 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the “share based payment reserve” was transferred to “share premium” in the consolidated statements of changes in equity.In addition, any difference between the carrying amount of treasury shares and the consideration received was recognized in the “share premium”. As of March 31, 2021 and 2020, the ESOS Trust had outstanding 575,201 and 395,950 shares, respectively, which it purchased from the secondary market for an aggregate consideration of Rs.1,967 and Rs.1,006, respectively. Refer to Note 29 of these consolidated financial statements for further details on the Dr. Reddy’s Employees Stock Option Scheme, 2018.

Share Capital (Details 1)

Share Capital (Details 1) - INR (₨) ₨ / shares in Units, ₨ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of classes of share capital [line items]
Dividend per share (in absolute Rs.)	₨ 25	₨ 20	₨ 20
Dividend distribution tax on the dividend paid	₨ 0	₨ 602	₨ 682
Dividend paid during the year	4,147	3,916	4,002
Ordinary shares [member]
Disclosure of classes of share capital [line items]
Dividend paid during the year	₨ 4,147	₨ 3,314	₨ 3,320

Share Capital (Details Textual)

Share Capital (Details Textual) ₨ / shares in Units, ₨ in Millions, $ in Millions	May 14, 2021INR (₨)₨ / shares	Mar. 31, 2021INR (₨)shares₨ / shares		Mar. 31, 2020INR (₨)shares₨ / shares		Mar. 31, 2021USD ($)shares	Mar. 31, 2019₨ / shares
Details of Equity [Line Items]
Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share	₨ 25
Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners \| ₨	₨ 4,158
Par value per share		₨ 5		₨ 5			₨ 5
Treasury shares		₨ 1,967	[1]	₨ 1,006	[1]	$ 27
Rights, preferences and restrictions attaching to class of share capital		The Company has only one class of equity shares having a par value of Rs.5 per share. For all matters submitted to vote in a shareholders meeting of the Company, every holder of an equity share, as reflected in the records of the Company as on the record date set for the shareholders meeting, shall have one vote in respect of each share held. Should the Company declare and pay any dividends, such dividends will be paid in Indian rupees to each holder of equity shares in proportion to the number of shares held to the total equity shares outstanding as on that date. Indian law on foreign exchange governs the remittance of dividends outside India. In the event of liquidation of the Company, all preferential amounts, if any, shall be discharged by the Company. The remaining assets of the Company shall be distributed to the holders of equity shares in proportion to the number of shares held to the total equity shares outstanding as on that date.
Dr Reddys Employees Stock Option Scheme 2018 [Member]
Details of Equity [Line Items]
Number of share options exercised \| shares		85,250		1,150
Number of Treasury shares outstanding \| shares		575,201		395,950		575,201
Treasury shares \| ₨		₨ 1,967		₨ 1,006
Weighted average exercise price of share options exercised in share-based payment arrangement		₨ 2,607		₨ 2,607
Weighted average share price		₨ 2,814

[1]	Pursuant to the special resolution approved by the shareholders in the Annual General Meeting held on July 27, 2018, the Dr. Reddy’s Employees ESOS Trust (the “ESOS Trust”) was formed to support the Dr. Reddy’s Employees Stock Option Scheme, 2018 by acquiring, from the Company or through secondary market acquisitions, equity shares which are used for issuance to eligible employees (as defined therein) upon exercise of stock options thereunder. During the years ended March 31, 2021 and 2020, an aggregate of 85,250 and 1,150 equity shares, respectively were issued as a result of the exercise of vested options granted to employees pursuant to the Dr. Reddy’s Employees Stock Option Scheme, 2018. The options exercised had an exercise price of Rs.2,607 or Rs.2,814 per share. Upon the exercise of such options, the amount of compensation cost (computed using the grant date fair value) previously recognized in the “share based payment reserve” was transferred to “share premium” in the consolidated statements of changes in equity.In addition, any difference between the carrying amount of treasury shares and the consideration received was recognized in the “share premium”. As of March 31, 2021 and 2020, the ESOS Trust had outstanding 575,201 and 395,950 shares, respectively, which it purchased from the secondary market for an aggregate consideration of Rs.1,967 and Rs.1,006, respectively. Refer to Note 29 of these consolidated financial statements for further details on the Dr. Reddy’s Employees Stock Option Scheme, 2018.

Earnings per share (Details)

Earnings per share (Details)	12 Months Ended
Earnings per share (Details)	Mar. 31, 2021₨ / sharesshares	Mar. 31, 2021$ / sharesshares	Mar. 31, 2020₨ / sharesshares	Mar. 31, 2019₨ / sharesshares
Basic earnings per share [abstract]
Number of equity shares at the beginning of the year (excluding treasury shares)	165,776,132	165,776,132	165,847,972	165,910,907
Effect of treasury shares held	(56,014)	(56,014)	(154,020)	(100,672)
Effect of equity shares issued on exercise of stock options	124,222	124,222	64,432	103,801
Weighted average number of equity shares – Basic	165,844,340	165,844,340	165,758,384	165,914,036
Earnings per share of par value Rs.5 – Basic \| (per share)	₨ 103.94	$ 1.42	₨ 117.63	₨ 113.28

Earnings per share (Details 1)

Earnings per share (Details 1)		12 Months Ended
Earnings per share (Details 1)		Mar. 31, 2021₨ / sharesshares	Mar. 31, 2021$ / sharesshares	Mar. 31, 2020₨ / sharesshares	Mar. 31, 2019₨ / sharesshares
Diluted earnings per share [abstract]
Weighted average number of equity shares – Basic		165,844,340	165,844,340	165,758,384	165,914,036
Dilutive effect of stock options outstanding	[1]	471,701	471,701	323,601	278,718
Weighted average number of equity shares – Diluted		166,316,041	166,316,041	166,081,985	166,192,754
Earnings per share of par value Rs.5 - Diluted \| (per share)		₨ 103.65	$ 1.52	₨ 117.40	₨ 113.09

[1]	As of March 31, 2021 and 2020, 235,460 and 475,575 options, respectively, were excluded from the diluted weighted average number of equity shares calculation because their effect would have been anti-dilutive. The average market value of the Company’s shares for the purpose of calculating the dilutive effect of stock options was based on quoted market prices for the year during which the options were outstanding.

Earnings per share (Details Tex

Earnings per share (Details Textual) - INR (₨) ₨ / shares in Units, ₨ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Profit (loss), attributable to ordinary equity holders of parent entity	₨ 17,238	₨ 19,498	₨ 18,795
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amounts	235,460	475,575
Par value per share	₨ 5	₨ 5	₨ 5

Revenue from contracts with c_3

Revenue from contracts with customers and trade receivables (Details) ₨ in Millions, $ in Millions		12 Months Ended
		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Revenue [abstract]
Sales		₨ 184,202		₨ 163,574	₨ 148,706
Service income		4,105		2,409	2,129
License fees	[1],[2]	1,415		8,617	3,016
Revenue	[3]	₨ 189,722	$ 2,594	₨ 174,600	₨ 153,851

[1]	During the year ended March 31, 2020, the Company entered into a definitive agreement with Upsher-Smith Laboratories, LLC for the sale of its U.S. and select territory rights for ZEMBRACE® SYMTOUCH® (sumatriptan injection) 3 mg and TOSYMRA® (sumatriptan nasal spray) 10 mg (formerly referred to as “DFN-02”), which formed part of its Proprietary Products segment. License fees includes an amount of Rs.7,486 towards the aforesaid sale transaction.
[2]	License fees for the year ended March 31, 2019 primarily includes out-licensing revenue of Rs.1,807 from Encore Dermatology Inc.
[3]	Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).

Revenue from contracts with c_4

Revenue from contracts with customers and trade receivables (Details 1) ₨ in Millions, $ in Millions		12 Months Ended
		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Statement [Line Items]
Revenue	[1]	₨ 189,722	$ 2,594	₨ 174,600	₨ 153,851
Global Generics
Statement [Line Items]
Revenue	[1]	154,404		138,123	122,903
Pharmaceutical Services and Active Ingredient
Statement [Line Items]
Revenue		31,982		25,747	24,140
Proprietary products
Statement [Line Items]
Revenue		523		7,949	4,750
Others
Statement [Line Items]
Revenue		₨ 2,813		₨ 2,781	₨ 2,058

[1]	Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).

Revenue from contracts with c_5

Revenue from contracts with customers and trade receivables (Details 2) ₨ in Millions, $ in Millions		12 Months Ended
		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Statement [Line Items]
Revenue	[1]	₨ 189,722	$ 2,594	₨ 174,600	₨ 153,851
Global Generics
Statement [Line Items]
Revenue	[1]	154,404		138,123	122,903
Global Generics \| Nervous System
Statement [Line Items]
Revenue		29,040		26,825	19,726
Global Generics \| Gastrointestinal
Statement [Line Items]
Revenue		21,132		19,394	19,250
Global Generics \| Oncology [Member]
Statement [Line Items]
Revenue		16,842		18,245	18,357
Global Generics \| Cardiovascular
Statement [Line Items]
Revenue		15,460		14,729	15,106
Global Generics \| Pain Management
Statement [Line Items]
Revenue		15,531		13,808	13,806
Global Generics \| Anti-Infective
Statement [Line Items]
Revenue		12,906		9,402	7,073
Global Generics \| Respiratory
Statement [Line Items]
Revenue		11,089		10,433	8,130
Global Generics \| Others
Statement [Line Items]
Revenue		₨ 32,404		₨ 25,287	₨ 21,455

[1]	Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).

Revenue from contracts with c_6

Revenue from contracts with customers and trade receivables (Details 3) ₨ in Millions, $ in Millions		12 Months Ended
		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Statement [Line Items]
Revenue	[1]	₨ 189,722	$ 2,594	₨ 174,600	₨ 153,851
Pharmaceutical Services and Active Ingredient [Member]
Statement [Line Items]
Revenue		31,982		25,747	24,140
Pharmaceutical Services and Active Ingredient [Member] \| Cardiovascular
Statement [Line Items]
Revenue		9,834		8,567	7,019
Pharmaceutical Services and Active Ingredient [Member] \| Pain Management
Statement [Line Items]
Revenue		4,657		5,073	3,364
Pharmaceutical Services and Active Ingredient [Member] \| Anti-Infective
Statement [Line Items]
Revenue		4,126		2,264	1,247
Pharmaceutical Services and Active Ingredient [Member] \| Nervous System
Statement [Line Items]
Revenue		2,704		2,797	2,741
Pharmaceutical Services and Active Ingredient [Member] \| Oncology [Member]
Statement [Line Items]
Revenue		2,385		1,798	2,212
Pharmaceutical Services and Active Ingredient [Member] \| Dermatology
Statement [Line Items]
Revenue		768		1,370	1,622
Pharmaceutical Services and Active Ingredient [Member] \| Others
Statement [Line Items]
Revenue		₨ 7,508		₨ 3,878	₨ 5,935

[1]	Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).

Revenue from contracts with c_7

Revenue from contracts with customers and trade receivables (Details 4) ₨ in Millions, $ in Millions		12 Months Ended
		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Statement [Line Items]
Revenue	[1]	₨ 189,722	$ 2,594	₨ 174,600	₨ 153,851
India
Statement [Line Items]
Revenue		36,252		32,089	28,804
United States
Statement [Line Items]
Revenue		76,702		76,028	69,299
Russia
Statement [Line Items]
Revenue		15,816		16,900	15,299
Others
Statement [Line Items]
Revenue	[2]	₨ 60,952		₨ 49,583	₨ 40,449

[1]	Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).
[2]	Others include Germany, the United Kingdom, Ukraine, China, Canada and other countries across the world.

Revenue from contracts with c_8

Revenue from contracts with customers and trade receivables (Details 5) - INR (₨) ₨ in Millions		12 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Details of Deferred revenue
Balance as of April 1		₨ 3,198	₨ 2,592
Revenue recognized during the year		(1,089)	(1,250)
Milestone payment received during the year		474	1,856
Balance as of March 31		2,583	3,198
Current	[1]	1,052	1,242
Non-current	[1]	₨ 1,531	₨ 1,956

[1]	Refer to Note 22 for details of deferred revenue.

Revenue from contracts with c_9

Revenue from contracts with customers and trade receivables (Details 6) ₨ in Millions, $ in Millions		12 Months Ended
		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)		Mar. 31, 2020INR (₨)	Mar. 31, 2020USD ($)		Mar. 31, 2019USD ($)
Statement [Line Items]
Beginning Balance \| ₨		₨ 3,854
Credits and payments \| ₨		(3,309)
Ending Balance \| ₨		3,493			₨ 3,854
Chargebacks [Member]
Statement [Line Items]
Beginning Balance			$ 156			$ 128		$ 170
Current provisions relating to sales during the year			1,702	[1]		1,468	[2]	1,415
Provisions and adjustments relating to sales in prior years	[3]
Credits and payments	[4]		(1,656)			(1,440)		(1,457)
Ending Balance			202			156		128
Rebates [Member]
Statement [Line Items]
Beginning Balance			80			92		161
Current provisions relating to sales during the year			245	[1]		319	[2]	461
Provisions and adjustments relating to sales in prior years			0			0		0
Credits and payments	[4]		(247)			(331)		(530)
Ending Balance			78			80		92
Medicaid [Member]
Statement [Line Items]
Beginning Balance			11			11		12
Current provisions relating to sales during the year			21	[1]		20	[2]	18
Provisions and adjustments relating to sales in prior years			0			0		0
Credits and payments	[4]		(19)			(20)		(19)
Ending Balance			13			11		11
Refund Liability [Member]
Statement [Line Items]
Beginning Balance	[5]		24			30		28
Current provisions relating to sales during the year	[5]		15	[1]		21	[2]	29
Provisions and adjustments relating to sales in prior years	[5]		0			0		0
Credits and payments		₨ (3,309)	(20)	[5]	₨ (3,224)	(27)	[5]	(27)	[5]
Ending Balance	[5]		$ 19			$ 24		$ 30

[1]	Chargebacks provisions and payments for the year ended March 31, 2021 were each higher as compared to the year ended March 31, 2020, primarily as a result of higher sales volumes and also due to higher pricing rates per unit for chargebacks, due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company’s products. The rebates provisions and payments for the year ended March 31, 2021 were each lower as compared to the year ended March 31, 2020, primarily as a result of lower pricing rates per unit for rebates, due to a reduction in the invoice price to wholesalers for certain of the Company’s products and also due to reduction in the contract prices through which the product is resold in the retail part of the supply chain for certain of the Company’s products, which were partially off-set by higher sales volumes during the year ended March 31, 2021 as compared to the year ended March 31, 2020.
[2]	Chargebacks provisions for the year ended March 31, 2020 were higher compared to the year ended March 31, 2019, primarily as a result of higher sales volumes, which were partially offset due to a lower pricing rates per unit for chargebacks. Such lower pricing was primarily on account of a reduction in the invoice price to wholesalers for certain of the Company’s products. The chargebacks payments for the year ended March 31, 2020 were lower compared to the year ended March 31, 2019, primarily as a result of higher pending chargebacks claims at March 31, 2020 as compared to March 31, 2019. The rebates provisions and the payments for the year ended March 31, 2020 were each lower as compared to the year ended March 31, 2019, primarily as a result of lower pricing rates per unit for rebates, due to a reduction in the invoice price to wholesalers for certain of the Company’s products, which were partially offset by higher sales volumes during the year ended March 31, 2020 as compared to the year ended March 31, 2019.
[3]	Currently, the Company does not separately track provisions and adjustments, in each case to the extent relating to prior years for chargebacks. However, the adjustments are expected to be non-material. The volumes used to calculate the closing balance of chargebacks represent approximately 1.3 months equivalent of sales, which corresponds to the pending chargeback claims yet to be processed.
[4]	Currently, the Company does not separately track the credits and payments, in each case to the extent relating to prior years for chargebacks, rebates, medicaid payments or refund liability.
[5]	The Company’s overall refund liability as of March 31, 2021 relating to its North America Generics business was U.S.$19, as compared to a liability of U.S.$24 as of March 31, 2020. This decrease in the Company’s liability was primarily attributable to a lower refund liability allowance for the year ended March 31, 2021 as compared to the year ended March 31, 2020. Such allowance change was primarily due to certain product mix changes and recent trends in actual sales returns, together with the Company’s historical experience and also the price reduction for certain products resulting into lower refund liability to be carried.

Revenue from contracts with _10

Revenue from contracts with customers and trade receivables (Details 7) ₨ in Millions, $ in Millions	12 Months Ended
	Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	[1]	Mar. 31, 2020INR (₨)	Mar. 31, 2020USD ($)	[1]	Mar. 31, 2019USD ($)	[1]
Statement [Line Items]
Provision made during the year, net of reversals	₨ 2,997
Provision used during the year	(3,309)
Effect of changes in foreign exchange rates	(49)
Refund Liability [Member]
Statement [Line Items]
Balance at the beginning of the year	3,252			₨ 3,581
Provision made during the year, net of reversals	2,934			2,675
Provision used during the year	(3,309)	$ (20)		(3,224)	$ (27)		$ (27)
Effect of changes in foreign exchange rates	(53)			220
Balance at the closing of the year	2,824			3,252
Current	2,824			3,252
Non-current	₨ 0			₨ 0

[1]	The Company’s overall refund liability as of March 31, 2021 relating to its North America Generics business was U.S.$19, as compared to a liability of U.S.$24 as of March 31, 2020. This decrease in the Company’s liability was primarily attributable to a lower refund liability allowance for the year ended March 31, 2021 as compared to the year ended March 31, 2020. Such allowance change was primarily due to certain product mix changes and recent trends in actual sales returns, together with the Company’s historical experience and also the price reduction for certain products resulting into lower refund liability to be carried.

Revenue from contracts with _11

Revenue from contracts with customers and trade receivables (Details 8) - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020
Statement [Line Items]
Advance from customers	₨ 981	₨ 668
Contract liabilities	₨ 981	₨ 668

Revenue from contracts with _12

Revenue from contracts with customers and trade receivables (Details Textual) ₨ in Millions, $ in Millions		12 Months Ended
		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)
Statement [Line Items]
Contract assets		₨ 37		₨ 23
Revenue	[1]	189,722	$ 2,594	174,600	₨ 153,851
Licence fee	[2],[3]	1,415		8,617	3,016
Global Generics- North America Operations [Member]
Statement [Line Items]
Refunds provision \| $						$ 19	$ 24
Encore Dermatology Inc [Member]
Statement [Line Items]
Licence fee					1,807
Proprietary products
Statement [Line Items]
Revenue		523		7,949	4,750
Proprietary products \| UpsherSmith Laboratories LLC [Member]
Statement [Line Items]
Licence fee				7,486
Major Customer 1 [Member]
Statement [Line Items]
Revenue		₨ 19,341		₨ 14,164	₨ 10,639
Percentage of entity's revenue		10.00%	10.00%	8.00%	7.00%
Major Customer 2 [Member]
Statement [Line Items]
Revenue		₨ 9,867		₨ 9,267	₨ 10,024
Percentage of entity's revenue		5.00%	5.00%	5.00%	7.00%

[1]	Revenues for the year ended March 31, 2021 do not include inter-segment revenues from the PSAI segment to the Global Generics segment, which amount to Rs.6,905 (as compared to Rs.5,910 and Rs.5,785 for the years ended March 31, 2020 and 2019, respectively).
[2]	During the year ended March 31, 2020, the Company entered into a definitive agreement with Upsher-Smith Laboratories, LLC for the sale of its U.S. and select territory rights for ZEMBRACE® SYMTOUCH® (sumatriptan injection) 3 mg and TOSYMRA® (sumatriptan nasal spray) 10 mg (formerly referred to as “DFN-02”), which formed part of its Proprietary Products segment. License fees includes an amount of Rs.7,486 towards the aforesaid sale transaction.
[3]	License fees for the year ended March 31, 2019 primarily includes out-licensing revenue of Rs.1,807 from Encore Dermatology Inc.

Other income, net (Details)

Other income, net (Details) ₨ in Millions, $ in Millions		12 Months Ended
Other income, net (Details) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Other operating income expense [Abstract]
Loss/(gain) on sale/disposal of non-current assets, net	[1]	₨ 42		₨ 10	₨ (1,264)
Sale of spent chemicals		(270)		(306)	(356)
Scrap sales		(142)		(167)	(179)
Miscellaneous income, net	[2]	(612)		(3,827)	(156)
Other (income)/expense, net		₨ (982)	$ (13)	₨ (4,290)	₨ (1,955)

[1]	Gain on disposal of assets for the year ended March 31, 2019 includes: a) an amount of Rs.582 representing the profit on sale of intangible assets forming part of the Company’s Proprietary Products segment after adjusting associated cost; b) an amount of Rs.423 representing the profit on sale of an API manufacturing business unit located in Jeedimetla, Hyderabad; and c) an amount of Rs.110 representing the profit on sale of all the membership interests in Dr. Reddy’s Laboratories Tennessee, LLC.
[2]	Miscellaneous income, net includes Rs.3,457 received from Celgene pursuant to a settlement agreement entered into in April 2019. The agreement effectively settles any claim the Company or its affiliates may have had for damages under section 8 of the Canadian Patented Medicines (Notice of Compliance) Regulations in regard to the Company’s ANDS for a generic version of REVLIMID® brand capsules (Lenalidomide) pending before Health Canada.

Other income, net (Details Text

Other income, net (Details Textual) - INR (₨) ₨ in Millions	12 Months Ended
Other income, net (Details Textual) - INR (₨) ₨ in Millions	Mar. 31, 2021	[1]	Mar. 31, 2020	Mar. 31, 2019
Statement [Line Items]
Gain (loss) on sale of an intangible assets				₨ 423
Miscellaneous income, net	₨ 0		₨ 5	0
Dr. Reddy's Laboratories Tennessee, LLC [Member]
Statement [Line Items]
Gain (loss) on sale of all the membership interests				110
Proprietary Products [Member]
Statement [Line Items]
Gain (loss) on sale of an intangible assets				₨ 582
Litigation settlement compensation received [Member]
Statement [Line Items]
Miscellaneous income, net			₨ 3,457

[1]	Rounded to the nearest million.

Finance income, net (Details)

Finance income, net (Details) ₨ in Millions, $ in Millions	12 Months Ended
Finance income, net (Details) ₨ in Millions, $ in Millions	Mar. 31, 2021INR (₨)		Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Finance expense income [Abstract]
Interest income	₨ 826			₨ 888	₨ 770
Fair value changes and profit on sale of units of mutual funds, net	557			929	773
Foreign exchange gain	1,240			639	737
Miscellaneous income, net	0	[1]		5	0
Finance income (A)	2,623		$ 36	2,461	2,280
Interest expense	(970)			(983)	(889)
Foreign exchange loss	0			0	(274)
Finance expense	(970)		(13)	(983)	(1,163)
Finance income, net	₨ 1,653		$ 23	₨ 1,478	₨ 1,117

[1]	Rounded to the nearest million.

Income taxes (Details)

Income taxes (Details) ₨ in Millions, $ in Millions	12 Months Ended
Income taxes (Details) ₨ in Millions, $ in Millions	Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Current taxes
Current taxes	₨ 8,172		₨ 6,616	₨ 4,710
Deferred taxes expense/(benefit
Deferred taxes expense/(benefit	1,003		(8,082)	(1,062)
Tax expense/(benefit), net	9,175	$ 125	(1,466)	3,648
Country of domicile [member]
Current taxes
Current taxes	5,849		5,157	3,003
Deferred taxes expense/(benefit
Deferred taxes expense/(benefit	2,736		(6,580)	244
Foreign countries [member]
Current taxes
Current taxes	2,323		1,459	1,707
Deferred taxes expense/(benefit
Deferred taxes expense/(benefit	₨ (1,733)		₨ (1,502)	₨ (1,306)

Income taxes (Details 1)

Income taxes (Details 1) - INR (₨) ₨ in Millions	12 Months Ended
Income taxes (Details 1) - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Current and deferred tax relating to items charged or credited directly to equity [abstract]
Tax effect on changes in fair value of other investments	₨ 293	₨ 0	₨ 411
Tax effect on foreign currency translation differences	0	0	(14)
Tax effect on effective portion of change in fair value of cash flow hedges	319	(232)	69
Tax effect on actuarial gains/losses on defined benefit obligations	(73)	22	3
Current and deferred tax relating to items credited (charged) directly to equity	₨ 539	₨ (210)	₨ 469

Income taxes (Details 2)

Income taxes (Details 2) ₨ in Millions, $ in Millions		12 Months Ended
Income taxes (Details 2) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Reconciliation of average effective tax rate and applicable tax rate [abstract]
Profit before income taxes		₨ 26,413	$ 361	₨ 18,032	₨ 22,443
Enacted tax rate in India		34.94%	34.94%	34.94%	34.94%
Computed expected tax expense		₨ 9,229		₨ 6,301	₨ 7,842
Effect of:
Differences between Indian and foreign tax rates		810		3,385	(734)
Unrecognized deferred tax assets/(recognition of previously unrecognized deferred tax assets, net)		1,220		(6,478)	482
Expenses not deductible for tax purposes		230		155	340
Reversal of earlier years' tax provisions		0		0	(282)
Income exempt from income taxes		(1,807)		(1,029)	(1,282)
Foreign exchange differences		(18)		(64)	(470)
Incremental deduction allowed for research and development costs	[1]	0		(1,241)	(1,134)
Tax expense on distributed/undistributed earnings of subsidiary outside India		0		254	0
Write off of accounts receivables		0		0	(1,294)
Income from sale of capital assets		0		(2,620)	0
Effect of change in tax rate		(333)		(37)	3
Others		(156)		(92)	177
Income tax expense/(benefit)		₨ 9,175	$ 125	₨ (1,466)	₨ 3,648
Effective tax rate		35.00%	35.00%	(8.00%)	16.00%

[1]	India’s Finance Act, 2016 incorporated an amendment that reduces the weighted deduction on eligible research and development expenditure in a phased manner from 200% to 150% commencing from April 1, 2017 and from 150% to 100% effective April 1, 2020.

Income taxes (Details 3)

Income taxes (Details 3) - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020
Disclosure of temporary difference, unused tax losses and unused tax credits [line items]
Deductible temporary differences, net	₨ 738	₨ 394
Operating tax loss carry-forward	4,742	3,926
Unrecognized Deferred Tax Assets And Liabilities	₨ 5,480	₨ 4,320

Income taxes (Details 4)

Income taxes (Details 4) - INR (₨) ₨ in Millions		Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of temporary differences in deferred tax assets and liabilities [Line Items]
Deferred tax (liability) asset		₨ 10,292	₨ 11,939	₨ 3,558
Inventory [Member]
Disclosure of temporary differences in deferred tax assets and liabilities [Line Items]
Deferred tax (liability) asset		3,997	3,216
Minimum Alternate Tax [Member]
Disclosure of temporary differences in deferred tax assets and liabilities [Line Items]
Deferred tax (liability) asset	[1]	4,748	6,246
Trade and other receivables [Member]
Disclosure of temporary differences in deferred tax assets and liabilities [Line Items]
Deferred tax (liability) asset		569	369
Operating and other tax loss carry-forward [Member]
Disclosure of temporary differences in deferred tax assets and liabilities [Line Items]
Deferred tax (liability) asset		2,593	3,399
Other current assets and other current liabilities, net [Member]
Disclosure of temporary differences in deferred tax assets and liabilities [Line Items]
Deferred tax (liability) asset		1,404	1,448
Property, plant and equipment [Member]
Disclosure of temporary differences in deferred tax assets and liabilities [Line Items]
Deferred tax (liability) asset		(2,547)	(2,361)
Other intangible assets [Member]
Disclosure of temporary differences in deferred tax assets and liabilities [Line Items]
Deferred tax (liability) asset		(283)	(477)
Others [Member]
Disclosure of temporary differences in deferred tax assets and liabilities [Line Items]
Deferred tax (liability) asset		₨ (189)	₨ 99

[1]	As per Indian tax laws, companies are liable for a Minimum Alternate Tax (“MAT”) when current tax, as computed under the provisions of the Income Tax Act, 1961 (“Tax Act”), is determined to be below the MAT computed under section 115JB of the Tax Act. If in any year the Company pays a MAT, then it is entitled to claim credit of the MAT paid over and above the normal tax liability in the subsequent years. The MAT credit is eligible to be carried forward and set-off in the future against the current tax liabilities over a period of 15 years starting from the succeeding fiscal year in which such credit was generated.

Income taxes (Details 5)

Income taxes (Details 5) - INR (₨) ₨ in Millions	12 Months Ended
Income taxes (Details 5) - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020
Disclosure Of Movement in deferred tax assets and liabilities [Line Items]
Balance, at the beginning	₨ 11,939	₨ 3,558
Recognized in income statement	(1,108)	8,171
Recognized in equity	(539)	210
Balance, at the end	10,292	11,939
Inventory [Member]
Disclosure Of Movement in deferred tax assets and liabilities [Line Items]
Balance, at the beginning	3,216	3,285
Recognized in income statement	781	(69)
Recognized in equity	0	0
Balance, at the end	3,997	3,216
Minimum Alternate Tax [Member]
Disclosure Of Movement in deferred tax assets and liabilities [Line Items]
Balance, at the beginning	6,246	1,630
Recognized in income statement	(1,498)	4,616
Balance, at the end	4,748	6,246
Trade and other receivables [Member]
Disclosure Of Movement in deferred tax assets and liabilities [Line Items]
Balance, at the beginning	369	316
Recognized in income statement	200	53
Balance, at the end	569	369
Operating and other tax loss carry-forward [Member]
Disclosure Of Movement in deferred tax assets and liabilities [Line Items]
Balance, at the beginning	3,399	297
Recognized in income statement	(806)	3,102
Balance, at the end	2,593	3,399
Other current assets and other current liabilities, net [Member]
Disclosure Of Movement in deferred tax assets and liabilities [Line Items]
Balance, at the beginning	1,448	1,315
Recognized in income statement	(44)	133
Balance, at the end	1,404	1,448
Property, plant and equipment [Member]
Disclosure Of Movement in deferred tax assets and liabilities [Line Items]
Balance, at the beginning	(2,361)	(2,665)
Recognized in income statement	(187)	304
Balance, at the end	(2,548)	(2,361)
Other intangible assets [Member]
Disclosure Of Movement in deferred tax assets and liabilities [Line Items]
Balance, at the beginning	(477)	(662)
Recognized in income statement	194	185
Balance, at the end	(283)	(477)
Others [Member]
Disclosure Of Movement in deferred tax assets and liabilities [Line Items]
Balance, at the beginning	99	42
Recognized in income statement	252	(153)
Recognized in equity	(539)	210
Balance, at the end	₨ (188)	₨ 99

Income taxes (Details Textual)

Income taxes (Details Textual) ₨ in Millions, $ in Millions, $ in Millions	12 Months Ended
	Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)	Mar. 31, 2021MXN ($)
Disclosure Of Movement in deferred tax assets and liabilities [Line Items]
Deferred income taxes not recognized on undistributed earnings of subsidiaries	₨ 19,543		₨ 22,988
Exchange Differences on Foreign Currency translations Recognised In Income Statement On Deferred Tax	(105)		89
Unused tax losses for which no deferred tax asset recognised	4,742		3,926
Tax expense (income)	9,175	$ 125	₨ (1,466)	₨ 3,648
Associated Tax Impact [Member]
Disclosure Of Movement in deferred tax assets and liabilities [Line Items]
Unrecognized tax benefits that would impact effective tax rate	801				$ 224
Profit Tax Impact [Member]
Disclosure Of Movement in deferred tax assets and liabilities [Line Items]
Unused tax losses for which no deferred tax asset recognised	2,291
Tax expense (income)	0
Unrecognized tax benefits that would impact effective tax rate	₨ 89				$ 25

Nature of Expense (Details)

Nature of Expense (Details) - INR (₨) ₨ in Millions	12 Months Ended
Nature of Expense (Details) - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Income Statement Nature of Expense [Line Items]
Employee benefits	₨ 36,299	₨ 33,802	₨ 33,562
Depreciation expense	8,527	8,640	8,362
Amortisation expense	4,269	3,832	3,828
Cost of revenues [Member]
Income Statement Nature of Expense [Line Items]
Employee benefits	11,529	10,643	10,644
Depreciation expense	6,061	6,366	6,484
Amortisation expense	0	175	284
Selling, general and administrative expenses [Member]
Income Statement Nature of Expense [Line Items]
Employee benefits	20,052	18,658	18,291
Depreciation expense	1,491	1,294	801
Amortisation expense	4,171	3,547	3,421
Research and development expenses [Member]
Income Statement Nature of Expense [Line Items]
Employee benefits	4,718	4,501	4,627
Depreciation expense	975	980	1,077
Amortisation expense	₨ 98	₨ 110	₨ 123

Operating leases (Details)

Operating leases (Details) - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of operating lease by lessee [Line Items]
Minimum Lease Payments Payable Under Noncancellable Operating Leases	₨ 0	₨ 0	₨ 1,291
Less than one year
Disclosure of operating lease by lessee [Line Items]
Minimum Lease Payments Payable Under Noncancellable Operating Leases	0	0	405
Between one and five years
Disclosure of operating lease by lessee [Line Items]
Minimum Lease Payments Payable Under Noncancellable Operating Leases	0	0	797
More than five years
Disclosure of operating lease by lessee [Line Items]
Minimum Lease Payments Payable Under Noncancellable Operating Leases	₨ 0	₨ 0	₨ 89

Operating leases (Details Textu

Operating leases (Details Textual) ₨ in Millions	12 Months Ended
Operating leases (Details Textual) ₨ in Millions	Mar. 31, 2019INR (₨)
Disclosure of operating lease by lessee [Line Items]
Minimum Operating Leases Payments	₨ 905

Employee benefits (Details)

Employee benefits (Details) - Parent Company Gratuity plan [Member] - INR (₨) ₨ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of defined benefit plans [line items]
Current service cost	₨ 281	₨ 276	₨ 265
Interest on defined benefit liability	8	(4)	(2)
Gratuity cost recognized in income statement	₨ 289	₨ 272	₨ 263

Employee benefits (Details 1)

Employee benefits (Details 1) - Parent Company Gratuity plan [Member] - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of net defined benefit liability (asset) [line items]
Present value of funded obligations	₨ 2,628	₨ 2,349	₨ 2,200
Fair value of plan assets	(1,997)	(2,160)
Net defined benefit liability recognized	₨ 631	₨ 189

Employee benefits (Details 2)

Employee benefits (Details 2) - Parent Company Gratuity plan [Member] - INR (₨) ₨ in Millions		12 Months Ended
		Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of defined benefit plans [line items]
Defined benefit obligations at the beginning of the year		₨ 2,349	₨ 2,200
Current service cost		281	276	₨ 265
Interest on defined obligations		140	152
Re-measurements due to:
Actuarial loss/(gain) due to change in financial assumptions		153	(96)
Actuarial loss/(gain) due to demographic assumptions		(26)	(48)
Actuarial loss/(gain) due to experience changes		51	59
Benefits paid		(345)	(194)
Liabilities assumed/(transferred)	[1]	25	0
Defined benefit obligations at the end of the year		₨ 2,628	₨ 2,349	₨ 2,200

[1]	Liabilities assumed/transferred of Rs.25 is comprised of: a) Rs.70 increase in liabilities on account of the acquisition of employees pursuant to the Business Transfer Agreement with Wockhardt Limited. Refer to Note 6 of these consolidated financial statements for further details. b) Rs.45 transfer of liabilities on account of a restructuring of the pharmaceutical services business between the parent company and its subsidiary.

Employee benefits (Details 3)

Employee benefits (Details 3) - Gratuity Benefits Of Parent [Member] - INR (₨) ₨ in Millions		12 Months Ended
		Mar. 31, 2021	Mar. 31, 2020
Disclosure of fair value of plan assets [line items]
Fair value of plan assets at the beginning of the year		₨ 2,160	₨ 2,174
Employer contributions		25	14
Interest on plan assets		132	156
Re-measurements due to:
Return on plan assets excluding interest on plan assets		(1)	10
Benefits paid		(345)	(194)
Assets acquired/(transferred)	[1]	26	0
Plan assets at the end of the year		₨ 1,997	₨ 2,160

[1]	Assets acquired/transferred of Rs.26 is comprised of: a) Rs.70 increase in assets on account of the acquisition of employees pursuant to the Business Transfer Agreement with Wockhardt Limited. Refer to Note 6 of these consolidated financial statements for further details. b) Rs.44 transfer of assets on account of a restructuring of the pharmaceutical services business between the parent company and its subsidiary.

Employee benefits (Details 4)

Employee benefits (Details 4) - Parent Company Gratuity plan [Member] - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Defined benefit obligation without effect of projected salary growth	₨ 1,795
Add: Effect of salary growth	833
Defined benefit obligation with projected salary growth	2,628	₨ 2,349	₨ 2,200
50 basis points increase \| Discount rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Defined benefit obligation	2,559
50 basis points increase \| Salary growth
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Defined benefit obligation	2,698
50 basis points decrease \| Discount rate
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Defined benefit obligation	2,700
50 basis points decrease \| Salary growth
Disclosure of sensitivity analysis for actuarial assumptions [line items]
Defined benefit obligation	₨ 2,560

Employee benefits (Details 5)

Employee benefits (Details 5) - Employee benefit obligations [Member] - Parent Company Gratuity plan [Member]	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Actuarial assumptions to determine benefit obligations [Line Items]
Discount rate	6.00%	6.65%	7.45%
Rate of compensation increase	8.00%	7.50%
First year [Member]
Actuarial assumptions to determine benefit obligations [Line Items]
Rate of compensation increase			8.00%
After first year [Member]
Actuarial assumptions to determine benefit obligations [Line Items]
Rate of compensation increase			9.00%

Employee benefits (Details 6)

Employee benefits (Details 6) - Employee gratuity cost [Member] - Parent Company Gratuity plan [Member]	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Actuarial assumptions to determine gratuity cost [Line Items]
Discount rate	6.65%	7.45%	7.75%
Rate of compensation increase	7.50%
First years [Member]
Actuarial assumptions to determine gratuity cost [Line Items]
Rate of compensation increase		8.00%	7.00%
Later than one year [member]
Actuarial assumptions to determine gratuity cost [Line Items]
Rate of compensation increase		9.00%	9.00%

Employee benefits (Details 7)

Employee benefits (Details 7) - Parent Company Gratuity plan [Member]	Mar. 31, 2021	Mar. 31, 2020
Funds managed by Insurers [Member]
Disclosure of defined benefit plans [line items]
Percentage of Weighted average asset allocation	100.00%	99.00%
Others [Member]
Disclosure of defined benefit plans [line items]
Percentage of Weighted average asset allocation	0.00%	1.00%

Employee benefits (Details 8)

Employee benefits (Details 8) - Parent Company Gratuity plan [Member] ₨ in Millions	Mar. 31, 2021INR (₨)
During the year ended March 31, 2022 (estimated)
Disclosure Of Expected Contribution To Post Employment Benefit Plans [Abstract]
Expected Contribution	₨ 317
March 31, 2022
Disclosure Of Expected Future Benefit Payments [Abstract]
Expected Future Benefit Payments	452
March 31, 2023
Disclosure Of Expected Future Benefit Payments [Abstract]
Expected Future Benefit Payments	390
March 31, 2024
Disclosure Of Expected Future Benefit Payments [Abstract]
Expected Future Benefit Payments	361
March 31, 2025
Disclosure Of Expected Future Benefit Payments [Abstract]
Expected Future Benefit Payments	339
March 31, 2026
Disclosure Of Expected Future Benefit Payments [Abstract]
Expected Future Benefit Payments	308
Thereafter
Disclosure Of Expected Future Benefit Payments [Abstract]
Expected Future Benefit Payments	₨ 1,971

Employee benefits (Details 9)

Employee benefits (Details 9) - Industrias Quimicas Falcon de Mexico Pension plan [Member] - INR (₨) ₨ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of net defined benefit liability (asset) [line items]
Current service cost	₨ 13	₨ 11	₨ 13
Interest on defined benefit liability	8	16	15
Total cost recognized in income statement	₨ 21	₨ 27	₨ 28

Employee benefits (Details 10)

Employee benefits (Details 10) - Industrias Quimicas Falcon de Mexico Pension plan [Member] - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 30, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of net defined benefit liability (asset) [line items]
Present value of funded obligations	₨ 307	₨ 234	₨ 234	₨ 223
Fair value of plan assets	(169)		(128)	₨ (70)
Net defined benefit liability recognized	₨ 138		₨ 106

Employee benefits (Details 11)

Employee benefits (Details 11) - Industrias Quimicas Falcon de Mexico Pension plan [Member] - INR (₨) ₨ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of defined benefit plans [line items]
Defined benefit obligations at the beginning of the year	₨ 234	₨ 223
Current service cost	13	11	₨ 13
Interest on defined obligations	21	25
Re-measurements due to:
Actuarial loss/(gain) due to change in financial assumptions	24	50
Actuarial loss/(gain) due to experience changes	19	(8)
Benefits paid	(32)	(41)
Foreign exchanges differences	28	(26)
Defined benefit obligations at the end of the year	₨ 307	₨ 234	₨ 223

Employee benefits (Details 12)

Employee benefits (Details 12) - Industrias Quimicas Falcon de Mexico Pension plan [Member] - INR (₨) ₨ in Millions	12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Disclosure of fair value of plan assets [line items]
Fair value of plan assets at the beginning of the year	₨ 128	₨ 70
Employer contributions	32	113
Interest on plan assets	13	9
Re-measurements due to:
Return on plan assets excluding interest on plan assets	12	(7)
Benefits paid	(32)	(41)
Foreign exchanges differences	16	(16)
Plan assets at the end of the year	₨ 169	₨ 128

Employee benefits (Details 13)

Employee benefits (Details 13) - Industrias Quimicas Falcon de Mexico Pension plan [Member] ₨ in Millions	Mar. 31, 2021INR (₨)
Disclosure Of Sensitivity Analysis For Actuarial Assumptions [Line Items]
Defined benefit obligation at present value without effect of salary growth	₨ 209
Add: Effect of salary growth	98
Defined benefit obligation with projected salary growth	307
50 basis points increase \| Discount rate [Member]
Disclosure Of Sensitivity Analysis For Actuarial Assumptions [Line Items]
Defined benefit obligation	294
50 basis points increase \| Salary growth [Member]
Disclosure Of Sensitivity Analysis For Actuarial Assumptions [Line Items]
Defined benefit obligation	321
50 basis points decrease \| Discount rate [Member]
Disclosure Of Sensitivity Analysis For Actuarial Assumptions [Line Items]
Defined benefit obligation	321
50 basis points decrease \| Salary growth [Member]
Disclosure Of Sensitivity Analysis For Actuarial Assumptions [Line Items]
Defined benefit obligation	₨ 294

Employee benefits (Details 14)

Employee benefits (Details 14) - Employee benefit obligations [Member] - Industrias Quimicas Falcon de Mexico Pension plan [Member]	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Actuarial assumptions to determine benefit obligations [Line Items]
Discount rate	7.75%	8.75%	11.25%
Rate of compensation increase	4.50%	4.50%	4.50%

Employee benefits (Details 15)

Employee benefits (Details 15) - Employee gratuity cost [Member] - Industrias Quimicas Falcon de Mexico Pension plan [Member]	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Actuarial assumptions to determine pension cost [Line Items]
Discount rate	8.75%	11.25%	9.00%
Rate of compensation increase	4.50%	4.50%	4.50%

Employee benefits (Details 16)

Employee benefits (Details 16) - Industrias Quimicas Falcon de Mexico Pension plan [Member]	Mar. 31, 2021	Mar. 31, 2020
Funds managed by Insurers [Member]
Weighted-average asset allocation [Line Items]
Percentage of Weighted average asset allocation	51.00%	51.00%
Others [Member]
Weighted-average asset allocation [Line Items]
Percentage of Weighted average asset allocation	49.00%	49.00%

Employee benefits (Details 17)

Employee benefits (Details 17) - Industrias Quimica Falcon de Mexico [Member] ₨ in Millions	Mar. 31, 2021INR (₨)
During the year ended March 31, 2022 (estimated)
Disclosure Of Expected Contribution To Post Employment Benefit Plans [Abstract]
Expected Contribution	₨ 36
March 31, 2022
Disclosure Of Expected Future Benefit Payments [Abstract]
Expected Future Benefit Payments	6
March 31, 2023
Disclosure Of Expected Future Benefit Payments [Abstract]
Expected Future Benefit Payments	6
March 31, 2024
Disclosure Of Expected Future Benefit Payments [Abstract]
Expected Future Benefit Payments	12
March 31, 2025
Disclosure Of Expected Future Benefit Payments [Abstract]
Expected Future Benefit Payments	16
March 31, 2026
Disclosure Of Expected Future Benefit Payments [Abstract]
Expected Future Benefit Payments	21
Thereafter
Disclosure Of Expected Future Benefit Payments [Abstract]
Expected Future Benefit Payments	₨ 608

Employee benefits (Details Text

Employee benefits (Details Textual) - INR (₨) ₨ in Millions		12 Months Ended
Employee benefits (Details Textual) - INR (₨) ₨ in Millions		Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Detailed Information About Employee Benefit Plans [Line Items]
Employee benefits expense			₨ 36,299	₨ 33,802	₨ 33,562
Gratuity Benefits Of Parent [Member]
Detailed Information About Employee Benefit Plans [Line Items]
Identifiable assets acquired (liabilities assumed)	[1]		26	0
Wockhardt Limited [Member]
Detailed Information About Employee Benefit Plans [Line Items]
Liabilities incurred			25
Increase in liabilities on acquisition of employees relating to business acquisition			70
Transfer of liabilities on restructuring of services			45
Identifiable assets acquired (liabilities assumed)			16,115
Increase in assets on acquisition of employees relating to business acquisition			70
Transfer of assets on restructuring of services			44
Provident Fund Benefits [Member]
Detailed Information About Employee Benefit Plans [Line Items]
Post-employment benefit expense, defined contribution plans			₨ 906	812	740
Contributions to Plan By Plan Participants Defined Contributions Plan (Percentage)			12.00%
Superannuation Benefits [Member]
Detailed Information About Employee Benefit Plans [Line Items]
Post-employment benefit expense, defined contribution plans			₨ 84	82	84
US 401kretirement savings Plan [Member]
Detailed Information About Employee Benefit Plans [Line Items]
Social security contributions			139	177	213
UK social securiy plan [Member]
Detailed Information About Employee Benefit Plans [Line Items]
Social security contributions			143	135	₨ 148
Compensated Absences [Member]
Detailed Information About Employee Benefit Plans [Line Items]
Liabilities Defined Contribution Plan			₨ 1,130	₨ 1,161
Industrias Quimicas Falcon de Mexico Pension plan [Member]
Detailed Information About Employee Benefit Plans [Line Items]
Estimate of contributions expected to be paid to plan for next annual reporting period		₨ 36
Parent Company Gratuity plan [Member]
Detailed Information About Employee Benefit Plans [Line Items]
Estimate of contributions expected to be paid to plan for next annual reporting period		₨ 317

[1]	Assets acquired/transferred of Rs.26 is comprised of: a) Rs.70 increase in assets on account of the acquisition of employees pursuant to the Business Transfer Agreement with Wockhardt Limited. Refer to Note 6 of these consolidated financial statements for further details. b) Rs.44 transfer of assets on account of a restructuring of the pharmaceutical services business between the parent company and its subsidiary.

Employee stock incentive plan_2

Employee stock incentive plans (Details) - DRL 2002 Plan [Member]	12 Months Ended
	Mar. 31, 2021shares
Options reserved under stock plan [Line Items]
Options reserved under original Plan	2,295,478
Options exercised prior to stock dividend date (A)	241,854
Balance of shares that can be allotted on exercise of options (B)	2,053,624
Options arising from stock dividend (C)	2,053,624
Options reserved after stock dividend (A+B+C)	4,349,102
Category A [Member]
Options reserved under stock plan [Line Items]
Options reserved under original Plan	300,000
Options exercised prior to stock dividend date (A)	94,061
Balance of shares that can be allotted on exercise of options (B)	205,939
Options arising from stock dividend (C)	205,939
Options reserved after stock dividend (A+B+C)	505,939
Category B [Member]
Options reserved under stock plan [Line Items]
Options reserved under original Plan	1,995,478
Options exercised prior to stock dividend date (A)	147,793
Balance of shares that can be allotted on exercise of options (B)	1,847,685
Options arising from stock dividend (C)	1,847,685
Options reserved after stock dividend (A+B+C)	3,843,163

Employee stock incentive plan_3

Employee stock incentive plans (Details 1)	12 Months Ended
Employee stock incentive plans (Details 1)	Mar. 31, 2021INR (₨)sharesNumberyr₨ / shares	Mar. 31, 2021USD ($)sharesNumberyr$ / shares	Mar. 31, 2020INR (₨)Numberyr₨ / shares	Mar. 31, 2021USD ($)sharesNumberyr$ / shares
Stock options activity under this category [Line Items]
Weighted average remaining useful life, Outstanding at the beginning of the year \| yr	73	73
Weighted average remaining useful life, Granted during the year \| yr	89	89
Weighted average remaining useful life, Outstanding at the end of the year \| yr			73
DRL 2002 Plan [Member] \| Category B Par Value Options [Member] \| Exercise Prices Rs 5 [Member]
Stock options activity under this category [Line Items]
Shares arising out of options, Outstanding at the beginning of the year \| Number	232,837	232,837	270,141
Shares arising out of options, Granted during the year \| Number	92,092	92,092	49,796
Shares arising out of options, Expired/forfeited during the year \| Number	(35,646)	(35,646)	(14,934)
Shares arising out of options, Exercised during the year \| Number	(72,030)	(72,030)	(72,166)
Shares arising out of options, Outstanding at the end of the year \| Number	217,253	217,253	232,837
Shares arising out of options, Exercisable at the end of the year \| Number	46,130		40,548	46,130
Ranges of exercise prices, Outstanding at the beginning of the year	₨ 5		₨ 5
Ranges of exercise prices, Granted during the year	5		5
Ranges of exercise prices, Expired/forfeited during the year	5		5
Ranges of exercise prices, Exercised during the year	5		5
Ranges of exercise prices, Outstanding at the end of the year	5		5
Ranges of exercise prices, Exercisable at the end of the year	₨ 5		₨ 5
Weighted average exercise price, Outstanding at the beginning of the year \| ₨ / shares	₨ 5		₨ 5
Weighted average exercise price, Granted during the year \| ₨ / shares	₨ 5		₨ 5
Weighted average exercise price, Expired/forfeited during the year	₨ 5		₨ 5
Weighted average exercise price, Exercised during the year \| ₨ / shares	₨ 5		₨ 5
Weighted average exercise price, Outstanding at the end of the year \| ₨ / shares	5		5
Weighted average exercise price, Exercisable at the end of the year \| ₨ / shares	₨ 5		₨ 5
Weighted average remaining useful life, Outstanding at the beginning of the year	69	69	73
Weighted average remaining useful life, Granted during the year	93	93	90
Weighted average remaining useful life, Outstanding at the end of the year	69	69	69
Weighted average remaining useful life, Exercisable at the end of the year	44		43	44
DRL 2007 Plan [Member] \| Category B Par Value Options [Member] \| Exercise Prices Rs 5 [Member]
Stock options activity under this category [Line Items]
Shares arising out of options, Outstanding at the beginning of the year \| Number	151,583	151,583	115,155
Shares arising out of options, Granted during the year \| Number	52,316	52,316	89,282
Shares arising out of options, Expired/forfeited during the year \| Number	(19,933)	(19,933)	(18,886)
Shares arising out of options, Exercised during the year \| Number	(41,967)	(41,967)	(33,968)
Shares arising out of options, Outstanding at the end of the year	141,999	141,999	151,583
Shares arising out of options, Exercisable at the end of the year	15,393		14,166	15,393
Ranges of exercise prices, Outstanding at the beginning of the year	₨ 5		₨ 5
Ranges of exercise prices, Granted during the year	5		5
Ranges of exercise prices, Expired/forfeited during the year	5		5
Ranges of exercise prices, Exercised during the year	₨ 5		5
Ranges of exercise prices, Outstanding at the end of the year		$ 5	5
Ranges of exercise prices, Exercisable at the end of the year			₨ 5	$ 5
Weighted average exercise price, Outstanding at the beginning of the year \| ₨ / shares	₨ 5		₨ 5
Weighted average exercise price, Granted during the year \| ₨ / shares	₨ 5		₨ 5
Weighted average exercise price, Expired/forfeited during the year	₨ 5		₨ 5
Weighted average exercise price, Exercised during the year \| ₨ / shares	₨ 5		₨ 5
Weighted average exercise price, Outstanding at the end of the year \| (per share)		$ 5	5
Weighted average exercise price, Exercisable at the end of the year \| (per share)			₨ 5	$ 5
Weighted average remaining useful life, Outstanding at the beginning of the year	73	73	73
Weighted average remaining useful life, Granted during the year			90
Weighted average remaining useful life, Outstanding at the end of the year	71	71	73
Weighted average remaining useful life, Exercisable at the end of the year	41		44	41

Employee stock incentive plan_4

Employee stock incentive plans (Details 2)	12 Months Ended
Employee stock incentive plans (Details 2)	Mar. 31, 2021sharesyr₨ / shares	Mar. 31, 2021sharesyr₨ / shares	Mar. 31, 2021sharesyr₨ / shares	Mar. 31, 2021sharesNumberyr₨ / shares	Mar. 31, 2021sharesyr₨ / shares	Mar. 31, 2020sharesyr₨ / shares	Mar. 31, 2020sharesyr₨ / shares	Mar. 31, 2020sharesyr₨ / shares	Mar. 31, 2020sharesNumberyr₨ / shares	Mar. 31, 2020sharesyr₨ / shares
Statement [Line Items]
Weighted average remaining useful life, Outstanding at the beginning of the year \| yr					73
Weighted average remaining useful life, Granted during the year \| yr					89
Weighted average remaining useful life, Outstanding at the end of the year \| yr										73
Category A [Member] \| DRL 2007 Plan [Member]
Statement [Line Items]
Shares arising out of options, Outstanding at the beginning of the year	202,760			202,760					146,060
Shares arising out of options, Granted during the year \| Number				96,080					61,700
Shares arising out of options, Expired/forfeited during the year \| Number				(13,348)					(5,000)
Shares arising out of options, Exercised during the year \| Number				(15,152)					0
Shares arising out of options, Outstanding at the end of the year	270,340					202,760			202,760
Shares arising out of options, Exercisable at the end of the year \| shares	69,530	69,530	69,530	69,530	69,530	35,265	35,265	35,265	35,265	35,265
Range of exercise prices, Granted during the year			₨ 3,679					₨ 2,814
Range of exercise prices,exercised/forfeited during the year								2,607
Range of exercise prices, Exercised during the year								0
Weighted average exercise price, Outstanding at the beginning of the year			2,353.62					2,166
Weighted average exercise price, Granted during the year			3,679					2,814
Weighted average exercise price, expired/forfeited during the year			2,678.03					2,607
Weighted average exercise price, Exercised during the year			2,643.48					0
Weighted average exercise price, Outstanding at the end of the year			2,791.65					2,353.62
Weighted average exercise price, Exercisable at the end of the year	₨ 2,182.21	₨ 2,182.21	₨ 2,182.21	₨ 2,182.21	₨ 2,182.21	₨ 2,150.81	₨ 2,150.81	₨ 2,150.81	₨ 2,150.81	₨ 2,150.81
Weighted average remaining useful life, Outstanding at the beginning of the year		72			72		81
Weighted average remaining useful life, Granted during the year		90					90
Weighted average remaining useful life, Outstanding at the end of the year					67		72			72
Weighted average remaining useful life, Exercisable at the end of the year \| yr	45	45	45	45	45	51	51	51	51	51
Category A [Member] \| DRL 2007 Plan [Member] \| Bottom of range [member]
Statement [Line Items]
Range of exercise prices, Outstanding at the beginning of the year			₨ 1,982					₨ 1,982
Range of exercise prices,exercised/forfeited during the year			2,607
Range of exercise prices, Exercised during the year			2,607
Range of exercise prices, Outstanding at the end of the year			1,982					1,982
Range of exercise prices, Exercisable at the end of the year	₨ 1,982	₨ 1,982	1,982	₨ 1,982	₨ 1,982	₨ 1,982	₨ 1,982	1,982	₨ 1,982	₨ 1,982
Category A [Member] \| DRL 2007 Plan [Member] \| Top of range [member]
Statement [Line Items]
Range of exercise prices, Outstanding at the beginning of the year			2,814					2,607
Range of exercise prices,exercised/forfeited during the year			2,814
Range of exercise prices, Exercised during the year			2,814
Range of exercise prices, Outstanding at the end of the year			3,679					2,814
Range of exercise prices, Exercisable at the end of the year	₨ 2,814	₨ 2,814	₨ 2,814	₨ 2,814	₨ 2,814	₨ 2,607	₨ 2,607	₨ 2,607	₨ 2,607	₨ 2,607

Employee stock incentive plan_5

Employee stock incentive plans (Details 3) - DRL 2018 Plan [Member]	12 Months Ended
	Mar. 31, 2021shares
Statement [Line Items]
Options reserved against equity shares	4,000,000
Options reserved against ADRs	1,000,000
Total	5,000,000
Number of securities to be acquired from secondary market
Statement [Line Items]
Options reserved against equity shares	2,500,000
Options reserved against ADRs	0
Total	2,500,000
Number of securities to be issued by the Company
Statement [Line Items]
Options reserved against equity shares	1,500,000
Options reserved against ADRs	1,000,000
Total	2,500,000

Employee stock incentive plan_6

Employee stock incentive plans (Details 4)	12 Months Ended
Employee stock incentive plans (Details 4)	Mar. 31, 2021Numberyr₨ / shares	Mar. 31, 2020Numberyr₨ / shares
Statement [Line Items]
Weighted average remaining useful life, Outstanding at the beginning of the year \| yr	73
Weighted average remaining useful life, Granted during the year \| yr	89
Weighted average remaining useful life, Outstanding at the end of the year \| yr		73
Drl Two Thousand Eighteen Plan [Member]
Statement [Line Items]
Shares arising out of options, Outstanding at the beginning of the year \| Number	375,775	229,600
Shares arising out of options, Granted during the year \| Number	150,740	169,900
Shares arising out of options, Expired/forfeited during the year \| Number	(55,335)	(22,575)
Shares arising out of options, Exercised during the year \| Number	(85,250)	(1,150)
Shares arising out of options, Outstanding at the end of the year \| Number	385,930	375,775
Shares arising out of options, Exercisable at the end of the year \| Number	71,225	53,100
Range of exercise prices, Outstanding at the beginning of the year		₨ 2,607
Range of exercise prices, Granted during the year	₨ 3,679
Range of exercise prices, Exercised during the year		2,607
Range of exercise prices, Exercisable at the end of the year		2,607
Weighted average exercise price, Outstanding at the beginning of the year	2,697.12	2,607
Weighted average exercise price, Granted during the year	3,679	2,817.07
Weighted average exercise price, Expired/forfeited during the year	2,904.51	2,687.84
Weighted average exercise price, Exercised during the year	2,671.71	2,607
Weighted average exercise price, Outstanding at the end of the year	3,056.51	2,697.12
Weighted average exercise price, Exercisable at the end of the year	₨ 2,665.63	₨ 2,607
Weighted average remaining useful life, Outstanding at the beginning of the year	75	84
Weighted average remaining useful life, Granted during the year	90	90
Weighted average remaining useful life, Outstanding at the end of the year	71	75
Weighted average remaining useful life, Exercisable at the end of the year	51	53
Drl Two Thousand Eighteen Plan [Member] \| Bottom of range [member]
Statement [Line Items]
Range of exercise prices, Outstanding at the beginning of the year	₨ 2,607
Range of exercise prices, Granted during the year		₨ 2,814
Range of exercise prices, Expired/forfeited during the year	2,607	2,607
Range of exercise prices, Exercised during the year	2,607
Range of exercise prices, Outstanding at the end of the year	2,607	2,607
Range of exercise prices, Exercisable at the end of the year	2,607
Drl Two Thousand Eighteen Plan [Member] \| Top of range [member]
Statement [Line Items]
Range of exercise prices, Outstanding at the beginning of the year	2,814
Range of exercise prices, Granted during the year		3,031
Range of exercise prices, Expired/forfeited during the year	3,679	3,031
Range of exercise prices, Exercised during the year	2,814
Range of exercise prices, Outstanding at the end of the year	3,679	₨ 2,814
Range of exercise prices, Exercisable at the end of the year	₨ 2,814

Employee stock incentive plan_7

Employee stock incentive plans (Details 5) - ₨ / shares	Oct. 27, 2020	May 19, 2020	Jan. 26, 2020	Oct. 31, 2019	May 16, 2019
Weighted average inputs used in the fair value of options granted [Line Items]
Expected volatility	30.81%		27.00%	27.10%
Exercise price	₨ 5		₨ 3,031	₨ 5
Option life	2 years 6 months		5 years	2 years 6 months
Risk-free interest rate	4.36%		6.61%	5.72%
Expected dividends	0.49%		0.66%	0.72%
Grant date share price	₨ 5,009		₨ 3,031	₨ 2,783.20
Option One on May 16, 2019 [Member]
Weighted average inputs used in the fair value of options granted [Line Items]
Expected volatility					28.25%
Exercise price					₨ 2,814
Option life					5 years
Risk-free interest rate					7.14%
Expected dividends					0.71%
Grant date share price					₨ 2,801
Option Two on May 16, 2019 [Member]
Weighted average inputs used in the fair value of options granted [Line Items]
Expected volatility					29.29%
Exercise price					₨ 5
Option life					2 years 6 months
Risk-free interest rate					6.76%
Expected dividends					0.71%
Grant date share price					₨ 2,801
Option One on May 19, 2020 [Member]
Weighted average inputs used in the fair value of options granted [Line Items]
Expected volatility		29.12%
Exercise price		₨ 3,679
Option life		5 years
Risk-free interest rate		5.67%
Expected dividends		0.68%
Grant date share price		₨ 3,700
Option Two on May 19, 2020 [Member]
Weighted average inputs used in the fair value of options granted [Line Items]
Expected volatility		30.47%
Exercise price		₨ 5
Option life		2 years 6 months
Risk-free interest rate		4.62%
Expected dividends		0.68%
Grant date share price		₨ 3,700

Employee stock incentive plan_8

Employee stock incentive plans (Details 6) - INR (₨) ₨ in Millions		12 Months Ended
		Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure of detailed information about share based payment expense [Line Items]
Share-based payment expense		₨ 741	₨ 615	₨ 474
Cash Settled Share-based Payment [Member]
Disclosure of detailed information about share based payment expense [Line Items]
Cash settled share-based payment expense	[1]	157	94	85
Equity Shared payment Settled [Member]
Disclosure of detailed information about share based payment expense [Line Items]
Equity settled share-based payment expense	[2]	₨ 584	₨ 521	₨ 389

[1]	Certain of the Company’s employees are eligible for share-based payment awards that are settled in cash. These awards entitle the employees to a cash payment, on the exercise date, subject to vesting upon satisfaction of certain service conditions which range from 1 to 4 years. The amount of cash payment is determined based on the price of the Company’s ADSs at the time of vesting. As of March 31, 2021 and 2020, there was Rs.126 and Rs.97, respectively of total unrecognized compensation cost related to unvested awards. This cost is expected to be recognized over a weighted-average period of 1.88 years and 1.93 years, respectively. This scheme does not involve dealing in or subscribing to or purchasing securities of the Company, directly or indirectly.
[2]	As of March 31, 2021 and 2020, there was Rs.612 and Rs.515, respectively, of total unrecognized compensation cost related to unvested stock options. This cost is expected to be recognized over a weighted-average period of 1.95 years and 1.93 years, respectively.

Employee stock incentive plan_9

Employee stock incentive plans (Details Textual) - INR (₨)	12 Months Ended
Employee stock incentive plans (Details Textual) - INR (₨)	Mar. 31, 2021	Mar. 31, 2020
DRL Two Thousand Eighteen Plan [Member]
Employee stock incentive plan [Line Items]
Employee Stock Option Treasury Shares Purchased	575,201
Value Of Stock Purchased	₨ 1,967
Equity Shared payment Settled [Member]
Employee stock incentive plan [Line Items]
Requisite period for recognition of expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets	1.95 years	1.93 years
Employees Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	₨ 612	₨ 515
Equity Shared payment Settled [Member] \| DRL Two Thousand Eighteen Plan [Member]
Employee stock incentive plan [Line Items]
Weighted average fair value at measurement date, share options granted	1,255	994
Intrinsic Value of Options exercised	165	₨ 0.35
Intrinsic Value of Options outstanding	563
Intrinsic Value of Options Exercisable	₨ 104
Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise	₨ 4,609	₨ 2,914
Cash Settled Share-based Payment [Member]
Employee stock incentive plan [Line Items]
Requisite period for recognition of expense from share-based payment transactions in which goods or services received did not qualify for recognition as assets	1.88 years	1.93 years
Employees Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	₨ 126	₨ 97
DRL 2007 Plans [Member]
Employee stock incentive plan [Line Items]
Number of instruments in share based payment arrangement available for grant	1,530,779
Categories A [Member] \| DRL 2007 Plans [Member]
Employee stock incentive plan [Line Items]
Weighted average fair value at measurement date, share options granted	₨ 1,255	993
Intrinsic Value of Options exercised	28
Intrinsic Value of Options outstanding	466
Intrinsic Value of Options Exercisable	₨ 120
Number of instruments in share based payment arrangement available for grant	382,695
Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise	₨ 4,506
Categories B [Member] \| DRL 2007 Plans [Member]
Employee stock incentive plan [Line Items]
Weighted average fair value at measurement date, share options granted	₨ 3,631	2,747
Intrinsic Value of Options exercised	182	₨ 93
Intrinsic Value of Options outstanding	641
Intrinsic Value of Options Exercisable	₨ 69
Par value of underlying equity shares	₨ 5
Number of instruments in share based payment arrangement available for grant	1,148,084
Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise	₨ 4,334	₨ 2,757
DRL 2002 Plan [Member]
Employee stock incentive plan [Line Items]
Weighted average fair value at measurement date, share options granted	₨ 3,677	₨ 2,746
Intrinsic Value of Options exercised	328	₨ 193
Intrinsic Value of Options outstanding	980
Intrinsic Value of Options Exercisable	₨ 208
Number of instruments in share based payment arrangement available for grant	2,295,478
Weighted average share price for share options in share-based payment arrangement exercised during period at date of exercise	₨ 4,565	₨ 2,681
DRL 2002 Plan [Member] \| Categories A [Member]
Employee stock incentive plan [Line Items]
Number of instruments in share based payment arrangement available for grant	300,000
DRL 2002 Plan [Member] \| Categories B [Member]
Employee stock incentive plan [Line Items]
Number of instruments in share based payment arrangement available for grant	1,995,478

Related parties (Details)

Related parties (Details) - INR (₨) ₨ in Millions	12 Months Ended
Related parties (Details) - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020		Mar. 31, 2019
Disclosure of transactions between related parties [line items]
Research and development services received	₨ 105	₨ 105		₨ 97
Sale of goods	22	14		23
Lease rentals received	1	1		0
Research and development services provided	93	58		103
Lease rentals paid	37	35		35
Catering expenses paid	301	344		270
Hotel expenses paid	8	22		26
Facility management services paid	36	24		0
Purchase of Solar power	127	108		0
Civil works	55	101		106
Professional consultancy services paid	30	4		1
Contributions towards social development	232	233		220
Salaries to relatives of Key Management Personnel	8	7		5
Others	₨ 0	₨ 0	[1]	₨ 0

[1]	Rounded to the nearest million.

Related parties (Details 1)

Related parties (Details 1) - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020
Key management personnel (towards rent deposits)
Due from/to related parties [Line Items]
Amounts receivable, related party transactions	₨ 8	₨ 8
Other related parties
Due from/to related parties [Line Items]
Amounts receivable, related party transactions	72	68
Amounts payable, related party transactions	₨ 93	₨ 91

Related parties (Details 2)

Related parties (Details 2) - INR (₨) ₨ in Millions	12 Months Ended
Related parties (Details 2) - INR (₨) ₨ in Millions	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2019
Disclosure Of Key Management Personnel Compensation [Line Items]
Salaries and other benefits	₨ 8	₨ 7	₨ 5
Total	36,299	33,802	33,562
Key Management Personnel [Member]
Disclosure Of Key Management Personnel Compensation [Line Items]
Salaries and other benefits	803	684	668
Contributions to defined contribution plans	34	34	35
Commission to directors	301	298	243
Share-based payments expense	259	165	99
Total	₨ 1,397	₨ 1,181	₨ 1,045

Financial instruments (Details)

Financial instruments (Details) ₨ in Millions, $ in Millions		Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)		Mar. 31, 2020INR (₨)
Assets:
Cash and cash equivalents		₨ 14,829	$ 203		₨ 2,053
Other investments		151
Derivative financial instruments		1,218	17		1,105
Liabilities:
Trade and other payables		23,744	325		16,659
Derivative financial instruments		326	4		1,602
Long-term borrowings		7,163			5,570	[1]
Short-term borrowings		23,136	316		16,441
Bank overdraft		9	$ 0	[2]	91
Total carrying value [Member]
Assets:
Cash and cash equivalents		14,829			2,053
Other investments	[3]	24,702			24,015
Trade and other receivables		49,759			52,015
Derivative financial instruments		1,218			1,105
Other assets	[4]	2,626			4,170
Total		93,134			83,358
Liabilities:
Trade and other payables		23,744			16,659
Derivative financial instruments		326			1,602
Long-term borrowings		7,163			5,570
Short-term borrowings		23,136			16,441
Bank overdraft		9			91
Other liabilities and provisions	[5]	23,233			25,317
Total		77,611			65,680
Total fair value [Member]
Assets:
Cash and cash equivalents		14,829			2,053
Other investments	[3]	24,702			24,015
Trade and other receivables		49,759			52,015
Derivative financial instruments		1,218			1,105
Other assets	[4]	2,626			4,170
Total		93,134			83,358
Liabilities:
Trade and other payables		23,744			16,659
Derivative financial instruments		326			1,602
Long-term borrowings		7,163			5,570
Short-term borrowings		23,136			16,441
Bank overdraft		9			91
Other liabilities and provisions	[5]	23,233			25,317
Total		₨ 77,611			₨ 65,680

[1]	Long-term debt obligations disclosed in the above table do not reflect any netting of transaction costs.
[2]	Rounded to the nearest million.
[3]	Interest accrued but not due on investments is included in other assets.
[4]	Other assets that are not financial assets (such as receivables from statutory authorities, export benefit receivables, prepaid expenses, advances paid and certain other receivables) of Rs.12,717 and Rs.10,476 as of March 31, 2021 and 2020, respectively, are not included.
[5]	Amounts as of March 31, 2021 includes contingent consideration of Rs.420 pursuant to the Business Transfer Agreement with Wockhardt Limited (Refer to Note 6 for details).

Financial instruments (Details

Financial instruments (Details 1) - INR (₨) ₨ in Millions		Mar. 31, 2021	Mar. 31, 2020
Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
Derivative Finanicial Assets And Liabilties	[1]	₨ 892	₨ (497)
Investment in MF [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL - Financial asset		13,263	13,832
Investment in Equity [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL - Financial asset		1	1
FVTOCI - Financial asset		4,532	303
Investment In Market Linked Debentures [Member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTOCI - Financial asset			1,993
Investment In Market Linked Debentures [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTOCI - Financial asset			1,993
Investment in Limited Liability Partnership Firm [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL - Financial asset		400
Contingent ConsiderationPursuant to the Business Transfer Agreement [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL- Contingent consideration		420
Level 1 of fair value hierarchy [member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
Derivative Finanicial Assets And Liabilties	[1]	0	0
Level 1 of fair value hierarchy [member] \| Investment in MF [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL - Financial asset		13,263	13,832
Level 1 of fair value hierarchy [member] \| Investment in Equity [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL - Financial asset		0	0
FVTOCI - Financial asset		4,532	303
Level 1 of fair value hierarchy [member] \| Investment In Market Linked Debentures [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTOCI - Financial asset			1,993
Level 1 of fair value hierarchy [member] \| Investment in Limited Liability Partnership Firm [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL - Financial asset		0
Level 1 of fair value hierarchy [member] \| Contingent ConsiderationPursuant to the Business Transfer Agreement [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL- Contingent consideration		0
Level 2 of fair value hierarchy [member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
Derivative Finanicial Assets And Liabilties	[1]	892	(497)
Level 2 of fair value hierarchy [member] \| Investment in MF [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL - Financial asset		0	0
Level 2 of fair value hierarchy [member] \| Investment in Equity [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL - Financial asset		0	0
FVTOCI - Financial asset		0	0
Level 2 of fair value hierarchy [member] \| Investment In Market Linked Debentures [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTOCI - Financial asset			0
Level 2 of fair value hierarchy [member] \| Investment in Limited Liability Partnership Firm [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL - Financial asset		0
Level 2 of fair value hierarchy [member] \| Contingent ConsiderationPursuant to the Business Transfer Agreement [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL- Contingent consideration		0
Level 3 of fair value hierarchy [member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
Derivative Finanicial Assets And Liabilties	[1]	0	0
Level 3 of fair value hierarchy [member] \| Investment in MF [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL - Financial asset		0	0
Level 3 of fair value hierarchy [member] \| Investment in Equity [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL - Financial asset		1	1
FVTOCI - Financial asset		0	0
Level 3 of fair value hierarchy [member] \| Investment In Market Linked Debentures [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTOCI - Financial asset			₨ 0
Level 3 of fair value hierarchy [member] \| Investment in Limited Liability Partnership Firm [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL - Financial asset		400
Level 3 of fair value hierarchy [member] \| Contingent ConsiderationPursuant to the Business Transfer Agreement [Member] \| Recurring fair value measurement [member]
Fair value hierarchy of assets and liabilities [Line Items]
FVTPL- Contingent consideration		₨ 420

[1]	The Company enters into derivative financial instruments with various counterparties, principally financial institutions and banks. Derivatives valued using valuation techniques with market observable inputs are mainly interest rate swaps, foreign exchange forward option and swap contracts. The most frequently applied valuation techniques include forward pricing, swap models and Black-Scholes-Merton models (for option valuation), using present value calculations. The models incorporate various inputs, including foreign exchange forward rates, interest rate curves and forward rate curves.

Financial instruments (Detail_2

Financial instruments (Details 2) ₨ in Millions, $ in Millions	12 Months Ended
	Mar. 31, 2021INR (₨)	Mar. 31, 2021USD ($)	Mar. 31, 2020INR (₨)	Mar. 31, 2019INR (₨)
Disclosure of detailed information about financial instruments [line items]
Net gain/(loss) recognized in finance costs in respect of foreign exchange derivative contracts and cross currency interest rate swaps contracts	₨ 2,619		₨ 155	₨ (257)
Net gain/(loss) recognized in equity in respect of hedges of highly probable forecast transactions	1,123	$ 15	(951)	180
Net gain/(loss) reclassified from equity and recognized as component of revenue occurrence of forecasted transaction	₨ 340		₨ (50)	₨ (524)

Financial instruments (Detail_3

Financial instruments (Details 3) ₽ in Millions, € in Millions, £ in Millions, SFr in Millions, R in Millions, $ in Millions, $ in Millions

Mar. 31, 2021USD ($)

Mar. 31, 2021AUD ($)

Mar. 31, 2021CHF (SFr)

Mar. 31, 2021GBP (£)

Mar. 31, 2021RUB (₽)

Mar. 31, 2021ZAR (R)

Mar. 31, 2021EUR (€)

Mar. 31, 2020USD ($)

Mar. 31, 2020AUD ($)

Mar. 31, 2020CHF (SFr)

Mar. 31, 2020GBP (£)

Mar. 31, 2020RUB (₽)

Mar. 31, 2020ZAR (R)

Mar. 31, 2020EUR (€)

Forward contract| US$ - INR| Sell [Member] | Hedges of recognised assets and liabilities [Member] | Contract One [Member]